Astellas (formerly Fujisawa) has been committed to the European transplant community since the early 1990s. By taking a leadership role in addressing the needs of surgeons, physicians, and patients, we are CHANGING TOMORROW.

Through sustained investment in almost 100 European clinical studies, Astellas is continually striving to advance transplant care by developing both new treatment regimens and innovative therapies that target specific pathways.

By partnering with you, and by supporting many of the patient organisations that offer hope for the future, we are all CHANGING TOMORROW as we work to fulfil the promise of transplantation.

www.astellas.eu

© February 2015 Astellas Pharma Europe Ltd. ADV/15/0005/GMSa

ASTELLAS, Leading Light for Life, the Star logo, CHANGING TOMORROW and the Ribbon logos are trade marks of Astellas Pharma Inc. and/or its related entities.
TABLE OF CONTENTS

About ISHLT ........................................... 2
Board of Directors ................................. 4
Scientific Program Committee ............... 6
Abstract Reviewers. ......................... 8
QR Codes ............................................. 19
Daily Time Table Schedule .................. 20
Continuing Medical Education .......... 30
Highlights of the Annual Meeting ........ 34
Nice Acropolis Floor Plans ............... 52
Annual Meeting Schedule At a Glance .... 56
Unrestricted Educational Grants .......... 73
Corporate Partners .............................. 74
Annual Meeting Scientific Program ...... 75
Moderated Poster Sessions ............... 194
Independent Events ......................... 266
ISHLT 2015 Exhibitors .................... 270
Exhibit Hall & Posters Floor Plan ....... 272
The International Society for Heart and Lung Transplantation (ISHLT) is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy.

ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 3,000 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, transplant coordinators and infectious disease specialists. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.
The purposes of the Society are:

1. To associate persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease and related sciences.

2. To encourage and stimulate basic and clinical research in these disciplines and to promote new therapeutic strategies.

3. To hold scientific meetings featuring presentations and discussions relevant to these disciplines.

4. To sponsor a scientific journal for the publication of manuscripts related to these disciplines.

5. To establish and maintain an international registry for heart and lung transplantation.

6. To award research grants and establish endowments for the study of these disciplines.
2014-2015
Board of Directors

OFFICERS
Hermann Reichenspurner, MD, PhD, PRESIDENT
Duane Davis, MD, MBA, PRESIDENT-ELECT
Allan R. Glanville, MBBS, MD, FRACP, PAST-PRESIDENT
Stuart C. Sweet, MD, PhD, SECRETARY-TREASURER

DIRECTORS
Christian Benden, MD, DIRECTOR
Lara Danziger-Isakov, MD, MPH, DIRECTOR
Andrew J. Fisher, FRCP, PhD, DIRECTOR
Daniel R. Goldstein, MD, PhD, DIRECTOR
Maryl R. Johnson, MD, DIRECTOR
Bronwyn J. Levvey, RN, Grad Dip Clin Ep, DIRECTOR
Francis D. Pagani, MD, PhD, DIRECTOR
Myung H. Park, MD, DIRECTOR
Joseph G. Rogers, MD, DIRECTOR
Martin Strueber, MD, DIRECTOR
Jeffrey J. Teuteberg, MD, DIRECTOR

EX OFFICIO BOARD MEMBERS
Andreas Zuckermann, MD, 2015 SCIENTIFIC PROGRAM COMMITTEE CHAIR
Mandeep R. Mehra, MD, MBBS FACP, EDITOR-IN-CHIEF JOURNAL OF HEART AND LUNG TRANSPLANTATION
Josef Stehlik, MD, MPH, TRANSPLANT REGISTRY MEDICAL DIRECTOR
Lori J. West, MD, DPhil, DEVELOPMENT COMMITTEE CHAIR
Christopher H. Wigfield, MD FRCS (C/Th), DIRECTOR OF EDUCATIONAL AFFAIRS
Amanda W. Rowe, ISHLT EXECUTIVE DIRECTOR
STAFF

Amanda W. Rowe  
EXECUTIVE DIRECTOR

Phyllis Glenn  
DIRECTOR OF MEMBERSHIP SERVICES

Lisa A. Edwards  
DIRECTOR OF MEETINGS

Lee Ann Mills  
DIRECTOR OF OPERATIONS

Susie Newton  
COMMUNICATIONS MANAGER

Megan Barrett  
COMMUNICATIONS ASSISTANT

14673 MIDWAY ROAD  
SUITE 200  
ADDISON, TX  75001  
PHONE: 972 490-9495  
FAX: 972 490-9499  
WWW.ISHLT.ORG
SYMPOSIUM PLANNING COMMITTEE

- Andreas O. Zuckermann, MD, Vienna, Austria, 2015 PROGRAM CHAIR
- Hermann Reichenspurner, MD, PhD, Hamburg, Germany, ISHLT PRESIDENT
- Jason Christie, MD, MS, Philadelphia, PA, USA, 2014 PROGRAM CHAIR
- Andrew J. Fisher, MD, FRCP, PhD, Newcastle upon Tyne, UK, 2016 PROGRAM CHAIR
- Ruchan Akar, MD, Ankara, Turkey
- Annalisa Angelini, MD, Padua, Italy
- Carla C. Baan, PhD, Rotterdam, The Netherlands
- David A. Baran, MD, Newark, NJ, USA
- Tuvia Ben Gal, MD, Petah Tikva, Israel
- Emma Birks, MBBS, PhD, BSc, FRCP, Louisville, KY, USA
- Kevin Carney, MSN, CRNP, CCTC, Philadelphia, PA, USA
- Adam B. Cochrane, PharmD, Falls Church, VA, USA
- Teresa De Marco, MD, FACC, San Francisco, CA, USA
- Howard J. Eisen, MD, Philadelphia, PA, USA
- Stephan Ensminger, MD, DPhil, Bad Oeynhausen, Germany
- Michele Estabrook, MD, St. Louis, MO, USA
- Peter M. Hopkins, FRACP, Brisbane, Australia
- Annemarie Kaan, MCN, RN, Vancouver, Canada
- Manreet Kanwar, MD, Pittsburgh, PA, USA
- Cassie C. Kennedy, MD, Rochester, MN, USA
- Ivan Knezevic, MD, Ljubljana, Slovenia
ABSTRACT SELECTION COMMITTEE

- Kiran K. Khush, MD, Stanford, CA, USA
- Pascal Leprince, MD, PhD, Paris, France
- Haifa Lyster, MSc, Harefield, UK
- Peter MacDonald, MD, PhD, Sydney, Australia
- Claudius Mahr, DO, Seattle, WA, USA
- Nicolas Manito, MD, Barcelona, Spain
- Marco Masetti, MD, Bologna, Italy
- Mandeep R. Mehra, MD, MBBS, FACC, FACP, Boston, MA, USA
- Bruno M. Meiser, MD, Munich, Germany
- Dylan V. Miller, MD, Murray, UT, USA
- Jignesh K. Patel, MD, PhD, Los Angeles, CA, USA
- Martin Schweiger, MD, Zurich, Switzerland
- Amparo Sole, MD, PhD, Valencia, Spain
- Zsolt Szepfalusi, MD, Vienna, Austria
- Jeffrey J. Teuteberg, MD, Pittsburgh, PA, USA
- Mitesh V. Thakrar, MD, Calgary, Canada
- Steven SL Tsui, MD, FRCS, Cambridge, UK
- Marian Urban, MD, Prague, Czech Republic
- Simon Urschel, MD, Edmonton, Canada
- Vincent G. Valentine, MD, Galveston, TX, USA
- Carmine Dario Vizza, MD, Rome, Italy
- Florian M. Wagner, MD, Hamburg, Germany
- Lori J. West, MD, DPhil, Edmonton, Canada
- Christopher H. Wigfield, MD FRCS(C/Th), Chicago, IL, USA
- Martin R. Zamora, MD, Aurora, CO, USA
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith D. Aaronson, MD</td>
<td>University of Michigan Medical Center, Ann Arbor, MI, USA</td>
</tr>
<tr>
<td>Richa Agarwal, MD</td>
<td>W. Penn Allegheny Hospital, Pittsburgh, PA, USA</td>
</tr>
<tr>
<td>Zargham Ahmadi, MD</td>
<td>Shahid Beheshti University of Medical School, Tehran, Iran</td>
</tr>
<tr>
<td>Clemens Aigner, MD</td>
<td>Medical University of Vienna, Vienna, Austria</td>
</tr>
<tr>
<td>Dimpna C. Albert, MD</td>
<td>Vall d’Hebron Hospital, Barcelona, Spain</td>
</tr>
<tr>
<td>Arezu Z. Aliabadi, MD</td>
<td>Medical University of Vienna, Vienna, Austria</td>
</tr>
<tr>
<td>Christopher Almond, MD</td>
<td>Boston Children’s Hospital, Boston, MA, USA</td>
</tr>
<tr>
<td>Rolando J. Alvarez, MD</td>
<td>Instituto Nacional de Cardiologia, Mexico City, Mexico</td>
</tr>
<tr>
<td>Samantha J. Anthony, PhD, MSW</td>
<td>Hospital for Sick Children, Toronto, ON, Canada</td>
</tr>
<tr>
<td>Abbas Ardehali, MD</td>
<td>UCLA School of Medicine, Los Angeles, CA, USA</td>
</tr>
<tr>
<td>Saima Aslam, MD, MS</td>
<td>University of California, San Diego, San Diego, CA, USA</td>
</tr>
<tr>
<td>Pavan Atluri, MD</td>
<td>University of Pennsylvania, Philadelphia, PA, USA</td>
</tr>
<tr>
<td>Agnes M. Azimzadeh, PhD</td>
<td>University of Maryland School of Medicine, Baltimore, MD, USA</td>
</tr>
<tr>
<td>Fernando Bacal, MD</td>
<td>Heart Institute, University of Sao Paulo, Sao Paolo, Brazil</td>
</tr>
<tr>
<td>Matthew D. Bacchetta, MD</td>
<td>NY Presbyterian Hospital/Columbia Univ, New York, NY, USA</td>
</tr>
<tr>
<td>Markus J. Barten, MD, PhD</td>
<td>Heart Center Leipzig, Sazonia, Germany</td>
</tr>
<tr>
<td>Christian Benden, MD</td>
<td>University Hospital Zurich, Zurich, Switzerland</td>
</tr>
</tbody>
</table>
Raymond L Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA
Alexander Bernhardt, MD, University Heart Center Hamburg, Hamburg, Germany
Gerald J. Berry, MD, Stanford University, Stanford, CA, USA
Sangeeta M. Bhorade, MD, Northwestern Memorial Hospital, Chicago, IL, USA
Nancy P. Blumenthal, CRNP, Hospital of University of Pennsylvania, Philadelphia, PA, USA
Hilde Bollen, RN, UZLeuven, Leuven, Belgium
Michael Bowdish, MD, Keck School of Medicine of USC, Los Angeles, CA, USA
Andrew J. Boyle, MD, Cleveland Clinic Florida, Weston, FL, USA
Nicolas A. Brozzi, MD, Cleveland Clinic Florida, Weston, FL, USA
Marie M. Budev, DO, MPH, The Cleveland Clinic, Cleveland, OH, USA
Deborah Budge, MD, Intermountain Medical Center, Murray, UT, USA
Caron L. Burch, MSN, Stanford Hospital & Clinics, Stanford, CA, USA
Margaret M. Burke, MD, FRCPATH, Harefield Hospital, Harefield, UK
Marco A. Caccamo, DO, Indiana University Health, Indianapolis, IN, USA
Martin Cadeiras, MD, University of California Los Angeles, Los Angeles, CA, USA
Fiorella Calabrese, MD, University of Padova, Padova, Italy
Charles E. Canter, MD, St. Louis Children’s Hospital, St. Louis, MO, USA
Edward Cantu, MD, Hospital of University of Pennsylvania, Philadelphia, PA, USA
Lilibeth M. Carlos, St. Vincent’s Hospital, Sydney, NSW, Australia
Chesney Castleberry, MD, Cincinnati Children’s Hospital MC, Cincinnati, OH, USA
Alexandre S. Cauduro, MD, Heart Institute Sao Paulo University, Sao Paulo, Brazil
Daniel Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, QLD, Australia
Kevin M. Chan, MD, University of Michigan Health System, Ann Arbor, MI, USA
Cecilia Chaparro, MD, Toronto General Hospital, Toronto, ON, Canada
Richard Cheng, MD, University of Washington, Seattle, WA, USA
Anson W. Cheung, MD, St. Paul’s Hospital, Vancouver, BC, Canada
Laveena Chhatwani, MD, Duke University Medical Center, Durham, NC, USA
Stephen C. Clark, MD, Freeman Hospital, Newcastle, United Kingdom
Rebecca J. Cogswell, MD, University of Minnesota, Minneapolis, MN, USA
Jennifer Conway, MD, Stollery Children’s Hospital, Edmonton, AB, Canada
Hannah Copeland, MD, Loma Linda University, Redlands, CA, USA
Maria Rosa Costanzo, MD, Midwest Heart Specialists-Advocate Medical, Naperville, IL, USA
Jennifer Cowger, MD, St. Vincent Heart Center, Indianapolis, ID, USA
Lara Danziger-Isakov, MD, MPH, Children’s Hospital Medical Center, Cincinnati, OH, USA
John Dark, MB, FRCS, Freeman Hospital, Newcastle Upon Tyne, UK
Marc De Perrot, MD, Toronto General Hospital, Toronto, Canada
Juan F. Delgado Jimenez, PhD, University Hospital 12 de Octubre, Madrid, Spain
Goran Dellgren, MD, PhD, Sahlgrenska University Hospital, Goteborg, Sweden
Mario C. Deng, MD, David Geffen School of Medicine, Los Angeles, CA, USA
Eugene C. DePasquale, MD, David Geffen School of Medicine, Los Angeles, CA, USA
Shashank S. Desai, MD, Inova Fairfax Hospital, Falls Church, VA, USA
Tobias Deuse, MD, PhD, University Heart Center Hamburg, Hamburg, Germany
Gundeep S. Dhillon, MD, Stanford University, Stanford, CA, USA
Rochelle M. Gellatly, PharmD, Alfred Hospital, Melbourne, VIC, Australia
James F. George, PhD, University of Alabama, Birmingham, AL, USA
Helen Gibbs, RN, Auckland City Hospital, Auckland, New Zealand
Simon R. Gibbs, MD, Hammersmith Hospital, London, UK
Patricia Ging, PharmD, Mater Misericordiae University Hospital, Dublin, Ireland
Allan R. Glanville, MBBS, MD, FRACP, St. Vincent’s Hospital, Sydney, NSW, Australia
Martin J. Goddard, FRCS, MRCPa, Papworth Hospital, Cambridge, UK
Samuel B. Goldfarb, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA
Ranny Goldwasser, MD, University Children’s Hospital Heidelberg, Heidelberg, Germany
Mardi Gomberg-Maitland, MD, University of Chicago Medical Center, Chicago, IL, USA
Jose Gonzalez-Costello, MD, Hospital Universitari de Bellvitge, Barcelona, Spain
Robert A. Gordon, MD, Northwestern University, Chicago, IL, USA
Jens Gottlieb, MD, Medical School Hannover, Hannover, Germany
Bartley P. Griffith, MD, University of Maryland, Baltimore, Baltimore, MD, USA
Paolo A. Grossi, MD, PhD, University of Insubria, Varese, Italy
Jan F. Gummert, MD, PhD, Herz-und Diabeteszentrum NRW, Bad Oeynhausen, Germany
Finn Gustafsson, MD, PhD, ViCare Medical, Birkerod, Denmark
Kieran Halloran, MD, University of Alberta, Edmonton, AB, Canada
Michele Hamilton, MD, University Cardiovascular Medical Group, Beverly Hills, CA, USA
Christopher S. Hayward, MD, St. Vincent’s Hospital, Sydney, NSW, Australia
Heather T. Henderson, MD, Duke University, Chapel Hill, NC, USA
Robert S. D. Higgins, MD, MSHA, Ohio State University Wexner Medical Center, Columbus, OH, USA
Alim Hirji, MD, University of Toronto, Toronto, ON, Canada
Seth A. Hollander, MD, Stanford University, San Carlos, CA, USA
Amresh Raina, MD, Allegheny General Hospital, Pittsburgh, PA, USA
Angela Rajek, MD, Medical University of Vienna, Vienna, Austria
Reinaldo Rampolla, MD, Ochsner Clinic Foundation, New Orleans, LA, USA
Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, ON, Canada
Leigh C. Reardon, MD, UCLA, Los Angeles, CA, USA
Alex Reyentovich, MD, New York University School of Medicine, Brooklyn, NY, USA
Joseph G. Rogers, MD, Duke University Medical Center, Durham, NC, USA
Antonio B. Roman, MD, PhD, Hospital General Vall D’Hebron, Barcelona, Spain
Heather J. Ross, MD, MHSc, FRCPC, Toronto General Hospital, Toronto, ON, Canada
Christopher T. Salerno, MD, St. Vincent’s Heart Center, Indianapolis, IN, USA
Juan F. Sanchez, MD, Baylor Scott & White, Texas A&M, Temple, TX, USA
Gianluca Santise, MD, Sant’Anna Hospital, Catanzaro, Italy
Murat Sargin, MD, Siyami Ersek Hospital, Istanbul, Turkey
Joanna M. Schaenman, MD, PhD, UCLA, Los Angeles, CA, USA
Jan D. Schmitto, MD, PhD, Medical University of Hannover, Hannover, Germany
Sonja Schreper, MD, PhD, University of Hamburg, Hamburg, CA, Germany
Stephan Schubert, MD, German Heart Center Berlin, Berlin, Germany
Paul Christian Schulze, MD, PhD, Columbia University, New York, NY, USA
Kurt R. Schumacher, MD, University of Michigan Congenital Heart Center, Ann Arbor, MI, USA
Mace M. Schuurmans, MD, University Hospital, Zurich, Switzerland
Nicolaus Schwerk, MD, Hannover Medical School, Hannover, Germany
Laurent Sebbag, MD, Hospital Louis Pradel, Bron Cedex, FRANCE
Javier Segovia, MD, PhD, Hospital Puerta De Hierro, Madrid, Spain
Ana Maria Segura, MD, Texas Heart Institute, Houston, TX, USA
Nedim Selimovic, MD, PhD, King Faisal Specialist Hospital & Research, Riyadh, Saudi Arabia
Ashish S. Shah, MD, Johns Hopkins Hospital, Baltimore, MD, USA
Jooyoung J. Shin, MD, Montefiore Medical Center, New York, NY, USA
Michael Shullo, PharmD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Sara J. Shumway, MD, University of Minnesota, Minneapolis, MN, USA
Fernanda P. Silveira, MD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
Scott C. Silvestry, MD, Washington University School of Medicine, St. Louis, MO, USA
Kathleen Simpson, MD, Washington University St. Louis, St. Louis, MO, USA
Cumara C. Sivathasan, MBBS, FRCS, National Heart Centre, Singapore, Singapore
Greg Snell, MD, Alfred Hospital, Melbourne, Australia
Heike Spaderna, PhD, Bergische Universitaet Wuppertal, Wuppertal, Germany
Joshua D. Sparks, MD, Kosair Children’s Hospital, Louisville, KY, USA
Ajay V. Srivastava, MD, Stanford University, San Jose, CA, USA
Lynne W. Stevenson, MD, Brigham & Women’s Hospital, Boston, MA, USA
Valentina Stosor, MD, Northwestern University/Feinberg School of Medicine, Chicago, IL, USA
Martin Strueber, MD, Spectrum Health Hospital, Grand Rapids, MI, USA
Linda J. Stuckey, PharmD, BCPS, University of Michigan Hospital, Ann Arbor, MI, USA
Stuart C. Sweet, MD, PhD, St. Louis Children’s Hospital, St. Louis, MO, USA
Jose A. Tallaj, MD, University of Alabama Birmingham, Birmingham, AL, USA
Carmela D. Tan, MD, Cleveland Clinic, Cleveland, Ohio, USA
Inna Tchoukina, MD, Virginia Commonwealth University, Chester, VA, USA
Ryan J. Tedford, MD, Johns Hopkins University, Baltimore, MD, USA
Sunu S. Thomas, MD, Massachusetts General Hospital, Boston, MA, USA
Veli Topkara, MD, Columbia University, New York, NY, USA
Guillermo Torre-Amione, MD, PhD, The Methodist Hospital, Houston, TX, USA
Wayne M. Tsuang, MD, Cleveland Clinic, Cleveland, OH, USA
A QR code will be printed on all meeting registrant name badges. This QR code will contain contact information that can be scanned by any QR reader.

Exhibitors can use the QR code as a lead generation tool and registrants can use it as a networking tool.

A QR reader is needed to scan a QR code. A QR reader is provided in the ISHLT Meeting Mobile App. There are free QR Readers available for iphone and android phones.

For iphone go to the APP store, search for a QR code reader (free), select, get and install.

For android phones go to google play, search for QR code reader (free) then download and install.

(QR codes will only be included for registrants as of March 23, 2015).
ANNUAL MEETING

Daily Time Table Schedule
<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:15</td>
<td>Poster Mounting 8 am - 10 am</td>
</tr>
<tr>
<td>9 am</td>
<td>Symposia 1: Intermacs 0: Heart Allocation Policies</td>
</tr>
<tr>
<td>9:45</td>
<td>Symposium 2: Treatment of the Patient in Shock</td>
</tr>
<tr>
<td>10:15</td>
<td>Symposium 3: Antigens in LTX Policies</td>
</tr>
<tr>
<td>11:15</td>
<td>Symposium 4: Allograft Vasculopathy</td>
</tr>
<tr>
<td>12:15</td>
<td>Symposium 5: Alcohol: Psychosocial Assessment</td>
</tr>
<tr>
<td>12:45</td>
<td>Symposium 6: Antibodies in LTX</td>
</tr>
<tr>
<td>1:15</td>
<td>Symposium 7: Patient in Shock</td>
</tr>
<tr>
<td>2:45</td>
<td>Symposium 8: Colloid Heart and Kidney</td>
</tr>
<tr>
<td>3:15</td>
<td>Symposium 9: Maximizing Donor Therapy Strategies in PH</td>
</tr>
<tr>
<td>4:45</td>
<td>Symposium 10: Therapy with MCS Forward</td>
</tr>
<tr>
<td>5:15</td>
<td>Symposium 11: The Future of Tolerance</td>
</tr>
<tr>
<td>5:45</td>
<td>Symposium 12: Drug Disposition in the Critically Ill Patient</td>
</tr>
<tr>
<td>6:15</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>7:45</td>
<td>JFT Council MTG Box Lunch Distribution</td>
</tr>
<tr>
<td>8:15</td>
<td>POSTER HALL OPEN 10 am - 8 pm</td>
</tr>
<tr>
<td>9 am</td>
<td>EXHIBIT HALL OPEN 10 am - 8 pm</td>
</tr>
</tbody>
</table>

**Agora 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:15</td>
<td>Exhibitor Set-up 8 am - 10 am</td>
</tr>
<tr>
<td>9 am</td>
<td>Symposia 1: Treatment of the Patient in Shock</td>
</tr>
<tr>
<td>9:45</td>
<td>Symposium 2: Colloid Heart and Kidney</td>
</tr>
<tr>
<td>10:15</td>
<td>Symposium 3: Maximizing Utilization of the Donor Therapy Strategies in PH</td>
</tr>
<tr>
<td>11:15</td>
<td>Symposium 4: Therapy with MCS Forward</td>
</tr>
<tr>
<td>12:15</td>
<td>Symposium 5: The Future of Tolerance</td>
</tr>
<tr>
<td>12:45</td>
<td>Symposium 6: Drug Disposition in the Critically Ill Patient</td>
</tr>
<tr>
<td>1:15</td>
<td>Symposium 7: Patient in Shock</td>
</tr>
<tr>
<td>2:45</td>
<td>Symposium 8: Colloid Heart and Kidney</td>
</tr>
<tr>
<td>3:15</td>
<td>Symposium 9: Maximizing Utilization of the Donor Therapy Strategies in PH</td>
</tr>
<tr>
<td>4:45</td>
<td>Symposium 10: Therapy with MCS Forward</td>
</tr>
<tr>
<td>5:15</td>
<td>Symposium 11: The Future of Tolerance</td>
</tr>
<tr>
<td>5:45</td>
<td>Symposium 12: Drug Disposition in the Critically Ill Patient</td>
</tr>
<tr>
<td>6:15</td>
<td>Lunch Break</td>
</tr>
<tr>
<td>7:45</td>
<td>JFT Council MTG Box Lunch Distribution</td>
</tr>
<tr>
<td>Time</td>
<td>2 PM</td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
</tr>
<tr>
<td><strong>LUNCH BREAK</strong></td>
<td><strong>LUNCH BREAK</strong></td>
</tr>
</tbody>
</table>

**Symposium 13:** Early Implantation: Extreme Donors: Optimizing Outcomes in High Risk LTX Recipient

**Symposium 14:** Extensive Donors: Pushing the Boundaries

**Symposium 15:** Is it too Soon? Challenges in PH Lung and Heart Transplantation

**Symposium 16:** Due to Left Heart Disease

**Symposium 17:** Lung TX

**Symposium 18:** B Cells in Transplantation

**Symposium 19:** When Things Don’t Go as Planned in Pediatric TX

**Symposium 20:** Management of Unusual Cardiomyopathies

**Symposium 21:** Chronic Lung Disease

**Symposium 22:** Infection, Chronic Lung Disease and Disease Management

**Symposium 23:** Infection, Chronic Lung Disease and Disease Management

**Symposium 24:** Clinical Thoracic Pathology: A Primer for Members of the TX Team

**Symposium 25:** Donor Management 13T: Infection, Chronic Lung Disease and Disease Management

**Opening Session 01:** 7 pm - 8 pm

**Athena Clio/Thalie Erato /Uranie Hermes Clio/Ope Euterpe Rhodes Agora 2**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session 1</th>
<th>Session 2</th>
<th>Session 3</th>
<th>Session 4</th>
<th>Session 5</th>
<th>Session 6</th>
<th>Session 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:15</td>
<td>Opening</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td>Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Lunch</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 PM</td>
<td>LUNCH BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:15</td>
<td>CONCURRENT 8: LVADS PreOp Factors Post Op Outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:30</td>
<td>CONCURRENT 9: Drivelines and Device Malfunction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:45</td>
<td>CONCURRENT 10: Lung CLAD I Translational Markers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:30</td>
<td>CONCURRENT 12: DMD Heart Lessons from Registries</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:45</td>
<td>CONCURRENT 13: Long Live the Graft</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 PM</td>
<td>LUNCH BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:15</td>
<td>CONCURRENT 14: Caves Award Presentations</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:30</td>
<td>CONCURRENT 15: Myocardial Recovery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:45</td>
<td>CONCURRENT 16: Strokes, Arrhythmias and LVADs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:15</td>
<td>CONCURRENT 17: Lung CLAD II New Observations Therapies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:30</td>
<td>CONCURRENT 18: Crystal Ball Outcomes in HTX</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:45</td>
<td>CONCURRENT 19: Emerging Country Session 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 PM</td>
<td>MINI ORALS 1: MCS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:15</td>
<td>MINI ORALS 2: HTX/MCS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:30</td>
<td>MINI ORALS 3: MCS-Complic.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6:45</td>
<td>MINI ORALS 4: DMD-H/HF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7 PM</td>
<td>MINI ORALS 5: NHSAH/PEEQ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:15</td>
<td>MINI ORALS 6: PEDS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:30</td>
<td>WINE &amp; CHEESE POSTER</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:45</td>
<td>POSTER SESSION 02: 6 pm - 7 pm</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 PM</td>
<td>EXHIBIT HALL OPEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:15</td>
<td>POSTER HALL OPEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td>POSTER 02 REMOVAL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:45</td>
<td>POSTER 02 REMOVAL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 PM</td>
<td>POSTER HALL OPEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:15</td>
<td>POSTER HALL OPEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>POSTER HALL OPEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:45</td>
<td>POSTER HALL OPEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Times are in 24-hour format.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Plenary</td>
<td>Calliope</td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td>Concurrent 1</td>
<td>Calliope</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td>Concurrent 2</td>
<td>Calliope</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>Concurrent 3</td>
<td>Calliope</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Concurrent 4</td>
<td>Calliope</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Concurrent 5</td>
<td>Calliope</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Concurrent 6</td>
<td>Calliope</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Concurrent 7</td>
<td>Calliope</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Lunch Break</td>
<td>Calliope</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Lunch Break</td>
<td>Calliope</td>
<td></td>
</tr>
</tbody>
</table>

---

**Day 2 - Thursday, April 17th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Plenary</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td>Concurrent 8</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td>Concurrent 9</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>Concurrent 10</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Concurrent 11</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Concurrent 12</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Concurrent 13</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Concurrent 14</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Lunch Break</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Lunch Break</td>
<td>Appolon</td>
<td></td>
</tr>
</tbody>
</table>

---

**Day 3 - Friday, April 18th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Plenary</td>
<td>Rhodes</td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td>Concurrent 15</td>
<td>Rhodes</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td>Concurrent 16</td>
<td>Rhodes</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>Concurrent 17</td>
<td>Rhodes</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Concurrent 18</td>
<td>Rhodes</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Concurrent 19</td>
<td>Rhodes</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Concurrent 20</td>
<td>Rhodes</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Concurrent 21</td>
<td>Rhodes</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Lunch Break</td>
<td>Rhodes</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Lunch Break</td>
<td>Rhodes</td>
<td></td>
</tr>
</tbody>
</table>

---

**Day 4 - Saturday, April 19th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Plenary</td>
<td>Eutérpe</td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td>Concurrent 22</td>
<td>Eutérpe</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td>Concurrent 23</td>
<td>Eutérpe</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>Concurrent 24</td>
<td>Eutérpe</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Concurrent 25</td>
<td>Eutérpe</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Concurrent 26</td>
<td>Eutérpe</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Concurrent 27</td>
<td>Eutérpe</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Concurrent 28</td>
<td>Eutérpe</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Lunch Break</td>
<td>Eutérpe</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Lunch Break</td>
<td>Eutérpe</td>
<td></td>
</tr>
</tbody>
</table>

---

**Day 5 - Sunday, April 20th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Plenary</td>
<td>Calliope</td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td>Concurrent 29</td>
<td>Calliope</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td>Concurrent 30</td>
<td>Calliope</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>Concurrent 31</td>
<td>Calliope</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Concurrent 32</td>
<td>Calliope</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Concurrent 33</td>
<td>Calliope</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Concurrent 34</td>
<td>Calliope</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Concurrent 35</td>
<td>Calliope</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Lunch Break</td>
<td>Calliope</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Lunch Break</td>
<td>Calliope</td>
<td></td>
</tr>
</tbody>
</table>

---

**Day 6 - Monday, April 21st**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Plenary</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td>Concurrent 36</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td>Concurrent 37</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>Concurrent 38</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Concurrent 39</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Concurrent 40</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Concurrent 41</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Concurrent 42</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Lunch Break</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Lunch Break</td>
<td>Appolon</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Location</td>
<td>Session</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>2:15 PM</td>
<td>AORGA 2</td>
<td>LUNCH BREAK</td>
<td></td>
</tr>
<tr>
<td>2:30 PM</td>
<td>EXHIBIT HALL</td>
<td>CONCURRENT 31: Emerging Issues in Lung Transplant: CAV, Lung-ALBO Path</td>
<td></td>
</tr>
<tr>
<td>3 PM</td>
<td>EXHIBIT HALL</td>
<td>CONCURRENT 32: Complex Solutions</td>
<td></td>
</tr>
<tr>
<td>4:15 PM</td>
<td>H.L.C.</td>
<td>CONCURRENT 41: Lung AMR, HLA, Heart Matters, and Beyond</td>
<td></td>
</tr>
<tr>
<td>4:30 PM</td>
<td>H.L.C.</td>
<td>CONCURRENT 42: The Silent Strike</td>
<td></td>
</tr>
<tr>
<td>5 PM</td>
<td>H.L.C.</td>
<td>CONCURRENT 43: Partner</td>
<td></td>
</tr>
<tr>
<td>5:15 PM</td>
<td>H.L.C.</td>
<td>CONCURRENT 44: Exhibit Hall</td>
<td></td>
</tr>
<tr>
<td>5:30 PM</td>
<td>H.L.C.</td>
<td>CONCURRENT 45: 4:30 - 11:59 pm</td>
<td></td>
</tr>
<tr>
<td>6 PM</td>
<td>POSTER REMOVAL</td>
<td>SESSION 03: MINI ORALS 12</td>
<td></td>
</tr>
<tr>
<td>6:30 PM</td>
<td>POSTER REMOVAL</td>
<td>MINI ORALS 11: ID/PHARM/LPH</td>
<td></td>
</tr>
<tr>
<td>7 PM</td>
<td>POSTER REMOVAL</td>
<td>MINI ORALS 10: LF/DMD-L</td>
<td></td>
</tr>
<tr>
<td>7:30 PM</td>
<td>POSTER REMOVAL</td>
<td>MINI ORALS 9: H.T.X</td>
<td></td>
</tr>
<tr>
<td>8 PM</td>
<td>POSTER REMOVAL</td>
<td>MINI ORALS 7: MCS</td>
<td></td>
</tr>
<tr>
<td>8:30 PM</td>
<td>POSTER REMOVAL</td>
<td>MINI ORALS 8: HTX</td>
<td></td>
</tr>
<tr>
<td>9 PM</td>
<td>POSTER REMOVAL</td>
<td>MINI ORALS 6: Spike</td>
<td></td>
</tr>
<tr>
<td>9:30 PM</td>
<td>POSTER REMOVAL</td>
<td>MINI ORALS 5: 6 PM - 11 PM</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>----------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8 AM</td>
<td>Committee/Council Reports</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:15</td>
<td>Concurrent 43: MCS New</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td>Concurrent 44: Aortic Valve in Countries</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:45</td>
<td>Concurrent 45: LVA D Patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 AM</td>
<td>Concurrent 46: Emerging Emerging</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:15</td>
<td>Concurrent 47: Old Problems</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td>Concurrent 48: New Solutions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:45</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10 AM</td>
<td>Plenary</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15</td>
<td>Concurrent 49: LVAD's Patient</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>Concurrent 50: LVA D's and Mitrul Valve</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>Concurrent 51: Classification</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11 AM</td>
<td>Concurrent 52: Risky Business</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td>Concurrent 53: Understanding TX in High Risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Concurrent 54: Pop</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 PM</td>
<td>Concurrent 43: Mc's New</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15</td>
<td>Concurrent 44: Aortic Valve in Countries</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Concurrent 45: LVA D Patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:45</td>
<td>Concurrent 46: Emerging Emerging</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:15</td>
<td>Concurrent 47: Old Problems</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:30</td>
<td>Concurrent 48: New Solutions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:45</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Sessions are held in various rooms (ATHENA, CALLIOPE, EUTERPE, GALLIENI, ERATO/URANIE, HERMES). Breaks are indicated by 'Break'.
<table>
<thead>
<tr>
<th>4/18</th>
<th>ATHENA</th>
<th>CLIOTHALIE</th>
<th>ERATO/URANIE</th>
<th>HERMES</th>
<th>CALLIOPE</th>
<th>EUTERPE</th>
<th>GALLIENI I</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 PM</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>2:15</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>2:30</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>2:45</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>3 PM</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>3:15</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>3:30</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>3:45</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>4 PM</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>4:15</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>4:30</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>4:45</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>5 PM</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>5:15</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>5:30</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>5:45</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>6 PM</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>6:15</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>6:30</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>6:45</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>7 PM</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>7:15</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>7:30</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
<tr>
<td>7:45</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
<td>2:00 - 7:30 pm</td>
<td>Strike</td>
</tr>
</tbody>
</table>

2:00 - 7:30pm ISHLT BOARD OF DIRECTORS MTG
2:00 - 7:30pm
ANNUAL MEETING
Continuing Medical Education Information

ACCME Accreditation Statement
The International Society for Heart and Lung Transplantation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Credit Designation Statement
ISHLT designates this live activity for a maximum of 27.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABTC Accreditation
The ABTC Board of Governors has granted a total of 27.75 Category 1 Continuing Education Points for Transplant Certification (CEPTCs) to International Society for Heart & Lung Transplantation’s ISHLT 35th Annual Meeting and Scientific Sessions.

ACPE Accreditation
Continuing Pharmacy Education Credits (CPE) will not be offered for this meeting.

Disclosure
Current guidelines state that participants in continuing medical and allied health profession education activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty, and Chairs participating in this meeting are required to disclose to the program...
audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

**Target Audience**

The audience for this program includes physicians, surgeons, scientists, nurses, and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end-stage heart or lung disease.

**Educational Goals**

The educational goals of this activity are: to enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and end-stage heart and lung disease and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.
Learning Objectives

1. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding the latest information and approaches regarding transplant research, surgical techniques, medical therapies, donor management, and patient management for the treatment of patients suffering from end-stage heart and lung disease.

2. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding the state-of-the-art treatment approaches, risk factors, risk management approaches, patient selection criteria, disease prevention strategies outcome implications, and psychosocial management strategies for patients with end-stage heart and lung failure.

3. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding emerging technologies, medical advances, and the clinical applications of basic science models of end-stage heart and lung disease management and prevention.
To help you navigate your way through the meeting content and find those sessions most likely to be of interest to you, we have coded each session according to the primary professional audience it was designed for.

**THESE CODES ARE EXPLAINED AS FOLLOWS:**

- **(ALL)** All ISHLT Members
- **(BSI) or (BSTR)** Basic Science and Translational Research
- **(DMD)** Donor Management/Organ Allocation
- **(HF)** Adult Heart Failure
- **(HTX)** Adult Heart Transplantation
- **(ID)** Infectious Diseases
- **(LF)** Adult Lung Failure
- **(LTX)** Adult Lung Transplantation
- **(MCS)** Adult Mechanical Circulatory Support
- **(NHSAH)** Nursing, Allied Health, Social Science
- **(PATH)** Pathology
- **(Peds)** Pediatrics
- **(PEEQ)** Public Policy, Economics, Ethics, Quality of Life
- **(PHARM)** Pharmacology
- **(PH)** Pulmonary Hypertension
It is springtime and you are headed to Nice on the French Riviera. What a great time to take in the sun, beach, French cuisine and the 2015 ISHLT Annual Meeting.

Following are some of the highlights of what the meeting has to offer. These symposia are certain to offer a feast for the hungry brain truly comparable to any gastronomic delights of the local French cuisine. As you can see, while there are many attractions in Nice (why do you think they call it nice?), there is nothing compelling enough to drag you away from the ISHLT Annual Meeting!
Bruno Reichart, MD, Past President of ISHLT, has been selected to give the Pioneer Lecture at the ISHLT 2015 Annual Meeting. After his education and training in Munich and Memphis, Professor Reichart directed the first successful heart transplant program in Germany and performed the first heart-lung transplant there. In 1984, he was elected as the Christiaan Barnard Chair of Cardiothoracic Surgery at the University of Cape Town, South Africa. In 1990, he became the Chair of Cardiac Surgery at the University of Munich. In Munich, Professor Reichart started a successful multi-institutional research program on xenotransplantation which has been funded by the German Research Council for many years. We are pleased to have Professor Reichart deliver this esteemed address to his colleagues during the ISHLT 2015 meeting in Nice.
The 2015 ISHLT Annual Meeting will highlight important advances in transplantation for basic science and translational research. Leading this off are two outstanding pre-meeting symposia. The first, B Cells in Transplantation 2015, will explore the current state of understanding of a variety of aspects of the role of B cells in the allo-immune response as well as how these can be modified therapeutically. The second symposium, The Future of Tolerance: Definitions, Directions and Design, will review both the present understanding of transplant tolerance as well as the novel approaches to implement tolerance clinically. Both symposia will bring together basic, translational, and clinical investigators who are experts in various aspects of these fields and will include leaders in clinical trials to induce tolerance in patients. The symposia will also take advantage of the proximity to Nice of many of the leaders in these fields to bring together an outstanding faculty.

The 2015 ISHLT Annual Meeting will provide an opportunity to focus on several areas of emerging interest in the fields of heart failure and cardiac transplantation. There will be four exciting pre-meeting symposia to lure you from the distractions of the Cote D’Azur. In an era of donor scarcity, the Extreme Donors: Pushing the Boundaries session will focus on the transplantation of hearts from extended criteria and DCD donors. Experts will discuss a broad arrange of topics including the definition of death, cardiac physiology during withdrawal of life support,
Explore Nice’s old town, “Vieux Nice.”
ex-vivo assessment of heart function, and donor heart protection. The fairness of organ allocation has become a subject of widespread discussion in recent years due to changing patient demographics. This subject will be the focus in Heart Allocation Policies: The Times Are A-Changin’. A highlight of this session will include debates by prominent authorities. The need for renal support or combined heart-kidney transplant is an area of increasing interest as older and sicker patients present for advanced therapies for heart failure. When Worlds Collide: Heart and Kidney will provide a comprehensive insight into our current understanding of cardio-renal syndrome and management options before and after transplant. The fourth symposium, The Road Less Traveled: The Management of Unusual Cardiomyopathies, will provide a grand tour of some of the rarer forms of cardiomyopathy.

**INFECTIONOUS DISEASES**

Join us at the 2015 ISHLT Annual Meeting for a provocative, cutting edge pre-meeting symposium entitled Bloody Virus: HIV, Hepatitis B and C as a multidisciplinary forum of experts discuss the new frontier of transplantation for recipients infected with one of these blood borne viruses. Previously, these were considered a relative or absolute contraindication for transplant but no more! Come learn how to guide these complex patients through a successful transplant and update your knowledge of epidemiology, new drugs, and how monitor the graft and the viral infection itself. The symposium will cap with a session on expanding the donor pool with Hepatitis B or C infected donors. This is your unique opportunity to spend these two hours sharing experiences and asking questions about this emerging area. Vampires however, are banned!
MECHANICAL CIRCULATORY SUPPORT

The 2015 ISHLT Annual Meeting program includes many outstanding sessions on mechanical circulatory support which will provide important new insights in the field. The most currently challenging and captivating MCS topics will be addressed in the session, Fifty Shades of Gray: When Things Don’t Go as Planned in VAD Patients, which will include pump thrombosis, RV failure, GI bleeding, aortic insufficiency, driveline infection and stroke in VAD patients. The controversial area of Early Implantation: Is It Too Soon? will be addressed in another lively symposium, with an animated debate, plus new results to be presented from trials along with what is needed from the patient’s and the engineer’s perspective. More provocative topics will be discussed in a symposium entitled Moving MCS Therapy Forward which will focus on the pivotal areas required to advance these current and emerging technologies. An update on the status of full implantability will be given, followed by a discussion on whether the field can move on from the strict indications of bridge to transplantation and destination therapy. Included will be a discussion on how to improve resource utilization, followed by two controversial debates. There are also many important MCS talks included in the pulmonary hypertension and pediatric symposia along with very relevant discussions on organ allocation in VAD patients in the transplant symposia. And finally, we can plan on numerous abstract presentations with new data from the MCS field throughout the meeting.
NURSING, HEALTH SCIENCES AND ALLIED HEALTH

The 2015 ISHLT Annual Meeting will showcase clinical care and research initiatives through a diverse program of informative sessions significant to nursing, health science, and allied health specialists. The pre-meeting symposium entitled *Psychosocial Assessment: Tools, Tips and Opportunities* will bring together seven experts in the area of psychosocial assessment and psychological distress to discuss the factors that affect post-transplant outcomes, the available tools to assess these factors, along with opportunities for future research.

PATHOLOGY

The 2015 ISHLT Annual Meeting will feature a pathology-focused symposium entitled *Clinically Relevant Thoracic Transplant Pathology: A Primer for Clinicians, Nurses, Pharmacists and Other Members of the Transplant Team*. The target audience for this session will be transplant clinicians and trainees, nurses, pharmacists, and other non-pathologist health care team members. Terminology and concepts from the ISHLT Working Formulations for scoring and reporting rejection will be reviewed with relevant examples. Clinical correlations and treatment options will be discussed. There have been significant changes in the diagnostic criteria and reporting schemes in thoracic transplant pathology in the last 5 years, especially for antibody mediated rejection. The goal of this simplified review is to help foster better communication and understanding between pathologists and other care team members.
PEDIATRIC TRANSPLANTATION

Children are unique; nevertheless there is much of relevance to learn from the much larger experience in adult transplant patients. The pediatric symposia focus on unsolved problems, ongoing challenges, and edges experienced in the daily routine of pediatric heart and lung transplantation. The session Allograft Vasculopathy – A Challenge for All Ages illuminates a problem with only limited improvement in the last 3 decades from various angles: standards and novelties in imaging of CAV. The concepts and clinical evidence of new treatments will also be discussed from an adult and pediatric perspective. The latest research on the role of endothelial function and recently discovered potential therapeutic targets will provide an outlook into a brighter future. Lung and Heart Lung Transplantation: Coming of Age will address optimal wait list management and allocation besides specific challenges including heart lung transplantation as an option for the patient with congenital heart disease and secondary pulmonary hypertension or which alternative therapies can be considered for these patients. In addition, ex-vivo regeneration as a window to successful pediatric DCD transplantation and the everlasting challenge of non-adherence in adolescence will be discussed. The session Frontiers in Pediatric Transplantation will explore the limits of pediatric transplantation: where are the margins of a “marginal donor”? Are HLA and ABO antibodies really relevant for organ allocation? Should we transplant children with genetic abnormalities and what are the outcomes if we do so? Can children with secondarily elevated pulmonary vascular resistance be transplanted with the option of a back-up RVAD or should they be prepared with an LVAD? Or should we use VADs as a destination therapy in childhood after all? Last but not least the everlasting afterthought: when and how should we involve palliative care in children needing VAD and transplantation?
Sample local specialties:

Socca

Nicoise

Pissaladière

Farcis
Pick up fresh local produce and flowers every morning, except Mondays, when Vieux Nice becomes a flea market...
Critical illness causes changes to the normal physiology of the body – there are ECMO circuits attached, renal replacement therapies, a ventilator. Following dosing guidelines, you put a drug in and then what? What happens to it with all this machinery attached? The symposium entitled Drug Dosing in the Critically Ill Patient is designed to try and explain what happens next, how to get drugs into the body despite these devices, and how to get drugs to very difficult to access places. This session will appeal to all members of ISHLT, so when you attend you will be able to see your Infectious Disease practitioner, your VAD surgeon, your pulmonologist and, of course, your pharmacist.
Every five years the world’s experts in Pulmonary Hypertension unite in an attempt to redefine the characteristics and treatment advances in this disease area. In 2013 it was Nice that played host to the World Symposium in Pulmonary Hypertension, so it’s therefore very fitting that the 2015 ISHLT Annual Meeting in Nice will have an outstanding program of PH symposia which again bring together those at the forefront of this field. The therapeutic options for patients with PAH and PH associated with chronic thromboembolic disease continue to grow and in the symposium entitled Therapeutic Strategies in Pulmonary Hypertension: Current Evidence and New Directions, the current and future strategies will be reviewed in detail, especially how the combination of different drug classes might be used together. The management of patients with secondary pulmonary hypertension continues to cause challenges to clinicians, and the paucity of clinical trials in this area makes it difficult to decide how or whether to use PH targeted therapies in these conditions. In two cutting edge symposia, the issues of secondary PH in chronic lung and chronic heart disease will be discussed. Chronic Lung Disease Associated Pulmonary Hypertension: Mechanism, Pathology, and Clinical Impact will help clinicians evaluate the pathophysiological mechanisms underlying this process in chronic lung disease and decide if targeted therapy might have a role to play. Finally, in Challenges in Pulmonary Hypertension Due to Left Heart Disease, the approach to the investigation and management of secondary PH in a range of left heart pathologies from cardiomyopathy to valvular disease or in association with LVAD insertion will be presented.
PULMONARY TRANSPLANTATION

At ISHLT 2015, four pre-meeting symposia will provide up-to-date information for all professionals involved in the care of patients with advanced lung diseases and lung transplantation. Content integrating the latest basic biological and clinical approaches will focus on areas including donor optimization, high risk recipients, auto- and allo-antibodies, and the interplay between infections and immune-mediated outcomes. The symposium entitled Making the Most of What We Have: Maximizing Donor Utilization will contain Pro-Con debates on the most burning topics in lung donor utilization including donor age, cold ischemic time, and DCD status, followed by lectures on donor scoring, use of ECMO and how these factors affect children and adolescents. Assessment and management of the high risk recipient will be detailed in Before, During and After – Optimizing Outcomes in the High Risk Recipient for Lung Transplantation. Topics covered include modifiable recipient factors, use of ECMO through the transplant process, and specific topics for recipients with secondary PH, connective tissue diseases and CF. The symposium entitled Antibodies in Lung Transplant: Mayhem, Mediators, Mechanisms and Management is a highly translational update on recent advances in the understanding of the importance of allo- and auto-antibodies to the pre- and post-transplant management of lung transplant patients. Included will be updates from the ISHLT multidisciplinary working group, case-based discussions, integrative immunology lectures, and pragmatic updates on therapeutic approaches. The symposium entitled Infection, Inflammation, and Immunity After Lung Transplantation will consider emerging evidence about the role of viral, bacterial, and fungal pathogens in determining the fate of the lung allograft. This symposium will integrate state-of-the-art information on new detection techniques.
with emerging basic and epidemiological data on the interplay between microbes and recipient immunity to help the lung transplant professional understand present and future approaches to managing infections in their patients.

SPECIAL ABSTRACT SESSION: FOCUS ON INTERNATIONAL TRANSPLANTATION

The 2015 ISHLT Annual Meeting in Nice will be a truly International meeting. To recognize ISHLT’s global network in the science and treatment of end-stage heart and lung disease, a special abstract session will be organized to showcase the developments in thoracic transplantation, mechanical circulatory support, and pulmonary hypertension treatment in emergent regions of the world. Countries and single programs from these regions are encouraged to submit abstracts that present their latest data to global leaders in the field.
...Or spend some free time at one of Nice’s acclaimed art museums.
The President’s Cocktail Reception will be held Friday, April 17 at the Negresco Palace. The Negresco is one of the most unique hotels in the world. A famous Belle Époque landmark that graces the promenade des Anglais, the hotel has welcomed celebrities and heads of state for over 100 years. The owner, Madam Jeanne Augier, reinvigorated the hotel with luxurious decorations and furnishings, including an outstanding art collection and rooms with mink bedspreads. The hotel-cum-museum has been listed as a Historical Monument since 1974, and is home to 3,000 objets d’art including 1,600 original paintings (one of three full-length portraits of Louis XIV is in the Versailles Ballroom, the other two being the Louvre and Versailles). The spectacular Baccarat 16,309 crystal chandelier in the Negresco’s Royal Lounge was
commissioned by Czar Nicholas II who, due to the October revolution, was unable to take delivery. Noted for its doormen dressed in the manner of the staff 18th-century elite bourgeois households, the hotel also offers renowned Michelin 2-star gourmet dining at the Regency-style Le Chantecler restaurant. Normally, access to the hotel and its artworks is limited to guests of the hotel. This gala will provide a special opportunity for ISHLT members to visit this unique venue.

As always, you can expect plenty of food, drink, music and friends.

Tickets are not included in the registration fee and must be purchased in advance. **Tickets will not be sold on-site.** Attendance is limited to 1200.
Level 1
AGORA 1  Registration

Level 2
APOLLON  Plenary
AGORA 2  Posters
HERMES LOUNGE  Speaker Ready Room
GALLIENI 1,2,3,4,5,7  Meetings
GALLIENI 6  Press Office
RHODES  Exhibits
HERMES  Symposiums/Sessions
ATHENA  Symposiums/Sessions

Level 3
CLIO/THALIE  Symposiums/Sessions
ERATO/URANIE  Symposiums/Sessions
EUTERPE  Symposiums/Sessions
CALLIOPE  Symposiums/Sessions
ANNUAL MEETING

Schedule at a Glance
All meetings and activities will take place at the Acropolis, Nice, France unless otherwise specified. All papers will be presented in English. Please check the ISHLT website (www.ishlt.org) for updates. This Final Program reflects the latest session schedule and room assignments.

**WEDNESDAY | April 15, 2015**

**7:00 AM – 7:00 PM**
REGISTRATION OPEN  (Agora 1)
SPEAKER READY ROOM OPEN  (Hermes Lounge)

**8:00 AM – 10:00 AM**
EXHIBITOR SET-UP  (Rhodes)
POSTER SESSION 01 MOUNT  (Agora 2)

**8:30 AM – 10:30 AM**

**PRE-MEETING SYMPOSIUM 01:**
INTERMACS 0: Treatment of the Patient in Shock  (Athena)
(MCS, HF, HTX, PEEQ)

**PRE-MEETING SYMPOSIUM 02:**
Heart Allocation Policies: The Times They Are A-Changin’  (Clio/Thalie)
(DMD, HF, HTX, MCS, NHSAH, PEEQ)

**PRE-MEETING SYMPOSIUM 03:**
Antibodies in Lung Transplant: Mayhem, Mediators, Mechanisms and Management  (Erato/Uranie)
(LTX, BSTR, DMD, ID, LF, NHSAH, PATH, PEDS, PHARM)

**PRE-MEETING SYMPOSIUM 04:**
Bloody Virus: HIV, Hepatitis B and C  (Hermes)
(ID, HTX, LTX, PHARM)

**PRE-MEETING SYMPOSIUM 05:**
Allograft Vasculopathy – A Challenge for All Ages  (Calliope)
(ALL)

**PRE-MEETING SYMPOSIUM 06:**
Psychosocial Assessment: Tools, Tips and Opportunities  (Euterpe)
(NHSAH, HF, HTX, LF, LTX, MCS, PEDS)
Schedule at a Glance

9:00 AM – 7:00 PM
PRESS OFFICE OPEN (Gallieni 6)

10:00 AM – 8:00 PM
EXHIBIT HALL OPEN (Rhodes)
POSTER HALL OPEN (Agora 2)

10:00 AM – 8:00 PM
POSTER SESSION 01 VIEWING (Agora 2)
Adult Heart Failure
(HF, BSI, DMD, HTX, MCS, NHSAH, PATH, PEDS, PH, PEEQ)

Mechanical Circulatory Support
(MCS, BSI, DMD, HF, HTX, ID, NHSAH,
PATH, PEDS, PH, PHARM, PEEQ)

Nursing, Health Science and Allied Health
(NHSAH, HF, HTX, LF, LTX, MCS, PEDS)

Pharmacy and Pharmacology
(PHARM, ID, LTX, MCS)

10:30 AM – 10:45 AM
COFFEE BREAK/VISIT EXHIBITS (Rhodes)
VIEW POSTERS (Agora 2)

10:45 AM – 12:45 PM
PRE-MEETING SYMPOSIUM 07:
Moving MCS Therapy Forward (Athena)
(MCS, HF, HTX, NHSAH)

PRE-MEETING SYMPOSIUM 08:
When Worlds Collide: Heart and Kidney
(Clio/Thalie)
(HF, HTX, NHSAH, MCS, PATH)

PRE-MEETING SYMPOSIUM 09:
Making the Most of What We Have:
Maximizing Donor Utilization (Erato/Uranie)
(LTX, DMD, LF, PEEQ)

PRE-MEETING SYMPOSIUM 10:
Therapeutic Strategies in Pulmonary Hypertension: Current Evidence and New Directions (Hermes)
This session is supported by educational grants from Actelion and Gilead.
(PH, HF, HTX, LF, LTX, MCS, PHARM)

PRE-MEETING SYMPOSIUM 11:
Drug Disposition in the Critically Ill Patient
(Calliope)
(PHARM, HTX, ID, LTX, NHSAH, PEDS)

PRE-MEETING SYMPOSIUM 12:
The Future of Tolerance: Definitions, Directions, and Design (Euterpe)
(ALL)
12:45 PM – 1:45 PM
JUNIOR FACULTY AND TRAINEE COUNCIL MEETING  (Euterpe)
BOX LUNCH DISTRIBUTION  (Rhodes)

12:45 PM – 2:45 PM
LUNCH BREAK

JHLT EDITORIAL BOARD LUNCH MEETING  (Gallieni 1 & 2)
EDUCATION COMMITTEE MEETING  (Gallieni)
GRANTS AND AWARDS COMMITTEE MEETING  (Gallieni 5)
STANDARDS AND GUIDELINES COMMITTEE MEETING  (Gallieni 7)
I2C2 COMMITTEE MEETING  (Gallieni 3)

2:45 PM – 4:45 PM
PRE-MEETING SYMPOSIUM 13: Early Implantation: Is It Too Soon?  (Athena) (MCS, HF, HTX, NHSAH, PEEQ)
PRE-MEETING SYMPOSIUM 14: Extreme Donors: Pushing the Boundaries  (Clio/Thalie) (HTX, BSTR, DMD, HF, PEDS, PEEQ)
PRE-MEETING SYMPOSIUM 15: Before, During, and After – Optimizing Outcomes in the High Risk Recipient for Lung Transplantation  (Erato/Uranie) (LTX, BSTR, LF)
PRE-MEETING SYMPOSIUM 16: Challenges in Pulmonary Hypertension Due to Left Heart Disease  (Hermes) This session is supported by educational grants from Actelion and Gilead. (PH, BSTR, HF, HTX, MCS, NHSAH, PEDS)
PRE-MEETING SYMPOSIUM 17: Lung and Heart Lung Transplantation: Coming of Age  (Calliope) (PEDS, BSTR, DMD, LF, LTX)
PRE-MEETING SYMPOSIUM 18: B Cells in Transplantation 2015  (Euterpe) (BSTR, HF, HTX, LTX, PATH, PEDS)

4:45 – 5:00 PM
COFFEE BREAK/VISIT EXHIBITS  (Rhodes)
VIEW POSTERS  (Agora 2)
5:00 PM – 7:00 PM

PRE-MEETING SYMPOSIUM 19:
50 Shades of Gray: When Things Don’t Go as Planned in VAD Patients  (Athena)
(MCS, HF, HTX, ID, NHSAH)

PRE-MEETING SYMPOSIUM 20:
The Road Less Traveled: The Management of Unusual Cardiomyopathies  (Clio/Thalie)
(HF, BSTR, HTX, MCS, NHSAH, PEDS)

PRE-MEETING SYMPOSIUM 21:
I3T: Infection, Inflammation and Immunity After Lung Transplantation  (Erato/Uranie)
(LTX, BSTR, ID, LF)

PRE-MEETING SYMPOSIUM 22:
Chronic Lung Disease Associated Pulmonary Hypertension: Mechanism, Pathology, and Clinical Impact  (Hermes)
(PH, LF, LTX, NHSAH, PATH)

PRE-MEETING SYMPOSIUM 23:
Frontiers in Pediatric Transplantation  (Calliope)
(PEDS, DMD, HTX, MCS)

PRE-MEETING SYMPOSIUM 24:
Clinically Relevant Thoracic Transplant Pathology: A Primer for Clinicians, Nurses, Pharmacists and Other Members of the Transplant Team  (Euterpe)
(ALL)

7:00 PM – 8:00 PM

EXHIBIT HALL OPENING RECEPTION  (Rhodes)

MODERATED POSTER SESSION 01  (Agora 2)

8:00 PM – 8:30 PM

POSTER SESSION 01 REMOVAL  (Agora 2)
THURSDAY | April 16, 2015

7:30 AM – 7:00 PM
REGISTRATION OPEN (Agora 1)
SPEAKER READY ROOM OPEN (Hermes Lounge)

8:00 AM – 9:00 AM
POSTER BOARD RENUMBERING (Agora 2)

8:30 AM – 10:30 AM
OPENING PLENARY SESSION (Apollon)

9:00 AM – 10:00 AM
POSTER SESSION 02 MOUNT (Agora 2)

9:00 AM – 7:00 PM
PRESS OFFICE OPEN (Gallieni 6)

10:00 AM – 7:00 PM
EXHIBITS OPEN (Rhodes)
POSTER HALL OPEN (Agora 2)

10:00 AM – 7:00 PM
POSTER SESSION 02 VIEWING (Agora 2)
Adult Lung Failure
(LF, BSI, DMD, LTX, MCS)

Adult Lung Transplant
(LTX, BSI, DMD, ID, LF, MCS, PATH, PEDS, PHARM)

Basic Science
(ALL)

Donor Management/Organ Preservation Heart
(DMD-HEART, HTX)

Donor Management/Organ Preservation Lung
(LTX, DMD)

Heart Transplantation
(ALL)

Infectious Diseases
(ALL)

10:30 AM – 11:00 AM
COFFEE BREAK/VISIT EXHIBITS (Rhodes)
VIEW POSTERS (Agora 2)
11:00 AM – 12:30 PM

**CONCURRENT SESSION 01**
Outcomes With Mechanical Circulatory Support (Apollon)
(MCS, BSI, HF, HTX, NHSAH, PHARM)

**CONCURRENT SESSION 02**
Anticoagulation For VADs: How Anticoagulated Do We Need To Be? (Athena)
(MCS, BSI, HF, NHSAH, PATH, PHARM)

**CONCURRENT SESSION 03**
Choosing the Best Recipients for Lung Transplant in the Era of Urgency (Clio/Thalie)
(LF, LTX, PEDS)

**CONCURRENT SESSION 04**
Donor Management/Organ Preservation-Heart: Extending the Margins (Erato,Uranie)
(DMD-HEART, HF, HTX)

**CONCURRENT SESSION 05**
JFTC Clinical Case Dilemmas in Thoracic Transplantation: The Best of the Best (Hermes)
(ALL)

**CONCURRENT SESSION 06**
Collected Experience: What Can We Learn from the Registries? (Calliope)
(PEDS, DMD, HF, HTX, ID, MCS, NHSAH, PEEQ)

**CONCURRENT SESSION 07**
Supporting the MCS Patient and Caregiver (Euterpe)
(NHSAH, HF, HTX, MCS)

12:30 PM – 2:30 PM

LUNCH BREAK

JUNIOR FACULTY MENTOR LUNCH (Gallieni 1)

12:30 PM – 1:30 PM

BOX LUNCH DISTRIBUTION (Rhodes)

DCD REGISTRY MEETING (Gallieni 3)
12:45 PM – 1:45 PM
BASIC SCIENCE AND TRANSLATIONAL RESEARCH SCIENTIFIC COUNCIL MEETING
(Gallieni 4)

NURSING, HEALTH SCIENCE, AND ALLIED HEALTH SCIENTIFIC COUNCIL MEETING
(Gallieni 7)

PHARMACY AND PHARMACOLOGY SCIENTIFIC COUNCIL MEETING (Gallieni 5)

1:30 PM – 2:30 PM
REGISTRIES AND DATABASES COMMITTEE MEETING (Gallieni 3)

2:30 PM – 4:00 PM

CONCURRENT SESSION 08
LVADs - Pre-Operative Factors Affecting Post-Operative Outcomes (Apollon)
(MCS, BSI, HF, HTX, NHSAH)

CONCURRENT SESSION 09
Drivelines and Device Malfunction (Athena)
(MCS, HF, HTX, NHSAH, ID)

CONCURRENT SESSION 10
Lung CLAD I: Translational Insights and Novel Markers (Clio/Thalie)
(LTX, BSI, LF, PATH, PEDS)

CONCURRENT SESSION 11
New Tools in the Fight Against Rejection (Erato/Uranie)
(HTX, DMD, ID, NHSAH, PATH, PEDS, PHARM)

CONCURRENT SESSION 12
Donor Management/Organ Preservation-Heart: Lessons from the Registries (Hermes)
(DMD-HEART, HTX)

CONCURRENT SESSION 13
Long Live the Graft! Factors Impacting Long-term Outcome (Calliope)
(PEDS, BSI, DMD, HF, HTX, ID, LTX, MCS, NHSAH, PATH, PH, PHARM, PEEQ)

CONCURRENT SESSION 14
Philip K. Caves Award Candidate Presentations (Euterpe)
(ALL)
Schedule at a Glance

4:00 PM – 4:30 PM
COFFEE BREAK/VISIT EXHIBITS (Rhodes)
VIEW POSTERS (Agora 2)

2016 ANNUAL MEETING SYMPOSIUM
PLANNING COMMITTEE MEETING (Gallieni 4)

4:30 PM – 6:00 PM

CONCURRENT SESSION 15
Myocardial Recovery – Moving Forward (Apollon)
(MCS, BSI, HF, HTX, PHARM)

CONCURRENT SESSION 16
Strokes, Arrhythmias and LVADs (Athena)
(MCS, BSI, HF, HTX, NHSAH, PHARM)

CONCURRENT SESSION 17
Lung CLAD II: New Observations and Therapies on the Horizon (Clio/Thalie)
(LTX, BSI, LF)

CONCURRENT SESSION 18
Crystal Ball: Predicting Outcomes in Heart Transplantation (Erato/Uranie)
(HTX, BSI, DMD, HF, MCS, NHSAH, PATH, PEDS, PHARM, PEEQ)

CONCURRENT SESSION 19
Emerging Countries Session 1 (Hermes)
(ALL)

CONCURRENT SESSION 20
Basic Science 1: Inflammation, Immune Monitoring, Immune Suppression (Calliope)
(ALL)

CONCURRENT SESSION 21
Kinetics, Coagulation, and Cardiology – Pharmacy of MCS and Transplant (Euterpe)
(PHARM, HTX, ID, LTX, MCS)
6:00 PM – 7:00 PM

MINI ORAL SESSION 01
Fear and Loathing in Mechanical Circulatory Support  (Athena)
(MCS, HTX)

MINI ORAL SESSION 02
Biology and the Rise of the Machine  (Clio/Thalie)
(HTX, MCS, HF)

MINI ORAL SESSION 03
For Whom the Bell Tolls: Complications of Mechanical Circulatory Support  (Erato,Uranie)
(MCS)

MINI ORAL SESSION 04
The Big Chill: Heart Failure and Donor Management  (Hermes)
(HF, BSI, DMD, HTX, MCS, PH)

MINI ORAL SESSION 05
Last Tango in Nice: Motion is the Potion – A Guide for Clinicians  (Calliope)
(NHSAH, PEEQ, HF, HTX, LTX, MCS)

MINI ORAL SESSION 06
The Heartbreak Kid: Donors, VADs and Long-Term Outcomes  (Euterpe)
(PEDS, BSI, DMD, HF, HTX, ID, MCS, NHSAH, PATH, PH, PHARM, PEEQ)

6:00 PM – 7:00 PM
WINE AND CHEESE RECEPTION  (Rhodes)

PAST PRESIDENT’S MEETING  (Gallieni 3)

MODERATED POSTER SESSION 02  (Agora 2)

6:00 PM – 7:30 PM
COMMITEE/COUNCIL LEADERSHIP ORIENTATION  (Gallieni 1 & 2)

7:00 PM – 7:30 PM
POSTER SESSION 02 REMOVAL  (Agora 2)
FRIDAY | April 17, 2015

7:30 AM – 7:00 PM
REGISTRATION OPEN (Agora 1)
SPEAKER READY ROOM OPEN (Hermes Lounge)

8:00 AM – 9:00 AM
POSTER BOARD RENUMBERING (Agora 2)

8:30 AM – 10:30 AM
PLENARY SESSION (Apollon)

9:00 AM – 10:00 AM
POSTER SESSION 03 MOUNT (Agora 2)

9:00 AM – 7:00 PM
PRESS OFFICE OPEN (Gallieni 6)

10:00 AM – 4:30 PM
EXHIBITS OPEN (Rhodes)

10:00 AM – 7:00 PM
POSTER HALL OPEN (Agora 2)

10:00 AM – 7:00 PM
POSTER SESSION 03 VIEWING (Agora 2)
Emerging Countries (ALL)
Junior Faculty Case Reports (ALL)
Pathology (PATH, BSI, HF, HTX, LF, LTX, MCS)
Pediatrics (PEDS, BSI, DMD, HF, HTX, ID, MCS, NHSAH, PATH, PH, PHARM, PEEQ)
Public Policy, Economics, Ethics and Quality of Life (MCS, HF, HTX, MCS, NHSAH)
Pulmonary Hypertension (PH, BSI, HF, HTX, LF, LTX, MCS, NHSAH, PHARM)

10:30 AM – 11:00 AM
ANNUAL BUSINESS MEETING (Apollon)
COFFEE BREAK/VISIT EXHIBITS (Rhodes)
VIEW POSTERS  (Agora 2)

11:00 AM – 12:30 PM

**CONCURRENT SESSION 22**  
LVADs: Factors Influencing Outcomes  (Apollon)  
(MCS, DMD, HF, HTX, NHSAH)

**CONCURRENT SESSION 23**  
An Update On Short Term Support  (Athena)  
(MCS, DMD, HF, HTX, NHSAH)

**CONCURRENT SESSION 24**  
Immunosuppression: The Tor Inhibitors Strike Back  (Clio/Thalie)  
(HTX, BSI, HF, ID, NHSAH, PATH, PEDS, PHARM)

**CONCURRENT SESSION 25**  
Pump Up the Jam, Don’t Jam Up the Pump! VAD-Management and Complications  
(Erato/Uranie)  
(PEDS, DMD-LUNG, HF, HTX, ID, LF, MCS, NHSAH, PH)

**CONCURRENT SESSION 26**  
Heart Failure – Omics, Kines and Stem Cells  
(Hermes)  
(BSI, HF, PATH)

**CONCURRENT SESSION 27**  
Basic Science 2: Organ Preservation Including Ex-Vivo Management, Ischemia/Reperfusion  
(Calliope)  
(ALL)

**CONCURRENT SYMPOSIUM 28**  
JHLT at ISHLT: The Year in a Capsule  (Euterpe)  
(ALL)

12:30 PM – 2:30 PM

LUNCH BREAK

12:30 PM – 1:30 PM

BOX LUNCH DISTRIBUTION  (Rhodes)

**PULMONARY HYPERTENSION SCIENTIFIC COUNCIL MEETING**  (Calliope)

**MECHANICAL CIRCULATORY SUPPORT SCIENTIFIC COUNCIL MEETING**  (Euterpe)

**PEDIATRIC TRANSPLANTATION SCIENTIFIC COUNCIL MEETING**  (Gallieni 1)

**INFECTIOUS DISEASES SCIENTIFIC COUNCIL MEETING**  (Gallieni 4)

**PATHOLOGY SCIENTIFIC COUNCIL MEETING**  (Gallieni 5)
1:00 PM – 2:30 PM
IMACS REGISTRY MEETING (Gallieni 7)

1:30 PM – 2:30 PM
PULMONARY TRANSPLANTATION
SCIENTIFIC COUNCIL MEETING (Calliope)

HEART FAILURE AND TRANSPLANTATION
SCIENTIFIC COUNCIL MEETING (Euterpe)

PEDIATRIC HEART FAILURE
WORKFORCE MEETING (Gallieni 1)

IPLTC MEETING (Gallieni 4)

2:30 PM – 4:00 PM
CONCURRENT SESSION 29
Transplanting Patients with Machines
(Apollon)
(MCS, DMD-HEART, HF, HTX, NHSAH)

CONCURRENT SESSION 30
EVLP – Learning To Handle This Technology
(Athena)
(LTX, DMD)

CONCURRENT SESSION 31
CAV and Rejection: A Tangled Web
(Clio/Thalie)
(HTX, BSI, ID, NHSAH, PATH, PEDS, PHARM)

CONCURRENT SESSION 32
Mechanical Cardiac Support in Children:
Outcomes and Registry Data (Erato/Uranie)
(PEDS, BSI, DMD, HF, HTX, ID, LF, MCS, NHSAH, PATH, PH, PHARM, PEEQ)

CONCURRENT SESSION 33
Emerging Issues in Pediatric Lung Transplant (Hermes)
(LTX, LF, PEDS)

CONCURRENT SESSION 34
Complement, CAV, and Lung Allograft Pathology (Calliope)
(PATH, BSI, HTX, PEDS, LTX)

CONCURRENT SESSION 35
Complex Patients Require Complex Solutions:
Predicting Adherence (Euterpe)
(NHSAH, HF, HTX, LTX, MCS)

4:00 PM – 4:30 PM
COFFEE BREAK/VISIT EXHIBITS (Rhodes)

VIEW POSTERS (Agora 2)

4:30 PM – 11:59 PM
EXHIBIT HALL STRIKE (Rhodes)
4:30 PM – 6:00 PM

**CONCURRENT SESSION 36**
Pump Thrombosis – Diagnosis and Outcomes  (Apollon)
(MCS, BSI, HF, HTX, NHSAH, PATH)

**CONCURRENT SESSION 37**
The Fate of the Right Heart after LVAD  (Athena)
(MCS, BSI, HF, HTX, NHSAH, PHARM)

**CONCURRENT SESSION 38**
Cloudy with a Chance of T-Cells: Rejection Forecast  (Clio/Thalie)
(HTX, BSI, ID, NHSAH, PATH, PEDS, PHARM)

**CONCURRENT SESSION 39**
Advances in Prognostic Stratification in Pulmonary Hypertension  (Erato/Uranie)
This session is supported by educational grants from Actelion and Gilead.
(PH, HF, HTX, LF, LTX, MCS)

**CONCURRENT SESSION 40**
Lung AMR: HLA and Beyond  (Hermes)
(LTX, BSI, LF, PATH, PEDS)

**CONCURRENT SESSION 41**
Heart Matters: Truth and Justice  (Calliope)
(PEEQ, HF, HTX, MCS, NHSAH)

**CONCURRENT SESSION 42**
The Silent Partner  (Euterpe)
(ID, BSI, HTX, LTX, PEDS)

6:00 PM – 7:00 PM

**MINI ORAL SESSION 07**
Mechanical Circulatory Support: Apocalypse Tomorrow  (Athena)
(MCS, HF)

**MINI ORAL SESSION 08**
A Heart Day’s Night  (Clio/Thalie)
(HTX, BSI, DMD, HF, ID, MCS, NHSAH, PATH, PEDS, PHARM, PEEQ)

**MINI ORAL SESSION 09**
The Man With The Golden Lungs  (Erato/Uranie)
(LTX, BSI, DMD, LF, MCS, PATH, PHARM)

**MINI ORAL SESSION 10**
Breathless: Insights on Lung Failure and Donor Lungs  (Hermes)
(LTX, BSI, DMD, LF)

**MINI ORAL SESSION 11**
What’s Up, Doc? Bugs, Drugs and PH  (Calliope)
(PH, HF, HTX, LF, LTX, MCS, PHARM)

**MINI ORAL SESSION 12**
Basic Instinct  (Euterpe)
(ALL)
6:00 PM – 7:00 PM
WINE AND CHEESE RECEPTION (Rhodes)

MODERATED POSTER SESSION 03 (Agora 2)

7:00 PM – 7:30 PM
POSTER SESSION 03 REMOVAL (Agora 2)

8:00 PM – 9:30 PM
PRESIDENT’S GALA COCKTAIL RECEPTION (Negresco Palace)
A Registration Badge and Ticket will be required at the door.
SATURDAY | April 18, 2015

7:30 AM – 12:15 PM
REGISTRATION OPEN (Agora 1)

7:30 AM – 1:45 PM
SPEAKER READY ROOM OPEN (Hermes Lounge)

8:00 AM – 10:00 AM
COUNCIL AND COMMITTEE REPORTS TO THE BOARD AND MEMBERSHIP (Gallieni 1)

8:15 AM – 9:45 AM
CONCURRENT SESSION 43
Mechanical Circulatory Support – New Surgical Approaches (Athena)
(MCS, HF, HTX, NHSAH)

CONCURRENT SESSION 44
The Aortic Valve in LVAD Patients (Clio/Thalie)
(MCS, BSI, HF, HTX, NHSAH, PHARM)

CONCURRENT SESSION 45
Candidate Selection – The Who, When and Why (Erato/Uranie)
(HF, DMD, HTX, MCS)

CONCURRENT SESSION 46
Emerging Countries Session 2 (Hermes)
(ALL)

CONCURRENT SESSION 47
Enhancing Surgical Therapeutics in Pulmonary Hypertension: Thrombectomy to Transplant (Calliope)
This session is supported by educational grants from Actelion and Gilead.
(PH, HF, LF, LTX)

CONCURRENT SESSION 48
Old Problems – New Solutions? (Euterpe)
(PEDS, BSI, HF, HTX, NHSAH, PATH)

9:45 AM – 10:00 AM
COFFEE BREAK (Agora 1)

10:00 AM – 12:00 NOON
PLENARY SESSION (Athena)

12:00 PM – 12:15 PM
COFFEE BREAK (Agora 1)
12:15 PM – 1:45 PM

CONCURRENT SESSION 49
LVADs - From Patient Classification to Cost
(Athena)
(MCS, BSI, HF, HTX, PEEQ)

CONCURRENT SESSION 50
LVADs and the Mitral Valve (Clio/Thalie)
(MCS, HF, HTX, NHSAH)

CONCURRENT SESSION 51
Risky Business: Transplant in High Risk Populations (Erato/Uranie)
(HTX, BSI, HF, ID, NHSAH, PATH, PEDS, PHARM, PEEQ)

CONCURRENT SESSION 52
Understanding Complications and Improving Lung Transplant Outcomes (Hermes)
(LTX, DMD, LF)

CONCURRENT SESSION 53
Beneficence and Nonmaleficence: The Breath of it All (Calliope)
(PEEQ, LF, LTX, NHSAH)

CONCURRENT SESSION 54
Basic Bazaar (Euterpe)
(ALL)

1:45 PM

ANNUAL MEETING ADJOURNS

2:00 PM – 7:30 PM

ISHLT BOARD OF DIRECTORS MEETING
(Gallieni 1)
The International Society for Heart and Lung Transplantation extends its heartfelt gratitude to the following companies for their *unrestricted educational grants* in support of the Thirty-fifth Annual Meeting and Scientific Sessions.

Actelion  
Gilead Sciences  
Medtronic

**ISHLT Academy: Core Competencies in Pulmonary Hypertension**

Bayer HealthCare
The International Society for Heart and Lung Transplantation is grateful for the support of the following companies for the Society and its endeavors in 2015

**TIER 1**
Actelion
Bayer HealthCare
HeartWare
Thoratec

**TIER 2**
Gilead

**TIER 3**
Astellas
CareDx
Maquet
Medtronic
Volkswagen Germany
All meetings and activities will take place at the Nice Acropolis Congress Centre unless otherwise specified. All papers will be presented in English. Please check the ISHLT web site (www.ishlt.org) for updates. The ISHLT 2015 mobile app, which will be available approximately 2 weeks prior to the Annual Meeting, and the Final Program, which is distributed on site, will reflect the latest session schedule and room assignments.
8:30 AM – 10:30 AM

PRE-MEETING SYMPOSIUM 01:

INTERMACS 0: Treatment of the Patient in Shock
(Athena)
(MCS, HF, HTX, PEEQ)

CHAIRS: Filip R.J. Rega, MD and Savitri E. Fedson, MD

SESSION SUMMARY: There is substantial evidence showing that patients presenting with critical cardiogenic shock/INTERMACS 0: Treatment of the Patient in Shock profile have an overall dismal outcome when referred for durable mechanical circulatory support and/or heart transplantation. In this context, several centers have provided major contributions to the role of temporary mechanical circulatory support as rescue therapy and as a bridge to decision in patients presenting in critical cardiogenic shock, but most have been anecdotal. The clinical and hemodynamic profiles associated with the selection of the various available options for temporary bridging warrants further discussion supported by a combination of available literature and a review from experienced front-line clinicians providing therapy for this particular subset of patients. This session will first discuss the different types and outcomes of patients presenting in INTERMACS Profile 1, then will review the options available for the patient in shock – counterpulsation, percutaneous MCS, ECMO, Centrimag and Impella. This will be followed by a discussion of the subsequent steps. The different hemodynamic profiles each has to offer, the data presently available and the future technologies and relevant studies will be discussed.

8:30 AM Are All INTERMACs Profile I Patients the Same?  
Definition, Categorization and Outcomes with Shock
Shashank S. Desai, MD, Inova Fairfax Hospital, Falls Church, VA, USA

8:45 AM Q & A

8:50 AM Is There a Role for Counterpulsation in Shock?
Valluvan Jeevanandam, MD, University of Chicago Medical Center, Chicago, IL, USA

9:05 AM Q & A

9:10 AM Percutaneous Devices in Shock: Options and Outcomes
Shelley A. Hall, MD, Baylor University Medical Center, Dallas, TX, USA

9:25 AM Q & A

9:30 AM When is it Time to Call the Surgeons? ECMO, Centrimag and Impella 5.0
Axel Haverich, MD, PhD, Hannover Medical School, Hannover, Germany

9:45 AM Q & A

9:50 AM Weaning versus Bridge to Bridge: What is the Next Step?
Daniel J. Goldstein, MD, Montefiore Medical Center, Bronx, NY, USA

10:05 AM Q & A

10:10 AM Case Presentation of a Patient Presenting in Shock
Jaime A. Hernandez-Montfort, MD, MPH, Newark Beth Israel Medical Center, Newark, NJ, USA

10:15 AM Panel Discussion
Heart Allocation Policies: The Times They Are A-Changin’

(Clio, Thalie)

(DMD, HF, HTX, MCS, NHSAH, PEEQ)

CHAIRS: Jon A. Kobashigawa, MD and Pascal N. Leprince, MD, PhD

SESSION SUMMARY: Organ allocation remains a challenging issue, as there continues to be a shortage of available organs to meet the needs of those on transplant waiting lists. Organ allocation algorithms and listing priorities continue to be re-evaluated and adjusted in an effort to use this scarce resource fairly. This session will provide a forum to discuss this critical issue.

8:30 AM  Experience with U.S. Policy for Heart Allocation
Joseph G. Rogers, MD, Duke University Medical Center, Durham, NC, USA

8:45 AM  Experience with European Policy for Heart Allocation
Florian M. Wagner, MD, University Heart Center Hamburg Eppendorf, Hamburg, Germany

9:00 AM  Experience with Canadian Policy for Heart Allocation
Debra L. Isaac, MD, Foothills Hospital, Calgary, AB, Canada

9:15 AM  DEBATE: VAD Patients Should NOT Receive Priority for Urgent Heart Transplant

9:15 AM  PRO:
Uwe Schulz, MD, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany

9:30 AM  CON:
Martin Stueber, MD, Spectrum Health Hospitals, Grand Rapids, MI, USA

9:45 AM  DEBATE: Heart Organ Allocation Should Be Done By Scoring Systems, Not Time On List

9:45 AM  PRO:
Jacqueline M. Smits, MD, PhD, Eurotransplant International, Leiden, Netherlands

10:00 AM  CON:
David O. Taylor, MD, Cleveland Clinic Foundation, Cleveland, OH, USA

10:15 AM  Panel Discussion
**SCIENTIFIC PROGRAM**

**PRE-MEETING SYMPOSIUM 03:**

**8:30 AM – 10:30 AM**

**Antibodies in Lung Transplant: Mayhem, Mediators, Mechanisms and Management** *(Erato, Uranie)*

**(LTX, BSTR, DMD, ID, LF, NHSAH, PATH, PEDS, PHARM)**

**CHAIRS:** Deborah J. Levine, MD and Monique Malouf, FRACP

**SESSION SUMMARY:** Antibodies are associated with graft dysfunction but there is little reliable information in the literature to define this process. The ISHLT Pulmonary AMR working group is a multi-disciplinary group made up of clinicians, HLA experts and pathologists who have met to create a set of criteria and a standard working definition of pulmonary AMR. The group will discuss the results of the international survey, diagnosis, and working definition of pulmonary AMR. A review HLA versus non-HLA antibodies and the role of complement pathways will be undertaken. The interplay of the innate and the adaptive immune system in AMR will be discussed. The session will provide a comprehensive review of management strategies. Cases will be used to discuss HLA issues and the management of pulmonary AMR.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
<th>Institution(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 AM</td>
<td>Pulmonary AMR: Recent Debates on Definitions and Diagnosis</td>
<td>Roger D. Yusen, MD, Washington University, St. Louis, MO, USA</td>
<td></td>
</tr>
<tr>
<td>8:45 AM</td>
<td>Q &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:50 AM</td>
<td>Are All Antibodies Created Equal? Complement and Non-Complement Mechanisms of Injury</td>
<td>William Baldwin, MD, PhD, Cleveland Clinic, Cleveland, OH, USA</td>
<td></td>
</tr>
<tr>
<td>9:05 AM</td>
<td>Q &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:10 AM</td>
<td>Role of HLA- and Non-HLA Antibodies in AMR</td>
<td>Kathryn J. Tinckam, MD, University Health Network, Toronto, ON, Canada</td>
<td></td>
</tr>
<tr>
<td>9:25 AM</td>
<td>Q &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30 AM</td>
<td>The Role of the Innate and Adaptive Immune System in AMR</td>
<td>Tereza Martinu, MD, Toronto Medical Center, Toronto, ON, Canada</td>
<td></td>
</tr>
<tr>
<td>9:45 AM</td>
<td>Q &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:50 AM</td>
<td>Management of Pulmonary AMR 2015: Where Are We Now?</td>
<td>Ramsey R. Hachem, MD, Washington University School of Medicine, St. Louis, MO, USA</td>
<td></td>
</tr>
<tr>
<td>10:05 AM</td>
<td>Q &amp; A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:10 AM</td>
<td>HLA: A Tale of Two Cases:</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1) Sensitized Patient</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>2) Patient With AMR</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adriana Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:25 AM</td>
<td>Q &amp; A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**PRE-MEETING SYMPOSIUM 04:**

**Bloody Virus: HIV, Hepatitis B and C (Hermes)**

**CHAIRS:**
Antonio B. Roman, MD, PhD and Patricia A. Uber, PharmD

**SESSION SUMMARY:** Cardiothoracic transplantation for patients with HIV, and hepatitis B and C remains a controversial topic. Historically, infection with any of these viruses was considered a relative or even absolute contraindication for transplantation. However, favorable experience in liver and kidney recipients has led some programs to progressively adjust selection criteria. The recent ISHLT listing criteria guidelines now include HIV, HCV and HBV positive patients and more programs are performing transplantation in these complex populations. Having a current understanding of these diseases, therapy and monitoring will assist the transplant team. This includes knowledge of drug interactions and the concerns for the various types of immunosuppression (Induction, maintenance) on these patients and if there are preferred agents to use. Lastly developing an approach with an understanding of how to manage complications is necessary for success. Therefore, the focus of this symposium is to increase the knowledge of the CT transplant community about the management and pharmacological treatment options for CT transplant candidates with HIV, hepatitis B or C, before and after transplant.

8:30 AM **What Transplant Professionals Need to Know About HIV Disease**
Paolo A. Grossi, MD, PhD, University of Insubria, Varese, Italy

8:45 AM **Balancing Immunosuppression Medications and HIV: Don’t Try This at Home**
Kyle L. Dawson, PharmD, Houston Methodist, Houston, TX, USA

9:00 AM **Dangerous Curves Ahead: Developing a Plan to Approach the HIV-Infected Patient**
Donna M. Mancini, M.D, New York Presbyterian Hospital, New York, NY, USA

9:15 AM **HCV Up-to-Date Management: Review of Pre- and Post-Transplant Treatment**
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy

9:30 AM **HBV Epidemiology and Treatment Guidelines**
Emily A. Blumberg, MD, University of Pennsylvania, Philadelphia, PA, USA

9:45 AM **Expanding the Pool of High Risk Donors, HCV- and HBV-Infected Donors: What to Expect and How to Manage Transplant Recipients**
Piedad Ussetti, MD, Hospital Puerta Hierro, Madrid, Spain

10:00 AM **Case Presentation: Not for the Faint of Heart**
Irina Timofte, MD, University of Maryland Medical Center, Baltimore, MD, USA

10:05 AM **Panel Discussion**
8:30 AM – 10:30 AM

PRE-MEETING SYMPOSIUM 05:

Allograft Vasculopathy – A Challenge for All Ages
(Calliope)
(ALL)

CHAIRS: Elfriede Pahl Schuette, MD and Richard Kirk, FRCP, FRCPC

SESSION SUMMARY: Cardiac Allograft Vasculopathy limits intermediate and late survival in children, as well as adult transplant recipients, and affects even infant transplants. This symposium will address mechanisms and pathophysiology, as well as newer diagnostic tools and treatment agents, including basic science talks on potential targets for therapy. Our goal is to have pediatric and adult cardiologists share their experiences, and perhaps forge new collaborations to study this most challenging problem. We will invite experts in CAV from both Pediatric and Adult transplant community to speak of their experience with these patients, as well as start with basic science background. The ending 15 minute panel discussion will have opinions from the group on an ideal research proposal to study this complex problem in the future. Attendees can ask questions regarding optimal immunosuppression for 2015, help design the ideal randomized clinical trial for all ages, and determine what endpoints and tools should be used for study.

8:30 AM Cardiac Allograft Vasculopathy, the Unsolved Problem: Registry Experience and Clinical Correlations
Steve Kindel, MD, Children’s Hospital of Omaha, Omaha, NE, USA

8:45 AM Endothelial Dysfunction and Cardiac Allograft Vasculopathy: New Assessment Tools for Patient Risk Stratification?
Monica M. Colvin-Adams, MD, University of Minnesota, Minneapolis, MN, USA

9:00 AM Imaging Techniques for Graft Vasculopathy in Adults: Angiogram, IVUS, OCT, Coronary Flow Reserve
Daniel H. Kim, MD, University of Alberta Medical School, Edmonton, AB, Canada

9:15 AM Smaller Vessels – Same Approach? Angiogram, IVUS, OCT and Coronary Flow Reserve in Children After Heart Transplant
Stephan Schubert, MD, German Heart Center, Berlin, Germany

9:30 AM mTOR Inhibitors: Where’s the Beef?
Howard J. Eisen, MD, Drexel University College of Medicine, Philadelphia, PA, USA

9:45 AM mTOR Inhibitors: Where’s the Chicken Fingers?
Richard E. Chinnock, MD, Loma Linda University Children’s Hospital, Loma Linda, CA, USA

10:00 AM The Future is Friendly: New Treatment Targets to Prevent or Delay Cardiac Allograft Vasculopathy
Sonja Schrepfer, MD, PhD, University Heart Center Hamburg, Hamburg, Germany

10:15 AM Panel Discussion
8:30 AM – 10:30 AM

PRE-MEETING SYMPOSIUM 06:

Psychosocial Assessment: Tools, Tips and Opportunities (Euterpe) (NHSAH, HF, HTX, LF, LTX, MCS, PEDS)

CHAIRS: Annemarie Kaan, MCN, RN and Jo Wray, PhD

Session Summary: This session will review a range of tools available for teams to use to assist with the difficult process of psychosocial evaluation. Seven experts in the area of psychosocial assessment and psychological distress will present the available tools with supporting evidence, as well as provide an opportunity to discuss and explore future opportunities for research.

8:30 AM Soft Factors, Hard Outcomes: Psychosocial Predictors of Post-transplant Success
Fabienne Dobbels, MSc, PhD, University Hospital Leuven, Leuven, Belgium

8:45 AM The Psychosocial Assessment of Adult Organ Transplant Candidates: A Comprehensive Approach
Jose R. Maldonado, MD, Stanford University School of Medicine, Stanford, CA, USA

9:00 AM The Psychosocial Assessment of the Pediatric Transplant Candidate: Issues and Controversies
Samantha J. Anthony, PhD, MSW, Hospital for Sick Children, Toronto, ON, Canada

9:15 AM Screening and Managing Nonadherence to Medical Therapy
Sabina M. De Geest, RN, PhD, University of Basel, Basel, Switzerland

9:30 AM Screening and Addressing Psychosocial Distress: How Best to Do It?
Quincy Young, PhD, RPsych, St. Paul’s Hospital, Vancouver, BC, Canada

9:45 AM Caregiver Psychosocial Distress: Now What Should We Do?
Michael G. Petty, PhD, RN, CNS, University of Minnesota Medical Center, Minneapolis, MN, USA

10:00 AM If I Had a Crystal Ball: When to Implement Palliative Care in Heart and Lung Transplant Recipients
Mi-Kyung Song, PhD, University of North Carolina School of Nursing, NC, USA

10:15 AM Panel Discussion

9:00 AM – 7:00 PM
PRESS OFFICE OPEN (Gallieni 6)

10:00 AM – 8:00 PM
EXHIBIT HALL OPEN (Rhodes)
POSTER HALL OPEN (Agora 2)

10:30 AM – 10:45 AM
COFFEE BREAK/VISIT EXHIBITS (Rhodes)
VIEW POSTERS (Agora 2)
### Moving MCS Therapy Forward (Athena)

**MCS, HF, HTX, NHSAH**

**CHAIRS:** Steven S.L. Tsui, MD, FRCS and Robert L. Kormos, MD

**SESSION SUMMARY:** This session will focus on the key topics pivotal to advancing the field. We will first address where we are with fully implantable LVADs, followed by the need for them and both the current and projected status. Next to be discussed are the traditional indications of bridge to transplantation, bridge to recovery and destination therapy and whether or not it is now appropriate, and possible, to start moving away from these indications. Then there will be a presentation on how to improve resource utilization – how to reduce length of stay and reduce readmissions, including the use of long term care facilities, rehabilitation units, etc., to reduce the cost of this therapy and make it more widely useable. Finally there will be two debates; one on whether all VAD patients should be started on heart failure medications and the second, on whether, going forward, it will be desirable for the VAD to be run with patients having a pulse again or not.

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
</table>
| 10:45 AM | **Fully Implantable LVADs: Where Are We?**  
Mark S. Slaughter, MD, University of Louisville, Louisville, KY, USA |
| 11:00 AM | **Q & A**                                                 |
| 11:05 AM | **BTT, BTR and Destination Therapy: Is it Time to Get Rid of These Terms?**  
Francis D. Pagani, MD, PhD, University of Michigan Medical Center, Ann Arbor, MI, USA |
| 11:20 AM | **Q & A**                                                 |
| 11:25 AM | **Improving Resource Utilization: Reducing Length of Stay, Readmissions, etc.**  
Claudius Mahr, DO, University of Washington, Seattle, WA, USA |
| 11:40 AM | **Q & A**                                                 |
| 11:45 AM | **DEBATE: All VAD Recipients Should Be on Heart Failure Medications** |
| 11:45 AM | **PRO:**  
Emma Birks, MD, PhD, University of Louisville, Louisville, KY, USA |
| 11:55 AM | **CON:**  
Jeffrey J. Teuteberg, MD, University of Pittsburgh, Pittsburgh, PA, USA |
| 12:05 PM | **Rebuttal PRO**  
Emma Birks, MD, PhD |
| 12:10 PM | **Rebuttal CON**  
Jeffrey J. Teuteberg, MD |
| 12:15 PM | **DEBATE: All VAD Patients Should Have a Pulse** |
| 12:15 PM | **PRO:**  
Stephan Schueler, MD, PhD, FRCS, Freeman Hospital, Newcastle upon Tyne, United Kingdom |
| 12:25 PM | **CON:**  
Evgenij V. Potapov, MD, PhD, Berlin Heart Institute, Berlin, Germany |
| 12:35 PM | **Rebuttal PRO**  
Stephan Schueler, MD, PhD, FRCS |
| 12:40 PM | **Rebuttal CON**  
Evgenij V. Potapov, MD, PhD |
When Worlds Collide: Heart and Kidney (Clio, Thalie) (HF, HTX, NHSAH, MCS, PATH)

CHAIRS: Jose Gonzalez-Costello, MD and David A. Baran, MD

SESSION SUMMARY: This session will focus on venous congestion in acute and advanced heart failure and will review: 1) the relationship between venous congestion and outcome; 2) the role of venous congestion in the pathophysiology of end-organ dysfunction and damage; 3) the epidemiology and outcome of the cardiorenal syndrome; 4) the hemodynamic and intrabdominal contributors to acute kidney injury; 5) the treatment strategies for decongestion; 6) the role of hemoconcentration as a potential treatment target during decongestion.

10:45 AM The Role of Venous Congestion in the Pathophysiology of Acute Heart Failure
Paolo Colombo, MD, Columbia University, New York, NY, USA

11:00 AM Q & A

11:05 AM Cardiorenal Syndrome
Maria Rosa Costanzo, MD, Midwest Heart Specialists-Advocate Medical, Naperville, IL, USA

11:20 AM Q & A

11:25 AM Hemoconcentration as a Treatment Goal in Acute Heart Failure
Jeffrey M. J. Testani, MD, MTR, Yale University, New Haven, CT, USA

11:40 AM Q & A

11:45 AM Management of the Failing Fontan
Michael Burch, MD, Great Ormond Street Hospital, London, United Kingdom

12:00 PM Q & A

12:05 PM Heart-Kidney Transplantation
Lawrence S. C. Czer, MD, Cedars-Sinai Medical Center, Los Angeles, CA, USA

12:20 PM Q & A

12:25 PM Renal Sparing Strategies in Heart Transplantation
Markus J. B. Barten, MD, PhD, Heart Center Leipzig, Leipzig, Germany

12:40 PM Q & A
Making the Most of What We Have: Maximizing Donor Utilization (Erato, Uranie) (LTX, DMD, LF, PEEQ)

CHAIRS: Gabriel Loor, MD and Dirk E. Van Raemdonck, MD, PhD

SESSION SUMMARY: This session will focus on maximizing donor yield through reevaluation of key issues that cause practitioners to decline offers. There are clearly differences between high volume and low volume centers related to perception of donor quality, mechanisms for evaluating offers and strategies for optimizing donor organs. The data supporting donor criteria is not perfectly consistent. This leaves difficult decisions to the discretion of implanting surgeons. Centers with high import to export ratios often accept organs that others have refused while maintaining similar if not superior outcomes. This session will review and debate important donor criteria that raise concern for potential implanters. There is no right or wrong answer, rather a spectrum that requires thoughtful consideration for the benefit of recipients on the wait list. The session will evaluate the strongest available data on donor ischemic time, donor age and donation after cardiac death. There will be an update on the status of donor scoring systems and checklists that integrate a variety of elements into positive or negative scores. There will be discussion on implementation of donor screening programs to maximize the interpretation, evaluation and management of donor offers. Furthermore, this session will highlight the practical aspects of using extracorporeal optimization technology to increase donor yield. Finally, donor selection and management relevant to pediatric transplantation will be highlighted.

10:45 AM DEBATE: Cold Ischemic Time Should Affect the Decision to Decline a Donated Lung

10:45 AM PRO: Michiel E. Erasmus, MD, PhD, University Medical Center, Groningen, Netherlands.

10:55 AM CON: Marcelo Cypel, MD, University of Toronto, Toronto, ON, Canada

11:05 AM DEBATE: DCD Status Should Influence Refusal of a Donated Lung

11:05 AM PRO: Christopher H. Wigfield, MD, FRCS, University of Chicago, Chicago, IL, USA

11:15 AM CON: Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Alfred Hospital, Melbourne, Australia

11:25 AM DEBATE: We Should Use Older Donors for Lung Transplantation

11:25 AM PRO: Christian A. Bermudez, MD, UPMC Presbyterian, Pittsburgh, PA, USA

11:35 AM CON: Florian M. Wagner, MD, University Heart Center Hamburg Eppendorf, Hamburg, Germany

11:45 AM Pooling Complex Factors – Can Donor Scores Remove Bias in Donor Selection? Takahiro Otto, MD, Okayama University Hospital, Okayama, Japan

12:00 PM Current Status of Extra Corporeal Optimization Technology for Maximizing Donor Yield Robert B. Love, MD, Medical College of Wisconsin, Milwaukee, WI, USA
### PRE-MEETING SYMPOSIUM 10:

**Therapeutic Strategies in Pulmonary Hypertension: Current Evidence and New Directions** *(Hermes)*

This session is supported by educational grants from Actelion and Gilead.

**CHAIRS:** Myung H. Park, MD and Irene Lang, MD

**SESSION SUMMARY:** Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension now have multiple therapeutic options for the practicing physician. This session will present focused discussions on combination therapeutic approaches. It will discuss the results of recent clinical trials in support of sequential versus upfront combination therapies and look at new options in medical and non-surgical management of chronic thromboembolic pulmonary hypertension.

#### 10:45 AM – 12:45 PM

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 AM</td>
<td><strong>The Rationale for Combination Therapy in Pulmonary Arterial Hypertension</strong></td>
<td>Mardi Gomberg-Maitland, MD</td>
<td>University of Chicago</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medical Center</td>
<td>Chicago, IL, USA</td>
</tr>
<tr>
<td>11:05 AM</td>
<td><strong>Sequential or Upfront Combination Therapy for Pulmonary Arterial Hypertension?</strong></td>
<td>Nazzareno Galie, MD</td>
<td>Università degli Studi di Bologna</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bologna, Italy</td>
<td></td>
</tr>
<tr>
<td>11:25 AM</td>
<td><strong>Therapies in Development: Investigational and Emerging</strong></td>
<td>Marc Humbert, MD, PhD</td>
<td>Hopital Bicetre</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paris, France</td>
<td></td>
</tr>
<tr>
<td>11:45 AM</td>
<td><strong>The Hemodynamic/Phenotypic Paradox: Pulmonary Hypertension Classification in Clinical Trials</strong></td>
<td>J. Simon R. Gibbs, FRCP</td>
<td>Hammersmith Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td>London, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>12:05 PM</td>
<td><strong>Evolving Management of Chronic Thromboembolic Pulmonary Hypertension: Medical, Interventional and Surgical</strong></td>
<td>David P. Jenkins, FRCS</td>
<td>Papworth Hospital</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cambridge, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>12:25 PM</td>
<td><strong>Panel Discussion</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
10:45 AM – 12:45 PM

PRE-MEETING SYMPOSIUM 11:

**Drug Disposition in the Critically Ill Patient** (Calliope)
(PHARM, HTX, ID, LTX, NHSAH, PEDS)

**CHAIRS:** Adam B. Cochrane, PharmD and Martha L. Mooney, MD, FACP

**SESSION SUMMARY:** Critically ill patients constitute unique and complex pharmacologic challenges to clinicians. These patients are often dealing with altered gastrointestinal absorption, hepatic function, volume of distribution, numerous drug-drug interactions and dependence on various devices, all of which can cause significant alteration in drug pharmacokinetics and pharmacodynamics. Many of the drugs used in transplantation and MCS show great degree of interindividual and intraindividual pharmacokinetic and pharmacodynamic variability. Moreover, these drugs often have a narrow therapeutic window, with potential toxicity or treatment failure. In this setting, pharmacokinetics and pharmacodynamics play an important role in the optimal management of these patients to improve patient outcomes.

10:45 AM **ECMO: Hungry, Hungry Circuits**
Haifa Lyster, MSc, Royal Brompton & Harefield NHS Trust, Harefield, United Kingdom

11:05 AM **Renal Replacement Therapy and Plasmapheresis: Where is the Drug Going?**
Christopher R. Ensor, PharmD, BCPS-CV, University of Pittsburgh, Pittsburgh, PA, USA

11:20 AM **Up in the Air: Can My Drug Be Nebulized?**
Katie Watkins, PharmD, University of California, San Francisco, CA, USA

11:35 AM **Sanctuary Sites of Infection: Hide and Seek**
Kate Gould, FRCPath, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

11:55 AM **Therapeutic Drug Monitoring in Special Populations**
Eliane Billaud, PhD, PharmD, Hospital Georges Pompidou, Paris Cedex, France.

12:15 PM **A Sticky Situation – Device Infections and Biofilms**
Stanley I. Martin, MD, Ohio State University Medical Center, Columbus, OH, USA

12:30 PM **Panel Discussion**
The Future of Tolerance: Definitions, Directions, and Design (Euterpe) (ALL)

**CHAIRS:** James George, PhD and Stephan M. Ensminger, MD, DPhil

**SESSION SUMMARY:** This session approaches tolerance from a conceptual perspective, shedding light on the forces that moved tolerance in the past and the directions that it will likely take in the future. While, to many, the concept of tolerance is a fading dream, this session will show that with fresh insight, persistence, and a creative approach using new technologies, the entity of tolerance may still be achievable.

10:45 AM  **Tolerance, Chimerism, and Cytokines:** Definitions and Historical Perspective
Kimberly L. Gandy, MD, PhD, University of Missouri, Kansas City, MO, USA

11:00 AM  **Myeloid and Mesenchymal Stem Cells:** The Rising Tolerizers
Jos Domen, PhD, Children’s Mercy Hospital and Clinics, Kansas City, MO, USA

11:15 AM  **The Role of Cytokines in Tolerance**
Carla C. Baan, PhD, Erasmus Medical Center, Rotterdam, Netherlands.

11:30 AM  **T Regulatory Cells in Tolerance Induction: Translation From Bench to Bedside**
Manuella Battaglia, PhD, Ospedale San Raffaele, Milan, Italy

11:45 AM  **The Role of Cellular Immunotherapy in Solid Organ Transplantation: Lessons from the ONE Study**
Edward Geissler, PhD, University of Regensburg, Regensburg, Germany

12:00 PM  **Inflammation and Transplantation Tolerance**
Daniel R. Goldstein, MD, Yale New Haven Hospital, New Haven, CT, USA

12:15 PM  **Immune Monitoring for Clinical Tolerance**
Birgit S. Sawitzki, PhD, Institute of Medical Immunology Charite, Berlin, Germany

12:30 PM  **Tolerance in Pediatric Transplant Recipients: A Window of Opportunity**
Lori J. West, MD, DPhil, University of Alberta, Edmonton, AB, Canada

12:45 PM – 1:45 PM
**JUNIOR FACULTY AND TRAINEE COUNCIL MEETING** (Euterpe)
BOX LUNCH DISTRIBUTION (Rhodes)

12:45 PM – 2:45 PM
**LUNCH BREAK**
**JHLT EDITORIAL BOARD LUNCH MEETING** (Gallieni 1 & 2)
**EDUCATION COMMITTEE MEETING** (Gallieni 4)
**GRANTS AND AWARDS COMMITTEE MEETING** (Gallieni 5)
**STANDARDS AND GUIDELINES COMMITTEE MEETING** (Gallieni 7)
**12C2 COMMITTEE MEETING** (Gallieni 3)
Early Implantation: Is It Too Soon? (Athena)
(MCS, HF, HTX, NHSAH, PEEQ)

CHAIRS: Salpy V. Pamboukian, MD, MSPH and Jan F. Gummert, MD, PhD

SESSION SUMMARY: This symposium will explore the movement to extend the benefits of MCS to the earlier stage, principally class III, HF patient. This area is ripe for discussion and debate. Strong arguments exist on both sides as to whether the field is ready for this. In the era of expanded use of MCS, this topic merits further debate, especially within the international context of our society, as treatment availability and application varies between countries. The fate of the Class III patient with medical therapy will be presented with new data from the current MEDAMACs trial, followed by a debate as to whether or not the timing is right for an evaluation of the outcomes of implantation in INTERMACs profile 4-7 patients. The needs from the patient’s perspective and ideal pump requirements from an engineering perspective will be discussed. New data on outcomes in ambulatory Class IV patients will be discussed, followed by a case presentation and panel discussion.

2:45 PM Results From MEDAMACs – What is the Fate of the Class III Patient with Medical Therapy?
Garrick C. Stewart, MD, Brigham & Women’s Hospital, Boston, MA, USA

3:00 PM DEBATE: INTERMACS Profile 4+: The Timing is Right

3:00 PM PRO:
Keith D. Aaronson, MD, University of Michigan Medical Center, Ann Arbor, MI, USA

3:10 PM CON:
Randall C. Starling, MD, MPH, Cleveland Clinic, Cleveland, OH, USA

3:20 PM Rebuttal PRO
Keith D. Aaronson, MD

3:25 PM Rebuttal CON
Randall C. Starling, MD, MPH

3:30 PM What are the Needs for Class III Patients: The Patient’s Perspective
Tonya I. Elliot, MSN, RN, CCTC, CHFN, MedStar Washington Hospital Center, Washington, DC, USA

3:45 PM Future Needs for Functional Class III Patients: The Engineering Perspective
Francesco Moscato, PhD, Medical University of Vienna, Vienna, Austria

4:00 PM Highlights From ROADMAP: Outcomes in Ambulatory Class IV Patients
Douglas A. Horstmanshof, MD, Integris Baptist Medical Center, Oklahoma City, OK, USA

4:15 PM Case Presentation of a Patient Presenting with Ambulatory Class III Heart Failure
Alexander Bernhardt, MD, University Heart Center, Hamburg, Germany

4:25 PM Panel Discussion
**PRE-MEETING SYMPOSIUM 14:**

**Extreme Donors: Pushing the Boundaries** (Clio, Thalie)  
(HTX, BSI, DMD, HF, HTX, PEDS, PEEQ)

**CHAIRS:** Ivan Knezevic, MD and Kumud K. Dhital, MD, PhD

**SESSION SUMMARY:** This session will focus on the transplantation of hearts from extended criteria and DCD donors. Subjects to be covered are:
1. definition of death: implications for retrieving hearts from DCD donors;
2. pathophysiology of myocardial injury during withdrawal of life support – implications for retrieval and transplantation of hearts from DCD donors;
3. surgical Perspective on procuring and transplanting extended criteria donors;
4. human heart transplantation from DCD donors – a pediatric perspective; and
5. human heart transplantation from DCD donors – an adult perspective.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Institution</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:45 PM</td>
<td><strong>Definition of Death – Implications for Heart Donation from DCD Donors</strong></td>
<td>Sam Shemie, MD, Montreal Children's Hospital, McGill University</td>
<td>Montreal, QC, Canada</td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td><strong>Myocardial Injury During Withdrawal of Life Support</strong></td>
<td>Peter MacDonald, MD, PhD, St. Vincent's Hospital</td>
<td>Sydney, Australia</td>
<td></td>
</tr>
<tr>
<td>3:15 PM</td>
<td><strong>Ex-Vivo Assessment of Hearts from DCD Donors</strong></td>
<td>Darren H. Freed, MD, PhD, University of Alberta Hospital</td>
<td>Edmonton, AB, Canada</td>
<td></td>
</tr>
<tr>
<td>3:30 PM</td>
<td><strong>Heart Transplantation from DCD Donors – A Pediatric Perspective</strong></td>
<td>Richard Kirk, FRCP, FRCPCH, Freeman Hospital, Newcastle</td>
<td>Newcastle upon Tyne, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>3:45 PM</td>
<td><strong>Human Heart Transplantation from DCD Donors – An Adult Perspective</strong></td>
<td>Stephen R. Large, MB, FRCS, FRCP, Papworth Hospital</td>
<td>Cambridge, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td><strong>Donor Heart Protection – What Works, What Doesn’t</strong></td>
<td>Yoshifumi Naka, MD, PhD, New York Presbyterian Hospital</td>
<td>New York, NY, USA</td>
<td></td>
</tr>
<tr>
<td>4:15 PM</td>
<td><strong>Would You Take This Donor? When is the Risk Too High?</strong></td>
<td>David A. Baran, MD, Newark Beth Israel Med Center</td>
<td>Newark, NJ, USA</td>
<td></td>
</tr>
<tr>
<td>4:30 PM</td>
<td><strong>Panel Discussion</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
2:45 PM – 4:45 PM

**PRE-MEETING SYMPOSIUM 15:**

**Before, During, and After – Optimizing Outcomes in the High Risk Recipient for Lung Transplantation**
(Erato, Uranie)
(LTX, BSI, LF)

**CHAIRS:** Vibha N. Lama, MD and Cassie C. Kennedy, MD

**SESSION SUMMARY:** This session will focus on modifiable factors in the pre-, peri- and post- transplant period and steps needed to improve outcomes after lung transplantation. The role of ECMO as a bridge to transplant and perioperative recovery will be reviewed. Challenging patient cohorts, including those with connective tissue disease and pulmonary hypertension complicating ILD, will be highlighted. Complex medical issues in the CF patient will be reviewed.

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:45</td>
<td>Modifiable Factors Pre-Transplantation – Improving Survival by Candidate Selection</td>
<td>Andrew Chang, MD</td>
<td>University of Michigan Medical Center, Ann Arbor, MI, USA</td>
</tr>
<tr>
<td>3:05</td>
<td>ECMO and Lung Transplantation- Bridge to and After</td>
<td>Walter Klepetko, MD</td>
<td>Medical University of Vienna, Vienna, Austria</td>
</tr>
<tr>
<td>3:25</td>
<td>Managing Secondary Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis Patients Before, During, and After Transplant</td>
<td>Paul A. Corris, MB, FRCP</td>
<td>Freeman Hospital, Newcastle upon Tyne, United Kingdom</td>
</tr>
<tr>
<td>3:45</td>
<td>Connective Tissue Disease in Interstitial Lung Disease – Is the Baggage Too Heavy?</td>
<td>Elana J. Bernstein, MD</td>
<td>Columbia University, New York, NY, USA</td>
</tr>
<tr>
<td>4:05</td>
<td>The Medically-Challenging Cystic Fibrosis Patient – Diabetes, Digestion, and Drug-Seeking Behavior</td>
<td>A. Whitney Brown, MD</td>
<td>Inova Advanced Lung Disease &amp; Transplant, Fairfax, VA, USA</td>
</tr>
<tr>
<td>4:25</td>
<td>Panel Discussion</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| 90 |
Challenges in Pulmonary Hypertension Due to Left Heart Disease (Hermes)
(PH, BSTR, HF, HTX, MCS, NHSAH, PEDS)

This session is supported by educational grants from Actelion and Gilead.

CHAIRS: Jean-Luc Vachiery, MD and Van N. Selby

SESSION SUMMARY: Pulmonary hypertension (PH) is common among patients with left heart disease (LHD), and the development of PH-LHD is associated with a worse prognosis. This session will review evidence in several sub-categories of left heart disease including heart failure with preserved ejection fraction (HFP EF), restrictive, and hypertrophic cardiomyopathies and valvular disease in the setting of LVAD implantation. The prevalence, prognostic significance, and diagnostic evaluation of PH in each of these conditions will be discussed, as will the implications for management.

2:45 PM Pulmonary Hypertension Due to Left Heart Disease: Novel Hemodynamic Predictors
Rebecca J. Cogswell, MD, University of Minnesota Division of Cardiology, Minneapolis, MN, USA

3:05 PM Q & A

3:09 PM Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction
Marco Guazzi, MD, PhD, IRCCS, Policlinico San Donato University Hospital, Milan, Italy

3:29 PM Q & A

3:33 PM Pulmonary Hypertension in Restrictive, Infiltrative and Hypertrophic Cardiomyopathy
Robert P. Frantz, MD, Mayo Clinic, Rochester, MN, USA

3:53 PM Q & A

3:57 PM Pulmonary Hypertension in Mitral and Aortic Valve Disease
Evelyn M. Horn, MD, Weill Cornell Medical Center, New York, NY, USA

4:17 PM Q & A

4:21 PM Pulmonary Hypertension Pre and Post LVAD: Should It Be Treated?
Ryan J. Tedford, MD, Johns Hopkins University Hospital, Baltimore, MD, USA

4:41 PM Q & A
PRE-MEETING SYMPOSIUM 17:

Lung and Heart-Lung Transplantation: Coming of Age (Calliope)  
(PEDS, BSTR, DMD, LF, LTX)

CHAIRS: Carol K. Conrad, MD and Nicolaus Schwerk, MD

SESSION SUMMARY: The primary aim of this session is to present and discuss child specific aspects of lung and heart lung transplantation. Due to the scarcity of potential donors, lung allocation remains a big challenge, especially in children. Different approaches to expand the donor pool, like single lobe transplantation or atypical size reduction, have been developed to resolve this dilemma. Recent advances, as well existing challenges and limitations, of donor pool expansion will be discussed, including the option of ex-vivo perfusion and DCD-donation. A further talk will give insights into the current state of pediatric lung transplantation from the surgical point of view. The number of children with congenital heart disease developing pulmonary hypertension prohibiting a cardiac transplantation is rising. Heart-lung transplantation may be the only solution in these patients. Possibilities and challenges of this approach will be discussed. Non-adherence is another major problem, especially in adolescents and is responsible for a significant amount of morbidity and mortality after lung transplantation. Therefore, options for early detection and intervention are crucial.

2:45 PM Waiting List Management and Allocation Policies – What Works Best for Children?  
Samuel B. Goldfarb, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, USA

3:00 PM Q & A

3:05 PM Ex-vivo Perfusion: An Option to Preserve and Rehabilitate Pediatric Donor Lungs  
Jayan Nagendran, MD, University of Alberta, Edmonton, AB, Canada

3:20 PM Q & A

3:25 PM Surgical Challenges in Pediatric Lung Transplantation  
Gregor Warnecke, MD, Hannover Medical School, Hannover, Germany

3:40 PM Q & A

3:45 PM Under Pressure – Type II Pulmonary Hypertension in Children with End-Stage Heart Failure  
Maurice Beghetti, MD, HUG Children’s University Hospital, Geneva, Switzerland

4:00 PM Q & A

4:05 PM Heart-Lung Transplantation for Children with Congenital Heart Disease and Pulmonary Hypertension: A Feasible Option?  
Stuart C. Sweet, MD, PhD, St. Louis Children’s Hospital, St. Louis, MO, USA

4:20 PM Q & A

4:25 PM Non-Adherence: How to Detect and How to Deal With It?  
Doris Staab, MD, Charite University, Berlin, Berlin, Germany

4:40 PM Q & A
PRE-MEETING SYMPOSIUM 18:

B Cells in Transplantation 2015 (Euterpe)
(BSTR, HF, HTX, LTX, PATH, Peds)

CHAIRS: Marilia Cascalho, MD, PhD and A. G. Kfoury, MD, FACC

SESSION SUMMARY: This session will illustrate the cutting edge of knowledge and present key questions yet unanswered concerning basic B cell function and control, and the clinical impact of immune therapeutics on humoral immunity, rejection and potentially tolerance. These presentations will be followed by a panel discussion, in workshop format, designed to draw from the speakers and from the audience a synthesis of how basic knowledge can potentially be applied and what information and level of resolution are needed for clinical applications.

2:45 PM The Role of B cells in the Alloimmune Response
Esme Dijke, PhD, University of Alberta, Edmonton, AB, Canada

3:05 PM Tolerance and Accommodation After Transplantation: The Role of B cells
Jeffrey L. Platt, MD, University of Michigan, Ann Arbor, MI, USA

3:25 PM Harnessing the Power of B Regulatory Cells to Modulate the Immune Response
Paul Blair, PhD, University College London, London, United Kingdom

3:45 PM Targeting Plasma Cells in Transplantation
Meena Clatworthy, PhD, University of Cambridge, Cambridge, United Kingdom

4:05 PM B cell Therapeutics in Transplantation
Jignesh K. Patel, MD, PhD, Cedars-Sinai Heart Institute, Los Angeles, CA, USA

4:25 PM Panel Discussion

4:45 PM – 5:00 PM
COFFEE BREAK/VISIT EXHIBITS (Rhodes)
VIEW POSTERS (Agora 2)
5:00 PM – 7:00 PM

PRE-MEETING SYMPOSIUM 19:

50 Shades of Gray: When Things Don't Go as Planned in VAD Patients (Athena)
(MCS, HF, HTX, ID, NHSAH)

CHAIRS: Ulrich P. Jorde, MD and O. Howard Frazier, MD

SESSION SUMMARY: The common, serious adverse events that occur in LVAD patients, which result in morbidity and mortality, will be discussed. Their incidence, diagnosis and management will be presented and discussed by experts in the field. These topics will include: 1) Device thrombosis: when/how to screen for and diagnose device thrombosis, when/how to treat device thrombosis medically and surgically; 2) Post-operative right ventricular failure: when to treat, followed by a discussion of the medical and surgical treatment options and when to use each; 3) Aortic Insufficiency: when/how to adjust pump speed to prevent/treat aortic insufficiency, when/how to repair/replace the aortic valve, including a discussion on the use of TAVR in VAD patients; 4) Driveline infection with/without pocket involvement, when/how to perform ID and when/how to replace the device; 5) GI bleeding in VAD patients: why it occurs and its current incidence, when/how to adjust anticoagulation, how to identify and treat AVFs; 6) Stroke: incidence and changing trends, how to prevent, diagnose and manage stroke in VAD patients.

5:00 PM Device Thrombosis – What Now?
Nir Uriel, MD, University of Chicago, Chicago, IL, USA

5:15 PM Q & A

5:20 PM Post-Operative RV Failure: Medicine or Machines?
Alexander M. Bernhardt, MD, University Heart Center Hamburg, Hamburg, Germany

5:35 PM Q & A

5:40 PM Aortic Insufficiency in VAD Patients – Observe, Treat or Fix?
Daniel Zimpfer, MD, Medical University Vienna, Vienna, Austria.

5:55 PM Q & A

6:00 PM Driveline Infection – Debride, Reroute, Replace?
Scott C. Silvestry, MD, Washington University, St Louis, MO, USA

6:15 PM Q & A

6:20 PM GI Bleeding in VAD Patients. Why, Where, What Now?
Anna L. Meyer, MD, Leipzig Heart Center, Leipzig, Germany

6:35 PM Q & A

6:40 PM Strokes in VAD Patients – Incidence, Changing Trends and Management
Jeffrey A. Morgan, MD, Henry Ford Hospital, Detroit, MI, USA

6:55 PM Q & A
PRE-MEETING SYMPOSIUM 20:

The Road Less Traveled: The Management of Unusual Cardiomyopathies

(CHF, BSTR, HTX, MCS, NHSAH, PEDS)

CHAIRS: Eugene C. DePasquale, MD and Marco Masetti, MD

SESSION SUMMARY: Inherited cardiomyopathies, which may include dilated, hypertrophic, restrictive and arrhythmogenic right ventricular cardiomyopathy, can progress to end stages and may ultimately lead to the requirement of heart transplantation. A better understanding of the pathophysiology and management specific to these heritable conditions is crucial to the heart failure/transplant specialist to aid in overall care, as well as timing of listing for heart transplantation. It is also critical for the heart failure/transplant physician to understand the role and limitations of presently available genetic testing and the potential medical and psychological impact of testing on the patient and their family members. This symposium will review genetic testing for cardiomyopathies, when to consider testing in patients with cardiomyopathy, the limitations of presently available testing, and the importance of genetic counseling.

5:00 PM  Chagas Cardiomyopathy
Alejandro M. F. Bertolotti, Sr., MD, University Hospital Favaloro Foundation, Buenos Aires, Argentina

5:15 PM  Hypertrophic Cardiomyopathy
Neal K. Lakdawala, MD, Brigham & Women's Hospital, Boston, MA, USA

5:30 PM  Arrhythmogenic Right Ventricular Cardiomyopathy
Ray E. Hershberger, MD, Ohio State University College of Medicine, Columbus, OH, USA

5:45 PM  Amyloid Heart Disease
Marc J. Semigran, MD, Massachusetts General Hospital, Boston, MA, USA

6:00 PM  Adults with Congenital Heart Disease: When is Transplant the Answer?
Evan M. Zahn, MD, Cedars-Sinai Medical Center, Los Angeles, CA, USA

6:15 PM  Muscular Dystrophies and Mitochondrial Myopathies
Pradeep P.A. Mammen, MD, FACC, FAHA, UT Southwestern Medical Center, Dallas, TX, USA

6:30 PM  Role of Genetic Counseling
Kathleen Hickey, EdD, FNP, ANP, FAHA, FAAN, Columbia University, New York, NY, USA

6:45 PM  Panel Discussion
SESSION SUMMARY: A growing body of evidence suggests that there are important links between infection and rejection in the setting of lung transplantation. In addition, there is an increasing appreciation that colonization with pathogenic organisms may both predispose to future invasive disease, as well as influence the inflammatory and allo-immune environment of the lung allograft. Both colonization and invasive infection with certain bacteria, including Pseudomonas aeruginosa may predispose to development of CLAD. Fungal colonization and infection with Aspergillus spp. has also been shown to be associated with a decrease in FEV1, even in the absence of invasive fungal infection. Viruses, including CMV and community-acquired respiratory viruses, have also been shown to exert pro-inflammatory and immune modulating effects that can lead to CLAD via cytokine and chemokine expression. The delineation of these links and potential mechanisms for these effects have important implications for the screening and response to colonizing pathogens and should lead to new interventions to prevent and possibly reverse CLAD.
5:00 PM – 7:00 PM

PRE-MEETING SYMPOSIUM 22:

Chronic Lung Disease Associated Pulmonary Hypertension: Mechanism, Pathology, and Clinical Impact (Hermes)
(PH, LF, LTX, NHSAH, PATH)

CHAIRS: Teresa De Marco, MD, FACC and Rajeev Saggar, MD

SESSION SUMMARY: The use of targeted pulmonary vascular therapies in patients with pulmonary hypertension secondary to chronic lung disease is controversial. The 5th World PH symposium developed recommendations for the diagnosis and management of this entity. This symposium will present the key aspects in the pathology, mechanisms, and treatment opportunities for patients in this group.

5:00 PM Pathology of Pulmonary Fibrosis Associated Pulmonary Hypertension
Gerald J. Berry, MD, Stanford University, Stanford, CA, USA

5:20 PM Q & A

5:25 PM Combined Pulmonary Fibrosis and Emphysema: A Unique Pattern of Pulmonary Vascular Disease
Vincent Cottin, MD, Université Claude Bernard Lyon, Lyon, France.

5:45 PM Q & A

5:50 PM Gas Exchange in Lung Disease and Pulmonary Hypertension: The Myths and Facts
Joan A. Barbera, MD, University of Barcelona, Barcelona, Spain

6:10 PM Q & A

6:15 PM When to Treat Pulmonary Hypertension in Association with Pulmonary Fibrosis
Steven D. Nathan, MD, Inova Fairfax Hospital, Falls Church, VA, USA

6:35 PM Q & A

6:40 PM Case Presentation: Applying the Evidence to the Individual Patient
Ioana R. Preston, MD, Tufts Medical Center, Boston, MA, USA

6:45 PM Panel Discussion

WEDNESDAY APRIL 15
## Frontiers in Pediatric Transplantation (Calliope)
*(PEDS, DMD, HTX, MCS)*

**CHAIRS:** Martin Schweiger, MD and Jennifer Conway, MD

**SESSION SUMMARY:** Heart transplantation during childhood remains a last treatment resort fraught with many risks and subjected to very difficult decisions involving medical, psychosocial and ethical aspects with small case numbers and treatments at the current limits of modern medicine. This session includes some newer and disputed approaches as well as the most challenging ethical aspects of pediatric heart transplantation. In this session, we hope to address the pitfalls and perils of managing pediatric patients with advanced heart failure requiring consideration for transplant or mechanical circulatory support, the limitations and problems of heart and lung transplantation with respect to systemic genetic diseases, such as chromosomal abnormalities or Duchenne’s muscular dystrophy, and the roles of alternative therapies such as MCS. Outcomes and quality of life of children who have been transplanted with chromosomal abnormalities and the implications for advanced heart failure management decisions, outcomes of thoracic transplantation with organs from extended criteria heart donors including those with high risk infections, CPR, or other concerning features and to discuss the future of MCS for children, including feasibility of permanent support including total artificial hearts in teenager, algorithm for myocardial recovery testing and the role of MCS therapy in patients with failing, surgically palliated congenital heart disease will also be discussed.

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>5:00 PM</td>
<td>Organ Donor Shortage – How Far Can We Extend the Donor Pool?</td>
<td>John Dark, MB, FRCS, Freeman Hospital, Newcastle upon Tyne, United Kingdom</td>
</tr>
<tr>
<td>5:15 PM</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>5:20 PM</td>
<td>Antibodies to HLA and Blood Groups: Match, Treat or Ignore for Allocation?</td>
<td>Simon Urschel, MD, University of Alberta, Edmonton, AB, Canada</td>
</tr>
<tr>
<td>5:35 PM</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>5:40 PM</td>
<td>Thoracic Transplantation in Children with Genetic Abnormalities</td>
<td>Rachel E. Andrews, MD, Great Ormond Street Hospital, London, United Kingdom</td>
</tr>
<tr>
<td>5:55 PM</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>6:00 PM</td>
<td>Elevated Pulmonary Vascular Resistance in Congenital Heart Disease: LVAD Before or RVAD After Heart Transplantation?</td>
<td>Holger W. Buchholz, MD, University of Alberta Hospital, Edmonton, AB, Canada</td>
</tr>
<tr>
<td>6:15 PM</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>6:20 PM</td>
<td>Lifetime VAD: A Destination for Children?</td>
<td>Angela Lorts, MD, Cincinnati Children’s Hospital, Cincinnati, OH, USA</td>
</tr>
<tr>
<td>6:35 PM</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>6:40 PM</td>
<td>Facing the Truth: When and How to Include Palliative Care for Children Before and After Transplant and VAD</td>
<td>Roxanne E. Kirsch, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, USA</td>
</tr>
<tr>
<td>6:55 PM</td>
<td>Q &amp; A</td>
<td></td>
</tr>
</tbody>
</table>
5:00 PM – 7:00 PM
PRE-MEETING SYMPOSIUM 24:
Clinically Relevant Thoracic Transplant Pathology: A Primer for Clinicians, Nurses, Pharmacists and Other Members of the Transplant Team (Euterpe) (ALL)
CHAIRS: Annalisa Angelini, MD and Carol F. Farver, MD

SESSION SUMMARY: The aim of this session will be to provide clinicians, nurses, pharmacists and other allied health members with a tutorial of current criteria, terminology, and classifications of cellular and antibody-mediated rejection of the heart and lung allograft, as well as an update on risk factors and morphologic lesions that constitute chronic allograft rejection in both organs. Appropriate treatment options for each form of rejection will also be discussed. The speakers are all experienced transplant pathologists who have actively participated in the elucidation of current grading schemes.

5:00 PM Acute Cellular Rejection of the Heart
Carmela Tan, MD, Cleveland Clinic, Cleveland, OH, USA

5:15 PM Q & A

5:20 PM Antibody-Mediated Rejection of the Heart
Dylan Miller, MD, Intermountain Medical Center, Salt Lake City, UT, USA

5:35 PM Q & A

5:40 PM Cardiac Allograft Vasculopathy
Claus B. Andersen, MD, DMSc, Rigshospitalet, Copenhagen, Denmark

5:55 PM Q & A

6:00 PM Acute Cellular Rejection of the Lung
Desley Neil, FRCPath, Queen Elizabeth Hospital, Birmingham, United Kingdom

6:15 PM Q & A

6:20 PM Antibody-Mediated Rejection of the Lung
Joseph J. Maleszewski, MD, FACC, Mayo Clinic, Rochester, MN, USA

6:35 PM Q & A

6:40 PM Chronic Lung Allograft Dysfunction
Alexandra Rice, MD, Royal Brompton and Harefield NHS, London, United Kingdom

6:55 PM Q & A

7:00 PM – 8:00 PM
EXHIBIT HALL OPENING RECEPTION (Rhodes)
MODERATED POSTER SESSION 1 (Agora 2)
THURSDAY | April 16, 2015

7:30 AM – 7:00 PM
Registration Open (Agora 1)
Speaker Ready Room Open (Hermes Lounge)

8:00 AM – 9:00 AM
Poster Board Renumbering (Agora 2)

8:30 AM – 10:30 AM
OPENING PLENARY SESSION

(Apollon)
(ALL)

CHAIRS: Hermann Reichenspurner, MD, PhD and Andreas Zuckermann, MD

8:30 AM Welcome/Program Chair Report
Andreas Zuckermann, MD, Medical University of Vienna, Vienna, Austria

8:35 AM Thoracic Registry Report
Josef Stehlik, MD, MPH, University of Utah School of Medicine, Salt Lake City, UT, USA

8:50 AM IMACS Registry Report
James K. Kirklin, MD, University of Alabama at Birmingham, Birmingham, AL, USA

9:00 AM Presidential Address: Youth and Enthusiasm – Our Obligations Towards the Next Generation
Hermann Reichenspurner, MD, PhD, University Heart Centre Hamburg, Hamburg, Germany

9:30 AM Vision ZERO – Cutting Edge Technology For Ultimate Protection
Wolfgang Müller-Pietralla, Volkswagen Group, Wolfsburg, Germany

9:50 AM (1) FEATURED ABSTRACT: HeartWare HVAD for the Treatment of Patients With Advanced Heart Failure Ineligible for Cardiac Transplantation: Results of the ENDURANCE Destination Therapy Trial;
F. D. Pagani1, C. A. Milano2, A. J. Tatooles3, G. Bhat3, M. S. Slaughter3, E. J. Birks1, S. W. Boyce1, S. S. Najjar5, V.jeevanandam6, A. S. Anderson7, I. D. Gregoric8, R. M. Delgado9, K. Leadley10, K. D. Aaronson1, J. G. Rogers1. 1University of Michigan, Ann Arbor, MI, 2Duke University School of Medicine, Durham, NC, 3Advocate Christ Medical Center, Oak Lawn, IL, 4University of Louisville, Louisville, KY, 5MedStar Heart Institute, Washington, DC, 6University of Chicago Medicine, Chicago, IL, 7Northwestern Memorial Hospital, Chicago, IL, 8Surgical Associates of Texas, Houston, TX, 9Texas Heart Institute, Houston, TX, 10HeartWare, Framingham, MA.

10:05 AM PIONEER LECTURE: From Allogeneic to Xenogeneic Heart and Lung Transplantation – A 30 Year Journey
Bruno Reichart, MD, University of Munich/Grosshadern, Munich, Germany

| 100 |
9:00 AM – 7:00 PM
Press Office Open (Gallieni 6)

10:00 AM – 7:00 PM
EXHIBITS OPEN (Rhodes)
POSTER HALL OPEN (Agora 2)

10:30 AM – 11:00 AM
COFFEE BREAK/VISIT EXHIBITS (Rhodes)
VIEW POSTERS (Agora 2)

11:00 AM – 12:30 PM
CONCURRENT SESSION 1

Outcomes With Mechanical Circulatory Support
(Apollon)
(MCS, BSI, HF, HTX, NHSAH, PHARM)

CHAIRS: Emma Birks, MD, PhD and Gianluca Santise, MD

11:00 AM
(2) Long Term Support of Patients Receiving an LVAD for Advanced Heart Failure: A Subgroup Analysis of the Registry to Evaluate the HeartWare® Left Ventricular Assist System (The REVOLVE Registry);
J. D. Schmitto1, D. Zimpfer2, A. E. Fiane3, R. Larbalestier4, S. Tsui5, P. Jansz6, A. Simon7, S. Schueler8, M. Strueber9, 1Hanover Medical School, Hanover, Germany, 2Medical University of Vienna, Vienna, Austria, 3Oslo University Hospital, Oslo, Norway, 4Royal Perth Hospital, Perth, Australia, 5Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom, 6St Vincent’s Clinic, Sydney, Australia, 7Royal Brompton and Harefield Hospital, London, United Kingdom, 8Fresenius Medical Care, Leweak, Germany

11:15 AM
(3) A Multi-Institutional Outcome Analysis of Patients Undergoing Left Ventricular Assist Device Implantation Stratified By Sex and Race;
J. Van Meeteren1, S. Maltais2, S. Dunlay3, N. Haglund4, M. E. Davis5, F. D. Pagani6, K. D. Aaronson7, J. Cowger7, P. Shah8, J. M. Stulak1. 1Cardiovascular Surgery, Mayo Clinic, Rochester, MN, 2Cardiac Surgery, Vanderbilt Heart and Vascular Institute, Nashville, TN, 3Cardiovascular Diseases, Mayo Clinic, Rochester, MN, 4Cardiovascular Diseases, Vanderbilt Heart and Vascular Institute, Nashville, TN, 5Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI, 6Cardiovascular Diseases, University of Michigan Health System, Ann Arbor, MI, 7Cardiovascular Diseases, St. Vincent’s Health System, Indianapolis, IN, 8Cardiovascular Diseases, Inova Fairfax, Fairfax, VA

11:30 AM
(4) The HeartMate II Pump in Clinical Practice – Results From 479 Patients Analyzed in a Retrospective European Multi-Center Study;
E. V. Potapov1, J. Garbade2, K. Hakim-Meibodi3, M. Strueber2, J. Gummert2, F. Mohr4, V. Falk4, T. Krabatsch1, M. Morshuis4. 1Thoracic and Cardiovascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany, 2Thoracic and Cardiovascular Surgery, Herzzentrum Leipzig, Leipzig, Germany, 3Thoracic and Cardiovascular Surgery, Herzzentrum Berlin, Berlin, Germany, 4Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany
11:45 AM

(5) The HeartWare HVAD Pump in Clinical Practice – Results From 1,035 Patients Analyzed in a Retrospective European Multi-Center Study;
T. Krabatsch1, M. Morschus2, J. Garbade3, D. Zimpfer4, E. Potapov5, G. Laufers6, F. Mohr7, V. Falk8, J. Gummert8. 1Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany, 2Medizinische Universität Wien, Vienna, Austria, 3Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany, 4Herzcentrum Leipzig, Leipzig, Germany, 5Kardiologische Universitätsklinik, München, Germany

12:00 PM

(6) Temporal Analysis of Outcomes During Long-Term Mechanical Circulatory Support: An Initial Report From the Mechanical Circulatory Support Research Network;
S. Maltais1, N. A. Haglund2, M. E. Davis3, M. R. Danter1, M. Xu4, S. M. Dunlay5, J. Cowger6, P. Shah7, K. D. Aaronson8, F. D. Pagan9, J. M. Stulak10. 1Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, 2Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN, 3Vanderbilt Univ Med Ctr, Nashville, TN, 4Biomathematics, Vanderbilt Univ Med Ctr, Nashville, TN, 5Cardiovascular Medicine, Mayo Clinic, Rochester, MN, 6Cardiovascular Medicine, St Vincent Heart, Indianapolis, IN, 7Cardiovascular Medicine, Inova Fairfax, Falls, VA, 8Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, 9Cardiac Surgery, University of Michigan, Ann Arbor, MI, 10Cardiac Surgery, Mayo Clinic, Rochester, MN

12:15 PM

(7) Preliminary Results From ITAMACS, the Italian Multi Center Registry for Mechanically Assisted Circulatory Support;
G. Feltrin1, M. Frigerio2, L. Martinelli2, M. De Bonis3, M. Rinaldi4, M. Pilato5, L. Martinelli2, M. De Bonis3, M. Rinaldi4, M. Pilato5, F. Musumeci6, G. Faggian1, U. Livi1, M. Maccherini1, M. Massetti20, L. Rizzato21, G. Gerosa22, A. Nanni Costa23. 1Veneto Region, Regional Centre for Transplant Coordination, Padova, Italy, 2De Gasperis Cardiocenter, Ospedale Niguarda Ca’Granda, Milan, Italy, 3Cardiac Surgery, University of Turin, Città della Salute e della Scienzia, Turin, Italy, 4Department of Cardiothoracic Surgery, ISMETT Mediterranean Institution for Transplant and High Specialty Therapy, Palermo, Italy, 5Department of Cardiovascular Surgery, Azienda Ospedaliera San Camillo Forlanini, Roma, Italy, 6Division of Cardiovascular Surgery, University of Verona, Verona, Italy, 7Cardiothoracic Department, University Hospital of Udine, Udine, Italy, 8Cardiac, Thoracic and Vascular Department, Cardio Surgery and Transplantation Unit, Siena, Italy, 9Cardiovascular Department, Ospedale Papa Giovanni XXIII, Bergamo, Italy, 10Cardiac Surgery Unit, Humanitas Research Hospital, Milan, Italy, 11Neuroscienze, Imaging e Scienze Cliniche, Università “G. D’annunzio” Chieti, Chieti, Italy, 12Department of Cardiovascular Surgery, AORN Ospedali dei Colli, napoli, Italy, 13Department of Cardiothoracic and Vascular Surgery, Cardiac Surgery and Transplantation Unit, Bologna, Italy, 14Cardiovascular Surgery Cardiological Center Monzino, University of Milan, Milan, Italy, 15Cardiothoracic Department, University of Perugia School of Medicine, Perugia, Italy, 16Cardiac Surgery, University of Bari, Bari, Italy, 17Department of Cardiology, Azienda Ospedaliero Universitaria “Policlinico – V. Emanuele,” Catania, Italy, 18Cardiac Surgery Department, IRCCS Foundation Policlinico San Matteo, Pavia, Italy, 19UC Oncologia Chirurgica dell’Ospedale di Bologna, Italy, 20Department of Cardiology, Universitat Politecnica de Valencia, Valencia, Spain, 21Department of Cardiac Surgery, National Sanità, National Transplant Centre, Rome, Italy, 22Cardiothoracic Department, University of Pavia Medical School, Pavia, Italy, 23Superior Health Institute, National Transplant Centre, Rome, Italy
Anticoagulation For VADs: How Anticoagulated Do We Need To Be?  
(Athena)  
(MCS, BSI, HF, NHSAH, PATH, PHARM)  

CHAIRS: Jeffrey Teuteberg, MD and Anna L. Meyer, MD

11:00 AM

(8) Long Term Outcomes in HeartMate II Patients Managed With Vitamin K Antagonists Without Antiplatelet Therapy – Results of the EU-TRACE Study;  
1Department of Thoracic and Cardiovascular Surgery, Charles Nicolle University Hospital, Rouen, France,  
2Department of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany,  
3Department of Cardiovascular Surgery Freiburg, University Heart Center Freiburg-Bad Krozingen, Freiburg, Germany,  
4Department of Thoracic and Cardiovascular Surgery, CHU Pontchaillou, Rennes, France,  
5Department of Cardiothoracic Surgery, University of Vienna, Vienna, Austria,  
6Thoratec Europe Limited, London, United Kingdom,  
7Research and Scientific Affairs, Thoratec Corporation, Pleasanton, CA,  
8Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

11:15 AM

(9) Chronic Management With Reduced Anti-Thrombotic Therapy in HeartMate II Patients With Persistent Bleeding – Results From the US-TRACE Study;  
1Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY,  
2University of North Carolina, Chapel Hill, NC,  
3University of Minnesota, Minneapolis, MN,  
4 Advocate Christ Medical Center, Oak Lawn, IL,  
5Thoratec Corporation, Pleasanton, CA,  
6 Sharp Memorial Hospital, San Diego, CA

11:30 AM

(10) LVAD-Associated von Willebrand Factor Degradation Alters Angiogenesis: A Mechanistic Link Between LVAD Support, Gastrointestinal Angiodysplasia, and Bleeding?;  
Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA

11:45 AM

(11) Association of Warfarin Genotype With Thrombosis and Bleeding Events in Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Patients;  
V. K. Topkara1, A. Levin1, K. Mody1, A. Garan1, K. O. Ronquillo2, M. Tiburcio2, J. S. Murphy2, G. Parkis2, K. Takeda2, H. Takayama1, M. Yuzefpolskaya1, D. Mancini1, Y. Naka1, P. C. Colombo1, U. P. Jorde1.  
1Cardiology, Columbia University New York Presbyterian Hospital, New York, NY,  
2Cardiothoracic Surgery, Columbia University New York Presbyterian Hospital, New York, NY,  
3Cardiology, Montefiore Medical Center, New York, NY

12:00 PM

(12) Thrombophilias Prospective Detection Tailored Anticoagulation Protocol Without Antiplatelet Therapy in Patients With Axial-Flow Ventricular Assist Device;  
I. Netuka1, M. Urban1, P. Ivak1, J. Maly1, J. Besik1, H. Riha2, Z. Dorazilova3, M. Hegarova3, J. Pirk1, O. Szarszo1.  
1Dept. of Cardiac Anaesthesia, Inst Clinical & Exp Med, Prague, Czech Republic,  
2Dept. of Cardiac Surgery, Inst Clinical & Exp Med, Prague, Czech Republic,  
3Dept. of Cardiology, Inst Clinical & Exp Med, Prague, Czech Republic
12:15 PM (13) Blood Product Utilization With Left Ventricular Assist Device Implantation: A Decade of Statewide Data;
M. A. Quader1, L. G. Wolfe1, G. Ailawadi2, J. B. Rich3, A. M. Speir4, D. LaPar5, C. E. Fonner6, V. Kasirajan1. 1Cardio-Thoracic Surgery, Virginia Commonwealth University, Richmond, VA, 2Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, VA, 3Research & Writing Committee, Virginia Cardiac Surgery Quality Initiative, Washington, DC, 4Cardiothoracic Surgery, Inova Heart and Vascular Institute, Falls Church, VA

11:00 AM – 12:30 PM

CONCURRENT SESSION 3

Choosing the Best Recipients for Lung Transplant in the Era of Urgency (Clio, Thalie) (LF, LTX, PEDS)

CHAIRS: Christopher H. Wigfield, MD, FRCS and Michiel E. Erasmus, MD, PhD

11:00 AM (14) Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation Based on Intent to Treat: A Single-Center Experience;
M. Biscotti1, W. D. Gannon2, C. Agerstrand2, D. Abrams3, J. Sonett1, D. Brodie1, M. Bacchetta1. 1Surgery, Columbia University Medical Center, New York, NY, 2Pulmonary, Allergy, and Critical Care, Columbia University Medical Center, New York, NY

11:15 AM (15) Impact of Diastolic Dysfunction on Primary Graft Dysfunction (PGD) After Lung Transplantation;
M. K. Porteous1, B. Ky1, J. Kirkpatrick1, T. Plappert2, J. M. Diamond1, R. J. Shah1, M. Brown1, J. D. Christie1, S. M. Kawut1. 1Medicine, University of Pennsylvania, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA

11:30 AM (16) Outcomes of High Emergency for More Than 1000 Lung Transplant Recipients Results of the Cohort of Lung Transplantation (COLT) Study;
P. Lacoste1, A. Tissot2, P. Royer3, C. Gomez4, A. Roux5, R. Kessler6, C. Dromer7, F. Phillil8, V. Boussaud9, C. Pison10, S. Mussot11, O. Brugièrep1, M. Dahan1, C. Knopf1. 1cardio-thoracic surgery, CHU Nantes, Nantes, France, 2pneumology, CHU Nantes, Nantes, France, 3Institut du Thorax, Inserm UMR 1087, Nantes, France, 4Mar- seille Hospital, Marseille, France, 5Hospital Foch, Suresnes, France, 6Novel Hospital Civil, Strasbourg, France, 7Hospital Haut Leveque, Bordeaux, France, 8Hospital Louis Pradel, Lyon, France, 9Hospital European Georges Pompidou, Paris, France, 10CHU Grenoble, Grenoble, France, 11Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France, 12Bichat Hospital, Paris, France, 13Larrey Hospital, Toulouse, France, 14Brussels Hospital, Brussels, France
(17) Frailty Is Associated With Pre-Operative Delisting and Death in Lung Transplant Candidates;
J. P. Singer1, J. M. Diamond2, C. J. Gries3, J. McDonnough4,
P. D. Blanc1, R. Shah1, M. Y. Dean1, B. Hersch1, J. Dolan5,
S. Arcasoy1, J. R. Greenland1, N. Smith1, S. Patterson1,
L. Shah6, J. A. Golden1, N. Blumenthal1, J. Sonett6, S. Hays1,
M. Oyster7, F. D’Ovidio5, P. P. Katz1, H. Robbins8, M. Brown2,
L. E. Leard1, J. Kukreja8, M. Bacchetta3, M. Rushefski2,
K. Raza4, J. D. Christie1, D. J. Lederer4. 1Medicine, UC San Francisco, San Francisco, CA, 2Medicine, University of Pennsylvania, Philadelphia, PA, 3Medicine, University of Pittsburgh, Pittsburgh, PA, 4Medicine, Columbia, New York, NY, 5Surgery, Columbia, New York, NY, 6Surgery, UC San Francisco, San Francisco, CA

(18) Association of Thoracic Muscle Cross-Sectional Area and Clinical Outcomes in Lung Transplant Candidates;
D. Rozenberg1, L. G. Singer1, P. Mendes2, S. Mathur3. 1Medicine, Division of Respirology, Toronto Lung Transplant Program, University of Toronto, Toronto General Hospital, Toronto, ON, Canada, 2Physical Therapy, University of Toronto, Toronto, ON, Canada

(19) Body Mass Index Impacts Short, Intermediate, and Long-Term Survival in Lung Transplantation;
B. A. Whitson1, A. Pope-Harman2, P. Lee1, A. Kilic1, C. B. Sathrak1, S. Kirkby4, R. S. Higgins1, J. D. Tobias5, D. Hayes, Jr.4. 1Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, 2Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, 3Division of Cardio-Thoracic Surgery, Baylor Scott and White Heart and Vascular Institute, Temple, TX, 4Department of Pediatrics, Nationwide Children’s Hospital, Columbus, OH, 5Department of Anesthesia, Nationwide Children’s Hospital, Columbus, OH
**Donor Management/Organ Preservation-Heart: Extending the Margins** (Eratou, Uranie)  
(DMD-HEART, HF, HTX)

**CHAIRS:** Christoph Knosalla, MD, PhD and Darren Freed, MD, PhD, FRCSC

**11:00 AM**  

**11:15 AM**  
(21) **Technique of Adult Heart Procurement in the Donation After Circulatory Death Multi-Organ Retrieval Scenario**; M. Connellan1, A. Iyer1, H. Chew1, C. Soto1, E. Granger2, P. Jansz2, P. Spiratt1, M. Crawford3, D. Verran4, H. Pleas5, P. Mac-Donald1, K. Dhital1, 1Heart and Lung Transplant Unit, St. Vincent’s Hospital, Sydney, Australia, 2Transplant Institute, Royal Prince Alfred Hospital, Sydney, Australia, 3Transplant Unit, Westmead Hospital, Sydney, Australia

**11:30 AM**  
(22) **Functional Assessment of the DCD Heart Within the Donor and Ex-Vivo**; S. Messer1, R. Axell2, P. White2, M. Roman2, S. Colah2, A. Ali3, S. Large4, 1Transplant Surgery, Papworth Hospital, Cambridge, United Kingdom, 2Clinical Engineering, Addenbrookes Hospital, Cambridge, United Kingdom, 3Cambridge Perfusion Service, Papworth Hospital, Cambridge, United Kingdom, 4Cardiothoracic Surgery, Papworth Hospital, Cambridge, United Kingdom

**11:45 AM**  
(23) **Shorter Cold Ischemic Time in Older Donors Post-Heart Transplant Appears to Be Protective**; F. Esmailian1, J. Patel, M. Kittleson, T. Kao, F. Liou, S. Siddiqui, B. Aazarbal, D. H. Chang, L. Czer, A. Trento, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

**12:00 PM**  
(24) **Donor Under Sizing Results in Worse Post-Transplant Survival in LVAD Patients: A UNOS Database Analysis**; E. M. Schumer1, J. R. Trivedi1, E. J. Birks2, A. J. Lonneman2, A. Cheng2, M. S. Slaughter1. 1Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY, 2Department of Medicine, Cardiovascular Medicine, University of Louisville, Louisville, KY

**12:15 PM**  
(25) **Do Donor Lifestyle Choices and Polysubstance Abuse Affect Long Term Survival in Heart Transplant Recipients?**; Y. Ravi1, S. Bansal2, K. Jeong3, S. Emani4, B. Whitson5, C. Tong6, C. B. Sai-Sudhakar1, 1Cardio-Thoracic Surgery, Baylor-Scott & White, Temple, TX, 2Cardio-Thoracic Surgery, Mayo Clinic Florida, Jacksonville, FL, 3Department of Bio-Statistics, University of Pittsburgh, PA, PA, 4Cardiology, The Ohio State University, Columbus, OH, 5Cardio-Thoracic Surgery, The Ohio State University, Columbus, OH, 6Cardiology, Baylor-Scott & White, Temple, TX
11:00 AM – 12:30 PM

**CONCURRENT SESSION 5**

**JFTC Clinical Case Dilemmas: The Best of the Best**

(Hermes) (ALL)

**CHAIRS:** Marian Urban, MD and Pali Shah, MD

11:00 AM **(26)** Fatal Fulminant Accelerated Rejection in a Cardiac Transplant Recipient With Natural Killer Cell Infiltrate; A. R. Wang, A. Javaheri, E. L. Prak, P. Lal, Z. Arany, M. Jesup, M. Kamoun. Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 1Department of Internal Medicine, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, PA

11:10 AM EXPERT DISCUSSANT: Dolly B Tyan, PhD, Stanford University, Palo Alto, CA, USA

11:18 AM **(27)** Autoantibodies Against Lung Tissue Can Cause Hyper Acute as Well as Acute Antibody Mediated Rejection Following Lung Transplantation; A. Bharat, N. Steward, M. M. DeCamp, P. Garcha, S. Bhorade, M. Ison, T. Mohanakumar, C. Farver, M. Askar, M. Budov. Thoracic Surgery, Northwestern Univ, Chicago, IL, Surgery, Washington University, St Louis, MO, Pulmonary, Cleveland Clinic, Cleveland, OH, Pulmonary, Northwestern Univ, Chicago, IL, Infectious Diseases, Northwestern Univ, Chicago, IL, Pathology, Cleveland Clinic, Cleveland, OH, Cleveland Clinic, Cleveland, OH

11:28 AM EXPERT DISCUSSANT: Adriana Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

11:36 AM **(28)** Successful Treatment of Severe Acute Graft Versus Host Disease Post Lung Transplantation; A. Ataya, A. Biswas, S. Chandrashokaran, J. C. Salgado, A. Emtiajoo. Lung Transplantation Program, Division of Pulmonary, Sleep and Critical Care Medicine, University of Florida, Gainesville, FL

11:46 AM EXPERT DISCUSSANT: Stuart C Sweet, MD, PhD, St. Louis Children’s Hospital, St. Louis, MO, USA

11:54 AM **(29)** Breaking Bad: Dissimulated Amphetamine Abuse as a Rare Cause of Recurrent LVAD Pump Thrombosis; C. Heim, M. Weyand, R. Tandler. University of Erlangen Department of Cardiac Surgery, Erlangen, Germany

12:04 PM EXPERT DISCUSSANT: Martin Strueber, MD, PhD, Spectrum Health Hospital, Grand Rapids, MI, USA


12:22 PM EXPERT DISCUSSANT: Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA
Collected Experience: What Can We Learn from the Registries?  (Calliope)
(PEDS, DMD, HF, HTX, ID, MCS, NHSAH, PEEQ)

CHAIRS: Charles E. Canter, MD and Dimpna C. Albert, MD

11:00 AM (31) Comparison of Transplant Waitlist Outcomes for Pediatric Candidates Supported By Ventricular Assist Devices vs. Medical Therapy Alone; S. Law¹, A. Oron², M. Kemna³, E. Albers⁴, D. McMullan⁴, J. Chen⁵, Y. Law⁵. ¹Columbia University College of Physicians and Surgeons, New York, NY, ²Seattle Children’s Research Institute, Seattle, WA, ³Seattle Children’s Hospital, Seattle, WA, ⁴Seattle Children’s Hospital, New York, WA

11:15 AM (32) Recipient-Donor Height Ratio and Outcomes in Pediatric Heart Transplantation; A. Patel¹, M. J. Bock¹, A. Wollstein¹, K. Nguyen², S. Malerba¹, I. D. Lytrivi³. ¹Pediatrics, Mt Sinai Med Ctr, New York, NY, ²Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ³Cardiothoracic Surgery, Mt Sinai Med Ctr, New York, NY

11:30 AM (33) Donor to Recipient Age Difference in Weight-Matched Pediatric Heart Transplants Predicts Mortality; F. Zafar¹, M. S. Khan¹, C. D. Castleberry², R. Bryant², C. Chin², D. L. Morales³. ¹Cardiothoracic Surgery, Cincinnati Children’s Hospital Med Ctr, Cincinnati, OH, ²Cardiology, Cincinnati Children’s Hospital Med Ctr, Cincinnati, OH

11:45 AM (34) The Impact of Ischemic Time on Early Rejection After Pediatric Heart Transplant; H. S. Magdo, J. M. Friedland-Little, S. Yu, R. J. Gajarski, K. S. Schumacher. Congenital Heart Center, C.S. Mott Children’s Hospital, University of Michigan, Ann Arbor, MI

12:00 PM (35) High BMI Predicts Poor Outcomes in DCM But Not CHD Patients: The Differential Impact of Obesity on Outcomes in Pediatric Heart Transplantation; R. R. Davies, S. S. Gidding, M. A. McCulloch, S. Haldeman, C. Pizarro. Nemours Cardiac Center, Nemours Cardiac Center Lucile Packard Children’s Hospital, Wilmington, DE

11:00 AM – 12:30 PM

CONCURRENT SESSION 7

Supporting the MCS Patient and Caregiver (Euterpe) (NHSAH, HF, HTX, MCS)

CHAIRS: Annette DeVito Dabbs, PhD, RN and Fabienne Dobbels, MSc, PhD

11:00 AM (37) Quality of Life and Burden in Caregivers at 3 Months After Left Ventricular Assist Device Implantation;
N. Kato¹, T. Jaarsma¹, I. Okada², Y. Kagami³, M. Endo³, M. Ono³, K. Kinugawa². ¹Social and Welfare Studies, Linköping University, Norrköping, Sweden, ²Therapeutic Strategy for Heart Failure, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, ³Cardiovascular Surgery, The University of Tokyo Graduate School of Medicine, Tokyo, Japan

11:15 AM (38) Mechanical Circulatory Support (MCS) Caregivers After Hospital Discharge: How Do They Want to Be Supported?;
M. G. Petty¹, D. Christensen². ¹University of Minnesota Medical Center, Minneapolis, MN, ²Innovative Program Solutions, LLC, Pine Grove, PA

11:30 AM (39) Pre-Hospital Care for VAD Patients: Where Are the Gaps?;
K. R. Powell¹, M. P. Flattery¹, L. F. Cei¹, S. P. Pinney², M. Peberdy¹, K. B. Shah¹. ¹Pauley Heart Center, Va Commonwealth Univ, Richmond, VA, ²Division of Cardiology, Mount Sinai Hospital, New York, NY

11:45 AM (40) Use of Facebook as a Virtual Community and Support Group By Left Ventricular Assist Device (LVAD) Patients;

12:00 PM (41) Evolution of Depressive Symptomatology and Caregiver Burden in Partners of LVAD Patients;
H. Bollen¹, K. Vandersmissen¹, J. Driesen¹, S. Mijten¹, W. Droognè², B. Meyns³, F. Dobbels³, ¹Cardiac Surgery, UZ Leuven, Leuven, Belgium, ²Cardiology, UZ Leuven, Leuven, Belgium, ³KULeuven, Leuven, Belgium

12:15 PM (42) Improving Bone Health in Children Supported on Ventricular Assist Devices;
B. Hawkins, J. Nobrega, S. Reidy, F. Fynn-Thompson, C. J. VanderPluym. Cardiology, Boston Children’s Hospital, Boston, MA
12:30 PM – 2:30 PM
LUNCH BREAK
JUNIOR FACULTY MENTOR LUNCH (Gallieni 1)

12:30 PM – 1:30 PM
BOX LUNCH DISTRIBUTION (Rhodes)
DCD REGISTRY MEETING (Gallieni 3)

12:45 PM – 1:45 PM
BASIC SCIENCE AND TRANSLATIONAL RESEARCH SCIENTIFIC COUNCIL MEETING (Gallieni 4)
NURSING, HEALTH SCIENCE AND ALLIED HEALTH SCIENTIFIC COUNCIL MEETING (Gallieni 7)
PHARMACY AND PHARMACOLOGY SCIENTIFIC COUNCIL MEETING (Gallieni 5)

1:30 PM – 2:30 PM
REGISTRIES AND DATABASES COMMITTEE MEETING (Gallieni 3)
2:30 PM – 4:00 PM

CONCURRENT SESSION 8

LVADs – Pre-Operative Factors Affecting Post-Operative Outcomes (Apollon) (MCS, BSI, HF, HTX, NHSAH)

CHAIRS: Claudius Mahr, DO and Andrew J. Lenneman, MD

2:30 PM (43) Risk Assessment for HeartWare HVAD Support as a Bridge to Transplant: Is the HeartMate II Risk Score Applicable?; L. Castle1, K. Aaronson1, M. Slaughter1, C. Salerno1, S. Moainie1, M. Walsh1, J. Cowger1. 1St. Vincent Hospital, Indianapolis, IN


3:00 PM (45) Gender Differences in Mechanical Circulatory Support – Insights From a European Registry; A. M. Bernhardt1, B. Sill1, F. M. Wagner1, T. M. deby2, J. Gum- mert1, P. Mohacsi1, H. Reichenspurner1, T. Deuse1. 1Department of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany, 2EUROMACS, Berlin, Germany, 3Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany, 4Clinic of Cardiolog- y, University Hospital Bern, Bern, Switzerland

3:15 PM (46) Characteristics and Outcomes in Patients Receiving Mechanical Circulatory Support With a History of Diabetes; R. S. Cantor, MSPH1, S. V. Pamboukian, MD, MSPH2, J. A. Tallaj, MD2, D. C. Naftel, PhD1, J. K. Kirklin, MD1. 1Cardiothoracic Surgery, The University of Alabama at Birmingham, Birmingham, AL, 2Cardiovascular Diseases, The University of Alabama at Birmingham, Birmingham, AL

3:30 PM (47) Inclusion of Cognitive and Mood Domains in the Assessment of Frailty Enhances Outcome Prediction in Patients Undergoing Ventricular Assist Device Implantation; M. K. Hannu1, S. Jha2, K. Wilhelm3, E. Montgomery4, P. Tunnicliff5, S. Shaw6, C. Hayward7, M. Harkess8, E. Kotlyar9, A. Jab- bouri10, A. M. Keogh11, E. Granger12, K. Dhta13, P. C. Jansz14, P. Newton15, D. Robson16, P. MacDonald17, P. M. Spratt18. 1Occupational Therapy, St. Vincent’s Hospital, Sydney, Australia, 2Heart & Lung Transplant Unit, St. Vincent’s Hospital, Sydney, Australia, 3Psychiatry, St. Vincent’s Hospital, Sydney, Australia, 4Health Science, University of Technology, Sydney, Australia, 5St. Vincent’s Hospital, Sydney, Australia

3:45 PM (48) Postoperative Liver Dysfunction Adversely Affects Survival After Continuous Flow LVAD Placement; K. Majumder1, L. Harvey1, S. Roy1, C. Holley1, P. M. Eckman2, K. Liao1, R. John1. 1Department of Surgery, University of Min- nesota, Minneapolis, MN, 2Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, MN
2:30 PM – 4:00 PM

CONCURRENT SESSION 9

Drivelines and Device Malfunction (Athena)

(MCS, HF, HTX, NHSAH, ID)

CHAIRS: Jan D. Schmitto, MD, PhD, MBA and Steven W. Boyce, MD

2:30 PM (49) Device Malfunction in Contemporary Rotary Blood Pumps: The Relevant Burden of All Components; R. L. Kormos1, M. McCall1, R. D. Schaub2, K. L. Lockard1, C. A. Bermudez3, N. M. Kunz1, E. M. Dunn1, L. F. Lagazzi1, J. J. Teuteberg1. 1Heart and Vascular Institute, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 2Bioengineering, Univ of Pittsburgh Med Ctr, Pittsburgh, PA.

2:45 PM (50) Outcomes of External Repair of HeartMate II Percutaneous Leads; J. D. Pal1, J. W. Smith1, T. Dardas2, C. Mahrt2, D. J. Farrar2, J. Pinette2, N. A. Mokadam1. 1Surgery, Univ of Washington, Seattle, WA, 2Medicine, Univ of Washington, Seattle, WA, 3Thoratec Corporation, Pleasanton, CA.

3:00 PM (51) Driveline Infection Is Not Associated With Increased Risk of Thrombotic Events in CF-LVAD Patients; J. Fried1, B. Cagliostro1, A. Levin1, O. Weyer-Pinzon1, A. R. Garan1, R. Te-Frey1, K. O. Ronquillo1, H. Takayama1, M. Yuzefpoliksaya1, D. M. Mancini1, Y. Naka1, P. C. Colombo1, U. Jorde2, N. Uriel3, V. Topkara1. 1Cardiology, Columbia University New York Presbyterian Hospital, New York, NY, 2Cardiology, Montefiore, New York, NY, 3Cardiology, University of Chicago, Chicago, IL.

3:15 PM (52) The Impact of Inflow Cannula Misalignment on Unloading in Patients With a Ventricular Assist Device; C. Swinney, A. Itoh, A. Keith, K. Balsara, S. Silvestry. Cardiovascular Surgery, Washington University School of Medicine, St. Louis, MO.

3:30 PM (53) Does Device Type Differentially Influence Pulmonary Vascular Resistance in Patients Bridged to Transplantation With a Continuous Flow Left Ventricular Assist Device?; L. Doss1, M. E. Davis2, M. Djunaidi1, M. Ruel1, S. Maltais1, N. A. Haglund1. 1Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN, 2Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, 3University of Ottawa Heart Institute, Ottawa, ON, Canada.

3:45 PM (54) Ventricular Assist Device in Acute Myocardial Infarction—Findings From INTERMACS; D. Acharya1, R. Y. Loyaga-Rendon2, J. A. Tallaj2, S. V. Pamboukian3, W. L. Holman1, J. F. George1, R. S. Cantor2, D. C. Nafte1, J. K. Kirklin1. 1Cardiovascular Diseases, The University of Alabama at Birmingham, Birmingham, AL, 2Cardiovascular Diseases, The University of Alabama at Birmingham, Birmingham, AL, 3Cardiothoracic Surgery, The University of Alabama at Birmingham, Birmingham, AL.
2:30 PM – 4:00 PM

CONCURRENT SESSION 10

Lung CLAD I: Translational Insights and Novel Markers (Clio, Thalie) (LTX, BSI, LF, PATH, PEDS)

CHAIRS:
Marie M. Budev, DO, MPH and Erik A.M. Verschuren, MD, PhD

(55) WITHDRAWN

2:30 PM (364) Lung Transplant Recipients Carrying rs2241880 GG Genotype of the Autophagy Gene ATG16L1 Are at Accelerated Risk for BOS Development;
C. Chen1, C. Santos1, H. J. Huang2, A. E. Gelman3. 1Medicine, Washington Univ Sch Med, St. Louis, MO, 2Medicine, Baylor University Medical Center at Dallas, St. Louis, MO, 3Surgery, Washington Univ Sch Med, St. Louis, MO

2:45 PM (56) Soluble CD59 Is a Novel Biomarker for the Prediction of the Bronchiolitis Obliterans Syndrome After Lung Transplantation;
K. Budding1, E. A. van de Graaf1, T. Kardol-Hoefnagel1, J. M. Kwakkel-van Erp2, B. Luijk3, E. D. Oudijk4, D. A. van Kessel1, J. C. Grutters5, C. E. Hack1, H. G. Otten1. 1Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Department of Respiratory Medicine, University Medical Center Utrecht, Utrecht, Netherlands, 3Center of Interstitial Lung Diseases, St Antonius Hospital Nieuwegein, Nieuwegein, Netherlands

3:00 PM (57) The Role of B-Cells in Phenotypes of Chronic Lung Allograft Dysfunction;

3:15 PM (58) New Predictive Proteic Biomarkers of Chronic Lung Allograft Dysfunction Identified in SysCLAD FP-7 Project;
J. Claudre1, C. Trocmé2, S. Bourgoin-Voilllard3, H. Flamant-Ware4, T. Bérardi, T. Bousquet4, A. Magnan4, L. P. Nicod5, C. Pison6, S. Consortium7. 1CHU de Grenoble, Grenoble, France, 2Laboratoire BEP, TIMC-IMAG, CHU de Grenoble, Grenoble, France, 3Prométhée Proteomic Platform, INSERM – IAB, Grenoble, France, 4Institut du Thorax, CHU de Nantes, Nantes, France, 5Service de Pneumologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, 6Clinique Universitaire de Pneumologie, CHU de Grenoble, Grenoble, France, 7FP-7 EU funded project, Lyon, France

3:30 PM (59) Transbronchial Brush (Tbbr) Reliably Quantifies Lymphocytic Bronchiolitis and Predicts Subsequent Chronic Lung Allograft Dysfunction;
S. T. Yerkovich, L. Samson, K. Sinclair, M. Tan, H. Gallagher, A. Fiene, P. Hopkins, D. Chambers. The Prince Charles Hospital, Brisbane, Australia

3:45 PM (60) Differential Airway Involvement in Restrictive Phenotypes of Chronic Lung Allograft Dysfunction;
S. E. Verleden1, R. Vos1, D. Ruttens1, E. Vandermeulen1, H. Bellon1, J. Mcdonough2, E. Verbeken2, J. Verschakelen3, D. E. Van Raemdonck1, B. Rondelet2, C. Knoop3, J. Hogg4, G. Verleden1, B. M. Vanaudenaerde1. 1Department of Clinical and Experimental Medicine, Division of Pneumology, KU Leuven, Leuven, Belgium, 2Unite de Transplantation Cardiaque et Pulmonaire, Université Libre de Bruxelles, Brussels, Belgium, 3Unite de Transplantation Cardiaque et Pulmonaire, Université Libre de Bruxelles, Brussels, Belgium, 4Center for Heart and Lung Innovation, University of British Columbia, Vancouver, BC, Canada
New Tools in the Fight Against Rejection (Erato, Uranie) (HTX, DMD, ID, NHSAH, PATH, PEDS, PHARM)

CHAIRS: Michal Zakliczynski, MD and Tuvia Ben Gal, MD

2:30 PM (61) Plasmapheresis and Bortezomib for Sensitized Patients Awaiting Heart Transplantation – Worth the Effort?:
Cedars-Sinai Heart Institute, Los Angeles, CA

2:45 PM (62) Terminal Complement Inhibition for Highly Sensitized Patients Undergoing Heart Transplantation – Doable?:
Cedars-Sinai Heart Institute, Los Angeles, CA

3:00 PM (63) Personalized Therapeutic Use of Intravenous Immunoglobulin in Heart Recipients With Severe Infections and IgG Hypogammaglobulinemia: Impact on Clinical Outcomes:
Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, Cardiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, Infectious Diseases, Hospital General Universitario Gregorio Marañon, Madrid, Spain, Anesthesiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain

3:15 PM (64) Increased Plasma Levels of Donor-Derived Cell-Free DNA Correlate With Rejection in Heart Transplant Recipients: The CARGO II Multicenter Trial:
Hospital Universitario A Coruña, A Coruña, Spain, Medical University of Vienna, Vienna, Austria, University Hospital Münster, Münster, Germany, University Hospital Bern, Bern, Switzerland, CareDx, Inc, Brisbane, CA, University Hospital Leuven, Leuven, Belgium

3:30 PM (65) Multicentre Study to Evaluate Conversion From Standard-Release Tacrolimus (SRT) to Extended-Release Tacrolimus (ERT) in a Large Series of Heart Transplanted Patients:
The Effect of Everolimus Initiation and Calcineurin Inhibitor Reduction on Allograft Vasculopathy in Maintenance Heart Transplant Recipients: Results of the NOCTET Trial After 5 Years; S. Arora, K. Karason, H. Eisjaer, H. Bøtker, F. Gustafsson, K. Saunamaki, G. Radegran, E. Gude, L. Aaberge, T. Ueland, P. Akrust, D. Solbu, L. Gullestad. 1Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 2Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, 3Cardiology, Skeby University Hospital, Aarhus, Denmark, 4Cardiology, Rigshospitalet, Copenhagen, Djibouti, 5Cardiology, Rigshospitalet, Copenhagen, Denmark, 6Cardiology, Lund Hospital, Lund, Sweden, 7Research Institute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 8Novartis Norge, Oslo, Norway
CONCURRENT SESSION 12

Donor Management/Organ Preservation-Heart: Lessons from the Registries (Hermes) (DMD-HEART, HTX)

CHAIRS: Ugolino Livi, MD and Rajamiyer Venkateswaran, FRCS

2:30 PM (67) Heart Transplant Survival Based on Recipient and Donor Risk Scoring: A UNOS Database Analysis; J. R. Trivedi1, M. Ising1, A. Cheng1, A. Lenneman1, E. Birks2, M. S. Slaughter1, 1Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY, 2Cardiovascular Medicine, University of Louisville, Louisville, KY

2:45 PM (68) Virtual Size Matching in Heart Transplantation: Novel Method Outperforms Weight-Based Matching; Z. Taimeh1, S. Duval1, C. Martin2, P. Eckman1, 1Cardiovascular Medicine, University of Minnesota School of Medicine, Minneapolis, MN, 2Cardiovascular Medicine, University of Minnesota School of Medicine, Minneapolis, MN

3:00 PM (69) Cardiac Donor Characteristics Predictive of One Year Post-Heart Transplant Mortality: Analysis of the UNOS Transplant Database; R. A. Sorabella1, M. Najjar1, E. Castillero1, A. Kantor1, A. Liu1, V. Topkara2, P. Colombo2, M. Farr3, H. Takayama4, P. C. Schulze1, D. Mancini1, Y. Naka4, I. George1, 1Cardiothoracic Surgery, Columbia University College of Physicians and Surgeons, New York, NY, 2Cardiology, Columbia University College of Physicians and Surgeons, New York, NY

3:15 PM (70) Transplantation of Center for Disease Control “High Risk” Donor Hearts Does Not Adversely Impact Long Term Outcomes in Adults; A. C. Gaffey1, A. J. Cucchiara1, G. Hung1, L. R. Goldberg2, E. A. Blumberg1, M. A. Acker1, P. Atluri1, 1Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, PA, 2Institute for Translational Medicine & Therapeutics; Clinical & Translational Research Center, University of Pennsylvania, Philadelphia, PA, 3Division of Cardiology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, 4Division of Infectious Disease, Department of Medicine, University of Pennsylvania, Philadelphia, PA

3:30 PM (71) Does Lung Donation By Heart Donors Impact Survival in Heart Transplant Recipients; Y. Xia1, P. Friedmann2, R. Bello1, D. Goldstein1, D. D’Alessandro1, 1Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY, 2Albert Einstein College of Medicine, Bronx, NY

3:45 PM (72) Prediction of Primary Graft Dysfunction After Heart Transplantation; J. Nilsson1, M. Ohlsson2, J. Stelhle1, L. Lund4, B. Andersson5, 1Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University Hospital, Lund, Sweden, 2Astronomy and Theoretical Physics, Computational Biology and Biological Physics, Lund University, Lund, Sweden, 3Cardiovascular Medicine, University of Utah School of Medicine, Utah, UT, 4Medicine, Unit of Cardiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, 5Clinical Sciences Lund, Surgery, Lund University and Skane University Hospital, Lund, Sweden
Long Live the Graft! Factors Impacting Long-term Outcome

CHAIRS: Anne I. Dipchand, MD and Tajinder P. Singh, MD, MS

2:30 PM  Hemodynamic Profiles in Children With End-Stage Heart Failure: Analysis of Data From the Pediatric Heart Transplant Study Group; S. Chen, R. J. Gajarski, A. Lin, L. J. May, D. N. Rosenthal, M. D. Evrirt, D. B. McElhinney, A. Y. Shin, S. A. Hollander, E. Pruitt, C. S. Almond, Division of Pediatric Cardiology, Stanford University, Palo Alto, CA. 1University of Michigan Congenital Heart Center, C. S. Mott Children’s Hospital, Ann Arbor, MI, 1Division of Pediatric Cardiology, Primary Children’s Hospital, Salt Lake City, UT, 2Department of Cardiovascular Surgery, Stanford University, Palo Alto, CA, 2Data Coordinating Center, University of Alabama at Birmingham, Birmingham, AL

2:45 PM  Does Oversizing Donors Have Any Benefit for Pediatric Heart Transplant Recipients With Elevated Pulmonary Vascular Resistance?; F. Zafar, M. S. Khan, R. Bryant, C. D. Castleberry, C. Chin, D. L. Morales, Cardiothoracic Surgery, Cincinnati Children’s Hospital Med Ctr, Cincinnati, OH, 2Cardiology, Cincinnati Children’s Hospital Med Ctr, Cincinnati, OH


3:15 PM  Early Cardiac Graft Performance in Pediatric Retransplantation: What Can We Learn?; M. Naguib, C. A. Cundiff, B. Shehata, W. Mahle, S. R. Deshpande, Emory University School of Medicine, Atlanta, GA, 2Department of Pathology, Emory University Children’s Healthcare of Atlanta, Atlanta, GA, 3Pediatric Cardiology, Emory University Children’s Healthcare of Atlanta, Atlanta, GA

3:30 PM  A Multi-Institutional Evaluation of Antibody-Mediated Rejection Utilizing the PHTS Database: Incidence, Therapies, and Outcomes; P. T. Thrush, E. Pahl, D. C. Naftei, E. Pruitt, M. D. Evrirt, H. Missler, S. D. Zangwill, M. Burch, T. M. Hoffman, R. J. Butts, W. T. Mahle, 1Cardiology, Nationwide Children’s Hospital, Columbus, OH, 2Cardiology, Ann & Robert H. Lurie Children’s Hospital, Chicago, IL, 3University of Alabama at Birmingham, Birmingham, AL, 4Primary Children’s Medical Center, Salt Lake City, UT, 5Children’s Hospital of Wisconsin, Milwaukee, WI, 6Great Ormond Street Hospital, London, United Kingdom, 7Medical University of South Carolina, Charleston, SC, 8Children’s Healthcare of Atlanta, Atlanta, GA

3:45 PM  Lipid Levels in the Post Heart Transplant Patient: Are They Predictive of Graft Failure?; S. Sexson Tejtel, A. Jeewa, A. Cabrera, J. F. Price, W. J. Dreyer, S. W. Denfield, Pediatric Cardiology, Texas Childrens Hospital/Baylor College of Medicine, Houston, TX
2:30 PM – 4:00 PM

CONCURRENT SESSION 14

Philip K Caves Award Candidate Presentations
(Euterpe)
(ALL)

CHAIRS: Bruno Reichart, MD and Stuart W. Jamieson, MB, FRCS

2:30 PM (79) Impact of the 18th Birthday on Wait-list Outcome for US Patients Listed for Heart Transplant; D. M. Peng1, N. McDonald1, O. Reinhardt2, L. Barkoff, S. A. Holdanner1, A. Lin1, J. Yeh1, D. N. Rosenthal1, C. S. Almond1. 1Department of Pediatrics, Division of Pediatric Cardiology, Stanford University/Lucile Packard Children's Hospital Stanford, Palo Alto, CA, 2Department of Cardiothoracic Surgery, Stanford University, Palo Alto, CA

2:45 PM (80) The Amount of Autophagy-Related Cardiomyocyte Cell Death Is Associated With the Type of Pathogenic Mutation in Genetic Dilated Cardiomyopathy; Z. J. van der Klooster1, S. Sepehrkhouy1, M. Harakalova1, R. Goldschmeding1, N. de Jonge1, A. J. Suurmeijer1, R. A. de Weger1, F. W. Asselbergs1, A. Vink1. 1Pathology, University Medical Center Utrecht, Utrecht, Netherlands, 2Pathology, University Medical Center Groningen, Groningen, Netherlands

3:00 PM (81) Coronary Allograft Arteriosclerosis: Local MicroRNA Modulation Using a Novel Anti-Mir-21-Eluting Stent Prevents in-Stent Restenosis; D. Wang1, T. Deuse2, M. Stubbendorff1, E. Chernogubova1, R. G. Erben1, S. M. Eken1, H. Jin3, C. Heeger4, B. Behnisch3, H. Reichenspurner1, R. C. Robbins5, J. M. Spin6, P. S. Tsao7, L. Maegdefessel1, S. Schrepfer1. 1University Heart Center Hamburg, Transplant and Stem Cell Immunobiology Lab (TSI), Hamburg, Germany, 2CT Surgery, University Heart Center Hamburg, Hamburg, Germany, 3Atherosclerosis Research Unit, Karolinska Institute, Stockholm, Sweden, 4Veterinary Medicine, University of Vienna, Vienna, Austria, 5Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany, 6Translumina GmbH, Hechingen, Hechingen, Germany, 7CT Surgery, Stanford University, Stanford, CA, 8Veterans Affairs Palo Alto Health Care System, Stanford University, Stanford, CA, 9josh.spin@gmail.com, Stanford University, Stanford, CA, 10Stanford University Transplant and Stem Cell Immunobiology Lab (TSI), Stanford, CA

3:15 PM (82) Human Induced Pluripotent Stem Cells for Tissue Engineered Cardiac Repair; S. Pecha1, F. Weinberger2, K. Breckwoldt2, B. Geertz2, J. Sambathy2, A. Hansen1, H. Reichenspurner1, T. Eschenhagen1. 1Cardiovascular Surgery, Univ Hospital Hamburg, Hamburg, Germany, 2Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 3Cardiovascular Surgery, University Hospital Hamburg, Hamburg, Germany

3:30 PM (83) TOWARDS DONOR LUNG RECOVERY – GENE EXPRESSION CHANGES DURING EX-VIVO LUNG PERFUSION; J. C. Yeung, R. Zamel, X. Bai, T. N. Machuca, M. Liu, M. Cypel, S. Keshavjee. Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada

3:45 PM (84) Long Term Measurements of Aortic Root and Left Ventricular Dimensions in Patients on HeartWare® Ventricular Assist Device – An Explanation for the Development of Aortic Incompetence in Chronic LVAD Support?; S. K. Bhagra1, C. J. Bhagra1, N. Wrightson2, G. A. MacGowan1, S. Schueler1. 1Cardiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom, 2Cardiopulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom, 3Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom
4:00 PM – 4:30 PM
Coffee Break/Visit Exhibits (Rhodes)
VIEW POSTERS (Agora 2)

2016 ANNUAL MEETING SYMPOSIUM PLANNING COMMITTEE MEETING (Gallieni 4)
4:30 PM – 6:00 PM

CONCURRENT SESSION 15

Myocardial Recovery – Moving Forward (Apollon) (MCS, BSI, HF, HTX, PHARM)

CHAIRS: Stavros G. Drakos, MD and J Eduardo Rame, MD

4:30 PM (85) Remission From Stage D Heart Failure (RESTAGE-HF): Early Results From a Prospective Multi-Center Study of Myocardial Recovery; E. J. Birks1, S. Drakos2, C. Selzman3, R. Starling4, C. Cunnigham5, M. Slaughter6, D. M. Spevack7, A. Salahuddin8, P. Alturi9, J. Um10, B. Loues11, S. Patel12, D. Farrar13, F. Kallel13, J. E. Rame13. 1Cardiovascular Medicine, University of Louisville, Louisville, KY, 2Cardiovascular Medicine, University of Utah, Salt Lake City, UT, 3Cardiovascular Surgery, University of Utah, Salt Lake City, UT, 4Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, 5Clinical Trials Unit, University of Louisville, Louisville, KY, 6Cardiovascular Surgery, University of Louisville, Louisville, KY, 7Department of Echocardiography, Montefiore, New York, NY, 8Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA, 9Cardiovascular Surgery, University of Nebraska, Omaha, NE, 10Cardiovascular Medicine, University of Nebraska, Omaha, NE, 11Cardiovascular Medicine, Montefiore, New York, NY, 12Thoratec Corporation, Pleasanton, CA, 13Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA


5:15 PM (88) Ventricular Reconditioning Enables De-escalation of Therapy in Young Patients Supported By Continuous Flow Left Ventricular Assist Devices; A. C. Baldwin, E. Sandoval, S. K. Singh, W. E. Cohn, H. R. Mallidi, C. Frazier. Cardiothoracic Transplant, Texas Heart Institute, Houston, TX

5:30 PM (89) Absolute Reduction in Left Ventricular End Diastolic Diameter (Greater Than 0.65cm) in Patients With Continuous Flow Left Ventricular Assist Devices (CF-LVAD) Reflects Complete LV Unloading Defined By Invasive Hemodynamics; C. Eshelbrenner, A. M. Cordero-Reyes, A. Bhimaraj, B. H. craftsmen, G. Ashrith, B. E. Cohn, A. Loebe, G. Torre-Amione, J. D. Estep. Cardiology, Houston Methodist Hospital, Houston, TX

(90) WITHDRAWN

5:45 PM (323) Structural and Functional Myocardial Improvement Following Continuous-Flow Mechanical Unloading in Chronic Ischemic and Non-Ischemic Cardiomyopathy; J. Wever-Pinzon, M. Al-Sarie, A. Catino, R. McCubre, J. Stehlik, A. Kfoury, B. Reid, O. Wever-Pinzon, R. Alharethi, S. Wright, D. Lit, E. Gilbert, S. McKellar, J. Barney, J. Fang, C. Selzman, S. Drakos. U.T.A.H Cardiac Transplant Program, (University of Utah, Intermountain Medical Center, VA Medical Center), Salt Lake City, UT
4:30 PM – 6:00 PM

CONCURRENT SESSION 16

Strokes, Arrhythmias and LVADs (Athena)

(MCS, BSI, HF, HTX, NHSAH, PHARM)

CHAIRS: Chetan B. Patel, MD and Cumara C. Sivathasan, MBBS, FRCS

4:30 PM (91) Neurological Events in Patients Bridged to Long-Term Mechanical Circulatory Support: A Device Specific Comparative Analysis; S. Maltais, N. A. Haglund, M. E. Davis, M. R. Danter, M. Xu, S. M. Dunlay, J. A. Cowger, P. Shah, K. Aaronson, F. D. Paganii, J. M. Stulak. 1Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, 2Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN, 3Cardiac Surgery, Vanderbilt University, Nashville, TN, 4Biostatistics, Vanderbilt Univ Med Ctr, Nashville, TN, 5Cardiovascular Medicine, Mayo Clinic, Rochester, MN, 6Cardiovascular Medicine, St Vincent Heart, Indianapolis, IN, 7Cardiovascular Medicine, Inova Fairfax, Falls Church, VA, 8Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, 9Cardiac Surgery, University of Michigan, Ann Arbor, MI, 10Cardiac Surgery, Mayo Clinic, Rochester, MN

4:45 PM (92) Ventricular Assist Device Patients Have Different Clinical Outcomes and Altered Pattern of Bleeding With Intracranial Hemorrhage; M. Ahmed, M. Rahman, D. Neal, J. Aranda, Jr, C. T. Klodell, Jr. 1Division of Cardiovascular Medicine, University of Florida, Gainesville, FL, 2Department of Neurosurgery, University of Florida, Gainesville, FL, 3Division of Thoracic and Cardiovascular Surgery, University of Florida, Gainesville, FL


5:15 PM (94) Preoperative Atrial Fibrillation Does Not Increase Thromboembolic Events Following LVAD Implantation: An INTERMACS Registry Analysis; D. Stern, Y. Xia, P. Friedmann, D. Goldstein. 1Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY, 2Albert Einstein College of Medicine, Bronx, NY

5:30 PM (95) Temporal Differences in Adverse Event Rates in Patients Bridged with the HeartWare Left Ventricular Assist Device; S. Maltais, K. D. Aaronson, J. J. Teuteberg, M. S. Slaughter, S. S. Najjar, V. Jeevanandam, D. T. Pham, E. C. McGee, K. Najiarian, R. L. Kormos. 1Vanderbilt University Medical Center, Nashville, TN, 2University of Michigan, Ann Arbor, MI, 3University of Pittsburgh Medical Center, Pittsburgh, PA, 4University of Louisville, Louisville, KY, 5MedStar Heart Institute, Washington, DC, 6University of Chicago Medicine, Chicago, IL, 7Tufts Medical Center, Boston, MA, 8Northwestern Memorial Hospital, Chicago, IL, 9HeartWare, Framingham, MA

Lung CLAD II: New Observations and Therapies on the Horizon (Clio, Thalie)
(LTX, BSI, LF)

CHAIRS: Geert M. Verleden, MD, PhD and Tereza Martinu, MD

4:30 PM (97) Chronic Lung Allograft Dysfunction After Bilateral Living Donor Lobar Lung Transplantation; K. Miyoshi, T. Oto, S. Sugimoto, M. Yamane, S. Miyoshi. Department of Thoracic Surgery / Organ Transplant Centre, Okayama University Hospital, Okayama, Japan


5:00 PM (99) Interleukin-1 Induced Interleukin-8 Production in Human Airway Epithelial Cells Pretreated With Azithromycin: A Possible Mechanism for Neutrophilic BOS?; H. Bellon, E. Vandermeulen, S. E. Verleden, D. Ruttens, H. Vriens, P. H. Hoet, B. M. Vanaudenaerde, R. Vos, G. M. Verleden. Department of Clinical and Experimental Medicine, KU Leuven University, Leuven, Belgium

5:15 PM (100) KL-6 Changes in Serum Can Be Predictive of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients; V. Besa, F. Bonella, S. Ohshimo, G. Weinreich, U. Costabel, H. Kamler, H. Teschler, U. Sommerwerck. Pneumology, Ruhrlandklinik, West German Lung Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Interstitial and Rare Lung Disease Unit, Ruhrlandklinik, West German Lung Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany; Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan; Thoracic Transplantation, University Hospital Essen, University Duisburg-Essen, Essen, Germany

5:30 PM (101) The Association of Donor Age and Survival Is Independent of Ischemic Time Following Cadaveric Lung Transplantation; B. C. Gulack, A. M. Ganapathi, P. J. Speicher, B. R. Englum, L. D. Snyder, R. D. Davis. Department of General Surgery, Duke University, Durham, NC; Department of Medicine, Duke University, Durham, NC

5:45 PM (102) Impact of Repeated Mismatch Human Leukocyte Antigen on the Outcome of Lung Retransplantation; H. Wang, L. Wan, Q. Yang, W. E. Hanshew, R. D. Davis. Clinical Transplantation Immunology Laboratory, Duke University Medical Center, Durham, NC; Transfusion Service, The Affiliate Hospital of Qingdao University, Qingdao, China; School of Nursing, Duke University, Durham, NC; Department of Surgery, Duke University Medical Center, Durham, NC
CONCURRENT SESSION 18

Crystal Ball: Predicting Outcomes in Heart Transplantation (Erato, Uranie) (HTX, BSI, DMD, HF, MCS, NHSAH, PATH, PEDS, PHARM, PEEQ)

CHAIRS: Donna M. Mancini, MD and Paul J. Mohacsi, MD


4:45 PM (104) The Impact of Postoperative Pulmonary Hypertension and Elevated Diastolic Pressure Difference on Outcome After Heart Transplantation; J. Lundgren, G. Rådegran. Dept. of Cardiology, Clinical Sciences, Lund University, Lund, Sweden

5:00 PM (105) Influence of Liver Dysfunction in Patients Undergoing Heart Transplantation With Left Ventricular Assist Device Explantation: Comparative Analysis Using the MELD Excluding INR (MELD-X1) Scoring System; S. Maltais1, M. E. Davis1, M. R. Danter1, J. M. Stulak2, N. A. Haglund1. 1Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, 2Cardiac Surgery, Mayo Clinic, Rochester, TN, 3Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN


5:45 PM (108) Prolonged LVAD Support Effects Morbidity But Not Mortality Following Heart Transplant; J. C. Grimm1, A. S. Shah1, G. J. Whitman1, C. M. Sciortino1, J. Magruder1, S. D. Russell1, G. A. Ewald1, S. C. Silvestry1. 1Surgery, The Johns Hopkins Medical Institution, Baltimore, MD, 2Medicine, The Johns Hopkins Medical Institution, Baltimore, MD, 3Medicine, Barnes Jewish Hospital, St. Louis, MO, 4Surgery, Barnes Jewish Hospital, St. Louis, MO
CONCURRENT SESSION 19

**Emerging Countries Session 1 (Hermes)**

**CHAIRS:** Mandeep R. Mehra, MD, MBBS, FACC, FACP
Lori J. West, MD, DPhil and
Theodoros Kofidis, MD, PhD, FRCS

**4:30 PM (109) Effective Transcutaneous Energy Transfer Allows for More Than 6 Hours of Freedom From External Gear – The Future Is Here;**

Y. Kassif, M. Zilbershlag, M. Levy, S. Schueler. 1Cardiac Surgery, Sheba Medical Center, Ramat Gan, Israel, 2Leviticus Cardio, Ramat Gan, Israel, 3cardiac surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom

**4:45 PM (110) VAD Destination Therapy Outcomes – Kazakhstan’s Experience;**

Y. Pya, A. Medressova, S. Murzagaliyev, S. Dzhetybayeva, S. Andossova, M. Bekbossynov, M. Bekbossynova. 1CEO, National Research Center for Cardiac Surgery, Astana, Kazakhstan, 2Cardiac Surgery, National Research Center for Cardiac Surgery, Astana, Kazakhstan, 3Cardiology, National Research Center for Cardiac Surgery, Astana, Kazakhstan, 4VAD Department, National Research Center for Cardiac Surgery, Astana, Kazakhstan, 5National Research Center for Cardiac Surgery, Astana, Kazakhstan

**5:00 PM (111) Outcomes of Implantable Left Ventricular Assist Devices in a South East Asian Population;**

L. L. Chan, C. Lim, C. Sivathasan, C. Lim, T. Tan, J. Soon, K. Kerk. 1Cardiology, National Heart Centre Singapore, Singapore, Singapore, 2Cardiothoracic and Vascular Surgery, National Heart Centre Singapore, Singapore, Singapore

**5:15 PM (112) The Current Status of Heart Transplantation and Mechanical Circulatory Support in Turkey: Facts and Factors;**

M. Sargin, G. Orhan, S. A. Aka, M. E. Mete, R. Akar, M. A. Ozatik, C. Engin, M. Balkanay, B. Omer, 1Cardiovascular Surgery, Siyami Ersek Hospital, Istanbul, Turkey, 2Cardiovascular Surgery, Ankara University, Ankara, Turkey, 3Heart Transplantation Council, Ministry of Health, Ankara, Turkey, 4Cardiovascular Surgery, Ege University, Istanbul, Turkey, 5Cardiovascular Surgery, Akdeniz University, Antalya, Turkey

**5:30 PM (113) More Than 200 Heart Transplantation From the Single Centre in the Middle East; Twenty Two Heart Transplantation During the First 10 Months at King Faisal Specialist Hospital and Research Centre, Riyadh;**


**5:45 PM (114) Primary Immunosuppression and Outcome Differences After Heart Transplantation: Cyclosporin/Azathioprine/Steroid vs. Tacrolimus/Mycophenolate mofetil/Steroid – 22 Years’ National Experience of Korea;**

H. Lee, J. Kim, G. Lee, E. Jeon. 1Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of, 2Internal Medicine, Asan Medical Center, Seoul, Korea, Republic of, 3Internal Medicine, Samsung Medical Center, Seoul, Korea, Republic of
Basic Science 1: Inflammation, Immune Monitoring, Immune Suppression (Calliope) (ALL)

**CHAIRS:** Kyung-Hee Kim, MD and Esme Dijke, PhD

**4:30 PM**

**(115) Correlative Changes in Macrophage Polarization and Pulmonary Microbiota in Lung Transplant Recipients:**

E. Bernasconi, A. Koutsokera, C. Pattaroni, D. Dumas, B. Camara, B. J. Marsland, C. Benden, C. Pison, J. Aubert, L. P. Nicod

1. Pulmonary Division, CHUV, Lausanne, Switzerland
2. CHU, Grenoble, France
3. University Hospital Zurich, Zurich, Switzerland
4. Pulmonary Division, CHUV and STCS, Lausanne, Switzerland
5. Pulmonary Division, CHUV and SysCLAD FP7 Consortium, Lausanne, Switzerland

**4:45 PM**

**(116) Cardiac Allograft Tolerance Induction via Anti-LFA-1 Monotherapy Is Dependent on an Indirect CD8 T-Cell:**


1. Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver, Aurora, CO
2. Division of Pediatric Cardiology, University of Florida, Gainesville, FL

**5:00 PM**

**(117) In Vivo Development of Transplant Arteriosclerosis in Humanized Mice Reflects Alloantigen Recognition of Lung Transplant Recipients and Is Controlled by Autologous Regulatory T Cells:**


**5:15 PM**

**(118) Acute Allograft Rejection Is Attenuated By CD26-Inhibition Through IL-17 Suppression in Mouse Lung Transplants:**

Y. Yamada, J. Jang, I. De Meester, I. Inci, W. Weder, W. Jungrichmayr

1. Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland
2. Department of Medical Biochemistry, University of Antwerp, Antwerp, Belgium

**5:30 PM**

**(119) A Novel Ex-Vivo Intrabronchial Delivery of Lentivirus IL-10 Gene Therapy Attenuates Both Acute Allograft Rejection and Bronchiolitis Obliterans After Murine Orthotopic Lung Transplantation:**


1. Latner Thoracic Surgery Research Laboratories, University Health Network, University of Toronto, Toronto, ON, Canada
2. Department of Thoracic Surgery, Kyoto University, Kyoto, Japan
3. Department of Surgery, Okayama Rosai Hospital, Okayama, Japan
4. Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan

**5:45 PM**

**(120) Quantification of Donor Specific Cell-Free DNA Yields Extremely High Sensitivity for Detection of Rejection Following Cardiac Transplantation:**


1. Surgery, Pediatric Cardiothoracic Surgery, Children's Hospital of Wisconsin, Milwaukee, WI
2. Pediatrics, Children's Hospital of Wisconsin, Milwaukee, WI
Kinetics, Coagulation, and Cardiology – Pharmacy of MCS and Transplant (Euterpe) (PHARM, HTX, ID, LTX, MCS)

**CHAIRS:** Michael Shullo, PharmD and Katrina Ford, BPharm

**4:30 PM** (121) Assessing Anticoagulation Practice Patterns in Patients on Durable Mechanical Circulatory Support Devices: An International Survey; D. L. Jennings1, E. Horn2, H. Lyster3, A. Panos4, J. Teuteberg5, H. Lehmkuhl3, W. Wolovich1, M. Shullo5. 1Nova Southeastern University, Miami, FL, 2Allegheny General Hospital, Pittsburgh, PA, 3Royal Brompton & Harefield NHS Foundation Trust, Middlesex, United Kingdom, 4Miami Transplant Institute, Miami, FL, 5University of Pittsburgh Medical Center, Pittsburgh, PA

**4:45 PM** (122) Optimal Low Density Lipoprotein Levels Prevent Cardiac Allograft Vasculopathy; J. Harris, J. Teuteberg, J. Coons, D. Winger, M. Shullo. University of Pittsburgh Medical Center, Pittsburgh, PA

**5:00 PM** (123) The Use of Three Factor Prothrombin Complex Concentrate to Reverse Warfarin Treated Mechanical Circulatory Device Patients Immediately Prior to Heart Transplant; R. H. Cosgrove1, A. E. Patanwala1, B. L. Sears1, Z. Khalpey2, R. Basken1, S. D. Lick1. 1Department of Pharmacy Services, University of Arizona Medical Center, Tucson, AZ, 2Department of Pharmacy Practice, University of Arizona College of Pharmacy, Tucson, AZ

**5:15 PM** (124) Achieving Therapeutic Posaconazole Levels for Fungal Prophylaxis After Lung Transplantation: Oral Suspension Versus Delayed-Release Tablets; M. L. Hurtik1, R. Bag2, D. C. Neujahr2. 1Pharmaceutical Services, Emory University Hospital, Atlanta, GA, 2Emory Transplant Center, Emory University, Atlanta, GA

**5:30 PM** (125) Trough Blood Levels Are a Poor Marker of Tacrolimus Exposure in Lung Transplantation; D. R. Darley, A. R. Glanville. Thoracic Medicine, St. Vincent's Hospital, Darlinghurst, Australia

**5:45 PM** (126) Potent P2Y12 ADP Receptor Inhibition With Ticagrelor Can Normalize Lactate Dehydrogenase and Avoid Pump Exchange in Acute HeartMate II Thrombosis; G. H. Oliveira, S. Al-Kindi, M. Qattan, M. Ginwalla, C. ElAmm, S. Deo, S. J. Park, D. I. Simon. University Hospitals Case Medical Center, Cleveland, OH
6:00 PM – 7:00 PM

MINI ORAL SESSION 1

Fear and Loathing in Mechanical Circulatory Support (Athena)
(MCS, HTX)

CHAIRS: Andrew J. Boyle, MD and Francesco Moscato, PhD

6:00 PM

(127) High Early Event Rates in Patients With Questionable Eligibility for Advanced Heart Failure Therapies; A. V. Ambardekar, MD, R. C. Forde-McLean, MD, MHS, M. M. Kittleson, MD, Ph.D, G. C. Stewart, MD, M. Palardy, MD, J. T. Thibodeau, MD, A. D. DeVore, MD, M. M. Mountis, DO, L. Cadaret, MD, J. J. Teuteberg, MD, S. V. Pamboukian, MD, MSPH, R. S. Cantor, MSPH, J. Lindenfeld, MD. Medicine-Cardiology, The University of Colorado, Aurora, CO, Medicine, University of Pennsylvania, Philadelphia, PA, Cardiology, Cedars-Sinai Heart Institute, Los Angeles, CA, Advanced Heart Disease, Brigham and Women's Hospital, Boston, MA, Internal Medicine/Cardiovascular, The University of Michigan, Ann Arbor, MI, Internal Medicine/Cardiology, UT Southwestern, Dallas, TX, Cardiology, Duke Clinical Research Institute, Durham, NC, Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, Cardiology, The University of Iowa, Iowa City, IA, Heart and Vascular Institute, The University of Pittsburgh, Pittsburgh, PA, Cardiovascular Diseases, The University of Alabama at Birmingham, Birmingham, AL, Cardiothoracic Surgery, The University of Alabama at Birmingham, Birmingham, AL, Medicine, The University of Colorado, Aurora, CO

6:05 PM

(128) DeRitis-Quotient Predicts Mortality After LVAD Implantation; H. Carstens, K. Pilarczyk, J. Heckmann, A. Canbay, H. Jakob, N. Pizanis, M. Kamler. University Essen, Essen, Germany

6:10 PM

(129) Early Reassessment of Ambulatory Advanced Heart Failure Detects High-Risk Trajectories Along a Dynamic Baseline; G. C. Stewart, M. M. Mountis, M. M. Kittleson, A. V. Ambardekar, M. Palardy, R. C. Forde-McLean, J. T. Thibodeau, J. J. Teuteberg, S. V. Pamboukian, A. D. DeVore, L. Cadaret, R. S. Cantor, L. W. Stevenson. Advanced Heart Disease, Brigham and Women's Hospital, Boston, MA, Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, Cardiology, Cedars-Sinai Heart Institute, Los Angeles, CA, Medicine-Cardiology, The University of Colorado, Aurora, CO, Cardiovascular/Internal Medicine, The University of Michigan, Ann Arbor, MI, Medicine, The University of Pennsylvania, Philadelphia, PA, Internal Medicine/Cardiology, UT Southwestern, Dallas, TX, Heart and Vascular Institute, The University of Pittsburgh Medical Center, Pittsburgh, PA, Cardiovascular Diseases, The University of Alabama at Birmingham, Birmingham, AL, Cardiothoracic Surgery, The University of Iowa, Iowa City, IA, Cardiothoracic Surgery, The University of Alabama at Birmingham, Birmingham, AL

6:15 PM

(130) Low Cardiac Power Index (CPI) Is Associated With Higher Mortality in Cardiogenic Shock; Stratifying INTERMACS 1 and 2 Patients Undergoing Continuous-Flow LVAD (CF-LVAD) Implantation; F. Kamdar, N. Sathnur, A. Klaassen Kamdar, P. M. Eckman, R. John. University of Minnesota, Minneapolis, MN

(131) Moved to Concurrent Session 44
6:20 PM (500) A Weekly Dressing Protocol Reduces the Incidence of Driveline Infection; M. Puhlman, L. Wang, R. Sullivan, K. Evenson, J. Remick, G. Ott, J. Abraham. Center for Advanced Heart Disease, Providence St Vincent Medical Center, Portland, OR

6:25 PM (132) Does Indication for Destination Therapy Affect Left Ventricular Assist Device Outcomes?; D. Abramov1, N. A. Haglund1, M. E. Davis2, Y. Song3, K. Aaronson4, P. D. Paganelli4, S. Dunlay4, J. Stulak5, S. Maltais5. 1Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN, 2Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, 3Biostatistics, Vanderbilt Univ Med Ctr, Nashville, TN, 4Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, 5Cardiac Surgery, University of Michigan, Ann Arbor, MI

6:30 PM (133) WITHDRAWN

6:35 PM (504) Continuous Flow LVAD Support in Restrictive and Obstructive Cardiomyopathies: An INTERMACS Registry Report; D. J. Goldstein1, S. R. Patel2, S. L. Myers3, D. C. Naftel3, J. K. Kirklin4. 1Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY, 2Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, 3Department of Surgery, University of Alabama at Birmingham, Birmingham, AL

6:40 PM (134) Patterns of Mechanical Circulatory Support By Heart Failure Etiology in Patients Listed for Heart Transplantation; S. Al-Kindi, S. Kumar, M. Ige, M. Ginwalla, C. ElAmm, S. Deo, S. J. Park, G. H. Oliveira. University Hospitals Case Medical Center, Cleveland, OH


6:50 PM (136) The Effect of Pre and Post Implant Anemia on Outcomes of Patients With Left Ventricular Assist Device; E. Y. Birati1, T. C. Hanff2, J. A. Mazurek1, S. Barber1, E. Grandin1, D. Pedrotti1, E. Vorovich1, J. L. Howard2, M. Acker1, J. N. Kirkpatrick1, L. R. Goldberg1, P. Atluri1, M. Jessup1. 1Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA, 2Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA

6:55 PM (137) Pre-MCS Prothrombin and Factor V Leiden Gene Mutation Testing May Lead to More Bleeding; A. K. Ravichandran1, J. A. Cowger1, T. P. Schleeter1, S. Moamie2, C. T. Salerno2. 1Division of Cardiology, St. Vincent Medical Group, Indianapolis, IN, 2Division of Cardiothoracic Surgery, St. Vincent Medical Group, Indianapolis, IN

6:50 PM (138) A Novel Socioeconomic Metric for Evaluating Outcomes After Left Ventricular Assist Device Implantation; A. D. Keith1, S. M. Joseph1, A. Godishala1, A. Khan1, N. Jarvis1, K. Balsara1, S. LaRue1, S. Silvestry1, A. Itoh2. 1Cardiothoracic Surgery, Washington University, St. Louis, MO, 2Cardiology, Washington University, St. Louis, MO
Biology and the Rise of the Machine (Clio, Thalie) (HTX, MCS, HF)

CHAIRS: Ivan Knezevic, MD and Tobias Deuse, MD, PhD

6:00 PM (139) Outcomes in Adult Congenital Heart Failure Patients Undergoing Heart Transplantation: A Systematic Review and Meta-Analysis; B. S. Doumouras, A. C. Alba, F. Foroutan, L. J. Burchill, A. I. Dipchand, H. J. Ross. 1Heart Failure and Transplantation Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada, 2Knight Cardiovascular Institute, Oregon Health and Science University, Portland, OR, 3Hospital for Sick Children, Toronto, ON, Canada

6:05 PM (140) Correlation Between Lipid Levels and Cardiovascular Events in Heart Transplant Recipients: 24-Month Analysis of the A2310 Study; L. Potena, C. Bara, G. Dong, P. Lopez, E. Epailly. 1Academic Hospital S.Orsola-Malpighi, Bologna University, Bologna, Italy, 2Hannover Medical School, Hannover, Germany, 3Novartis Pharmaceuticals, East Hanover, NJ, 4Novartis Pharma AG, Basel, Switzerland, 5Chirurgie Cardiaque Les Hôpitaux Universitaires de Strasbourg, Strasbourg, France

6:10 PM (141) Transition to Adulthood: Heart Transplant (HT) Recipient Outcomes By Age Group; L. Reardon, J. Alejos, M. Deng, A. Nsair, B. Reemtsen, R. Biniwale, E. Depasquale. UCLA, Los Angeles, CA


6:20 PM (143) Donor- and Recipient-Related Predictors of Mortality After Heart Transplantation: Results From a Contemporary French National Cohort; C. Jasseron, C. Legeai, C. Cantrelle, L. Sebbag, A. Mouly-Bandini, O. Huot, R. Dorent. 1Direction Prélèvement Greffe Organes-Tissus, Agence de la Biomédecine, Saint-Denis La Plaine, France, 2Hospices Civils de Lyon, Lyon, France, 3AP-HM Marseille, Marseille, France

6:25 PM (144) Early Diagnosis of Acute Kidney Injury After Heart Transplantation – The Prominent Role of Cystatin-C; L. Hoskova, J. Franekova, I. Malek, J. Kautzner, J. Pirkl, O. Szarszo, A. Jabor, O. Viklicky, V. Melenovsky. 1Heart Center, IKEM, Prague, Czech Republic, 2Department of Laboratory Methods, IKEM, Prague, Czech Republic, 3Department of Nephrology, IKEM, Prague, Czech Republic

6:35 PM (146) Influence of HLA Mismatch on Outcomes After Heart Transplantation: UNOS Registry Data; K. Pandya, J. Zhang, M. Hickey, A. Nsair, A. Baas, M. Cadeiras, D. Cruz, L. Reardon, M. Deng, A. Ardehali, E. Reed, E. De-pasquale. Advanced Heart Failure and Cardiac Transplantation, University of California, Los Angeles, Los Angeles, CA

6:40 PM (147) MELD-XI Score Predicts Early and Late Mortality in Patients Following Heart Transplantation; J. C. Grimm1, J. Magruder1, V. Valero, 3rd1, A. Kiliç1, G. J. Whitman1, R. J. Tedford2, S. D. Russell2, A. S. Shah1, C. M. Sciortino1. 1Surgery, The Johns Hopkins Medical Institution, Baltimore, MD, 2Medicine, The Johns Hopkins Medical Institution, Baltimore, MD

6:45 PM (148) Restoration of Pulsatile Flow Leads to a Reduction in Sympathetic Nerve Activity Among Patients With Continuous-Flow Left Ventricular Assist Devices; W. K. Cornwell1, T. Tarumi2, A. Stickford3, J. Kibe3, C. Fitzsimmons2, J. Moore3, M. Roberts2, R. Parker2, D. Markham4, M. Drazner1, B. Levine2. 1Cardiology, Univ of Texas SW, Dallas, TX, 2Institute of Exercise and Environmental Medicine, Dallas, TX, 3Cardiology, Univ of Texas SW, Coppell, TX, 4Cardiology, Emory University, Atlanta, GA

6:50 PM (149) Right Ventricular Adaptation to Afterload Worsens Up to 6 Months After LVAD Implantation But Improves Over Time; B. A. Houston1, R. J. Kalathiyi2, S. Maltais3, M. E. Keebler2, G. R. Stevens2, S. D. Russell1, J. Rickard2, E. Tampakakis1, C. M. Sciortino2, G. J. Whitman1, A. Shah2, R. J. Tedford. 1Cardiology, Johns Hopkins Hospital, Baltimore, MD, 2Internal Medicine, Johns Hopkins Hospital, Baltimore, MD, 3Cardiology, Vanderbilt University, Nashville, TN, 4Cardiology, Vanderbilt, Nashville, TN, 5Cardiovascular Surgery, Johns Hopkins Hospital, Baltimore, MD

6:00 PM – 7:00 PM

MINI ORAL SESSION 3

For Whom the Bell Tolls: Complications of Mechanical Circulatory Support (Erato,Uranie) (MCS)

CHAIRS: M. Angela Rajek, MD and Lars H. Lund, MD, PhD

6:00 PM (151) **Readmissions After Discharge to Home With Total Artificial Heart;**
A. J. Green1, L. G. Wolfe1, V. Kasirajan1, G. Katalaps1, D. Tang1, K. Shah2, M. Smallfield3, I. F. Troukina3, M. A. Quader1. *Cardio-Thoracic Surgery, Virginia Commonwealth University, Richmond, VA, 1Cardiology, Virginia Commonwealth University, Richmond, VA

6:05 PM (152) **Can Thrombolysis Safely Avert LVAD Exchange? A Single Center Experience;**
N. Nair, A. A. Schmitt, E. M. Rau, S. Anders, D. Sandler, T. B. Icenogle. Cardiology, Sacred Heart Medical Center, Spokane, WA

6:10 PM (153) **Mucosal Abnormalities on Nasal Endoscopy Are Associated With Bleeding in Patients on CF LVAD Support;**

6:15 PM (154) **Late Right Heart Failure Is Associated With Reduced Quality of Life and Functional Capacity in Continuous-Flow Left Ventricular Assist Device Recipients;**
M. S. Kiernan1, I. Gosev2, K. Sundareswaran2, J. Abraham3, B. Bethera1, J. Cowger3, P. Eckman3, S. Joseph3, J. N. Katz3, A. Kilic4, S. Lee3, B. Lima3, C. Patel3, J. Rich5, D. Farrar6, N. Uriel7. 1Tufts Medical Center, Boston, MA, 2Brigham and Women’s Hospital, Boston, MA, 3Thoratec Corporation, Pleasanton, CA, 4Providence Health, Portland, OR, 5Tenet Florida, Delray, FL, 6St. Vincent Heart Center, Indianapolis, IN, 7University of Minnesota, Minneapolis, MN, 8Washington University in St. Louis, St. Louis, MO, 9University of North Carolina, Chapel Hill, Chapel Hill, NC, 10The Ohio State University, Columbus, OH, 11Spectrum Health, Grand Rapids, MI, 12Baylor University Medical Center, Dallas, TX, 13Duke University Medical Center, Durham, NC, 14Northwestern University, Chicago, IL, 15University of Chicago, Chicago, IL

6:20 PM (155) **Late Right Heart Failure in Destination Therapy Patients With HeartMate II Continuous Flow Device;**
I. Gosev1, J. N. Katz2, C. B. Patel3, S. Joseph4, J. Cowger5, J. Rich5, M. Kiernan6, J. T. Abraham7, B. T. Bethera8, P. Eckman9, A. Kilic10, S. Lee11, B. Lima12, N. Mokadam13, B. Soleimani14, D. Farrar15, K. Sundareswaran16, N. Uriel17. 1Surgery, Brigham and Women’s Hospital, Boston, MA, 2Medicine, University of North Carolina Hospital, Chapel Hill, NC, 3Medicine, Duke University Medical Center, Durham, NC, 4Medicine, Barns and Jewish Hospital, St Louis, MO, 5Medicine, St Vincents Hospital, Indianapolis, IN, 6Medicine, Northwestern Memorial Hospital, Chicago, IL, 7Medicine, Tufts Medical Center, Boston, MA, 8Medicine, Providence Portland Medical Center, Portland, OR, 9Surgery, Delray Beach Hospital, Delray Beach, FL, 10Medicine, University of Minnesota Medical Center, Minneapolis, MN, 11Surgery, Wexner Medical Center, Columbus, OH, 12Medicine, Devos Childrens Hospital, Grand Rapids, MI, 13Surgery, Baylor University Medical Center, Dallas, TX, 14Surgery, Northwest Hospital and Medical Center, Seattle, WA, 15Surgery, Milton S Hershey Medical Center, Hershey, PA, 16Thoratec Corporation, Pleasanton, CA, 17Medicine, University of Chicago Medical Center, Chicago, IL
6:25 PM (156) Percutaneous Driveline Infection Does Not Increase Subsequent Risk of Stroke and Pump Thrombus During Support With a Left Ventricular Assist Device; J. Van Meeteren, S. Maltais, S. Dunlay, N. Haglund, M. E. Davis, F. D. Pagani, K. Aaronson, J. Cowger, P. Shah, J. M. Stulak. 1Cardiovascular Surgery, Mayo Clinic, Rochester, MN, 2Cardiac Surgery, Vanderbilt Heart and Vascular Institute, Nashville, TN, 3Cardiovascular Diseases, Mayo Clinic, Rochester, MN, 4Cardiovascular Diseases, Vanderbilt Heart and Vascular Institute, Nashville, TN, 5Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI, 6Cardiovascular Diseases, University of Michigan Health System, Ann Arbor, MI, 7Cardiovascular Diseases, St. Vincent’s Health System, Indianapolis, IN, 8Cardiovascular Diseases, Inova Fairfax, Fairfax, VA

6:30 PM (157) Systemic Inflammatory Response Syndrome in End-Stage Heart Failure Patients Following Controversial-Flow Left Ventricular Assist Device Implantation: Differences in Plasma Redox Status and Leukocyte Activation; N. K. Mondal, E. N. Sorensen, N. Hiivala, E. D. Feller, S. Pham, B. P. Griffith, Z. J. Wu. 1Surgery, University of Maryland School of Medicine, Baltimore, MD, 2Department of Clinical Engineering, University of Maryland Medical Center, Baltimore, MD


6:40 PM (159) Low Prevalence of Acquired von Willebrand Syndrome in Japanese Recipients of Continuous-Flow Ventricular Assist Devices; S. Nakajima, O. Seguchi, K. Kuroda, E. Hisamatsu, T. Sato, H. Sunami, T. Sato, M. Yanase, H. Hata, T. Fujita, J. Kobayashi, T. Nakatani. 1Department of Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, 2Department of Adult Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan

6:45 PM (160) Fortuity or Causality in Minimally Invasive LVAD Implantation: Relation Between Outflow Graft Height of Implantation Along the Ascending Aorta and Cerebral Ischemic Events; J. Bejko, T. Bottio, G. Borlolu, M. Gallo, R. Bianco, V. Tarzia, A. Guariento, G. Gerosa. Cardiac Surgery, Padova, Italy

6:50 PM (161) Anemia After Continuous Flow Left Ventricular Assist Device (CF-LVAD) Implantation Is Associated With Morbidity and Mortality; J. Amione-Guerra, A. M. Cordero-Reyes, N. Fida, A. Bhimaraj, B. Trachtenberg, M. Loebe, G. Ashrith. Cardiology, Houston Methodist Hospital, Houston, TX

6:55 PM (162) Does Delayed Sternal Closure Cause Increased Infection Rates After Left Ventricular Assist Device Implantation?; G. Yost, P. Pappas, A. Tatooles, G. Bhat. Center for Heart Transplant and Assist Devices, Advocate Christ Medical Center, Oak Lawn, IL
6:00 PM – 7:00 PM

MINI ORAL SESSION 4

The Big Chill: Heart Failure and Donor Management
(Hermes)
(HF, BSI, DMD, HTX, MCS, PH)

CHAIRS: Uwe Schulz, MD and Peter MacDonald, MD, PhD

6:00 PM

(163) Favorable Outcomes in Dialysis Dependent Patients on LVAD BTT Support;
A. Levin1, R. A. Garan1, V. K. Topkaral, K. Takeda2,
H. Takayama2, D. M. Mancini1, Y. Naka2, P. C. Colombo3,
M. Yuzeypolskaya1. Medicine, Columbia University, New York, NY,
2Surgery, Columbia University, New York, NY

6:05 PM

(164) Efficacy of Left Ventricular Assist Devices or Inotropes for Bridging Patients With Pulmonary Hypertension to Heart Transplantation;
G. H. Oliveira, S. Al-Kindi, S. Kumar, M. Ige, C. ElAmm,
M. Ginwalla, S. Deo, S. J. Park. University Hospitals Case Medical Center, Cleveland, OH

6:10 PM

(165) Control of Sinus Node Tachycardia as Additional Therapy in Patients With Decompensated Heart Failure (CONSTATHE);
M. S. Lofrano-Alves, V. S. Issa, E. A. Bocchi. Cardiology, University of Sao Paulo, Sao Paulo, Brazil

6:15 PM

(166) Increased Cardiorespiratory Fitness on Exercise Stress Testing Predicts Long-Term Survival in Patients With HFpEF;
A. J. Hicks, S. D. Russell, S. J. Keteyian, C. A. Brawner,
M. Al-Mallah, M. J. Blaha. Cardiology, Johns Hopkins Hospital, Baltimore, MD

6:20 PM

(167) The Impact of Miniaturized Hemodynamic Transesophageal Echocardiography (hTEE) on Decision-Making in Hemodynamically Unstable Patients in a Cardiothoracic Intensive Care Unit;
M. Hlaing1, A. Jayaraman2, B. Flynn1, R. Sladen1. 1Anesthesiology, Columbia University Medical Center, New York, NY,
2Anesthesiology, Weill Cornell Medical Center, NYPH, New York, NY

6:25 PM

(168) The Role of Bortezomib in Advanced Cardiac AL Amyloidosis;
I. Sayago1, I. Krsnik2, N. Jaramillo1, M. Gómez-Bueno1, P. García-Pavía1, L. Alonso-Pulpon1, J. Segovia1. 1Heart Transplant (Cardiology), Puerta de Hierro Hospital, Madrid, Spain,
2Hematology, Puerta de Hierro Hospital, Madrid, Spain

6:30 PM

(169) Multiple Listing for Adult Heart Transplantation in the United States: Analysis of OPTN Data From 2000 to 2013;
R. C. Givens1, T. Dardas1, K. J. Clerkin1, S. Restaino1, P. C. Schülze1, D. M. Mancini1. 1Medicine, Columbia University Medical Center, New York, NY,
2Medicine, University of Washington, Seattle, WA

6:35 PM

(170) Longer Waiting Time Increases Mortality in Heart Transplantation: An Instrumental Variable Analysis;
K. K. Khush1, J. G. Zaroff2, J. Nguyen3, B. A. Goldstein1. 1Cardiovascular Medicine, Stanford University, Stanford, CA,
2Division of Research, Kaiser Northern California, Oakland, CA,
3California Transplant Donor Network, Oakland, CA,
4Department of Biostatistics and Bioinformatics, Duke University, Durham, NC
6:40 PM  (171) Adult Heart Transplant Survival Is Not Affected By Use of Centers of Disease Control High-Risk Donor Hearts;
G. H. Oliveira, S. Kumar, S. Al-Kindi, M. Ige, C. ElAmm, M. Ginwalla, S. Deo, S. J. Park. University Hospitals Case Medical Center, Cleveland, OH

6:45 PM  (172) Tolerance to Perioperative Cold Ischemia in Donor Myocardium: Gender Differences;
O. Szarszoi, M. Smetana1, L. Hoskova2, I. Netuka1, J. Besik1, J. Maly1, J. Maluskova2, A. Lodererova2, J. Pirk1. 1Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 2Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

6:50 PM  (173) Successful Orthotopic Heart Transplantation Using Donors With Left Ventricular Systolic Dysfunction: Evidence for Brain Death-Induced Takotsubo Cardiomyopathy;
S. D. Rao, A. Watson, P. Lo, A. Jabbour, C. S. Hayward, A. M. Keogh, E. Kotlyar, E. Granger, P. Jansz, P. Spratt, K. Dhitai, P. S. Macdonald. Heart and Lung Transplantion Unit, St Vincent's Hospital, Darlinghurst, Australia

6:55 PM  (174) Right Ventricular Dysfunction in Brain Death: Effect of Corticosteroids;
A. Belhaj, L. Dewachter2, C. Dewachter2, K. Mc Entee2, R. Naeije3, B. Rondelet1. 1Cardiovascular and Thoracic Surgery, CHU Dinant Godinne UCL, Yvoir, Belgium, 2Laboratory of Physiology, Université Libre de Bruxelles, Bruxelles, Belgium
MINI ORAL SESSION 5

Last Tango in Nice; Motion is the Potion – A Guide for Clinicians (Calliope) (NHSAH, PEEQ, HF, HTX, LTX, MCS)

CHAIRS: Kevin C. Carney, MSN, CRNP, CCTC and Johan Vanhaecke, MD

6:00 PM (175) Physical Activity Measurement in Advanced Chronic Lung Disease; S. S. Dhillon1, R. D. Levy1, P. G. Wilcox2, J. A. Guenette1, B. S. Quon3, C. J. Ryerson2, P. G. Camp1. 1Centre for Heart Lung Innovation, St. Paul's Hospital/University of British Columbia, Vancouver, BC, Canada, 2Medicine, St. Paul’s Hospital/University of British Columbia, Vancouver, BC, Canada

6:05 PM (176) A Supervised Pulmonary Rehabilitation Program Pre Lung Transplantation Is Associated With Higher 6-Minute Walk Distance in the Immediate Period Following Surgery; L. M. Fuller1, H. Whitford3, G. Snell3, A. E. Holland3. 1Physiotherapy Department, The Alfred Hospital, Melbourne, Australia, 2Lung Transplant & Respiratory Medicine Department, The Alfred Hospital, Melbourne, Australia, 3Physiotherapy Department, La Trobe University, The Alfred Hospital, Melbourne, Australia

6:10 PM (177) Predictors of Discharge Destination After Lung Transplantation; M. O. Alrawashdeh1, A. DeVito Dabbs1, M. Dew1, M. Song1, R. Zomak2, J. Pilewski4. 1School of Nursing, University of Pittsburgh, Pittsburgh, PA, 2School of Medicine, University of Pittsburgh, Pittsburgh, PA, 3School of Nursing, University of North Carolina, Chapel Hill, NC, 4Cardiothoracic Transplant Program, UPMC, Pittsburgh, PA

6:15 PM (178) Acute Blood Pressure Adaptations During Heavy Resistance Exercise in Patients With Heart Failure and Transplant Recipients: A Clinical Investigation Using Continuous Blood Pressure Surveillance; C. H. Dall1, F. Gustafsson1, B. Bellnage2, H. Langberg3, E. Prescott1. 1Department of Cardiology, Bispebjerg, University Hospital, Copenhagen, Denmark, 2The Heart Centre, Rigshospitalet, University Hospital, Copenhagen, Denmark, 3BRAIN, Bispebjerg University Hospital, Copenhagen, Denmark, 4Department of Public Health, University of Copenhagen, Copenhagen, Denmark

6:20 PM (179) Functional Outcomes and Quality of Life in Heart Transplant Patients Requiring Extracorporeal Membrane Oxygenation; K. Hayes1, A. E. Holland2, V. Pellegrino1, A. S. Leet4, L. M. Fuller1, C. L. Hodgson5. 1Physiotherapy Department, The Alfred Hospital, Melbourne, Australia, 2Physiotherapy Department, La Trobe University, Alfred Health, Melbourne, Australia, 3Intensive Care Unit, The Alfred Hospital, Melbourne, Australia, 4Heart Transplant Unit, The Alfred Hospital, Baker Heart Institute, Melbourne, Australia, 5Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia

6:30 PM (181) Presence and Type of Caregiver in LVAD Patient Populations: Does It Matter?

6:35 PM (182) Pre and Post Operative Factors Relate to Change in Health-Related Quality of Life From Before to 6 Months Following LVAD Implantation: An INTERMACS Analysis;
K. L. Grady1, D. C. Naftel2, S. L. Myers2, J. K. Kirklin2.
1Surgery/Cardiac Surgery, Northwestern University, Chicago, IL, 2Department of Surgery, University of Alabama at Birmingham, Birmingham, AL

(183) WITHDRAWN

6:40 PM (929) Improvements in Six Minute Walk Distance After Continuous Flow Ventricular Assist Device Placement: Comparison of Pre-Implant Ambulatory and Non-Ambulatory Patients;
S. V. Pamboukian1, F. D. Pagani2, D. C. Naftel1, S. L. Myers1, K. A. Hollifield1, J. K. Kirklin1. 1University of Alabama at Birmingham, Birmingham, AL, 2Cardiac Surgery, University of Michigan, Ann Arbor, MI

6:45 PM (184) Temporal Benefits of Continuous Flow Left Ventricular Assist Device Therapy Assessed With SF-36;

6:50 PM (185) Health-Related Quality of Life Improves Dramatically From Pre-Implant to Post Implant (6 months) for Continuous Flow LVAD Patients in INTERMACS;
S. Wissman1, D. C. Naftel2, S. L. Myers2, J. K. Kirklin2, A. C. Gelijns3, A. J. Moskowitz4, J. B. Young5, K. L. Grady5. 1Mechanical Circulatory Support, The Ohio State University Wexner Medical Center, Columbus, OH, 2Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, 3Department of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, 4Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, 5Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, 2Surgery/Cardiac Surgery, Northwestern University, Chicago, IL

6:55 PM (186) Factors Influencing Gains in Six Minute Walk Distance After Continuous Flow Ventricular Assist Device Placement;
S. V. Pamboukian1, F. D. Pagani2, D. C. Naftel1, S. L. Myers1, K. A. Hollifield1, J. K. Kirklin1. 1University of Alabama at Birmingham, Birmingham, AL, 2Cardiac Surgery, University of Michigan, Ann Arbor, MI
The Heartbreak Kid: Donors, VADs and Long-Term Outcomes (Euterpe)
(PEDS, BSI, DMD, HF, HTX, ID, MCS, NHSAH, PATH, PH, PHARM, PEEQ)

CHAIRS: Christina J. VanderPluym, MD and Francesco Parisi, MD

6:00 PM
(187) Determinates of Non-Utilization in Pediatric Heart Donors;
C. Castleberry1, M. Khan1, F. Zafar1, S. Shugh2, I. Wilmut1, T. D. Ryan1, C. Chin1, J. L. Jefferies1, A. Lorts1, D. Morales1. 1Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

6:05 PM
(188) Do the Duration Between Donor Brain Death and Heart Harvest or Administration of Thyroxine (T4) Affect Allograft Function After Pediatric Heart Transplantation?;
F. I. Lunze, K. Gauvreau, S. I. Colan, R. Narciso, F. Costantino, H. Bastardi, E. D. Blume, T. P. Singh. Cardiology, Boston Children's Hospital, Boston, MA

6:10 PM
(189) Impact of Initial Norwood Shunt Type on Young HLHS Patients Listed for Heart Transplant: A Multi-Institutional Study;
W. F. Carlo1, S. C. West1, M. McCulloch1, D. C. Naftel1, E. Prutt1, J. K. Kirklin1, M. Hubbard1, K. M. Molinar1, R. Gajarski1. 1University of Alabama, Birmingham, AL, 2Children's Hospital of Pittsburgh, Pittsburgh, PA, 3Nemours Cardiac Center, Wilmington, DE, 4Primary Children's Hospital, Salt Lake City, UT, 5CS Mott Children's Hospital, Ann Arbor, MI

6:15 PM
(190) Thromboelastography/Platelet Mapping® and Aspirin: Is There Evidence of a Meaningful Dose-Response Relationship in Children Supported With the Berlin Heart EXCOR Ventricular Assist Device?;
L. J. May1, C. Lo1, T. M. Tesoror1, J. L. Zehnder1, S. Chen1, J. Lee1, M. Desai1, D. B. McElhinney1, D. N. Rosenthal1, K. Maeda1, C. S. Almond1. 1Department of Pediatrics (Cardiology), Stanford University, Palo Alto, CA, 2Department of Pediatrics, Stanford University, Palo Alto, CA, 3Department of Pathology, Stanford University, Palo Alto, CA, 4Department of Medicine, Quantitative Sciences Unit, Stanford University, Palo Alto, CA, 5Department of Cardiothoracic Surgery, Stanford University, Palo Alto, CA

6:20 PM
(191) Somatic Growth in Pediatric Patients Undergoing Long-Term Ventricular Assist Device Support With a Miniaturized Implantable Device;
F. Guzman-Pruneda1, A. Jeewa2, W. J. Dreyer2, S. W. Denfield2, A. G. Cabrera2, J. F. Price2, S. Burki2, A. G. Cabrera2, J. F. Price2, S. Burki2, E. D. McKenzie1, I. Adachi1. 1Congenital Heart Surgery, Texas Children's Hospital, Houston, TX, 2Pediatric Cardiology, Texas Children's Hospital, Houston, TX

6:25 PM
(192) Timing of Ventricular Assist Device Insertion on Post-Transplant Outcomes: An Analysis of the UNOS Database;
J. Conway1, M. Lake2, D. Morales2, H. Buchholz1, A. Lorts2. 1Stollery Children’s Hospital, Edmonton, AB, Canada, 2The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

6:30 PM
(193) Peri-Transplant Acute Kidney Injury in Children: Risk Factors and Impact on Clinical Course;
C. MacDonald1, G. Alton2, A. Joffe3, C. Morgan3, S. Urschel3. 1Nursing, University of Alberta, Edmonton, AB, Canada, 2Nursing, Alberta Health Services, Edmonton, AB, Canada, 3Medicine, University of Alberta, Edmonton, AB, Canada
6:35 PM  **(194) Reducing Fluoroscopic Radiation Exposure During Endomyocardial Biopsy in Pediatric Transplant Recipients:**
1Pediatric Cardiology, Ann and Robert H Lurie Children’s Hosp, Chicago, IL, 2Radiology, Ann and Robert H Lurie Children’s Hosp, Chicago, IL, 3Stanley Manne Children’s Research Institute, Ann and Robert H Lurie Children’s Hosp, Chicago, IL

6:40 PM  **(195) Comparison of Segmental Versus Longitudinal Intravascular Ultrasound Analysis for Pediatric Cardiac Allograft Vasculopathy:**
M. A. Kuhn, R. E. Chinnock, M. Burch, M. J. Fenton.
1Pediatrics, Loma Linda Univ, Loma Linda, CA, 2Pediatrics, Great Ormond Street Hospital, London, United Kingdom

6:45 PM  **(196) Early Statin Therapy Is Not Associated With Improved Outcomes After Heart Transplantation in Children:**
1University of Alberta, Edmonton, AB, Canada, 2Medical University of South Carolina, Charleston, SC, 3University of Alabama at Birmingham, Birmingham, AL, 4Arkansas Children’s Hospital, Little Rock, AR, 5Seattle Children’s Hospital, Seattle, WA

6:50 PM  **(197) Lymphoproliferative Disorders Late After Pediatric Heart Transplantation: A Multicenter Analysis:**
S. C. West, J. M. Friedland-Little, K. Schowengerdt, D. Naftel, E. Pruitt, K. S. Smith, S. Urschel, M. Michaels, J. K. Kirklin, B. Feingold, 1Pediatric Cardiology, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, 2Pediatric Cardiology, University of Michigan, CS Mott Children’s Hospital, Ann Arbor, MI, 3Pediatric Cardiology, Saint Louis University, Cardinal Glennon Children’s Medical Center, St Louis, MO, 4Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL, 5Pediatric Cardiology, University of Alberta, Edmonton, AB, 6Infectious Disease, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA

6:55 PM  **(198) Psychosocial Milestones and Risk Behaviour in Adolescent Heart Transplant Patients:**
1Division of Adolescent Medicine, Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 2Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 3Department of Psychology, The Hospital for Sick Children, Toronto, ON, Canada, 4Labatt Family Heart Centre, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
6:00 PM – 7:00 PM
MODERATED POSTER SESSION 2 (Agora 2)
WINE AND CHEESE RECEPTION (Rhodes)
PAST PRESIDENT’S MEETING (Gallieni 3)

6:00 PM – 7:30 PM
COMMITTEE/COUNCIL LEADERSHIP ORIENTATION (Gallieni 1 & 2)
FRIDAY | April 17, 2015

7:30 AM – 7:00 PM
Registration Open (Agora 1)
Speaker Ready Room Open (Hermes Lounge)

8:00 AM – 9:00 AM
Poster Board Renumbering (Agora 2)

8:30 AM – 10:30 AM
PLENARY SESSION (APOLLON)

(ALL)

CHAIRS: Stephan Schueler, MD, PhD, FRCS and Robert L. Kormos, MD

8:30 AM Fighting Transplant Commercialism: The Impact of the Declaration of Istanbul
Francis L. Delmonico, MD, New England Organ Bank, Waltham, MA, USA

8:50 AM Fighting Transplant Commercialism: A Criminological Approach is Needed
Willem Weimar, MD, University Hospital Rotterdam-Dijkzigt, Rotterdam, Netherlands

9:10 AM FEATURED ABSTRACT: Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients (ROADMAP);
J. D. Estep1, R. C. Starling2, D. A. Horstmanshof3, C. A. Milano4, C. H. Selzman5, K. B. Shah1, M. Loebe1, N. Moazami6, J. W. Long7, J. Stehlik2, V. Kasirajan8, D. C. Haas9, J. O’Connell10, A. J. Boyle11, P. Kallet12, D. J. Farrar13, Houston Methodist Hospital, Houston, TX, 2Cleveland Clinic, Cleveland, OH, 3Integris Baptist, Oklahoma, OK, 4Duke University, Durham, NC, 5University of Utah, Utah, UT, 6Virginia Commonwealth University, Richmond, VA, 7Abington Memorial Hospital, Abington, PA, 8Thoratec Corporation, Pleasanton, CA, 9Piedmont Hospital, Atlanta, GA

9:25 AM Heralding the End of Vascular Obstruction
Tobias Deuse, MD, PhD, University Heart Center Hamburg, Hamburg, Germany

9:45 AM The Health eHeart Study: Harnessing the Power of the Internet to Advance Clinical Research and Patient Care World-Wide
Gregory Marcus, MD, UCSF, San Francisco, CA, USA

10:05 AM The Psychology of Judgment and Decision Making
Alexandra L Quittner, PhD, University of Miami, Miami, FL, USA

9:00 AM – 7:00 PM
Press Office Open (Gallieni 6)
EXHIBITS OPEN (Rhodes)
POSTER HALL OPEN (Agora 2)
10:30 AM – 11:00 AM
ANNUAL BUSINESS MEETING (Apollon)
Coffee Break/Visit Exhibits (Rhodes)
VIEW POSTERS (Agora 2)

11:00 AM – 12:30 PM
CONCURRENT SESSION 22

LVADs: Factors Influencing Outcomes (Apollon) (MCS, DMD, HF, HTX, NHSAH)

CHAIRS: Shashank S. Desai, MD and Sangjin Lee, MD

11:00 AM (200) Duration of Heart Failure Influences the Outcomes After Mechanical Circulatory Support;
R. Y. Loyaga-Rendon1, R. C. Starling2, R. S. Cantor3, S. V. Pamboukian1, J. A. Tallaij, D. A. Acharya4, D. C. Naftel5, J. K. Kirklin6. 1Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, AL, 2Heart Failure and Cardiac Transplant Medicine, Cleveland Clinic, Cleveland, OH, 3Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL

11:15 AM (201) Long Term Survival in Continuous Flow Left Ventricular Assist Devices;
I. Gosev1, S. M. Joseph2, P. Eckman3, A. Kilić4, N. Uriel5, J. D. Rich6, J. N. Katz7, J. Cowger8, B. Lima9, S. McGurk10, C. B. Patel10. 1Surgery, Brigham and Women’s Hospital, Boston, MA, 2Medicine, Barns and Jewish Hospital, St Louis, MO, 3Medicine, University of Minnesota Medical Center, Minneapolis, MN, 4Surgery, Wexner Medical Center, Columbus, OH, 5Medicine, University of Chicago Medicine, Chicago, IL, 6Medicine, Northwestern Memorial Hospital, Chicago, IL, 7Medicine, University of North Carolina Hospital, Chapel Hill, NC, 8Medicine, St Vincent Hospital, Indianapolis, IN, 9Surgery, Baylor University Medical Center, Dallas, TX, 10Medicine, Duke University Medical Center, Durham, NC

11:30 AM (202) Device Implant Strategy and Patient Characteristics Have a Profound Impact on Early, Mid and Late Outcomes After MCS Implant;
D. C. Naftel1, F. D. Pagani2, M. A. Miller3, J. B. Young4, S. L. Myers5, J. K. Kirklin5. 1Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, 2Cardiac Surgery, University of Michigan, Ann Arbor, MI, 3National Heart, Lung, Blood Institute, Bethesda, MD, 4Lerner College of Medicine, Cleveland Clinic, Cleveland, OH,

11:45 AM (203) Association Between Age, Bridge to Transplant Continuous Flow LVAD Use, and Outcomes After Heart Transplantation;
A. Ciarka1, L. Edwards2, J. Stehlik3, L. Lund4. 1Department of Cardiovascular Diseases, Catholic University of Leuven, Leuven, Belgium, 2ISHLT Transplant Registry, Dallas, TX, 3University of Utah Health, Salt Lake City, UT, 4Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden

12:00 PM (204) Pre-Implant Glomerular Filtration Rate (GFR) as a Predictor of Adverse Outcomes Post Left Ventricular Assist Device Placement;
B. Mohamedali1, G. Yost, G. Bhat. Center for Heart Transplant and Assist Devices, Advocate Christ Medical Center, Oak Lawn, IL

12:15 PM (205) Albuminuria Is Common in Patients Undergoing Left Ventricular Assist Device and Predicts Subsequent Renal Recovery;
M. A. Brisco1, A. Hale1, D. P. Heyward2, M. L. Craig3, J. M. Testani4. 1Medicine-Cardiology, Med Univ of South Carolina, Charleston, SC, 2Program of Applied Translational Research, Yale University School of Medicine, New Haven, CT
11:00 AM – 12:30 PM

**CONCURRENT SESSION 23**

**An Update On Short Term Support** (Athena)

**CHAIRS:** Ranjit John, MD and Michel Morshuis, MD

**11:00 AM (206) Temporary Extracorporeal Membrane Oxygenation: Ten-Year Experience at a Cardiac Transplant Center;**

B. G. Tran, E. Depasquale, J. Meltzer, A. Ardehali, D. Cruz, M. Deng, R. Schem, A. Nsair, Cardiology, University of California, Los Angeles, Los Angeles, CA, Anesthesiology, University of California, Los Angeles, Los Angeles, CA, Surgery, University of California, Los Angeles, Los Angeles, CA

**11:15 AM (207) Early Crossover From Extracorporeal Membrane Oxygenation to More Durable Mechanical Circulatory Support Improves Survival;**

R. Cheng, B. Azarbal, J. Herr, D. Ramzy, J. A. Kobashigawa, F. A. Arabia, J. D. Moriguchi, Cedars-Sinai Heart Institute, Los Angeles, CA

**11:30 AM (208) Management and Outcome of Left Ventricular Distention During Venoarterial Extracorporeal Membrane Oxygenation Support;**


**11:45 AM (209) A Prospective Multicenter Study to Evaluate Safety and Probable Benefit of a Novel Percutaneous Ventricular Assist Device for Right Ventricular Failure: The RECOVER RIGHT Study;**

M. Anderson, J. Goldstein, L. Morris, C. Milano, R. Kormos, J. Bham, N. Kapurst, A. Bansal, J. Garcia, S. Silvestry, W. Holman, W. O'Neill, Cardiothoracic Surgery, Einstein Healthcare Network, Bryn Mawr, PA, William Beaumont Hospital, Royal Oak, MI, Einstein Healthcare Network, Bryn Mawr, PA, Duke University Medical Center, Durham, NC, University of Pittsburgh Medical Center, Pittsburgh, PA, Tufts University Medical Center, Boston, MA, Oschner Foundation, New Orleans, LA, Massachusetts General Hospital, Boston, MA, Barnes Jewish Hospital, St. Louis, MO, University of Alabama, Birmingham, AL, Henry Ford Hospital, Detroit, MI

**12:00 PM (210) Outcome of the Impella Device for Mechanical Circulatory Support in Patients With Refractory Cardiogenic Shock;**

P. Farahmand, A. Quessard, G. Lebreton, C. d'Alessandro, C. Mastroianni, P. Leprince, Cardio-Thoracic Surgery, Hopital Pitie Salpetriere, Paris, France

**12:15 PM (211) Feasibility of Long Term Use of External Continuous Flow Ventricular Assist Device;**

Immunosuppression: The Tor Inhibitors Strike Back
(Clio, Thalie)
(HTX, BSI, HF, ID, NHSAH, PATH, PEDS, PHARM)

CHAIRS: Howard J. Eisen, MD and Markus J. Barten, MD, PhD

11:00 AM (212) *The Effect of Everolimus Initiation and Early Calcineurin Inhibitor Withdrawal on Allograft Vasculopathy in De-Novo Heart Transplant Recipients: Results of the SCHEDULE Trial After 36 Months;* S. Arora1, O. Solberg1, K. Karason2, B. Andersson3, F. Gustafsson3, H. Eiskjær4, G. Rådegran6, E. Gude1, T. Ueland6, P. Aukrust6, D. Solbu5, G. Dellgren1, A. Andreassen1, L. Gullestad1. 1Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 2Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, 3Cardiology, Rigshospitalet, Copenhagen, Denmark, 4Cardiology, Skejby University Hospital, Aarhus, Denmark, 5Cardiology, Skåne University Hospital, Lund, Sweden, 6Research Institute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 6Novartis Norge, Oslo, Norway

11:15 AM (213) *Long Term Outcomes in Thoracic Transplant Recipients After Conversion to Everolimus With Reduced Calcineurin Inhibitor Within a Multicenter, Open-Label, Randomized Trial;* L. Gullestad1, H. Eiskjær2, F. Gustafsson3, G. Riise4, K. Karason5, G. Dellgren5, G. Rådegran6, L. Hansson6, E. Gude1, Ø. Bjertuft1, K. Jansson8, D. Solbu8, M. Iversen3. 1Oslo Univ Hospital, Oslo, Norway, 2Aarhus University Hospital, Aarhus, Denmark, 3Rigshospitalet, Copenhagen, Denmark, 4Sahlgrenska University Hospital, Gothenburg, Sweden, 5Sahlgenska University Hospital, Gothenburg, Sweden, 6Skåne University Hospital and Lund University, Lund, Sweden, 7Skåne University Hospital and Lund University, Lund, Sweden, 8Linköping University Hospital, Linköping, Sweden, 8Novartis Norway, Oslo, Norway

11:30 AM (214) *Use of Rapamycin One-Year Post Heart Transplantation Stabilizes Transplant Allograft Vasculopathy – The Mid America Experience;* A. Kao1, M. Eaton1, C. Knutson1, J. Linard1, J. House1, B. A. Austin1, M. P. Everley1, T. M. Khumri1, S. L. Lawhorn1, A. Magalski1, A. M. Borkon2, D. Safley1. 1Cardiology, St. Luke’s Mid America Heart Institute, Kansas City, MO, 2Cardiothoracic Surgery, St. Luke’s Mid America Heart Institute, Kansas City, MO

11:45 AM (215) *A Multi-Center, Randomized, Open-Label, Parallel Group Phase IV Trial Investigating the Outcome on Renal Function, Efficacy and Safety of CNI-Reduction or Elimination With Everolimus in De Novo Heart Transplant Recipients: The MANDELA Study Design;* T. Deuse1, C. Bara1, M. Barten1, S. Hirt1, A. Doesch1, C. Knoalsa1, C. Ginninger1, J. Stypmann1, M. Portner1, P. Wimmer1, U. Schulz1. 1Mandela, Study Group, Germany, 2Novartis Pharma, Nuremberg, Germany

12:00 PM (216) *Sirolimus Based Immunosuppression Results in Lower Incidence of Post-Transplantation Lymphoproliferative Disorders in Heart Transplant Recipients;* D. Vucicevic1, R. C. Daly2, D. E. Steidle1, R. L. Scott3, W. K. Kremers2, B. S. Edwards2, K. S. Sudhir2. 1Mayo Clinic Arizona, Scottsdale, AZ, 2Mayo Clinic Rochester, Rochester, MN, 3Mayo Clinic Rochester, Rochester, AZ

FRIDAY APRIL 17 143
1Pathology, UCLA, Los Angeles, CA, 2Pathology and Laboratory Medicine, UCLA, Los Angeles, CA, 3Discovery Research, Immucor, Inc., Stamford, CT, 4Cardiology, UCLA, Los Angeles, CA, 5Cardiology, University of Puerto Rico, Carolina, PR, 6Cardiology, University of Puerto Rico, Rio Piedras, PR, 7Cardiology, Tufts University School of Medicine, Boston, MA, 8Cardiology, Drexel University College of Medicine, Philadelphia, PA, 9Cardiovascular Diseases, Washington University, St. Louis, MT, 10Cardiovascular Medicine, LDS Hospital, Salt Lake City, UT, 11Heart Transplant, Cedars-Sinai Heart Institute, Los Angeles, CA, 12Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, 13Cardiology, Methodist, Houston, TX, 14Cardiology, Medical University of South Carolina, Charleston, SC
11:00 AM – 12:30 PM

**CONCURRENT SESSION 25**

**Pump Up the Jam, Don’t Jam Up the Pump! VAD-Management and Complications** *(Erato,Uranie)*

**(PEDS, DMD-LUNG, HF, HTX, ID, LF, MCS, NHSAH, PH)**

**CHAIRS:** Ivan M. Rebeyka, MD and Brigitte Stiller, MD, PhD

11:00 AM **(218) Temporal Distribution of Hematologic Complications During Berlin EXCOR Support:**
S. Burki1, D. H. Mahoney1, A. Jeewa1, W. Zhang1, E. McKenzie1, D. L. Morales2, C. M. Mery1, J. S. Heinle1, C. D. Fraser1, I. Adachi1, 1Texas Children’s Hospital, Houston, TX, 2Cincinnati Children’s Hospital, Cincinnati, OH

S. R. Deshpande1, S. Hastings2, S. Wagoner3, D. Ku4, K. Maher4, 1Pediatric Cardiology, Emory University Children’s Healthcare of Atlanta, Atlanta, GA, 2Biofluids and Medical Device Research Group, Georgia Institute of Technology, Atlanta, GA, 3Manager, ECMO Program, Children’s Healthcare of Atlanta, Atlanta, GA, 4Department of Engineering, Georgia Institute of Technology, Atlanta, GA

11:30 AM **(220) Impact of a Modified Anti-Thrombotic Protocol on the Risk of Stroke and Thromboembolism in Children Supported With the Berlin Heart Excor Pediatric Ventricular Assist Device:**
C. A. Lancaster1, C. S. Almond2, S. A. Hollander2, M. L. Stein3, A. Lin4, L. Doan1, J. Murray1, D. N. Rosenthal5, 1School of Medicine, University of Kansas, Kansas City, KS, 2Pediatries, Stanford University, Palo Alto, CA, 3Anesthesia, Stanford University, Palo Alto, CA, 4Pediatrics, LPCH, Palo Alto, CA, 5Stanford University, Palo Alto, CA

11:45 AM **(221) Wound Infections in Children With Ventricular Assist Device Support: Are Intracorporeal Devices Better?**
C. J. Vander Pluym1, K. R. Schmitt1, B. Hawkins1, N. Speckmann1, E. D. Blume2, O. Miera1, 1Cardiology, Boston Children’s Hospital, Boston, MA, 2Cardiology, Deutsches Herzzentrum Berlin & Charité Berlin, Berlin, Germany

12:00 PM **(222) Refining of the Pump Exchange Procedure in Children Supported With the Berlin Heart EXCOR Ventricular Assist Device: 10 Years Experience at a Single Institution:**

12:15 PM **(223) Virtual Implantation of the 50cc Total Artificial Heart:**
R. A. Moore, P. C. Madueke, A. Lorts, D. L. Morales, M. D. Taylor. The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Heart Failure – Omics, Kines and Stem Cells (Hermes)

CHAIRS: Sonja Schrepfer, MD, PhD and Pradeep P.A. Mammen, MD, FACC, FAHA


11:15 AM (225) Thymosin 4 and Its Cleavage Product Ac-SDKP Are Down-Regulated in Left Ventricular Myocardium of Patients With Advanced Heart Failure; H. N. Sabbah, R. C. Gupta, V. Singh-Gupta. Medicine, Henry Ford Hospital, Detroit, MI

11:30 AM (226) Myocardial Lipid Metabolism in the End-Stage Failing Heart: Evidence for an Energy-Starved State; J. E. Rame1, K. Bedi1, N. Snyder2, J. Brandimarto2, C. Mesaros2, E. Y. Birati1, I. A. Blair2, K. B. Margulies1. 1Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, 2Center of Cancer Pharmacology, University of Pennsylvania, Philadelphia, PA

11:45 AM (227) The Effect of Diabetes Mellitus on Cardiac Mitochondria in Patients With End-Stage Heart Failure; V. Melenovsky1, J. Benes1, J. Pirk2, T. Pelikanova3, T. Mracek4, H. Nuskova4, J. Draho4, J. Kovačikova4, J. Houšek4. 1Dept.of Cardiology, IKEM, Prague, Czech Republic, 2Cardiac Surgery, IKEM, Prague, Czech Republic, 3Dept. of Diabetology, IKEM, Prague, Czech Republic, 4Department of Bioenergetics, Institute of Physiology, Academy of Sciences of CR, Prague, Czech Republic

12:00 PM (228) Response to CD34+ Cell Therapy Is Associated With Myocardial Scar Burden in Patients With Ischemic and Non-Ischemic Chronic Heart Failure; B. Vrtovec1, G. Poglagen, G. Zemljic1, M. Sever1, M. Cukjati2, F. Haddad1, J. C. Wu2. Advanced Heart Failure and Transplantation Ctr, UMC Ljubljana, Ljubljana, Slovenia, 2Department of Hematology, UMC Ljubljana, Ljubljana, Slovenia, 3National Blood Transfusion Ctr, Ljubljana, Slovenia, 4Stanford Cardiovascular Institute, Stanford, CA

12:15 PM (229) Metabolic Status Determines the Efficacy of CD34+ Stem Cell Therapy in Patients With Non-Ischemic Dilated Cardiomyopathy; B. Vrtovec1, M. Sever1, M. Jensterle1, G. Poglagen1, A. Janez1, N. Kravos1, F. Haddad1, J. C. Wu2, U. P. Jorde1. Advanced Heart Failure and Transplantation Ctr, UMC Ljubljana, Ljubljana, Slovenia, 2Department of Hematology, UMC Ljubljana, Ljubljana, Slovenia, 3Department of Endocrinology, UMC Ljubljana, Ljubljana, Slovenia, 4Stanford Cardiovascular Institute, Stanford, CA, 5Albert Einstein College of Medicine, New York, NY
Basic Science 2: Organ Preservation Including Ex-Vivo Management, Ischemia/Reperfusion (Calliope) (ALL)

CHAIRS: Paul Christian Schulze, MD, PhD and Andrew E. Gelman, PhD

11:00 AM (230) Nrf2 Inhibits NF-κB Activation and Attenuates Ischemia-Reperfusion Injury in Heart Transplantation; H. Kawajiri, L. Tumiati, A. Ghashghai, J. Lazarte, L. Grosman-Rimon, F. Billia, R. Li, M. Badiwala, V. Rao. Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada


12:15 PM (235) Lymphatic Endothelial Cell VEGFR3 Controls Cardiac Allograft Rejection; A. Dashkevich, A. Raisasadat, G. Zarkada, K. Altalo, A. Nykanen, K. Lemström, LMU Medical Centre, Munich, Germany, 2Haartman Institute, University of Helsinki, Helsinki, Finland, 3Biomedicum, University of Helsinki, Helsinki, Finland
JHLT at ISHLT: The Year in a Capsule (Euterpe) (ALL)

CHAIRS: Paul A. Corris, MB, FRCP and Keyur B. Shah, MD

SESSION SUMMARY: This session will highlight the most exciting publications in JHLT over the past year, followed by a discussion by one of the senior editorial consultants of the journal to relate the presented articles to the greater body of published literature and discuss how they advance our understanding in the field.

11:00 AM  Highlights of Heart Transplantation and Mechanical Circulatory Support
Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA

11:15 AM  DISCUSSANT: Highlights of Heart Transplantation and Mechanical Circulatory Support
Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy

11:20 AM  Highlights of Lung Transplantation and Pulmonary Hypertension
Robin Vos, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

11:35 AM  DISCUSSANT: Highlights of Lung Transplantation and Pulmonary Hypertension
Edward R. Garrity, MD, University of Chicago Medical Center, Chicago, IL, USA

11:40 AM  Highlights of Pediatrics Heart/ Lung Transplantation
Jonathan N. Johnson, MD, Mayo Clinic, Rochester, MN, USA

11:55 AM  DISCUSSANT: Highlights of Pediatric Heart and Lung Transplantation
Christian Benden, MD, University Hospital Zurich, Zurich, Switzerland

12:00 PM  Highlights of Transplant Infectious Diseases
Saima Aslam, MD, MS, University of California San Diego, San Diego, CA, USA

12:15 PM  DISCUSSANT: Highlights of Transplant Infectious Diseases
Lara Danziger-Isakov, MD, MPH, Children’s Hospital Medical Center, Cincinnati, OH, USA
12:30 PM – 2:30 PM
Lunch Break

12:30 PM – 1:30 PM
Box Lunch Distribution (Rhodes)

12:30 PM – 1:30 PM
PULMONARY HYPERTENSION
SCIENTIFIC COUNCIL MEETING (Calliope)
MECHANICAL CIRCULATORY
SUPPORT SCIENTIFIC COUNCIL MEETING (Euterpe)
PEDIATRIC TRANSPLANTATION
SCIENTIFIC COUNCIL MEETING (Gallieni 1)
INFECTIOUS DISEASES SCIENTIFIC
COUNCIL MEETING (Gallieni 4)
PATHOLOGY SCIENTIFIC COUNCIL MEETING (Gallieni 5)

1:00 PM – 2:30 PM
IMACS REGISTRY MEETING (Gallieni 7)

1:30 PM – 2:25 PM
PULMONARY TRANSPLANTATION
SCIENTIFIC COUNCIL MEETING (Calliope)
HEART FAILURE AND TRANSPLANTATION
SCIENTIFIC COUNCIL MEETING (Euterpe)
PEDIATRIC HEART FAILURE
WORKFORCE MEETING (Gallieni 1)
IPLTC MEETING (Gallieni 4)
2:30 PM – 4:00 PM

CONCURRENT SESSION 29

Transplanting Patients with Machines (Apollon) (MCS, DMD-HEART, HF, HTX, NHSAH)

CHAIRS: Joseph G. Rogers, MD and Arnt E. Fiane, MD

2:30 PM (236) Panel Reactive Antibody Levels Are Associated With Survival in Heart Transplant Recipients Without But Not With a Ventricular Assist Device at the Time of Transplant; P. Chiu1, J. M. Schaffer1, P. E. Oyer1, B. Banerjee1, J. Wool1, R. Hal1. 1Cardiothoracic Surgery, Stanford University, School of Medicine, Stanford, CA, 2Cardiology, Stanford University, School of Medicine, Stanford, CA


3:00 PM (238) Contemporary Use of Continuous Flow Left Ventricular Assist Devices Are No Longer Associated With Post-Transplant Mortality; S. Kumar, S. Al-Kindi, M. Ige, C. ElAm, M. Ginwalla, S. Deo, S. J. Park, G. H. Oliveira. University Hospitals Case Medical Center, Cleveland, OH


3:30 PM (240) One-Year Survival of Patients Treated With Left Ventricular Assist Device (LVAD) as Bridge to Transplantation (BTT) or Bridge to Candidacy (BTC) vs. Heart Transplantation (HTx) With Donors Older Than 55 Years; E. Ammirati, M. G. Cipriani, M. Varrenti, F. Macera, L. D’Angelo, A. Garascia, F. Oliva, F. M. Turazza, G. Masciocco, A. Cannata, T. Colombo, C. Russo, G. Poti, M. P. Gagliardone, G. Pedrazzini, M. Frigerio. Cardiovascular and Thoracic Department, Niguarda Hospital, Milan, Italy

3:45 PM (241) The Use of Circulatory Support While Awaiting Heart Transplant in Patients With AL and TTR Amyloidosis: A Report From iCCAT, the International Consortium for Cardiac Amyloid Transplant; S. Tabatabai, J. Steiner, M. Vaduwanathan, J. Stone, J. Estep, R. Witteles, F. Giuseppe, M. Zucker, D. Baran, D. Seldin, J. Patel, M. Hanna, A. Cordero-Reyes, V. Selby, M. Maurer, M. J. Semigran. 1Cardiology, Massachusetts General Hospital, Boston, MA, 2Cardiology, Houston Methodist Hospital, Houston, TX, 3Cardiology, Stanford University Medical Center, Stanford, CA, 4Cardiology, University of Padova, Padova, Italy, 5Cardiology, Newark Beth Israel Medical Center, Newark, NJ, 6Hematology, Boston University Medical Center, Boston, MA, 7Cardiology, Cedars Sinai Hospital, Los Angeles, CA, 8Cardiology, Cleveland Clinic, Cleveland, OH, 9Cardiology, University of California San Francisco, San Francisco, CA, 10Cardiology, Columbia Medical Center, New York City, NY
2:30 PM – 4:00 PM

CONCURRENT SESSION 30

EVLP – Learning To Handle This Technology (Athena) (LTX, DMD)

CHAIRS: Clemens Aigner, MD and Florian M. Wagner, MD

2:30 PM (242) WITHDRAWN

2:45 PM (243) Post EVLP Cold Preservation Period Is Associated With Clinical Outcomes;
E. Arango Tomas1, P. Sanchez2, R. D. Davis3, E. Cantu4, M. J. Weyant4, D. Lederer5, P. C. Camp6, B. P. Griffith7, F. D’Ovidio1.
1Columbia University Medical Center, New York, NY, 2University of Maryland Medical Center, Baltimore, MD, 3Duke University, Durham, NC, 4University of Pennsylvania, Philadelphia, PA, 5University of Colorado Denver, Denver, CO, 6Brigham and Women’s Hospital, Boston, MA

3:00 PM (244) Metabolic Assessment of Marginal Donor Lungs During Ex-Vivo Perfusion (EVLP): New Parameters for Decision Making;
A. Slama, M. Barta, L. Schillab, A. Mitterbauer, P. Jaksch, K. Hoetzenecker, W. Klepetko, C. Aigner. Medical Univ of Vienna, Vienna, Austria

3:15 PM (245) Lung Compliance During Ex-Vivo Lung Perfusion Predicts Early Post Transplant Outcomes;
P. G. Sanchez1, G. J. Bittle2, E. Cantu, III2, F. D Ovidio3, M. Weyant3, R. D. Davis4, B. P. Griffith4. 1Cardiac Surgery, University of Maryland, Baltimore, MD, 2Cardiac Surgery, University of Pennsylvania, Philadelphia, PA, 3Thoracic Surgery, Columbia University, New York, NY, 4Thoracic Surgery, University of Colorado, Aurora, CO, 5Cardiac Surgery, Duke University, Durham, NC

3:30 PM (246) A Prospective Randomized Trial of Ex-Vivo Lung Perfusion in Standard Donor Lungs: Can It Improve the Results?;
A. Slama, L. Schillab, M. Barta, A. Mitterbauer, K. Hötze-necker, S. Taghavi, G. Lang, J. Matilla, P. Jaksch, W. Klepetko, C. Aigner. Medical Univ of Vienna, Vienna, Austria

3:45 PM (247) Ex-Vivo Lung Perfusate Cell Death Markers May Predict Long Term Outcomes After Transplantation;
CAV and Rejection: A Tangled Web (Clio, Thalie) (HTX, BSI, ID, NSHA, PATH, PEDS, PHARM)

CHAIRS: Hannah A. Valantine, MD and Nedim Selimovic, MD, PhD

2:30 PM – 4:00 PM

CONCURRENT SESSION 31

2:30 PM (248) Clonal Composition and Specificity of Graft Infiltrating B Cells in Human Cardiac Allograft Vasculopathy:
1Massachusetts General Hospital, Boston, MA, 2Columbia University Medical Center, New York, NY, 3Brigham and Women Hospital, Boston, MA

2:30 PM

2:45 PM (249) Complement Negative AMR: Does It Confer a Different CV Mortality Risk From Other Categories of AMR?:
M. P. Revelo1, D. V. Miller1, J. Stehlik1, M. D. Everitt1, G. L. Snow2, D. Budge1, J. Fang1, J. N. Nicolau1, C. Selzmann1, B. Reid1, E. H. Hammond3, A. G. Kfoury1, 1UTAH Cardiac Transplant Program, Salt Lake City, UT, 2UTAH Medical Data Center, Salt Lake City, UT

3:00 PM

3:15 PM (250) Mixed Cellular and Antibody-Mediated Rejection in Heart Transplantation: A Distinct Entity or Simply the Sum of Two?:

3:15 PM

3:30 PM (251) Human Leukocyte Antigen-G Polymorphisms as Predictors of Early Cardiac Allograft Vasculopathy:
J. Lazarte1, L. Goldraich1, H. Kawajiri3, A. Ghashghai1, L. Grosman-Rimon1, L. Tumiani1, V. Raö1, D. Delgado1, 1Faculty of Medicine, University of Toronto, Toronto, ON, Canada, 2Cardiology, Toronto General Hospital, Toronto, ON, Canada, 3Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada

3:30 PM

3:45 PM (252) Influence of Angiotensin-Type 1-Receptor Antibodies in Chronic Vascular Injury on Heart Transplant Patients:
L. Borggärd1, L. Potena2, E. Resciniti1, S. Capelli1, A. Bontadini1, S. Iannelli1, F. Fruet1, M. Sabatino1, F. Scardino1, M. Masetti1, P. Prestinzeni1, V. Manfredini1, C. Raperazzi1, F. Grigioni1, 1University of Bologna, Bologna, Italy, 2Cardiovascular Department, S.Orsola-Malpighi Hospital, Bologna, Italy, 3Immunogenetic Unit, S.Orsola-Malpighi Hospital, Bologna, Italy

3:45 PM

3:45 PM (253) WITHDRAWN

3:45 PM

3:45 PM (332) Three Year Follow Up of the Randomized SCHEDULE Trial With Everolimus Initiation and Early Withdrawal of Calcineurin Inhibitor Therapy in De Novo Heart Transplant Recipients – A Multicenter, Randomized Scandinavian Trial:
A. K. Andreassen1, B. Andersson2, F. Gustafsson3, H. Eiskjær4, G. Rådegran5, G. Dellgren8, I. Gullestad1. 1Dept. of Cardiology, Oslo University Hospital Oslo University Hospital, Oslo, Norway, 2Dept. of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, 3Dept. of Cardiology, Rigshospitalet, Copenhagen, Denmark, 4Dept. of Cardiology, Aarhus University Hospital, Skejby, Denmark, 5Dept. of Cardiology, The Clinic of Heart Failure and Valvular Disease, Skåne University Hospital and Lund University, Lund, Sweden, 6Dept. of Cardiology, Heart and Medicine Center County Council of Östergotland and Linkoping University, Linkoping, Sweden, 7Novartis Norge AS, Novartis, Oslo, Norway, 8Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden

153 | F R I D A Y  A P R I L 1 7
2:30 PM – 4:00 PM

CONCURRENT SESSION 32

Mechanical Cardiac Support in Children: Outcomes and Registry Data
(PEDS, BSI, DMD, HF, HTX, ID, LF, MCS, NHSAH, PATH, PH, PHARM, PEEQ)

CHAIRS: Janet N. Scheel, MD and Christopher Almond, MD


3:00 PM (256) Berlin Heart EXCOR Outcomes in Pediatric Patients With Restrictive and Hypertrophic Cardiomyopathy; J. A. Su, J. R. Woolley, C. Tjoossem, J. Menteer. Pediatric Cardiology, Children's Hospital of Los Angeles, Los Angeles, CA, Berlin Heart Inc., The Woodlands, TX

3:15 PM (257) Berlin Heart Post Approval Outcomes in North America; R. D. Jaquiss, C. D. Fraser, D. N. Rosenthal, T. Humph, C. Canter, D. L. Morales, C. Tjoossem, R. Kroslovitz. Pediatric Cardithoracic Surgery, Duke Childrens Heart Center, Durham, NC, Cardiothoracic Surgery, Texas Children's Hospital, Houston, TX, Pediatric Cardiology, Stanford University, Palo Alto, CA, Pediatric Cardiology, Hospital for Sick Children, Toronto, ON, Canada, Pediatric Cardiology, Washington University in St. Louis, St. Louis, MO, Pediatric Cardithoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, Berlin Heart, Inc., the Woodlands, TX

3:30 PM (258) Adverse Events in Children Implanted With Ventricular Assist Devices in the US: Data From the Pediatric Interagency Registry for Mechanical Circulatory Support (PediMACS); D. N. Rosenthal, C. S. Almond, R. D. Jaquiss, C. E. Peyton, S. R. Auerbach, D. L. Morales, D. J. Epstein, R. S. Cantor, R. L. Kormos, D. C. Naftel, R. J. Butts, N. S. Ghanayem, J. K. Kirklin, E. D. Blume. Pediatrics, Stanford University, Palo Alto, CA, Pediatric Cardiology, Stanford University, Palo Alto, CA, Pediatric Cardiac Surgery, Duke University School of Medicine, Durham, NC, Children's Hospital Heart Institute, Children's Hospital Colorado, Aurora, CO, Pediatrics, University of Colorado, Aurora, CO, Pediatric Cardithoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, Pediatric Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO, Cardiothoracic Surgery, The University of Alabama at Birmingham, Birmingham, AL, Heart and Vascular Institute, The University of Pittsburgh Medical Center, Pittsburgh, PA, Pediatrics, Medical University of South Carolina, Charleston, SC, Pediatrics (Critical Care Section), Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, WI, Cardiology, Boston Children's Hospital, Boston, MA
Utilization and Outcomes of Continuous-Flow Ventricular Assist Devices in Pediatric Patients: A Report From the Pediatric Interagency Registry for Mechanical Circulatory Support (PediMACS);


1Cardiology, Children’s Hospital of Philadelphia, Philadelphia, PA, 2The Heart Institute, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 3Cardiology, Boston Children’s Hospital, Boston, MA, 4Cardiology, Texas Children’s Hospital/ Baylor College of Medicine, Houston, TX, 5Pediatric Cardiothoracic Surgery, UT Southwestern/Children’s Medical Center Dallas, Dallas, TX, 6Surgery and Pediatrics, University of Florida, Gainesville, FL, 7Pediatric Cardiothoracic Surgery, Stanford University, Stanford, CA, 8Pediatrics, Stanford University, Palo Alto, CA, 9Cardiothoracic Surgery, The University of Alabama at Birmingham, Birmingham, AL
Emerging Issues in Pediatric Lung Transplant (Hermes) (LTX, LF, PEDS)

CHAIRS: Christian Benden, MD and Simon Urschel, MD

2:30 PM (260) The Era Effect on Pediatric Lung Transplantation Outcomes; D. Bobylev1, C. Mueller1, N. Schwerk2, W. Sommer1, I. Todorache1, F. Tius1, C. Kuehn3, M. Avsar1, A. Horke1, D. Boethig1, J. Gottlieb1, A. Haverich1, G. Warnecke1. 1Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Pediatric Pneumology and Neonatology, Hannover Medical School, Hannover, Germany, 3Pulmonary Medicine, Hannover Medical School, Hannover, Germany

2:45 PM (261) Cystic Fibrosis Patients and Lung transplantation: A Changing Relationship; M. S. Khan1, F. Zafar1, R. Bryant III1, C. Towe2, M. G. Schecter2, D. L. Morales1. 1Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

3:00 PM (262) Comparing Serum and BAL Markers of Inflammation and Oxidation Pre and Post Lung Transplant in Children: Defining Biomarkers for Signal in Epithelial-Mesenchymal Transition to Bronchiolitis Obliterans; C. K. Conrad1, Y. Rosenberg-Hasson1. 1Lucile Packard Children's Hosp, Palo Alto, CA, 2Human Immune Monitoring Core, Stanford University, Palo Alto, CA

3:15 PM (263) Post Transplant De Novo Donor Specific Antibodies Correlate With the Development of Bronchiolitis Obliterans Syndrome Following Pediatric Lung Transplantation; R. H. Kerman1, E. Melicoff2, J. Maddox2, M. Ebenbichler2, J. Heinle1, D. McKenzie1, P. Jindra1, G. Mallory1. Baylor College of Medicine, Houston, TX, 1Texas Children's Hospital and Baylor College of Medicine, Houston, TX

3:30 PM (264) Risk Factors for Bronchiolitis Obliterans in Pediatric Lung Transplantation Across the United States; M. S. Khan1, F. Zafar1, R. Bryant III1, C. Towe2, J. K. Johnson2, M. G. Schecter2, D. L. Morales1. Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 1Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

3:45 PM (265) International Experience in Pediatric Extracorporeal Membrane Oxygenation (ECMO) Bridge to Lung Transplantation; J. Y. Wong1, A. R. Glanville2, G. P. Westall3, S. B. Goldfarb3, M. Griese3, B. Rottier4, M. Budde4, J. Balcels-Ramirez5, N. Schwerk6, Division of Pediatric Respiratory Medicine, McMaster University, Hamilton, ON, Canada, 1Department of Thoracic Medicine, St.Vincent's Hospital, Darlinghurst, Australia, 2Dept of Respiratory, Alfred Hospital, Melbourne, Australia, 3Children's Hospital of Philadelphia, Philadelphia, PA, 4Ludwig-Maximilians University of Munich Hospital, Muich, Germany, 5Beatrix Children's Hospital/University Medical Center, Groningen, Netherlands, 6Cleveland Clinic, Cleveland, OH, 1Pediatric Intensive Care Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain, 2Hannover Medical School, Hannover, Germany
Complement, CAV, and Lung Allograft Pathology
(Calliope)
(PATH, BSI, HTX, PEDS, LTX)

CHAIRS: Margaret M. Burke, MD, FRCPath and Gerald J. Berry, MD

2:30 PM (266) IgM De Novo Donor Specific HLA Antibodies (dnDSA) Claws Switch to IgG and DQ dnDSA Are Associated With C4d+ Biopsies Conversion to C4d+/C3d+ and Progression of Subclinical Antibody Mediated Rejection in Heart Transplant Recipients;
M. Askar1, R. Rodriguez2, L. Klingman1, D. Thomas1, A. Zhang1, H. Morf3, N. Hamon1, N. Moazami4, E. Hsich5, D. Taylor5, R. Starling1, C. Tan1. 1Transplant Center, Cleveland Clinic, Cleveland, OH, 2School of Medicine, Leipzig University, Leipzig, Germany, 3Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, 4Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, 5Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH

2:45 PM (267) Capillary Complement Deposition in the Early Posttransplant Period Correlates With Antibody-Mediated Rejection and Not With Ischemic Injury;
E. Rodriguez, M. Askar, C. D. Tan. Pathology, Cleveland Clinic, Cleveland, OH

3:00 PM (268) Characterization of Antigenic Targets of Local Antibodies Produced in Ectopic Lymphoid Structures in Cardiac Allografts;
M. Huibers1, S. Beerthuijzen1, A. Gareau2, E. Siera-de Koning1, J. van Kuijk1, N. de Jonge3, T. Lee1, H. Otten5, R. de Weger1. 1Pathology, UMC Utrecht, Utrecht, Netherlands, 2Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, 3Cardiology, UMC Utrecht, Utrecht, Netherlands, 4Pathology, Surgery, Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada, 5Immunology, UMC Utrecht, Utrecht, Netherlands

3:15 PM (269) Antibody-Mediated Rejection Is Associated With Worse Survival But Not With Cardiac Allograft Vasculopathy (CAV) in a Large Cohort of 295 Heart Transplant Recipients;
E. Rodriguez, M. Askar, C. D. Tan. Pathology, Cleveland Clinic, Cleveland, OH

3:30 PM (270) Comparison of Transbronchial Cryobiopsies With Conventional Forceps Biopsies in Evaluation of Lung Allografts;
A. C. Roden1, R. M. Kern2, M. C. Aubry1, S. M. Jenkins3, J. P. Scott1, F. Maldonado2. 1Laboratory Medicine & Pathology, Mayo Clinic Rochester, Rochester, MN, 2Division of Pulmonary & Critical Care Medicine, Mayo Clinic Rochester, Rochester, MN, 3Biomedical Statistics and Informatics, Mayo Clinic Rochester, Rochester, MN

3:45 PM (271) Pathologic Spectrum of Murine Obliterative Bronchiolitis and Other Features of Chronic Lung Allograft Dysfunction;
T. Martinu, H. Oishi, D. M. Hwang, M. Cypel, M. Liu, S. Keshavjee. Toronto Lung Transplant Program, University of Toronto & University Health Network, Toronto, ON, Canada
Complex Patients Require Complex Solutions: Predicting Adherence
(NHSAH, HF, HTX, LTX, MCS)

CHAIRS: Christiane Kugler, PhD and Sabina M. De Geest, RN, PhD

2:30 PM (272) The Predictive Value of the SIPAT for Clinical Outcomes in End-Stage Heart Failure Candidates; S. D. Grogan1, C. R. Bruce2, A. M. Cordero-Reyes3, A. Soliman4, J. D. Estep5. 1Transplant Psychiatry, Houston Methodist Hospital, Houston, TX, 2Medicine & Medical Ethics, Baylor College of Medicine & Houston Methodist Hospital, Houston, TX, 3Transplant Cardiology Research, Houston Methodist Hospital, Houston, TX, 4Critical Care Intensivist, Houston Methodist Hospital, Houston, TX, 5Transplant Cardiology, Houston Methodist Hospital, Houston, TX

2:45 PM (273) Patients With Visuospatial Constructional Deficits May Successfully Manage LVADs; C. M. Murks1, C. Juricek2, G. Kim1, G. Sayer1, N. Uriel1, T. Ota2, V. Jeevanandam1, S. Fedson1. 1Medicine, University of Chicago, Chicago, IL, 2Surgery, University of Chicago, Chicago, IL

3:00 PM (274) Cost-Related Non-Adherence and Its Relationship to Medication Non-Adherence Among Adult Heart Transplant Recipients in Ten Countries – A Multicenter Cross-Sectional Study; S. Schoenfeld1, L. Berben2, F. Dobbels2, C. L. Russell3, S. Salcso de Almeida4, S. M. de Geest5. 1University of Basel, Basel, Switzerland, 2School of Nursing and Health Studies, University of Missouri-Kansas City, Kansas City, MO, 3Institute of Nursing Science, University of Basel, Basel, Switzerland

3:15 PM (275) Variability in Chronic Illness Management Implemented Among Heart Transplant Centers – Preliminary Data From the International BRIGHT Study; C. Vetter1, L. Berben2, F. Dobbels2, C. L. Russell3, S. M. de Geest5. 1University of Basel, Basel, Switzerland, 2School of Nursing and Health Studies, University of Missouri-Kansas City, Kansas City, MO

3:30 PM (276) A Closer Look at Adherence: Sociodemographic Differences Long-Term After Heart Transplantation; C. White-Williams1, P. Fazeli2, B. Rybarczyk3, K. Grady4. 1University of Alabama, Birmingham, AL, 2Virginia Commonwealth University, Richmond, VA, 3Northwestern University Hospital, Chicago, IL

3:45 PM (277) Long-Term Clinical Impact of an mHealth Intervention for Lung Recipients; E. M. Rosenberger1, A. DeVito Dabbs2, A. F. DiMartini3, D. Landisettel, C. A. Bermudez2, M. A. Dew5. 1Clinical and Translational Science, University of Pittsburgh School of Medicine, Pittsburgh, PA, 2Acute and Tertiary Care, University of Pittsburgh School of Nursing, Pittsburgh, PA, 3Psychiatry, Surgery, and Clinical and Translational Science, University of Pittsburgh School of Medicine, Pittsburgh, PA, 4Medicine, Biostatistics, and Clinical and Translational Science, University of Pittsburgh School of Medicine, Pittsburgh, PA, 5Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, 6Psychiatry, Psychology, Epidemiology, Biostatistics, and Clinical and Translational Science, University of Pittsburgh School of Medicine, Pittsburgh, PA

4:00 PM – 4:30 PM Coffee Break/Visit Exhibits (Rhodes)

VIEW POSTERS (Agora 2)
Pump Thrombosis – Diagnosis and Outcomes
(Apollon)
(MCS, BSI, HF, HTX, NHSAH, PATH)

CHAIRS: Francis D. Pagani, MD, PhD and Michael McDonald, MD

4:30 PM (278) Effect of Device Thrombosis and Malfunction on Clinical Outcomes of Patients Bridging With Continuous-Flow LVADs;
Q. Wever-Pinzon1, A. P. Levin1, J. Fried1, A. R. Garan1, K. Takeda1, H. Takayama1, M. Yuzefpolskaya1, D. Mancini1, Y. Naka1, P. Colombo1, V. K. Topkara2. 1Cardiology, Columbia University Medical Center, New York, NY, 2Cardiology, Columbia University Medical Center, Englewood, NJ

4:45 PM (279) Treatment of Device Thrombus in the HeartWare HVAD: Success and Outcomes Depend Significantly on Initial Treatment Strategy;
J. M. Stulak1, S. Dunlay2, N. Haglund3, M. E. Davis4, F. Masood5, F. D. Pagani1, K. Aaronson1, S. Maltais1, Cardiovascular Surgery, Mayo Clinic, Rochester, MN, Cardiovascular Diseases, Mayo Clinic, Rochester, MN, Cardiovascular Diseases, Vanderbilt Heart and Vascular Institute, Nashville, TN, 2Cardiac Surgery, Vanderbilt Heart and Vascular Institute, Nashville, TN, 3Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI, 4Cardiovascular Diseases, University of Michigan Health System, Ann Arbor, MI

5:00 PM (280) From Bench to Bedside: Impact of LVAD Outflow Conduit Anastomosis Position on Outcome;
V. Tarzia1, G. Di Giamburaco2, G. Bortolussi3, D. Marinelli3, M. Maccherini3, M. Maiani3, M. Foschi3, S. Bernazzali3, V. Tursi3, S. Dito3, U. Livi3, G. Sani3, T. Bottio3, G. Gerosa3. 1Department of Cardio, Thoracic and Vascular Sciences, University of Padua, Cardiac Surgery, Padova, Italy, 2Cardiac Surgery, Chiari, Italy, 3Cardiac Surgery, Siena, Italy, 4Cardiac Surgery, Udine, Italy

5:15 PM (281) Hemolysis, Device Thrombosis, and Risk of CVA in HM II Patients: Role of Watchful Waiting?
A. P. Levin1, J. Z. Willey2, J. A. Fried3, C. J. Levin3, M. Dionizovik4, A. R. Garan5, V. Topkara2, M. Yuzefpolskaya2, P. C. Colombo5, H. Takayama5, Y. Naka5, N. Uriel6, U. P. Jorde7. 1Cardiology, Columbia University, New York, NY, 2Neurology, Columbia University Medical Center, New York, NY, 3Cardiology, Columbia University Medical Center, New York, NY, 4Cardiology, Columbia University Medical Center, New York, NY, 5Cardiology, University of Chicago, Chicago, IL, 6Cardiology, Monfioore Medical Center / Albert Einstein College of Medicine, Bronx, NY

5:30 PM (282) Spontaneous Microbubble Formation Is an Indicator of LVAD Pump Thrombosis;
L. Letarte1, P. Sears-Rogan1, S. Boyce1, M. Tyson1, Z. Wang1. 1Cardiology, Georgetown/Washington Hospital Center, Washington, DC, 2Cardiology, Washington Hospital Center, Washington, DC

5:45 PM (283) One-Year Hospital Charges Do Not Differ Between Redo Left Ventricular Assist Device Patients and Bridge to Transplantation Patients;
J. Magruder1, J. C. Grimm1, G. J. Arnaoutakis1, A. Kilic1, R. J. Tedford1, S. D. Russell2, C. Sciortino1, J. V. Conte1, A. S. Shah1. 1Division of Cardiac Surgery, Johns Hopkins, Baltimore, MD, 2Division of Cardiology, Johns Hopkins, Baltimore, MD
The Fate of the Right Heart after LVAD (Athena)

MCS, BSI, HF, HTX, NHSAH, PHARM

CHAIRS: Jeffrey J. Teuteberg, MD and Thomas Krabatsch, MD, PhD

4:30 PM

**Discriminatory Power of Commonly Used Indices and Scores in Predicting Early Severe Right Ventricular Failure After Continuous-Flow Left Ventricular Assist Device Implantation**;

V. Tchantchaleishvili, S. Maltais, S. Dunlay, A. Haglund, M. E. Davis, H. T. Massey, F. D. Pagani, K. D. Aaronson, J. M. Stulak, Cardiac Surgery, University of Rochester Medical Center, Rochester, NY, "Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN," Cardiovascular Medicine, Mayo Clinic, Rochester, MN, "Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN," Cardiovascular Medicine, University of Rochester Medical Center, Rochester, NY, "Cardiac Surgery, University of Michigan, Ann Arbor, MI," Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, "Cardiac Surgery, Mayo Clinic, Rochester, MN"

4:45 PM

**Modeling the Spectrum of Right Ventricular Failure (RVF) After LVAD Therapy**;

N. A. Loghmanpour, R. L. Kormos, M. K. Kanwar, J. J. Teuteberg, S. Murali, J. J. Teuteberg, S. Murali, J. F. Antaki, Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA, "Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA," "Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA"

5:00 PM

**Update on Temporary Mechanical Circulatory Support for Right Ventricular Failure**;

U. Bansal, K. Jackson, D. G. Winger, J. J. Teuteberg, C. Bermudez, R. L. Kormos, A. Bansal, J. K. Bhama, Heart & Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, "Clinical and Translational Science Institute, University of Pittsburgh Medical Center, Pittsburgh, PA," "Department of Cardiothoracic Surgery, Ochsner Clinic, New Orleans, LA," "Heart & Vascular Center, University of Iowa Health Care, Iowa City, IA"

5:15 PM

**Use of Phosphodiesterase 5 Inhibitors in Continuous-Flow Left Ventricular Assist Device Patients With Pulmonary Hypertension: A Contemporary Analysis**;


5:30 PM

**An Analysis of Early Versus Late Right Heart Failure With an Intrapericardial Continuous Flow LVAD**;

J. E. Rame, J. J. Teuteberg, E. J. Birks, J. G. Rogers, M. A. Acker, E. Y. Birati, M. S. Slaughter, K. D. Aaronson, K. Leadley, F. D. Pagani, R. L. Kormos, Hospital of the University of Pennsylvania, Philadelphia, PA, "University of Pittsburgh Medical Center, Pittsburgh, PA," "University of Louisville, Louisville, KY," "Duke University School of Medicine, Durham, NC," "University of Michigan, Ann Arbor, MI," "HeartWare, Framingham, MA"

5:45 PM

**Outcomes of Patients Complicated With Late Right Heart Failure During Continuous Left Ventricular Device Support: Should Patients Stay on Device or Be Transplanted?**;

K. Takeda, H. Takayama, S. Fukuhara, J. Han, P. C. Colombo, M. Yuzefpolskaya, V. K. Topkara, D. M. Mancini, Y. Naka, Columbia University, NY, NY
CONCURRENT SESSION 38

Cloudy with a Chance of T-Cells: Rejection Forecast
(Clio, Thalie)
(HTX, BSI, ID, NHSAH, PATH, PEDS, PHARM)

CHAIRS: Kiran K. Khush, MD and Luciano Potena, MD, PhD

4:30 PM (290) A Novel Human Leukocyte Antigen Score Improves Prediction for Rejection After Heart Transplant;
E. P. Kransdorf1, L. Gragert2, M. Cheng1, D. E. Steidley1,
R. L. Scott4, M. J. Pando4, M. Maiers2, O. E. Pajaro5. 1Division of Cardiovascular Diseases, Mayo Clinic Arizona, Scottsdale, AZ, 2Bioinformatics Research, National Marrow Donor Program/Be The Match, Minneapolis, MN, 3Division of Health Sciences Research, Mayo Clinic Arizona, Scottsdale, AZ, 4Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale, AZ, 5Division of Cardiothoracic Surgery, Mayo Clinic Arizona, Scottsdale, AZ

4:45 PM (291) Genetic Risk Score (GRS) Predicts Worse Survival in African American Heart Transplant Recipients at 10 Years;
B. Coleman1, X. Guo2, J. Patel1, N. Reinsmoen1, Y. Jia2, J. A. Kobashigawa1. 1Cedars-Sinai Heart Institute, Los Angeles, CA, 2Los Angeles Biomedical Research Institute, Torrance, CA

5:00 PM (292) Donor-Derived Cell-Free DNA Decreases Following Effective Treatment of Acute Cellular Rejection in Heart Transplant Recipients: The CARGO II Multicenter Trial;

5:15 PM (293) Correlation of Longitudinal Gene-Expression Profiling (GEP) Score to Cytomegalovirus (CMV) Infection: Results From the Outcomes AlloMap® Registry (OAR);
M. Kanwar1, J. Yee2, G. Ewald3, S. Murali1. 1Allegheny Singer Research Institute, Pittsburgh, PA, 2CareDx, Inc, Brisbane, CA, 3Washington University, St. Louis, MO

5:30 PM (294) Predictive Value of Gene Expression Profiling as Assessed By AlloMap® Score for Long-Term Survival After Heart Transplantation;
B. Fujita, E. Prashovikj, U. Schulz, J. Sunavsky, U. Fuchs, J. Börgermann, J. Gummert, S. Ensminger. Department for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany

5:45 PM (295) The Time Course of Development of Anti-Human Leukocyte Antigen Antibodies Crucial for Monitoring and Potential Intervention Following Heart Transplantation;
4:30 PM – 6:00 PM

CONCURRENT SESSION 39

Advances in Prognostic Stratification in Pulmonary Hypertension (Erato,Uranie)
(PH, HF, HTX, LF, LTX, MCS)

This session is supported by educational grants from Actelion and Gilead.

CHAIRS: Aaron B. Waxman, MD, PhD and Dana P. McGlothlin, MD

4:30 PM (296) Determinants and Prognostic Significance of Right Ventricular Reverse Remodeling in Idiopathic Pulmonary Arterial Hypertension Receiving Specific Medical Treatment;
R. Badagliacca1, R. Poscia1, B. Pezzuto1, M. Mezzapesa1, M. Nocioni1, S. Papa1, M. Francone2, S. Sciomer1, C. Iacoboni1, E. Giannetta1, F. Fedele1, C. Vizza1. 1Cardiovascular and Respiratory Disease, Sapienza University of Rome, Rome, Italy, 2Radiology, Sapienza University of Rome, Rome, Italy, 3Experimental Medicine, Sapienza University of Rome, Rome, Italy

4:45 PM (297) Concentric Hypertrophy Protects Against Clinical Worsening in Idiopathic Pulmonary Arterial Hypertension: Insights From Magnetic Resonance Imaging;
R. Badagliacca1, R. Poscia1, B. Pezzuto1, M. Mezzapesa1, M. Nocioni1, S. Papa1, M. Francone2, S. Sciomer1, C. Iacoboni1, E. Giannetta1, F. Fedele1, C. Vizza1. 1Cardiovascular and Respiratory Science, Sapienza University of Rome, Rome, Italy, 2Radiology, Sapienza University of Rome, Rome, Italy, 3Experimental Medicine, Sapienza University of Rome, Rome, Italy

5:00 PM (298) Measurement of Contractile Reserve During Exercise Using Cardiac MRI in Pulmonary Hypertension: A Pilot Study;
N. Morris1, H. Seale2, W. Strugnell3, K. Hall2, C. Hamilton-Craig3. 1Griffith University, Gold Coast, Australia, 2Queensland Lung Transplant Service The Prince Charles Hospital, Brisbane, Australia, 3Richard Slaughter Center of Excellence in CVMRI, The Prince Charles Hospital, Brisbane, Australia

5:15 PM (299) Hemodynamic Markers of Pulmonary Vascular Disease in Pulmonary Hypertension Due to Left Heart Disease;
R. R. Vanderpool, M. T. Gladwin, M. A. Simon. Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA

5:30 PM (300) A Non-Invasive Risk Score for the Prediction of Combined Post- and Pre-Capillary Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction;
D. D. Dixon1, R. Cogswell2, M. A. Burke3, M. J. Cuttica1, B. H. Freed1, L. Beussink-Nelson, T. Thenappan1, S. J. Shah1. 1Northwestern University, Chicago, IL, 2University of Minnesota, Minneapolis, MN, 3Harvard University, Boston, MA

5:45 PM (301) Comparison of Pulmonary Artery (PA) Wave Reflections in Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction (PH-HFpEF);
S. A. Gandhi1, A. Singal2, N. Gadela2, H. Kelner2, C. Carlson2, M. Pritzker1, T. Thenappan2. 1Department of Medicine, University of Minnesota, Minneapolis, MN, 2Cardiovascular Division, University of Minnesota, Minneapolis, MN

| 162 |
**4:30 PM – 6:00 PM**

**CONCURRENT SESSION 40**

**Lung AMR: HLA and Beyond (Hermes)**

**(LTX, BSI, LF, PATH, PEDS)**

**CHAIRS:**
Gregory I. Snell, FRACP, MBB and Enrique Diaz Guzman Zavala, MD

**4:30 PM (302) HLA Matching at the Epitope Level Protects Against Chronic Lung Allograft Dysfunction:**
D. C. Walton1, S. J. Hiho1, L. S. Cantwell1, M. B. Diviney1, G. I. Snell2, M. A. Paraskeva2, G. P. Westall2. 1Victorian Transplantation and Immunogenetics Service, Australian Red Cross Service, Melbourne, Australia, 2Lung Transplant Service, Alfred Hospital, Melbourne, Australia

**4:45 PM (303) A Three Center Study Reveals New Insights into the Impact of Non-HLA Antibodies on the Acute Rejection Process in Lung Transplantation:**
N. L. Reinsmoen1, J. Mirocha2, C. Ensor2, M. Marrari3, G. E. Chaux4, C. Lai4, D. Levine5, A. Zeevi6. 1HLA & Immunogenetics Laboratory, Cedars-Sinai Health Systems, Los Angeles, CA, 2Cedars-Sinai Research Institute, Cedars-Sinai Health Systems, Los Angeles, CA, 3Pharmacy and Therapeutics, University of Pittsburgh Medical Center, Pittsburgh, PA, 4Division of Transplant Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, 5Lung Transplant Center, Cedars-Sinai Health Systems, Los Angeles, CA, 6Pulmonary Diseases & Critical Care Medicine, Univ. of Texas Health Science Center, San Antonio, TX, 7Pathology, Surgery and Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA

**5:00 PM (304) The Deleterious Effect of De Novo DQ Donor Specific Antibody in Lung Transplant Is Not Related to the MFI Values of Luminex Single Antigen Assays:**
A. Zhang1, T. S. Panchabhai2, Y. Sun3, H. Morf4, M. M. Budev2, C. Farver5, K. R. McCurry6, L. Klingman1, M. Askari1. 1Allogen Laboratories, Cleveland Clinic, Cleveland, OH, 2Respiratory Institute, Cleveland Clinic, Cleveland, OH, 3Avalon University School of Medicine, Curaçao, Netherlands, 4Leipzig University School of Medicine, Leipzig, Germany, 5Anatomic Pathology, Cleveland Clinic, Cleveland, OH, 6Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH

**5:15 PM (305) New Insights in to the Impact of Auto-Antibodies on the Acute Rejection Process in Lung Transplantation:**
N. L. Reinsmoen1, J. Mirocha2, C. Ensor2, M. Marrari3, G. E. Chaux4, C. Lai4, D. Levine5, A. Zeevi6. 1HLA & Immunogenetics Laboratory, Cedars-Sinai Health Systems, Los Angeles, CA, 2Cedars-Sinai Research Institute, Cedars-Sinai Health Systems, Los Angeles, CA, 3Pharmacy and Therapeutics, University of Pittsburgh Medical Center, Pittsburgh, PA, 4Division of Transplant Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, 5Lung Transplant Center, Cedars-Sinai Health Systems, Los Angeles, CA, 6Pulmonary Diseases & Critical Care Medicine, Univ. of Texas Health Science Center, San Antonio, TX, 7Pathology, Surgery and Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA
5:30 PM (306) **Donor-Specific HLA Antibodies After Lung Transplantation: Extended Follow-Up From the HALT Study;**

R. R. Hachem1, M. Budev2, M. Askar3, C. Farver4, J. Lee5, M. Kamoun6, G. Dhillon6, D. Tyan7, D. J. Levine8, M. Pollack9, L. E. Leard10, R. Raja11, T. Mohanakumar12, R. D. Yusen13. 1Pulmonary & Critical Care Medicine, Washington Univ Sch Med, Saint Louis, MO, 2Respiratory Institute, Cleveland Clinic, Cleveland, OH, 3Surgery, Cleveland Clinic, Cleveland, OH, 4Pathology, Cleveland Clinic, Cleveland, OH, 5Pulmonary & Critical Care Medicine, University of Pennsylvania, Philadelphia, PA, 6Pathology, University of Pennsylvania, Philadelphia, PA, 7Pulmonary & Critical Care Medicine, Stanford University, Palo Alto, CA, 8Pathology, Stanford University, Palo Alto, CA, 9Pulmonary & Critical Care Medicine, UT Health Sciences Center, San Antonio, TX, 10Pathology, UT Health Sciences Center, San Antonio, TX, 11Pulmonary & Critical Care Medicine, University of California San Francisco, San Francisco, CA, 12Surgery, University of California San Francisco, San Francisco, CA, 13Surgery, Washington Univ Sch Med, Saint Louis, MO

5:45 PM (307) **Human Intravenous Immunoglobulins With Rituximab vs. Therapeutic Plasma Exchange With Rituximab for Pre-Emptive Treatment of Early Donors Specific Antibodies After Lung Transplantation: Preliminary Result;**

F. Ius1, W. Sommer1, D. Kienke1, I. Tudorache1, C. Kühn1, M. Avsar1, T. Siemen1, J. Salman1, M. Greer1, M. Hallensleben1, N. Schwerk1, J. Gottlieb1, T. Welte1, A. Haverich1, G. Warnecke1. 1Department of Cardiothoracic, Transplant and Vascular Surgery, Hanover Medical School, Hanover, Germany, 2Department of Transfusion Medicine, Hanover Medical School, Hanover, Germany, 3Department of Respiratory Medicine, Hanover Medical School, Hanover, Germany, 4Department of Paediatrics, Hanover Medical School, Hanover, Germany
4:30 PM – 6:00 PM

CONCURRENT SESSION 41

Heart Matters: Truth and Justice (Calliope)
(PEEQ, HF, HTX, MCS, NHSAH)

CHAIRS: Bruno M. Meiser, MD and
Kathleen L. Grady, PhD, APN, FAAN

4:30 PM (308) The Effect of Everolimus vs. Calcineurin Inhibitors on Quality of Life During 3 Years Follow Up: The Result of a Randomized Controlled Trial (SCHEDULE Trial);
I. Groy1, A. Relbo1, K. Karason1, F. Gustafsson1, H. Eiskjaer1, G. Radegran1, E. Gude1, K. Jansson1, D. Solbu1, S. Arora1, G. Dellgren1, A. Andreassen1, L. Gullesstad1. 1Oslo University Hospital Rikshospitalet, Oslo, Norway, 2Sahlgrenska University Hospital, Gothenburg, Sweden, 3Copenhagen University Hospital, Copenhagen, Denmark, 4Skejby University Hospital, Aarhus, Denmark, 5Skane University Hospital, Lund University Hospital, Lund, Sweden, 6Linkoping University Hospital, Linkoping, Sweden, 7Novartis Norge AS, Oslo, Norway, 8Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden

4:45 PM (309) International Comparison of Heart Failure Rehospitalizations: An Analysis of the Global Comparators Administrative Database;
V. N. Selby1, B. Ide2, P. Copeland3, P. Bergin4, H. P. Brunner-La Rocca5, T. E. Meyer5, R. Morgan5, N. Casey7, J. Lewis8, T. De Marco1. 1Division of Cardiology, University of California, San Francisco, San Francisco, CA, 2UCSF Medical Center, San Francisco, CA, 3Chelsea & Westminster Hospital NHS Foundation Trust, London, United Kingdom, 4Cardiovacular Medicine, Alfred Hospital, Melbourne, Australia, 5Department of Cardiology, Maastricht University Medical Center, Maastricht, Netherlands, 6Medicine (Cardiology), University of Massachusetts Medical Center, Worcester, MA, 7Chelsea and Westminster Hospital, London, United Kingdom, 8Dr Foster Intelligence, London, United Kingdom

5:00 PM (310) A Comprehensive Analysis of Hospital Charges Between Direct Heart Transplantation and Patients Bridged With a Left Ventricular Assist Device;
M. R. Dantzer1, M. Djuraadi2, M. E. Davis3, E. Y. Zavala4, N. A. Haglund5, S. Malais5, 1Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, 2Vanderbilt Univ Med Ctr, Nashville, TN, 3Transplant Administration, Vanderbilt Univ Med Ctr, Nashville, TN, 4Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN

5:15 PM (311) Cardiac Replacement Therapies – A Comparative Analysis of Cost and Survival – Heart Transplantation vs. Circulatory Assist;
E. Gude1, V. Mishra2, A. Flade1, B. Persson1, O. Geiran4, G. Sorensen1, T. Hagen1, 1Department of Cardiology, Oslo University Hospital, Oslo, Norway, 2Department of Finance and Resource Management Unit, Oslo University Hospital, Oslo, Norway, 3Department of Cardiotoracic Surgery, Oslo University Hospital, Oslo, Norway, 4Faculty of Medicine, University of Oslo, Oslo, Norway, 5Department of Health Management and Health Economics, Faculty of Medicine, University of Oslo, Oslo, Norway

5:30 PM (312) Impact of Insurance Status on LVAD Utilization and Health Outcomes for Patients Listed for Heart Transplantation;
A. A. Morris1, A. Kelkar1, Y. Ko2, S. R. Laskar1, A. L. Smith1, J. D. Vega1. 1Emory University, Atlanta, GA, 2Emory Rollins School of Public Health, Atlanta, GA
5:45 PM (313) Quality of Life/Mid-Term Survival of Patients Bridged With ECMO to LVAD: S. Unai, K. Yamane, G. Cook, H. Hirose, N. C. Cavarocchi, J. W. Entwistle. 1Cardiothoracic Surgery, Thomas Jefferson University, Philadelphia, PA, 2Cardiothoracic Surgery, Penn State Hershey Medical Center, Hershey, PA
The Silent Partner (Euterpe)
(ID, BSI, HTX, LTX, PEDS)

**CHAIRS:** Orla Morrissey, MD and Stanley I. Martin, MD

**4:30 PM** (314) **Microbial Communities and Cytokine Responses Associated With Respiratory Tract Infections Following Lung Transplant (LTX);**
C. Cianci1, J. Shankar2, M. Crespo1, J. Pilewski1, C. Bermudez1, W. Nierman1, M. Nguyen1. University of Pittsburgh, Pittsburgh, PA, 2JCVI, Rockville, MD

**4:45 PM** (315) **CMV-Specific CD8+ T Cells Persist During Early Chronic Infection With Impaired Function and an EomeshiPD-1hi Exhausted Phenotype in Lung Transplant Recipients With Relapsing Viremia;**
I. Popescu1, M. R. Pipeling1, H. Otepka1, P. Shäh2, J. B. Orens2, J. F. McDyer1. Medicine, University of Pittsburgh, Pittsburgh, PA, 2Medicine, Johns Hopkins University, Baltimore, MD

**5:00 PM** (316) **Hypogammaglobulinemia Can Be Immunomodulated as a Risk Factor of Infection in Heart Recipients By Preventive Use of Intravenous Immunoglobulin: Results of a Clinical Trial;**
J. Carbone1, P. Diez2, M. Arraya1, M. Jaramillo1, L. Calahorra1, J. Fernandez-Yanez2, J. Palomo1, J. Hortal1, P. Munoz2, J. Navarro1, E. Sarmiento1. Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 2Cardiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 3Anesthesiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 4Microbiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain

**5:15 PM** (317) **Early Secondary Combined Immunodeficiency After Heart Transplantation: Impact on Development of Severe Infections;**
J. Carbone1, J. Palomo2, J. Fernandez-Yanez2, P. Diez2, P. Muñoz2, J. Hortal1, E. Sarmiento1. Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 2Cardiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 3Infectious Diseases, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 4Anesthesiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain

**5:30 PM** (318) **Mannose-Binding Lectin Serum Levels and Pre-Transplant Genotypes for Personalized Anti-CMV Prophylaxis in Heart Recipients;**
J. Carbone1, M. Arraya1, F. Lozano2, J. Palomo1, E. Sarmiento1. Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 2Immunology, Hospital Clinic, Barcelone, Spain, 3Cardiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain

**5:45 PM** (319) **Boosting the Adaptive Immune Response Prevents the High Incidence of Herpes Zoster After Lung or Heart Transplantation;**
N. M. van Besouw1, S. Roest1, J. M. Zuijderwijk1, R. de Kuiper1, R. J. van Weezel1, R. A. Hoek1, A. A. van der Eijk2, W. Weimar1, P. T. van Hal1, O. C. Manintveld1. Internal Medicine-Transplantation, Erasmus MC, Rotterdam, Netherlands, 2Cardiology, Erasmus MC, Rotterdam, Netherlands, 3Respiratory Medicine, Erasmus MC, Rotterdam, Netherlands, 4Viroscience, Erasmus MC, Rotterdam, Netherlands

---

**EXHIBIT HALL STRIKE (Rhodes)**
6:00 PM – 7:00 PM

MINI ORAL SESSION 7

Mechanical Circulatory Support: Apocalypse Tomorrow (Athena) (MCS, HF)

CHAIRS: David S. Feldman, MD, PhD and Guenther Lauffer, MD

6:00 PM (320) Contributing Factors to the Successful Medical Management of Suspected Left Ventricular Assist Device Thrombosis;
M. Bradbury1, K. Poppiti2, R. Connolly2, D. Goffman1, N. Burton1, S. Desai1, P. Shah1. 1Inova Fairfax Hospital, Falls Church, VA, 2Georgetown University Hospital, Washington, DC, DC

6:05 PM (321) The Risk of Hospital Readmissions Following Mechanical Circulatory Support Placement;

WITHDRAWN

6:10 PM (322) WITHDRAWN

6:15 PM (505) Left Ventricular Assist Device Support Provides Drastic Restoration of Gene Expression Together With Myocardial Recovery in Patients With Advanced Heart Failure;
K. Kuroda1, O. Seguchi1, E. Hisamatsu1, T. Sato1, S. Nakajima1, H. Sunami1, T. Sato1, S. Muto2, M. Nishigori3, H. Hata4, K. Ohgo5, M. Asakura5, M. Yanase1, T. Fujita5, H. Ishibashi-Ueda6, N. Minamino7, J. Kobayashi8, T. Nakatani8. 1Department of Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, 2Department of Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan, 3Department of Molecular Pharmacology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, 4Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan

Moved to Concurrent Session 15

6:20 PM (324) Results of the SynCardia temporary Total Artificial Heart (TAH-t) Postmarket Surveillance Study (PSS) vs. Pre-Market Approval (PMA);
F. A. Arabia1, V. Kasirajan2, J. G. Copeland3, R. G. Smith4, D. Covington5, Surgery, Cedars-Sinai Med Ctr, Los Angeles, CA, 2Surgery, Virginia Commonwealth University, Richmond, VA, 3None, Los Angeles, CA, 4Artificial Heart, University of Arizona, Tucson, AZ

6:25 PM (325) Discriminatory Performance of Simple Urine Dipstick for Detection of Significant Hemolysis in CF-LVAD Patients;
M. Gavalas1, A. Breskin2, A. B. Eisenberger1, M. Yuzefpolskaya1, V. K. Topkara1, M. R. Torres1, M. Tiburcio2, J. S. Murphy1, B. Cagliostro1, R. Te-Frey1, K. Ross1, M. Flannery2, K. Wong1, R. A. Garan1, D. M. Mancini1, K. Takeda1, H. Takayama1, Y. Naka1, R. T. Demmer1, P. C. Colombo1. 1Medicine, Columbia University, New York, NY, 2Columbia University, New York, NY, 3Surgery, Columbia University, New York, NY, 4Epidemiology, Columbia University, New York, NY
6:30 PM  (326) Outcomes of Off-Pump Minimally Invasive Exchange of the HeartMate II (HMII) Left Ventricular Assist Device (LVAD);
B. Soleimani1, C. Pietras1, E. Stephenson1, K. High2, W. Pae1.
1Cardiothoracic Surgery, Penn State Hershey Medical Center, Hershey, PA, 2Anesthesiology, Penn State Hershey Medical Center, Hershey, PA

6:35 PM  (327) Anticoagulation Reversal With 4-Factor Prothrombin Complex Concentrate in Left Ventricular Assist Device Patients With Acute Hemorrhagic Stroke;
P. Chen1, J. Falvey2, L. Lowenstein3, A. Miranpuri4, W. Hallinan1, T. Massey1. Cardiac Surgery, University of Rochester, Rochester, NY, 2Pharmacology, University of Rochester, Rochester, NY, 3Medicine, University of Rochester, Rochester, NY, 4Neurosurgery, University of Rochester, Rochester, NY

6:40 PM  (328) Gold standard in biventricular circulatory support – excellent results with an old school device;
S. Bartfay1, H. Lidén2, M. Holmberg1, K. Karason1, J. Gäbel3, B. Redfors3, G. Dellgren4. Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, 2Department of Cardiologothoracic Surgery and Transplantation, Sahlgrenska University Hospital, Gothenburg, Sweden, 3Department of Cardiologothoracic Anesthesia and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden,

6:45 PM  (329) Partial Support for Bridged Patients With Previous Cardiac Surgery Implanted With a Miniaturized Centrifugal Continuous-Flow Pump: Are We There Yet?;
S. Maltais1, M. E. Davis1, M. Djunaidi1, M. R. Dantoni1, J. M. Stulak2, M. Xu3, N. A. Haglund4. Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, 2Cardiac Surgery, Mayo Clinic, Rochester, MN, 3Biostatistics, Vanderbilt Univ Med Ctr, Nashville, TN, 4Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN

6:50 PM  (330) The Use of a Portable Driver for the Total Artificial Heart in the United States: The Freedom Driver System Study;
V. Kasirajan1, F. Arabia2. Surgery, Va Commonwealth Univ Med, Pauley Heart Center, Richmond, VA, 2Cardiac Surgery, Cedars Sinai Medical Center, Los Angeles, CA

6:55 PM  (331) Hemodynamic Response to Nitroprusside as Predictor of Right Ventricular Failure After LVAD Implantation;
D. Mikhalkova, A. Godishala, M. Nassif, J. Vader, G. Ewald, S. LaRue, K. Lavine. Barnes Jewish Hospital Washington University, St Louis, MO
A Heart Day’s Night (Clio, Thalie) (HTX, BSI, DMD, HF, ID, MCS, NHSAH, PATH, PEDS, PHARM, PEEQ)

CHAIRS: Piotr Przybylowski, MD, PhD and Giuseppe Faggian, MD

(332) Moved to Concurrent Session 31

6:00 PM (780) Effect of Pre-Transplant Mechanical Circulatory Support on Early Cellular Rejection and Subsequent Risk of Allograft Vasculopathy; A. Grupper1, E. M. Nestorovic2, L. D. Joyce2, N. M. Milic3, J. M. Stulak4, B. S. Edwards5, N. L. Pereira6, R. C. Daly5, S. S. Kushwaha7. 1Divisions of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, 2Cardiac surgery, Hospital for Cardio Surgery, Clinical Center of Serbia, Belgrade, Serbia, 3Divisions of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, 4Institute for Medical Statistics and Informatics, Medical Faculty University of Belgrade, Belgrade, Serbia

6:05 PM (333) Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Heart Transplant Recipients After Conversion to Everolimus Therapy; J. Stypmann1, M. Fobker2, K. Rosing2, M. Engelen1, S. Gunia1, A. Dell'Aquila2, J. Nofer2. 1Department of Cardiovascular Medicine, University Hospital Münster, Muenster, Germany, 2Center of Laboratory Medicine, University Hospital Münster, Muenster, Germany, 3Internal Medicine D, Department of Nephrology, Hypertension and Rheumatology, University Hospital Münster, Muenster, Germany, 4Department of Cardiothoracic Surgery, University Hospital Münster, Muenster, Germany

6:10 PM (334) Complement-Fixing Donor-Specific HLA Antibodies Detected By Novel C3d Assay Are Associated With Antibody Mediated Rejection in Heart Transplant Recipients; J. Lan1, M. Hickey1, M. Cadeiras2, E. C. Depasquale2, N. Halnon1, A. Baas1, G. Perenz1, A. Nsa1, M. Kwon1, T. Khull1, A. Ardehali3, D. Gjerston1, J. Alejos2, L. Reardon1, E. F. Reed1, M. Deng1, Q. J. Zhang1. 1UCLA Immunogenetics Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, 2Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, 3Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA

6:15 PM (335) Three Years Outcome of Virtual Crossmatch Strategy in Heart Transplant Recipients; L. Borgese1, L. Potena2, V. Manfredini3, A. Bontadini3, S. Ianneli3, F. Frati4, S. Capelli5, M. Chiavaroli5, B. Barra1, P. Prestinanzi5, G. Magnani4, F. Grigioni5, C. Rapezzi2. 1University of Bologna, Bologna, Italy, 2Cardiovascular Department, S.Orsola-Malpighi Hospital, Bologna, Italy, 3Immunogenetic Unit, S. Orsola-Malpighi Hospital, Bologna, Italy

6:20 PM (336) Donor-Derived Cell-Free DNA Is Stable in Non-Rejecting Heart Transplant Recipients in the CARGO II Multicenter Trial; P. Mohacs1, M. Crespo-Leiro2, A. Zuckermann1, J. Stypmann4, D. Hiller5, M. Grskovic5, J. Beausang5, R. Sitt5, B. Christie6, J. Elechko7, R. Woodward7, J. Yee7, J. Vanhaecke7, 1University Hospital Bern, Bern, Switzerland, 2Hospital Universitario A Coruña, La Coruña, Spain, 3Medical University of Vienna, Vienna, Austria, 4University Hospital Münster, Münster, Germany, 5CareDx, Inc, Brisbane, CA, 6University Hospital Leuven, Leuven, Belgium
6:25 PM  (337) **Pretransplant Serum BAFF in Heart Transplantation: A Potential New Biomarker for Acute Cellular Rejection Risk**;  
J. Carbone1, L. Calañaor3, P. Diez2, J. Palomo2, J. Fernandez-Yanez2, E. Sarmiento. 1Clinical Immunology, Hospital General Universitario Gregorio Marañon, Madrid, Spain, 2Cardiology, Hospital General Universitario Gregorio Marañon, Madrid, Spain,

6:30 PM  (338) **Time Course of Immunosuppression Minimization and HLA Class I and Class II Antibody Emergence in Heart Transplantation**;  
M. Bakir1, C. Henriquez-Ticas1, E. Chang1, J. Maque1, J. Chittoor1, C. Starling1, G. Bondar1, N. Wisniewski1, S. Adigopula1, T. Khulu1, E. Reed1, J. Zhang1, M. Cadeiras1, M. Deng. 1Cardiology, UCLA, Los Angeles, CA, 2Cardiology, LMU, Los Angeles, CA

6:35 PM  (339) **Deep Sequencing Reveals Dynamics in Circulating miRNAs Following Heart Transplantation**;  
R. C. Givens2, K. M. Akaf1, D. Briskin2, D. J. Brunjes1, P. J. Kennel1, Y. Nakah1, H. Takayama1, I. George1, D. M. Mancini1, T. Tuschli2, P. C. Schulze1. 1Medicine, Columbia University Medical Center, New York, NY, 2Howard Hughes Medical Institute and Laboratory for RNA Molecular Biology, The Rockefeller University, New York, NY, 3Surgery, Columbia University Medical Center, New York, NY

6:40 PM  (340) **The Effect of Everolimus vs. Calcineurin Inhibitors on Surgical Complications: The Results of a De Novo Heart Transplant Randomized Controlled Trial (SCHEDULE Trial)**;  
M. Rashidi1, S. Esmaiily1, A. E. Fiane1, F. Gustafsson2, H. Eiskjær4, G. Rådegran5, G. Dellgren2, M. Cadeiras1, M. Deng1. 1Cardiothoracic Unit, Oslo University Hospital Rikshospitalet, Oslo, Norway, 2Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden, 3Department of Cardiology, Copenhagen University Hospital, Copenhagen, Denmark, 4Department of Cardiology, Skejby University Hospital, Aarhus, Denmark, 5The Clinic for Heart Failure and Valvular Disease, Skane University Hospital and Lund University, Lund, Sweden

6:45 PM  (341) **Non-Invasive Assessment of Vasculopathy Using Coronary Flow Velocity Reserve and 2D-Speckle Tracking Echocardiography During Exercise**;  
T. S. Clemmensen, H. Eiskjær, B. B. Løgstrup, S. H. Poulsen, Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, Aarhus N, Denmark

6:50 PM  (342) **Everolimus (EVE) vs. Mycophenolate (MMF) De Novo After Heart Transplantation (HTx): Does It Matter for Long Term Outcomes?**;  

6:55 PM  (343) **Survival Without Immunosuppression: The NoTAC Trial**;  
D. A. Baran, P. Rao2, D. Deo2, J. A. Hernandez-Montfort1, P. Dhesi1, J. Pieretti2, C. Gidea1, S. Murthy1, M. Camacho1, M. J. Zucker1. 1Transplant Center, Newark Beth Israel Med Ctr, Newark, NJ, 2New Jersey Sharing Network Laboratory, New Providence, NJ
The Man With The Golden Lungs (Erato,Uranie) (LTX, BSI, DMD, LF, MCS, PATH, PHARM)

CHAIRS: Lorriana Leard, MD and Gregor Warnecke, MD


6:05 PM (345) Prior Coronary Artery Bypass Surgery – Is It Still a Contraindication for Lung Transplantation?; S. H. McKellar1, B. C. Baird1, M. Bowen1, S. Raman2, B. Cahill2, C. H. Selzman1, 1Cardiothoracic Surgery, University of Utah, Salt Lake City, UT, 2Pulmonary and Critical Care, University of Utah, Salt Lake City, UT

6:10 PM (346) Elective Lobar Lung Transplantation – A Single Center Experience; B. Sill1, C. Oelschner1, M. Oldigs2, H. Klose3, C. Kugler2, M. Neuhaußs2, M. Barten1, H. Reichenspurner1, T. Deuse1, 1Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany, 2LungenClinic, Grosshansdorf, Germany, 3University Medical Center Hamburg-Eppendorf, Hamburg, Germany

6:15 PM (347) Early Donor Specific Antibodies After Lung Transplantation Lead to an Increase of CD56+CD16+ NK Cells in Peripheral Blood; J. Salman1, F. Ius1, A. Knoefel1, W. Sommer1, C. Kuehn1, I. Tudo-rache1, M. Avsar1, J. Gottlieb2, T. Welte2, C. Falk2, A. Haverich1, G. Warnecke1, 1Department for Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Department of Pneumology, Hannover Medical School, Hannover, Germany, 3Transplant Immunology, Institute of Transplant Immunology, Integrated Research and Treatment Center, Hannover Medical School, Hannover, Germany


6:25 PM (349) Peripheral Blood Gene Expression Identifies Damage-Associated Innate Immune Pathways in Patients With Primary Graft Dysfunction After Lung Transplantation; E. Cantu1, J. M. Diamond2, Y. Suzuki1, J. Tiwari1, B. Beduhn1, J. Neillen1, C. Borders1, J. Ellis1, D. J. Ledere1, K. Meyer1, R. J. Shahri1, N. J. Meyer1, K. Milewski1, J. W. Tobias1, D. A. Baldwin2, V. M. Van Deerlin2, K. M. Othoff1, A. Shaked1, J. D. Christi1, 1Surgery, University of Pennsylvania, Philadelphia, PA, 2Medicine, University of Pennsylvania, Philadelphia, PA, 3Medicine, Columbia University, New York, NY, 4Medicine, University of Wisconsin, Madison, WI, 5Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

6:30 PM (350) WITHDRAWN

6:40 PM (352) Contemporary Survival and Outcomes Following Airway Dehiscence Post Lung Transplantation: A Significant Price to Pay; A. J. Hayanga, J. Aboagye, H. K. Hayanga, E. Murphy, D. Meldrum, J. D'Cunha, A. Khaghani. 1Cardiothoracic Surgery, Spectrum Health – Michigan State University, Grand Rapids, MI, 2Cardiothoracic Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, 3Cardiac Anesthesiology, Johns Hopkins Medical Institutions, Baltimore, MD, 4Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

6:45 PM (353) Sparing Native Upper Lobe or Segment in Living-Donor Lobar Lung Transplantation Due to Small-for-Size Grafts; A. Aoyama, F. Chen, S. Tanaka, E. Miyamoto, M. Takahashi, K. Ohata, T. Kondo, H. Motoyama, K. Hijiya, M. Isomi, K. Minakata, T. Yamada, M. Sato, H. Date. 1Thoracic Surgery, Kyoto University, Kyoto, Japan, 2Cardiovascular Surgery, Kyoto University, Kyoto, Japan

6:50 PM (354) Non-Invasive Monitoring of Infection and Rejection After Lung Transplantation; I. D. Vlaminck, L. Martin, M. Kertesz, K. N. Patel, M. Kowarsky, C. Strehl, G. Cohen, H. Luikart, N. Neff, J. Okamoto, M. N. Nicolis, D. N. Cornfield, D. Weill, H. A. Valantine, K. K. Khush, S. R. Quake. 1Bioengineering and Applied Physics, Stanford University School of Medicine, Stanford, CA, 2Pulmonary and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, 3Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA

6:55 PM (355) Exposure to Moxifloxacin and Cytomegalovirus Replication Is Associated With Squamous Cell Carcinoma Development in Lung Transplant Recipients; S. R. Gerber, B. Seifert, I. Inci, A. L. Serra, M. Kohler, C. Benden, G. F. Hofbauer, M. M. Schuurmans. 1Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland, 2Division of Biostatistics, Institute for Social and Preventive Medicine, University of Zurich, Zurich, Switzerland, 3Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland, 4Division of Nephrology, University Hospital Zurich, Zurich, Switzerland, 5Division of Dermatology, University Hospital Zurich, Zurich, Switzerland
MINI ORAL SESSION 10

**Breathless: Insights on Lung Failure and Donor Lungs (Hermes)**
(LTX, BSI, DMD, LF)

CHAIRS: Jens Gottlieb, MD and Patrick Evrard, MD

**6:00 PM** (356) **The Impact of High-Risk Lung Donors on the Survival of Lung Recipients With Interstitial Pulmonary Fibrosis;**
P. G. Sanchez, M. Mulligan, C. Evans, S. Rahimpour, I. Timofte, K. Rajagopal, A. T. Iacono, R. Reed, J. S. Gammie, B. P. Griffith, S. M. Pham. 1Cardiac Surgery, University of Maryland, Baltimore, MD, 2Medicine, University of Maryland, Baltimore, MD

**6:05 PM** (357) **Should We Wait for the Perfect Donor for Lung Transplant Candidates on Mechanical Ventilation?;**
M. Mulligan, P. G. Sanchez, C. F. Evans, S. Rahimpour, I. Timofte, K. Rajagopal, A. T. Iacono, J. Kim, J. S. Gammie, B. P. Griffith, S. M. Pham. 1Department of Cardiac Surgery, University of Maryland, Baltimore, MD, 2Department of Medicine, University of Maryland, Baltimore, MD

**6:10 PM** (358) **An Analysis of In-Hospital Major Morbidity and Early Mortality After Transplantation in the Lung Allocation Score Era;**
N. M. Mollberg, E. Howell, A. Cheng, M. S. Mulligan. 1Bronson Methodist Hospital, Kalamazoo, MI, 2University of Washington, Seattle, WA

**6:15 PM** (359) **Hyaluronan – The First New Biomarker of Donor Organ Quality Since PO2?;**

**6:20 PM** (360) **Treatment With Sodium Nitrite Improves the Pulmonary Function of Rejected Human Lungs in Cellular Ex-Vivo Lung Perfusion Model;**
T. Okamoto, D. Wheeler, R. Chakravarti, Q. Liu, A. Janocha, D. Laskowski, C. Quintini, D. Stuehr, S. Erzurum, R. Dweik, K. R. McCurry. 1Transplant Center, Cleveland Clinic, Cleveland, OH, 2Cardiothoracic Anesthesia, Cleveland Clinic, Cleveland, OH, 3Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 4Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH

**6:25 PM** (361) **Assessing Human Lungs Unsuitable for Transplant By Ex-Vivo Lung Perfusion (EVLP) and Ex-Vivo CT Scan: Does EVLP Cause Inflammation?;**
6:30 PM (362) Clinical Outcomes of Lung Transplantation in Patients With Telomerase Complex Mutations; S. Tokman1, J. P. Singer1, M. S. Devine2, G. P. Westall3, J. Aubert4, M. Tamm5, G. I. Snell1, J. S. Lee1, H. J. Goldberg4, J. Kukrejia, J. A. Golden1, L. E. Leard1, C. K. Garcia1, S. R. Hays1. 1Division of Pulmonary and Critical Care Medicine, University of California, San Francisco Medical Center, San Francisco, CA, 2Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 3Division of Respiratory Medicine, Alfred Hospital, Melbourne, Australia, 4Division of Respiratory Medicine, Lausanne University Hospital, Lausanne, Switzerland, 5Division of Respiratory Medicine, Basel University Hospital, Basel, Switzerland, 6Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital, Boston, MA, 7Division of Cardiothoracic Surgery, University of California, San Francisco Medical Center, San Francisco, CA

(363) Moved to Concurrent Session 52

6:35 PM (764) Recipient Outcomes in Donation After Circulatory Determination of Death Lung Donors Within the United States; J. J. Mooney1, H. Hedlin1, P. K. Mohabir1, R. V. Guillamet2, R. Ha3, P. Chiu2, K. Patel4, D. Weill1, M. R. Nicolls1, G. S. Dhillon1. 1Department of Medicine, Stanford University, Stanford, CA, 2Department of Medicine, University of New Mexico, Albuquerque, NM, 3Department of Cardiothoracic Surgery, Stanford University, Stanford, CA

(364) Moved to Concurrent Session 10

6:40 PM (766) Increasing Lung Utilization: Implementation of a Dedicated Donor Screening Program; G. Loor1, C. Lyon1, J. Morrow2, T. Grabowski3, R. Kelly1, M. Hertz1, J. Morancy1, J. Patil1, D. Frankel1. 1University of Minnesota, Minneapolis, MN, 2Fairview Medical Center, Minneapolis, MN

6:45 PM (365) Chronic Effects of Air Pollution on Lung Function in Lung Transplant Patients (SyzCLAD); M. Benmerad1, K. Botturi2, C. Pison3, A. Magnani1, J. Claustr1, A. Roux1, C. Gomez2, R. Kessler4, O. Brugiere5, J. Mornex6, S. Musso7, M. Dahan8, V. Boussad9, I. Danner-Boucher2, C. Dromer1, C. Knoopp2, L. Malherbe4, F. Meuleux5, R. Slama1, L. Nicoud6, V. Siroux1. 1Team 12 environmental epidemiology, INSERM/UJF U823, La Tronche, France, 2CHU Nantes, Nantes, France, 3CHU Grenoble, Grenoble, France, 4Hôpital Foch, Suresnes, France, 5AP-PM Hôpital Nord, Marseille, France, 6CHRU Strasbourg, Strasbourg, France, 7AP-HP Hôpital Bichat, Paris, France, 8Université Lyon 1, Lyon, France, 9Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France, 10CHU Toulouse, Toulouse, France, 11Hôpital européen Georges-Pompidou, Paris, France, 12CHU Bordeaux, Bordeaux, France, 13Hôpital Erasme, Bruxelles, Belgium, 14INERIS, Vernois-en-Halatte, France, 15CHU Vaudois, Lausanne, France

6:50 PM (366) Internet-Based Telemonitoring System of Daily Home Spirometry in Lung Transplant Recipients; L. Peysson1, C. Gomez2, P. Giovannetti1, B. Coltey3, N. Dufu4, F. Brégeon5, J. Gaubert6, H. Dutau1, P. Thomas2, M. Reynaud-Gaubert1. 1Department of Respiratory Medicine Lung Transplant Team, University North Hospital, Marseille, France, 2Lung Function Tests Laboratory, University North Hospital, Marseille, France, 3Radiology Department, University Timone Hospital, Marseille, France, 4Department of Thoracic and Transplant Surgery, University North Hospital, Marseille, France

6:00 PM – 7:00 PM

MINI ORAL SESSION 11

**What’s Up, Doc? Bugs, Drugs and PH** (Calliope)  
(PH, HF, HTX, LF, LTX, MCS, PHARM)

**CHAIRS:** Nicolas Manito, MD  
Margaret M. Hannan, MD and  
Rochelle M. Gellatly, PharmD

6:00 PM  
(368) **A Retrospective Analysis of the Safety and Efficacy of a 6-Week Pulmonary Rehabilitation Program in Patients With Severe Pulmonary Arterial Hypertension;**  
J. G. Weinkauf, G. Miciak, A. Kapasi, K. Jackson, K. Halloran,  
D. C. Lien. Medicine, University of Alberta, Edmonton, AB, Canada

6:05 PM  
(369) **A Study to Explore the Feasibility and Safety of Using an Implantable Hemodynamic Monitor in PAH Patients;**  

6:10 PM  
(370) **Characterization and Impact of Pulmonary Hypertension on Outcomes After Left Ventricular Assist Device Implantation;**  
V. N. Selby, J. J. Teuteberg, I. E. Allen, R. J. Tedford, R. L. Kormos, T. De Marco. Division of Cardiology, University of California, San Francisco, San Francisco, CA, *Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA*, *Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA*, *Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD*, *Department of Surgery, University of Pittsburgh, Pittsburgh, PA*

6:15 PM  
(371) **Initial Results of the Prospective Registry of Sarcoidosis Associated Pulmonary Hypertension (ReSAPH);**  
R. P. Baughman, P. L. Engel, S. Nathan, F. Cordova, O. Shlobin, J. B. Barney, D. Culver, Internal Medicine, University of Cincinnati, Cincinnati, OH, *The Christ Hospital, Cincinnati, OH*, *INOVA, Fairfax, VA*, *Temple University, Philadelphia, PA*, *University of Alabama Birmingham, Birmingham, AL*, *Cleveland Clinic Foundation, Cleveland, OH*

6:20 PM  
(372) **Pulmonary Hypertension in the Setting of Sjögren’s Syndrome;**  
M. Lyle, E. Fenstad, R. Crespo-Diaz, T. Osborn, A. Behefar, G. Kane, R. Frantz. Internal Medicine, Mayo Clinic, Rochester, MN, *Cardiovascular Diseases, Mayo Clinic, Rochester, MN*, *University of Puerto Rico School of Medicine, Ponce, Puerto Rico*, *Rheumatology, Mayo Clinic, Rochester, MN*

6:25 PM  
(373) **Late Diastolic Strain Index Is a Marker of Right Ventricular Fibrosis Content in Precapillary Pulmonary Hypertension;**  
D. Boulate, F. Haddad, P. Noly, T. Kuznetsova, G. Girard, Dorfman, Y. Kobayashi, B. Decante, J. C. Wu, D. Liang, I. Schnitter, M. Humbert, E. Fadel, O. Mercier. Laboratory of Surgical Research, Marie Lannelongue Surgical Center, Le Plessis Robinson, France, *Biocenter and Phenotypic Core Laboratory, Cardiovascular Institute, Stanford University, Stanford, CA*, *Research Unit Hypertension and Cardiovascular Epidemiology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium*, *Cardiovascular Medicine, Stanford University, Stanford, CA*, *Department of Pathology, Marie Lannelongue Surgical Center, Le Plessis Robinson, France*, *Cardiovascular Institute, Stanford*
University, Stanford, CA, INSERM U888, Pulmonary Arterial Hypertension, Pathophysiology and Therapeutic Innovation, Marie Lannelongue Surgical Center, Le Plessis Robinson, France

6:30 PM (374) Tolerability and Biological Effects of Long Acting Octreotide in Patients With Continuous Flow Left Ventricular Assist Devices; R. Malhotra1, D. Tang2, C. T. DeWilde1, M. Basseem2, A. Pridai, K. Shah3, Internal Medicine/Critical Care Medicine, VCU Health System, Richmond, VA, 2Surgery/Cardiothoracic Surgery, VCU Health System, Richmond, VA, 3Internal Medicine, VCU Health System, Richmond, VA, 4Internal Medicine/Cardiology, VCU Health System, Richmond, VA

6:35 PM (375) Ketamine Infusion for Patients Receiving Extracorporeal Membrane Oxygenation Support; B. Tellor, M. Avidan1, Barnes-Jewish Hospital, St. Louis, MO, 1Washington University School of Medicine, St. Louis, MO

6:40 PM (376) Pre Operative Administration of Vitamin K Reduces Bleeding in Continuous Flow Devices; A. Bansal1, J. Chan1, A. Egger, S. Desai2, J. K. Bhama3, P. Parse2, 1Division of Cardiothoracic Surgery, The University of Queensland School of Medicine, Ochsner Clinic Foundation, New Orleans, LA, 2Department of Biostatistics and Research, Ochsner Clinic Foundation, New Orleans, LA, 3Section of Heart Failure and Transplant Medicine, Ochsner Clinic Foundation, New Orleans, LA, 4Heart and Vascular Center, University of Iowa Health Care, Iowa City, IA, 5Division of Cardiothoracic Surgery, The University of Queensland School of Medicine, Ochsner Clinic Foundation, New Orleans, LA, 6:45 PM


6:55 PM (379) The Impact of Preoperative Antimicrobial Prophylaxis on Device-Related Infections in Recipients of Long-Term Mechanical Circulatory Support (MCS); I. El Lakkis1, K. Lietz2, C. J. Derber1, U. M. Kelly1, C. D. Wilson1, A. C. Hoedt2, P. W. Bourassa2, B. H. Smith3, M. F. McGrath4, J. M. Herre2, M. L. Mooney1, 1Division of Infectious Diseases, Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA, 2Division of Advanced Heart Failure, Sentara Norfolk General Hospital, Norfolk, VA
Basic Instinct (Euterpe) (ALL)

CHAIRS: Kimberly L. Gandy, MD, PhD and Martin Cadeiras, MD

6:00 PM (380) CTLA4Ig Administered During T-Cell Priming Suppresses De Novo Alloantibodies and Minimizes Recall Antibody Responses;
G. D. Wu, I. Kim, N. Chai, S. Jordan, A. S. Klein. Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

(381) Moved to Concurrent Session 54

6:05 PM (742) Development of the New Polymer Coating (MDM-Coating) for Reduce the Inflammatory Response During ECMO — Evaluation Using a Small Animal ECMO Model;
Y. Fujii, T. Mizuno, T. Takehisa, M. Shirai, E. Tatsumi. Department of Artificial Organs, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan, 2Central Research Laboratories, DIC Corporation, Sakura, Japan, 3Department of Cardiac Physiology, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan

6:10 PM (382) Phosphodiesterase 3b Inhibition Expands Stable Regulatory T Cells for Cell Therapy in Transplantation;
S. C. Juven, A. Whatcott, K. J. Wood, A. Bushell. Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom

6:15 PM (383) Rapamycin Enhances the Suppressive Capacity of Ex-Vivo Expanded Regulatory T Cells (Tregs) Isolated From Pediatric Thymus;
E. Dijke, R. Hoeppli, T. Ellis, J. Pearcey, I. Larsen, I. Rebyka, D. Ross, M. Levings, L. West. Pediatrics, University of Alberta/Alberta Transplant Institute, Edmonton, AB, Canada, 2Surgery, University of British Columbia, Vancouver, BC, Canada, 3Surgery, University of Alberta/Alberta Transplant Institute, Edmonton, AB, Canada

6:20 PM (384) Mild Acute Cellular Rejection Is Associated With Systemic Donor-Specific Regulatory and Conventional T Cell Responses;

6:25 PM (385) Initial Reperfusion With a Hypocalcemic Cardioplegia Improves the Functional Recovery of DCD Hearts During Ex-Vivo Heart Perfusion;
C. W. White, E. Ambrose, A. Müller, J. Thilvière, R. C. Arora, G. Tian, J. Nagendran, L. V. Hryshko, D. H. Freed. 1Cardiac Surgery, University of Manitoba, Winnipeg, MB, Canada, 2Institute of Cardiovascular Sciences, St. Boniface Research Center, Winnipeg, MB, Canada, 3Human Anatomy and Cell Science, University of Manitoba, Winnipeg, MB, Canada, 4Institute for Biodiagnostics, National Research Council Canada, Winnipeg, MB, Canada, 5Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB, Canada
6:30 PM  (386) **Dual Ex-Vivo Lung Perfusion Technique Contributes to Better Preserving Microcirculation in Lung Grafts Following Transplantation:**
K. Noda, S. Haam, J. D’Cunha, J. D. Luketich, C. A. Bermudez, N. Shigemura. Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

6:35 PM  (387) **Hydrogen Sulfide (H2S) Prevents Ischemia-Reperfusion Injury (IRI) and Prolongs Survival of the Fully MHC-Disparate Lung Graft in CLAWN Miniature Swine:**
H. Sahara, M. Sekijima, S. Waki, Y. Ichinari, A. Shimizu, K. Yamada. Center for Advanced Biomedical Science and Swine Research, Kagoshima University, Kagoshima, Japan

6:40 PM  (388) **Correlation Between Bacterial Count and Levels of Endotoxin and Inflammatory Mediators During Ex-Vivo Treatment of Infection in Human Donor Lungs:**
D. Nakajima, M. Cypel, R. Bonato, T. N. Machuca, I. Iskender, V. Linacre, M. Chen, T. K. Waddell, T. Martinu, M. Liu, S. Husain, S. Keshavjee. 1Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, University Health Network, Toronto, ON, Canada, 2Transplant Infectious Disease Unit, University Health Network, Toronto, ON, Canada

6:45 PM  (389) **Functional and Biochemical Assessment of Porcine Hearts After Simulated Donation After Circulatory Death:**

6:50 PM  (390) **Three-Dimensional Human-Heart Derived Scaffolds:**

6:55 PM  (391) **Porcine B4GALNT2 a Source of New Xenogenic Glycan:**
G. W. Byrne, Z. Du, H. Kogelberg, C. McGregor, ‘Cardiovascular Science, University College London, London, United Kingdom, ‘Department of Surgery, Mayo Clinic, Rochester, MN

6:00 PM – 7:00 PM
WINE AND CHEESE RECEPTION (Agora 2)
MODERATED POSTER SESSION 2 (Agora 2)

8:00 PM – 9:30 PM
PRESIDENT’S GALA COCKTAIL RECEPTION
(Negresco Palace)
A Registration Badge and Ticket will be required at the door.
SATURDAY | April 18, 2015

7:30 AM – 12:15 PM
Registration Open (Agora 1)

7:30 AM – 1:45 PM
Speaker Ready Room Open (Hermes Lounge)

8:00 AM – 10:00 AM
COUNCIL AND COMMITTEE REPORTS TO THE BOARD AND MEMBERSHIP (Gallieni 1)
Mechanical Circulatory Support – New Surgical Approaches (Athena)
(MCS, HF, HTX, NHSAH)

CHAIRS: Andre R. Simon, MD, PhD and Daniel Zimpfer, MD

8:15 AM (392) Minimally Invasive Surgical and Anesthetic Approach for Ventricular Assist Device Implantation: A Single-Centre Experience;
T. Bottio, J. Bejko, G. Bortolussi, M. Gallo, R. Bianco, D. Pittarello, V. Tarzia, G. Gerosa. Cardiac Surgery, Padova, Italy

8:30 AM (393) Single-Centre Experience With the HeartWare HVAD for Biventricular Support;
S. Shehab1, D. Robson1, P. J. Newton2, P. M. Davidson2, A. M. Keogh3, E. Kotlyar4, A. Jabbour3, P. S. Macdonald1, K. Dhill5, E. Granger6, P. Spratt1, P. C. Jansz1, C. S. Hayward1. 1Heart and Lung Transplant Unit, St. Vincent’s Hospital, Darlinghurst, Australia, 2Centre for Cardiovascular & Chronic Care, University of Technology Sydney, Broadway, Australia, 3School of Nursing, Johns Hopkins University, Baltimore, MD

8:45 AM (394) Initial Outcomes of the Left Thoracotomy Technique for a Miniaturized Centrifugal Continuous-Flow Pump Compare Favorably to a Conventional Sternotomy;
S. Maltais1, B. Sileshi1, M. E. Davis1, M. Dijunaidi2, M. Xu1, M. R. Danter1, J. M. Stulak3, N. A. Haglund4, M. R. Danter1, J. M. Stulak3, N. A. Haglund4, 1Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, 2Biostatistics, Vanderbilt Univ Med Ctr, Nashville, TN, 3Cardiac Surgery, Mayo Clinic, Rochester, MN, 4Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN

9:00 AM (395) Bridging to Transplant With Fully Implantable Biventricular Assist Devices vs. Total Artificial Heart Implantation in Patients With Advanced Biventricular Failure;
A. P. Levin1, J. Fried2, O. Weyer-Pinzon1, A. R. Garan1, K. Takeda3, H. Takayama1, M. Yuzefopolskaya4, U. P. Jorde5, D. M. Mancini6, Y. Naka1, P. C. Colomb1, V. K. Topkara7. 1Cardiology, Columbia University New York Presbyterian Hospital, New York, NY, 2Cardiology, Columbia University New York Presbyterian Hospital, New York, NY, 3Cardiology, Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, 4Cardiology, Columbia University New York Presbyterian Hospital, New York, NY, 5Cardiology, Mayo Clinic, Rochester, MN, 6Cardiology, Columbia University New York Presbyterian Hospital, New York, NY

9:15 AM (396) Outcomes of Patients Receiving Temporary Circulatory Support Prior to Durable LVAD;
P. Shah1, F. D. Pagani2, S. S. Desai1, N. A. Burton1, S. Maltais1, N. A. Haglund1, S. M. Dunlay1, K. D. Aaronson1, J. M. Stulak1, M. Davis1, C. Salerno1, J. A. Cowger1. 1Inova Translational Medicine Institute, Inova Fairfax Hospital, Falls Church, VA, 2Cardiac Surgery, University of Michigan, Ann Arbor, MI, 3Heart Failure and Transplantation, Inova Fairfax Hospital, Falls Church, VA, 4Cardiac Surgery, Inova Fairfax Hospital, Falls Church, VA, 5Cardiac Surgery, Vanderbilt University, Nashville, TN, 6Heart Failure and Transplantation, Inova Fairfax Hospital, Falls Church, VA, 7Cardiac Surgery, Inova Fairfax Hospital, Falls Church, VA, 8Cardiac Surgery, Mayo Clinic, Rochester, MN, 9Heart Failure and Transplantation, University of Michigan, Ann Arbor, MI, 10Cardiology, Mayo Clinic, Rochester, MN, 11Cardiac Surgery, St. Vincent Heart Center of Indiana, Carmel, IN, 12Heart Failure and Transplant, St. Vincent Heart Center of Indiana, Carmel, IN

9:30 AM (397) Japanese Experience of Long-Term Mechanical Circulatory Support With EVAHEART LVAD;
T. Nishinaka, Y. Ichihara, M. Komagamine, N. Umehara, K. Kat-sue, K. Iizuka, S. Saito, S. Nunoada, K. Yamazaki. Cardiovascular Surgery, Tokyo Women’s Medical University, Tokyo, Japan
8:15 AM – 9:45 AM
CONCURRENT SESSION 44

The Aortic Valve in LVAD Patients (Clio, Thalie) (MCS, BSI, HF, HTX, NHSAH, PHARM)

CHAIRS: Ana Maria Segura, MD and Mark S. Slaughter, MD

8:15 AM

(398) Impact of Concomitant Cardiovascular Surgeries at the Time of CF-LVAD Implantation: An INTERMACS Analysis;
S. Lee1, J. B. Young2, D. C. Naftel1, J. K. Kirklin1, N. Moazami1, S. L. Myers3, M. G. Dickinson1, R. C. Starling6,
1Cardiovascular Services, Spectrum Health, Grand Rapids, MI, 2Cleveland Clinic, Lerner College of Medicine, Cleveland, OH, 3Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, 4Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, 5Spectrum Health, Grand Rapids, MI, 6Heart Failure and Cardiac Transplant Medicine, Cleveland Clinic, Cleveland, OH

8:30 AM

(399) Changes in Aortic Wall Structure, Composition and Stiffness With Continuous-Flow Left Ventricular Assist Devices;
A. V. Ambardekar1, R. B. Dodson2, K. S. Hunter3, A. N. Babu4, R. M. Tuder5, J. Lindenfeld1. 1Medicine-Cardiology, University of Colorado, Aurora, CO, 2Bioengineering and Pediatric Surgery, University of Colorado, Aurora, CO, 3Bioengineering and Pediatrics-Cardiology, University of Colorado, Aurora, CO, 4Cardiothoracic Surgery, University of Colorado, Aurora, CO, 5Medicine-Pulmonary, University of Colorado, Aurora, CO

8:45 AM

(400) Quantification of Aortic Insufficiency in Patients With Left Ventricular Assist Devices: A Novel Approach Combining Invasive Hemodynamics and Echocardiography;
J. Grinstein1, E. Kruse1, G. Sayer1, S. Fedson1, G. H. Kim1, U. P. Jorde2, C. Juricek3, T. Ota3, V. Jeevanandam3, R. M. Lang1, N. Uriel1. 1Medicine, University of Chicago Medical Center, Chicago, IL, 2Medicine, Montefiore Medical Center, New York, NY, 3Surgery, University of Chicago Medical Center, Chicago, IL

9:00 AM

(401) Intermittent Low Speed Software (ILS) May Reduce the Prevalence of De Novo Aortic Insufficiency in Patients Supported With HeartWare HVAD Pump;
D. Saeed1, R. Westenfeld2, A. Albert1, B. Maxhera1, S. Keymel2, U. Boeken1, A. Lichtenberg1. 1Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, 2Division of Cardiology, Pulmonology and Vascular Medicine, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany

9:15 AM

(131) Concurrent Valvular Procedures During HMII Insertion Are Not Associated With Short or Long-Term Decreased Survival;
R. M. Adamson1, W. P. Dembitsky1, K. K. Limmer2, H. Mehta2, P. Haagland2, B. Jaski2. 1Cardiac Surgery, Sharp Memorial Hospital, San Diego, CA, 2Cardiology, Sharp Memorial Hospital, San Diego, CA

9:30 AM

(403) Impact and Development of Aortic Insufficiency in CF-LVAD Recipients at 5 Years;
**CONCURRENT SESSION 45**

**Candidate Selection – The Who, When and Why**

**(Erato,Uranie)**

**(HF, DMD, HTX, MCS)**

**CHAIRS:** Maria G. Crespo-Leiro, MD and Fernando Bacal, MD

---

**8:15 AM**

**(404)** National Heart Failure Admissions and Associated Mortality Trends in Adults With Congenital Heart Disease in the United States, 1998-2011; L. J. Burchill1, C. S. Broberg1, B. G. Maxwell1, J. McLarry1, S. Opotowsky1, 1Adult Congenital Heart Disease, Knight Cardiovascular Institute, Oregon Health Sciences University, Portland, OR, 2Anesthesiology & Critical Care Medicine, John Hopkins University, Baltimore, MD, 3Cardiology, Boston Children's Hospital, Boston, MA

**8:30 AM**

**(405)** Evolution of Status 1A Heart Transplant Candidates; J. A. Yang, K. Takeda, Y. Naka, H. Takayama. Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY

**8:45 AM**

**(406)** Improvement of Waiting List Survival Among Patients With End-Stage Heart Failure (ESHF) Listed for Heart Transplantation (HT) – Analysis of OPTN/UNOS Data 1990-2013; K. Lietz1, E. C. DePasquale2, M. Deng2, M. McGrath1, J. M. Herre1. 1Division of Advanced Heart Failure, Sentara Norfolk General Hospital, Norfolk, VA, 2Division of Advanced Heart Failure, University of California Los Angeles Medical Center, Los Angeles, CA

**9:00 AM**

**(407)** PDE 5 Inhibition With Udenafil Improves Left Ventricular Systolic/Diastolic Function and Exercise Capacity in Patients With Chronic Systolic Heart Failure: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial (Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure) (ULTIMATE-SHF); K. Kim1, H. Kim2, J. Yoo1. 1Sejong General Hospital, Seoul, Korea, Republic of, 2Seoul National University Hospital, Seoul, Korea, Republic of

**9:15 AM**

**(408)** Results of Jehovah’s Witnesses Undergoing Surgical Treatment of Advanced CHF; Z. E. Asfaw1, A. Tanaka1, S. Fedson2, D. Onsager1, C. Juricek1, G. Sayert1, G. Kim1, C. Murks2, T. Ota1, N. Uriel2, Y. Jeevanandam1. 1Cardiothoracic Surgery, University of Chicago, Chicago, IL, 2Cardiology, University of Chicago, Chicago, IL

**9:30 AM**

**(409)** Outcomes of Heart Transplantation in Adults With Amyloidosis: UNOS Registry Analysis; E. C. DePasquale, K. Pandya, K. Lyons, L. Reardon, A. Nsair, M. Deng, A. Ardehali. UCLA, Los Angeles, CA
Emerging Countries Session 2 (Hermes) (ALL)

CHAIRS: Stephen C Clark, MD and Alejandro M. Bertolotti, Sr, MD


8:30 AM (411) Establishing Standard Heart Allocation Protocol in Iran; S. M. Mirhosseini, K. Najafizadeh, S. Shafaghi. Modarres Hospital, The University of Shahid Beheshti, Tehran, Iran, Islamic Republic of, The University of Shahid Beheshti, Director of Organ Transplantation Program, Ministry of Health, Tehran, Iran, Islamic Republic of, Organ Allocation Organ Transplant and Special Diseases, Department, Tehran, Iran, Islamic Republic of


9:00 AM (413) Lung Transplantation in a Developing Country: Experience, Lessons Learned and Obstacles in 81 Consecutive Cases; M. A. Villavicencio, E. Larrain, F. Rivera, J. Melo, M. Hurtado, P. Mena, E. Donoso, F. Gajardo. Unidad de Trasplante, Clinica Davila, Santiago, Chile, Unidad de Trasplante, Instituto Nacional del Tórax, Santiago, Chile

9:15 AM (414) “Heart Transplant Team” and Its Impact in the Results of Heart Transplant in a Brazilian Center; L. F. Seguro, F. Marcondes-Braga, M. S. Avila, S. Mangini, D. D. Lourenço Filho, R. H. Santos, F. A. Gaitto, F. Bacal. Heart Institute (InCor), Sao Paulo, Brazil

Enhancing Surgical Therapeutics in Pulmonary Hypertension: Thrombectomy to Transplant (Calliope) (PH, HF, LF, LTX)

This session is supported by educational grants from Actelion and Gilead.

CHAIRS: Arne K. Andreassen, MD, PhD and Marc De Perrot, MD

8:15 AM (416) Pre-operative Use of Pulmonary Arterial Hypertension-Targeted Medication and the Effects on Post-Pulmonary Endarterectomy Morbidity and Mortality;
T. M. Fernandes, D. S. Poch, D. G. Papamateakis, N. H. Kim, K. M. Kerr, P. F. Fedullo, V. G. Pretorius, M. M. Madani, W. R. Auger. Division of Pulmonary and Critical Care, University of California, San Diego, La Jolla, CA; Division of Cardiothoracic Surgery, University of California, San Diego, La Jolla, CA.

8:30 AM (417) Echocardiographic Evidence for Right Ventricular Functional Improvement After Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension;
K. Broch, A. Ragnarsson, R. Andersen, E. Gude, A. Fiane, J. Andreassen, S. Aakhus, A. K. Andreassen. Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway; Department of Radiology and Nuclear Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway; Department of Cardiothoracic Surgery, Oslo University Hospital Rikshospitalet, Oslo, Norway.

8:45 AM (418) Outcomes Following Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension in Octogenarians;
N. B. Langer, O. Mercier, M. Glorion, D. Fabre, S. Mussot, L. Lamrani, J. Lepavec, X. Jaïs, G. Simonneau, P. Darteville, E. Fadel. Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, Marie Lannelongue Hospital, Le Plessis Robinson, France; Department of Pulmonology and Critical Care Medicine, Kremlin-Bicetre Hospital, Le Kremlin-Bicetre, France.

9:00 AM (419) Six Years Experience With High Priority Allocation Program for Lung and Heart-Lung Transplantation in Pulmonary Hypertension;

9:15 AM (420) Lung Transplantation for PPH: Postoperatively Prolonged ECMO Improves Early Outcome;

9:30 AM (421) Postcapillary Pulmonary Hypertension as a Risk Factor for Post-Transplant Survival in Lung Transplantation – A 22 Year Single Centre Experience;
B. C. Nyholm, H. Schultz, K. H. Andersen, M. P. Iversen, F. Gustafsson, J. Carlsen. Department of Cardiology, Pulmonary Vascular Programme, Copenhagen University Hospital, Rigshospitalet, DK- Denmark, Copenhagen, Denmark.
Old Problems – New Solutions? (Euterpe)
(PEDS, BSI, HF, HTX, NHSAH, PATH)

CHAIRS: Scott R. Auerbach, MD and Zsolt Szepfalusi, MD

8:15 AM (422) Does the OPTN cPRA Calculator Accurately Predict HLA Antigen Frequencies in Pediatric Donors?; S. A. Hollander1, D. Tyan1, M. A. Fernandez-Vina2, D. N. Rosenthal1, D. Bernstein1, B. D. Kaufman1, S. Chen1, L. Barkoff1, K. Maeda1, C. S. Almond1. 1Pediatrics (Cardiology), Stanford University, Palo Alto, CA, 2Pathology, Stanford University, Palo Alto, CA, 3Pediatric Heart Transplantation, Lucile Packard Children's Hospital, Stanford, Palo Alto, CA, 4Cardiothoracic Surgery, Stanford University, Palo Alto, CA

8:30 AM (423) Alternative Pre-Transplant Hemodynamic Predictors of Graft Loss in Pediatric Heart Recipients; E. L. Albers1, M. C. Bradford2, M. S. Kemna1, J. M. Chen3, Y. M. Law1. 1Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA, 2Biomedical Statistics, Seattle Children's Research Institute, Seattle, WA, 3Cardiac Surgery, Seattle Children's Hospital, Seattle, WA

8:45 AM (424) Identification of Candidate MicroRNA as Pathological Markers of Pediatric Heart Transplant Rejection; A. K. Bhatia1, J. H. Phan1, C. Cundiff1, W. T. Mahle1, B. Shehata2, H. Jo3. 1Pediatric Cardiology, Emory University, Atlanta, GA, 2Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, 3Pathology, Emory University, Atlanta, GA, 4Biomedical Engineering, Emory University, Atlanta, GA

9:00 AM (425) Is Chimerism in Cardiac Transplant Allografts an Indicator of Decreased Longevity? Utilizing Quantitative Real Time PCR in Pediatric Patients; T. Roberts1, C. A. Cundiff1, B. Shehata1, W. Mahle1, S. R. Deshpande1. 1Department of Pathology, Emory University School of Medicine, Atlanta, GA, 2Department of Pathology, Emory University Children's Healthcare of Atlanta, Atlanta, GA, 3Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA

9:15 AM (426) Value of Cardiopulmonary Exercise Testing for Prediction of Outcomes in Ambulatory Patients With Dilated Cardiomyopathy; C. Chen1, C. Manlihot1, P. F. Kantor2, B. W. McCrindle2, J. Conway2. 1Cardiology Service, Department of Paediatric Subspecialties, KK Women's and Children's Hospital, Singapore, Singapore, 2The Labatt Family Heart Centre, Division of Cardiology, The Hospital for Sick Children, Toronto, ON, Canada, 3Division of Pediatric Cardiology, Stollery Children's Hospital, Edmonton, AB, Canada

9:30 AM (427) The Safety of Intravascular Ultrasound in a Multicenter Pediatric Heart Transplant Population: A Study of the International Paediatric Intravascular Ultrasound Consortium; S. R. Auerbach1, M. J. Fenton1, G. Gutter1, D. C. Albert1, S. DiFilippo1, R. Kozlik-Feldmann1, S. Rupp1, M. Burch1, M. Kuhn1. 1Pediatrics, Division of Cardiology, University of Colorado, Aurora, CO, 2Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 3Department of Pediatric Cardiology and Cardiac Surgery, Bambino Gesù Pediatric Hospital, Rome, Italy, 4Pediatrics, Division of Cardiology, University Vall d'Hebron Hospital, Barcelona, Spain, 5Pediatric Cardiology Unit., Louis Pradel Cardiology Hospital, Bron, Hospices Civils de Lyon, Lyon, France, 6Department of Pediatric Cardiology and Intensive Care Medicine., Muniz. Ludwig-Maximilians-University, Munich, Germany, 7Pediatric Heart Centre, Justus-Liebig-University, Giessen, Germany, 8Pediatrics, Division of Cardiology, Loma Linda University Medical Center, Loma Linda, CA
9:45 AM – 10:00 AM
Coffee Break (Agora 1)

10:00 AM – 12:00 PM
PLENARY SESSION

(Athena)

(ALL)

CHAIRS: R. Duane Davis, MD and Andrew J. Fisher, FRCP, PhD

10:00 AM Awards Presentations
Daniel R. Goldstein, MD and Andrew J Fisher, FRCP, PhD,
Grants & Awards Committee Co-Chairs

10:20 AM CONSENSUS REPORT: AMR in Lung Transplantation
Deborah J Levine, MD, UT Health Science Center,
San Antonio, TX, USA

10:30 AM CONSENSUS REPORT: Listing Criteria in Heart Transplantation
Mandeep R. Mehra, MD, MBBS, FACC, FACP,
Brigham & Women's Hospital, Boston, MA, USA

1. Istituto di Malattie dell'Apparato Cardiovascolare, University of Bologna, Bologna, Italy, 2Massachusetts General Hospital, Boston, MA, 3UT Southwestern Medical Center, Dallas, TX, 4Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, 5Mater Misericordiae University Hospital, Dublin, Ireland, 6University of Giessen and Marburg Lung Center, Giessen, Germany, 7 Hannover Medical School and German Center of Lung Research, Hannover, Germany, 8Medical University of Vienna, Vienna, Austria, 9University of Michigan Health System, Ann Arbor, MI, 10University of California, San Diego, CA, 11Hôpital Universitaire de Bicêtre, Paris, France, 12Cedars-Sinai Medical Center, Los Angeles, CA.

10:55 AM Supercooling of Organs for Transplantation
Korkut Uygun, PhD, Harvard Medical School, Boston, MA, USA

11:15 AM Going the Distance with DCD Heart Failures
Kumud K Dhital, MD, PhD, St Vincent's Hospital,
Sydney, Australia

11:30 AM PRESIDENT'S DEBATE: The 4 Q’s: Quagmire of The Quantity/Quality Quandary:

11:30 AM Live Long, Don't Prosper
Heather J Ross, MD, MHSc, FRCPC, Toronto General Hospital,
Toronto, ON, Canada

11:45 AM Live Fast, Die Young
Marshall I Hertz, MD, University of Minnesota, Minneapolis,
MN, USA

12:00 PM – 12:15 PM
Coffee Break (Agora 1)
12:15 PM – 1:45 PM

CONCURRENT SESSION 49

LVADs – From Patient Classification to Cost (Athena) (MCS, BSI, HF, HTX, PEEQ)

CHAIRS: Ruchan Akar, MD and Geetha Bhat, MD, PhD

12:15 PM (429) INTERMACS Profiles: Heterogeneity of LVAD Patient Classification;
J. A. Cowger1, C. Salerno2, F. D. Pagani3, S. Maltais4, J. M. Stulak5, P. Shah6, Heart Failure and Transplant, St. Vincent Heart Center of Indiana, Carmel, IN, 2Cardiac Surgery, St. Vincent Heart Center of Indiana, Carmel, IN, 3Cardiac Surgery, University of Michigan, Ann Arbor, MI, 4Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN, 5Cardiac Surgery, The Mayo Clinic, Rochester, MN, 6Heart Failure and Transplant, Inova Fairfax Hospital, Falls Church, VA

12:30 PM (430) In ADVANCE BTT, the HVAD Mortality Benefit Varies Markedly With Heart Failure Severity as Measured By the Seattle Heart Failure Model;
W. C. Levy1, C. Mahr1, R. Cheng1, P. Eckman2, K. Leadley3, F. Pagani3, K. Aaronson4. 1University of Washington, Seattle, WA, 2University of Minnesota, Minneapolis, MN, 3HeartWare, Inc, Framingham, MA, 4University of Michigan, Ann Arbor, MI

12:45 PM (431) Trends in Use of Mechanical Circulatory Support as Bridge to Heart Transplantation Across Different Age Groups;
A. Ciarka1, L. Edwards2, J. Stehlik3, L. Lund4, Department of Cardiovascular Diseases, Catholic University of Leuven, Leuven, Belgium, 1ISHLT Transplant Registry, Dallas, TX, 2University of Utah, Salt Lake City, UT, 3Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden

1:00 PM (432) Patients Undergoing LVAD Placement Demonstrate Marked Sarcopenia Leading to Overestimation of Pre-Implant Glomerular Filtration Rate;
M. A. Brisco1, A. Hale1, M. R. Zile1, D. P. Heyward1, J. L. Cook1, W. Uber1, J. Arthur1, J. M. Testani1, Medicine-Cardiology, Med Univ of South Carolina, Charleston, SC, 2Program of Applied Translational Research, Yale University, New Haven, CT

1:15 PM (433) What Can You Do With an LVAD? Survey of Programs Implanting Durable Devices;

1:30 PM (434) Multi-Disciplinary Team Management Is Cost Effective in Patients During the Index Hospitalization Across Left Ventriculat Assist Device Implantation;
M. Pinninti1, C. Cho2, V. Thohan1, O. Cheema1, T. Hastings1, J. Crouch1, F. X. Downey III1, N. Z. Sulemanjee1, Aurora St. Luke’s Medical Center, Milwaukee, WI, 2Aurora Cardiovascular Services, Aurora St. Luke’s Medical Center, Milwaukee, WI, 3Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, 4Aurora Cardiovascular Services – Cardiovascular and Thoracic Surgery, Aurora Sinai/Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI
12:15 PM – 1:45 PM

CONCURRENT SESSION 50

LVADs and the Mitral Valve (Clio, Thalie)
(MCS, HF, HTX, NHSAH)

CHAIRS: Nahush A. Mokadam, MD and Benjamin C. Sun, MD

12:15 PM (435) Concomitant Mitral Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis; J. O. Robertson, D. C. Naftel, S. L. Myers, R. J. Tedford, S. M. Joseph, J. K. Kirklin, S. C. Silvestry, 1Washington University, St. Louis, MO, 2Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, 3Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD


12:45 PM (437) The Impact of Concomitant Mitral Repair in Patients Receiving Continuous-Flow Left Ventricular Assist Devices; S. Fukuhara, K. Takeda, J. Han, P. Colombo, P. Kurlansky, D. Man cini, M. Yuzefpolskaya, V. Topkara, H. Takayama, Y. Naka, 1Surgery, Columbia University Medical Center, New York, NY, 2Medicine, Columbia University Medical Center, New York, NY

1:00 PM (438) Blood Transfusions Affect the Panel of Reactive Antibodies and Survival After Ventricular Assist Device Implantation; E. Y. Birati, T. C. Hanfi, J. A. Mazurek, S. Banerji, E. Grandin, E. Vorovich, D. Pedrotty, A. Kaiser, E. Phillips, M. Acker, L. R. Goldberg, J. Rame, P. Aturi, K. B. Margules, J. Messup, 1Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA, 2Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 3Cardiothoracic surgery, Hospital of the University of Pennsylvania, Philadelphia, PA

1:15 PM (439) Three Year Outcomes With Tricuspid Valve Annuloplasty in LVAD Recipients; R. Khodaverdian, J. A. Groves, A. A. Phancao, C. Elkins, J. S. Chaffin, D. A. Horstmanhoff, J. Tang, J. W. Long, 1Oklahoma Cardiovascular Surgeons, Integrisk Baptist Hospital, Oklahoma City, OK, 2Cardiology, Integrisk Baptist Hospital, Oklahoma City, OK, 3Advanced Cardiac Care, Integrisk Baptist Hospital, Oklahoma City, OK, 4Nazhi Zudhi Transplant Institute, Integrisk Baptist Hospital, Oklahoma City, OK

1:30 PM (440) Impact of Residual Mitral Regurgitation on Right Ventricular Systolic Function After Left Ventricular Assist Device Implantation; H. S. Kemal, S. Ertugay, U. Kahraman, C. Engin, S. Nalbantgil, T. Yagdi, M. Oz 1Baran, 1Cardiology, Ege University Faculty of Medicine, Izmir, Turkey, 2Cardiovascular Surgery, Ege University Faculty of Medicine, Izmir, Turkey
12:15 PM – 1:45 PM
CONCURRENT SESSION 51

Risky Business: Transplant in High Risk Populations
(Erato, Uranie)
(HTX, BSI, HF, ID, NPSAH, PATH, PEDS, PHARM, PEEQ)

CHAIRS: Debra L. Isaac, MD and Michael Pham, MD

12:15 PM (441) Across the United States Multiorgan Transplantation in Adults With Congenital Heart Disease Is a Frequent Occurrence;
M. S. Khan1, F. Zafar1, R. A. Vermi, C. Chin, G. M. Schecter1, G. Webb2, D. L. Morales1. 1Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

12:30 PM (442) Survival Benefit of Heart Transplantation in Patients on Veno-Arterial Extra-Corporeal Membrane Oxygenation: Results From a French National Cohort;
C. Jasseron1, C. Cantrelle1, C. Legeai1, P. Leprince2, E. Flecher2, A. Srinelli3, O. Huot1, R. Dorent1. 1Direction Prélèvement Griffe Organes-Tissus, Agence de la Biomédecine, Saint-Denis La Plaine, France, 2Hôpital de la Pitié-Salpêtrière, Paris, France, 3Service de Chirurgie Thoracique Cardiaque et Vasculaire, CHU de Rennes, Rennes, France, 4CHU Tours, Tours, France

12:45 PM (443) Pregnancy Outcomes Following Cardiac Transplantation;
C. J. Bhagra1, S. K. Bhagra1, A. Donado2, T. Butt1, L. Forrest1, G. MacGowan1, G. Parry1. 1Cardiology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 2Cardiothoracic surgery, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 3Cardiopulmonary Transplantation, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

1:00 PM (444) Center-Specific Variations in Donor Antigen Frequency: Does the OPTN cPRA Calculator Apply to Your Center?;
S. A. Hollander1, D. B. Tyan2, M. Fernandez-Vina3, D. Bernstein1, N. McDonald2, K. Maeda3, B. D. Kaufman1, L. J. May1, D. N. Rosenthal1, C. S. Almond1. 1Pediatrics (Cardiology), Stanford University, Palo Alto, CA, 2Pathology, Stanford University, Palo Alto, CA, 3Pediatric Heart Transplantation, Lucile Packard Children's Hospital, Stanford, Palo Alto, CA, 4Cardiothoracic Surgery, Stanford University, Palo Alto, CA

1:15 PM (445) Outcomes of Heart Transplantation in Adults With Congenital Heart Disease: UNOS Registry Analysis;
K. Pandya, K. Lyons, A. Nsair, A. Baas, M. Cadeiras, D. Cruz, L. Reardon, M. Deng, A. Ardehali, J. Alejos, J. Aboulhosn, E. Depasquale. Advanced Heart Failure and Cardiac Transplantation, University of California, Los Angeles, Los Angeles, CA

1:30 PM (446) Cardiac Retransplantation: How Far Have We Come?;
K. Pandya, K. Lyons, A. Nsair, A. Baas, M. Cadeiras, D. Cruz, L. Reardon, M. Deng, A. Ardehali, E. Depasquale. Advanced Heart Failure and Cardiac Transplantation, University of California, Los Angeles, Los Angeles, CA
12:15 PM – 1:45 PM

CONCURRENT SESSION 52

Understanding Complications and Improving Lung Transplant Outcomes (Hermes)
(LTX, DMD, LF)

CHAIRS: Daniel F. Dilling, MD and Helen M. Whitford, MBBS, FRACP

(447) WITHDRAWN

12:15 PM (363) Contemporary Redo Lung Transplantation: An Analysis of the UNOS Database; A. Iyengar, E. C. DePasquale, D. Ross, A. Ardehali. David Geffen School of Medicine, University of California – Los Angeles, Los Angeles, CA

12:30 PM (448) A Novel Risk Score to Predict 1-Year Mortality Following Lung Transplant in the Current Era; J. C. Grimm1, V. Valero, 1rdi, J. Magruder1, A. Kilkic1, L. L. Silhan1, P. D. Shah1, C. A. Merlo1, A. S. Shah1, Surgery, The Johns Hopkins Medical Institution, Baltimore, MD, 2Medicine, The Johns Hopkins Medical Institution, Baltimore, MD


1:00 PM (450) Pregnancies After Lung Transplantation: A Retrospective Multicenter French Study About 39 Pregnancies; C. Bry1, D. Hubert1, M. Reynaud-Gaubert1, C. Dromer4, H. Mal5, D. Grenet6, H. Mal5, D. Grenet6, V. Boussaud1, J. Claustre1, J. Le Pavec9, M. Murris-Espin10, I. Danner-Boucher1. 1Service de Pneumologie, Institut du Thorax, CHU de Nantes, Nantes, France, 2Service de Pneumologie, Hopital Cochin, Paris, France, 3Centre de Ressource et de Compétences de la Mucoviscidose Adulte, Equipe de Transplantation Pulmonaire, CHU Nord, Marseille, France, 4Service de Pneumologie, CHU Bordeaux, Bordeaux, France, 5Service de Pneumologie, Hopital Bichat - Claude Bernard, Paris, France, 6Pneumology, Hopital FOCH, Suresnes, France, 7Service de Pneumologie, Hopital European Georges-Pompidou, Paris, France, 8Clinique Universitaire de Pneumologie, Pôle Thorax et Vaisseaux, CHU de Grenoble, Grenoble, France, 9Service de Chirurgie Thoracique et Vasculaire, Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France, 10CRCM Adulte-Service de Pneumologie-Allergologie, CHU de Toulouse, Toulouse, France

1:15 PM (451) Lung Retransplantation in the Lung Allocation Score Era; J. M. Schaffer1, P. Chi1, B. A. Reitz1, G. Dhillon2, J. Woo1, R. Ha1. Cardiothoracic Surgery, Stanford University, School of Medicine, Stanford, CA, 2Pulmonary and Critical Care, Stanford University, School of Medicine, Stanford, CA

1:30 PM (452) Survival and Spirometry Outcomes Following Lung Transplantation From Donors >70 Years – Extended Criteria Coming of Age; W. Sommer1, F. Ius1, J. Salaman1, M. Avsar1, M. Greer2, J. Gottlieb2, T. Welte2, A. Haverich1, G. Warnecke1, 1Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany, 2Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
### Beneficence and Nonmaleficence: The Breath Of It All (Calliope) (PEEQ, LF, LTX, NHSAH)

**CHAIRS:** Gundeep S. Dhillon, MD and Allan R. Glanville, MBBS, MD, FRACP

**12:15 PM (453) Period of Transplant Influences Elderly Lung Transplant Recipient Survival: We Are Getting Better!**

Y. Ravi1, C. B. Sai-Sudhakar2, S. Kirkby2, S. M. Black2, J. D. Tobias2, D. Hayes, Jr.3, R. S. Higgins3, B. A. Whitson3. 1Division of Cardio-Thoracic Surgery, Baylor Scott and White Heart and Vascular Institute, Temple, TX, 2Department of Pediatrics, Nationwide Children’s Hospital, Columbus, OH, 3Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH

**12:30 PM (454) Delirium After Lung Transplantation: Occurrence and Its Relationship to Morbidity and Mortality**

Y. Sher1, G. Dhillon2, J. R. Maldonado1. 1Psychiatry and Behavioral Sciences, Stanford University Medical Center, Stanford, CA, 2Pulmonary and Critical Care Medicine, Stanford University Medical Center, Stanford, CA

**12:45 PM (455) Outcomes of Telehealth Care for Lung Transplant Recipients**

A. Sidhu, C. Chaparro, M. Binnie, C. Chow, J. Granton, M. Davies, L. G. Singer. Toronto Lung Transplant Program, University Health Network, Toronto General Hospital, Toronto, ON, Canada

**1:00 PM (456) Quality of Life, Depression, Anxiety and Sleep Disruptions in Patients With Bronchiolitis Obliterans**

A. Gilmour1, J. Sheridan1, S. Yerkovich2, A. Fiene3. 1School of Psychology and Counselling, Queensland University of Technology, Brisbane, Australia, 2Lung Transplant Service, Queensland Health, Brisbane, Australia, 3Thoracic Medicine, The Prince Charles Hospital, Brisbane, Australia

**1:15 PM (457) The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT): A Two-Year Follow-Up of a Prospective Study of Medical & Psychosocial Outcomes**

J. R. Maldonado1, Y. Sher1, A. Tobon1. 1Psychosomatic Medicine Service, Stanford University School of Medicine, Stanford, CA, 2School of Medicine, Stanford University School of Medicine, Stanford, CA

**1:30 PM (458) Cost Effectiveness of Ex-Vivo Lung Perfusion Warrants Analysis of Long Term Recipient Outcome and Donor Organ Utilization Rate**

P. M. Hopkins1, D. Chambers1, I. Smith1, R. Naidoo1, D. Wall1, S. Yerkovich1, W. Hunt1. 1Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia, 2Perfusion Services, The Prince Charles Hospital, Brisbane, Australia
Basic Bazaar (Euterpe) (ALL)

CHAIRS: Richard N. Pierson, III, MD and Carla C. Baan, PhD

(459) WITHDRAWN

12:15 PM (381) The Effects of Kidney Graftectomy on the Tolerance Induced by Heart-Kidney Cotransplantation in Miniature Swine Depends on the MHC Barrier Crossed; S. G. Michel, M. L. Madariaga, G. M. LaMuraglia, V. Villani, M. Sekijima, E. A. Farkash, R. Colvin, J. S. Allan, K. Yamada, D. H. Sachs, J. C. Madisen. Cardiac Surgery, Ludwig-Maximilians-University, Munich, Germany, Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA

12:30 PM (460) Activation of Oncostatin M Receptor in Cardiomyocytes Increases Serum Levels of FGF23 During Heart Failure; M. H. Richter, H. Lautze, W. Skwara, M. Schönburg, A. Beiras-Fernandez, I. Werner, K. Kostin, T. Kubin, T. Walther. Department of Cardiac Surgery, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, Department of Anesthesiology, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, Department of Cardiac Surgery, J.-W.-Goethe University, Frankfurt, Germany, Department of Heart and Lung Research, Max-Planck-Institute, Bad Nauheim, Germany

12:45 PM (461) Bendavia (MTP-131) – A Novel Mitochondria-Targeting Peptide Reverses Dysregulation of Mitochondrial Fission and Fusion Proteins in the Failing Heart; H. N. Sabbah, R. C. Gupta. Medicine, Henry Ford Hospital, Detroit, MI

1:00 PM (462) Organ-Preconditioning by CD26/DPP4-Inhibitor Improves Lung Transplants via SDF-1 – Mediated Pathway; J. Jang, Y. Yamada, I. Inci, W. Weder, W. Jungraithmayr. Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland

1:15 PM (463) IL-17 Mediates Post-Transplant Airway and Parenchymal Lung Fibrosis; T. Martinu, W. C. McManigle, F. L. Kelly, E. Nelson, J. Sun, H. Zhang, K. M. Gowdy, S. M. Palmer. Medicine, Duke University, Durham, NC, Pharmacology and Toxicology, Brody School of Medicine, East Carolina University, Greenville, NC

1:30 PM (464) A-Antigen Specific Tolerance in a Novel Transgenic Mouse Model of ABO-Incompatible Heart Transplantation (ABOi HTx); B. Motyká, K. Labonte, F. H. Rahman, J. Pearcey, K. Tao, M. Mengel, B. Sis, P. J. Cowan, L. J. West. Pediatrics, Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada, Laboratory Medicine & Pathology, Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada, Laboratory Medicine & Pathology, University of Alberta, Edmonton, AB, Canada, St Vincent’s Hospital, Melbourne, Australia, Pediatrics, Surgery and Medical Microbiology & Immunology, Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada

2:00 PM – 7:30 PM

ISHLT BOARD OF DIRECTORS MEETING (Gallieni 1)
MODERATED POSTER SESSIONS
Poster presenters and moderators will be present during the evening poster viewing session from 7:00 pm - 8:00 pm.

**ADULT HEART FAILURE**

**(HF, BSI, DMD, HTX, MCS, NHSAH, PATH, PEDS, PH, PEEQ)**

**465** BAG3 Variant Associated With Ventricular Remodeling But Not Clinical Outcomes in Chronic Heart Failure; E. Vorovich1, B. French1, R. Hu1, M. Morley1, J. Brandimarto1, E. Y. Birati2, S. E. Kimmel3, T. P. Cappola1. 1Penn Cardiovascular Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

**WITHDRAWN**

**466** Clinical Outcomes in Patients Receiving Simultaneous Heart and Abdominal Organ Transplantation; S. Fedson1, C. Murks1, L. Potter1, s. Qamar1, T. Riley1, G. Kim1, G. Sayer1, N. Uriel1, T. Ota1, V. Jeevanandam1. 1Medicine, University of Chicago, Chicago, IL, 2Pharmacy, University of Chicago, Chicago, IL, 3Surgery, University of Chicago, Chicago, IL

**467** Single Center Outcomes of Combined Heart and Liver Transplantation in the Failing Fontan; B. A. D’Souza1, S. Fuller2, N. Hornsby1, J. Wald1, K. Krok2, A. Shaked1, L. Goldberg1, A. Pochettino1, K. Othloff2, Y. Y. Kim1. 1Cardiology Division, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, 2Department of Surgery, Children’s Hospital of Philadelphia, Philadelphia, PA, 3Department of Gastroenterology, Penn State Hershey Medical Center, Hershey, PA, 4Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, 5Department of Cardiac Surgery, Mayo Clinic, Rochester, MN

**468** Feasibility of a Long-Term Transfemoral Power Lead for Aortix, a Novel Intravascular Blood Pump; W. Clifton1, O. Benavides1, T. Songjakul1, J. Heuring1, B. Hertzog1, R. Delgado2. 1Procyrion, Houston, TX, 2Texas Heart Institute, Houston, TX

**469** New Scoring System Using Cardiopulmonary Exercise Parameters Can Predict Prognosis in Heart Failure Patients Receiving Guideline-Directed Optimal Medical Therapy Including Beta-Blocker, Angiotensin Converting Enzyme Inhibitor, and Aldosterone Antagonist; T. Imamurg1, K. Kinugawa1, T. Inaba1, H. Maki1, M. Hatano1, O. Kimoshita1, K. Nawata1, M. Ono1. 1Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 2Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 3Department of Cardiac Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

**470** Cardiac Retransplantation: Third Time’s the Charm?; E. C. DePasquale, L. Reardon, A. Nsair, M. Deng, A. Ardehali. UCLA, Los Angeles, CA


Outcomes in Adult Heart Transplant Candidates and Recipients Bridged With Acute Circulatory Support Devices; S. C. Silvestry1, L. B. Edwards2, L. Robbins2, S. A. Hall1, J. G. Rogers3, D. M. Meyer4, 1Washington Univ Sch of Med, St. Louis, MO, 2UNOS, Richmond, VA, 3Transplant Cardiology and Mechanical Support/Heart Failure, Baylor University Medical Center, Dallas, TX, 4Internal Medicine, Duke University School of Medicine, Durham, NC, 5Surgery, University of Texas Southwestern Medical Schoo, Dallas, TX

A Novel Minimally Invasive Ovine Model of Ischemic Cardiomyopathy With Advanced Cardiac Imaging Yields Superior Results and Survival; J. E. Cohen1, A. B. Goldstone1, Y. Shudo1, J. W. MacArthur2, J. B. Patel1, B. B. Edwards1, W. L. Patrick1, C. N. Aribiema1, Y. Wool1, Cardiothoracic Surgery, Stanford University, Stanford, CA, 5Surgery, University of Pennsylvania, Philadelphia, PA

Outcomes in Patients Bridged With Univentricular and Biventricular Devices Prior to Heart Transplantation; J. C. Grimm1, C. M. Sciortino1, J. Magruder1, V. Valero, 3rd1, R. J. Tedford1, S. D. Russell1, G. J. Whitman1, S. C. Silvestry2, A. S. Shah1, Surgery, The Johns Hopkins Medical Institution, Baltimore, MD, 3Medicine, The Johns Hopkins Medical Institution, Baltimore, MD, 5Surgery, Barnes Jewish Hospital, St. Louis, MO

Strategies for Bridge to Heart Transplantation (HTx) – High Urgent Listing (HU) vs. Mechanical Circulatory Support (MCS); J. Sunavsky, A. Zittermann, B. Fujita, U. Fuchs, J. F. Gummert, S. Ensinger, U. Schulz. Department for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany

Use of Extra-Corporeal Membrane Oxygenation in Patients Listed for Heart Transplantation; A. Cheng1, J. R. Trivedi1, A. Lenneman1, E. Birks1, M. S. Slaughter1, 1Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY, 2Cardiovascular Medicine, University of Louisville, Louisville, KY

Inclusion of Cognitive and Mood Domains in the Assessment of Frailty Enhances Outcome Prediction in Heart Transplant-Eligible Patients With Advanced Heart Failure; S. Jha1, M. K. Hannu1, P. Newton1, K. Wilhelm1, C. Hayward1, A. Jaboulet1, E. Kotlyar1, A. M. Keogh1, K. Dhiyal1, E. Ganger1, P. C. Jansz1, P. M. Spratt1, E. Montgomery1, M. Harkess1, P. Tunnicliff1, S. Shaw1, P. MacDonald1, 1Heart & Lung Transplant Unit, St. Vincent’s Hospital, Sydney, Australia, 2Health Science, University of Technology, Sydney, Australia, 3Psychiatry, St. Vincent’s Hospital, Sydney, Australia

Long Term Follow-Up of Coronary Sinus Delivery of Bone Marrow Cells for Congestive Heart Failure; J. Tuma1, A. Carrasco1, A. A. Winters2, S. Chirinos1, A. N. Patel8, 1Maison de Sante, Lima, Peru, 2University of Utah, Salt Lake City, UT
(481) Echocardiographic Assessment of Intrinsic Right Ventricular Dysfunction Using Arrhythmogenic Right Ventricular Cardiomyopathy as a Model; S. Shah, S. H. Baldinger, W. G. Stevenson, N. K. Lakdawala. Brigham and Women’s Hospital, Boston, MA

(482) Post-Exercise Heart Rate Recovery Independently Predicts Clinical Outcome in Patients With Acute Decompensated Heart Failure; J. Youn1, S. Lee1, S. Lee2, Y. Youn2, B. Chang3, S. Kang3. 1Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, 2Division of Cardiovascular Surgery, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

(483) Intra-Coronary Transfusion of Circulatory Derived CD34+ Cells Improves Left Ventricular Function in Patients With Diffuse Coronary Artery Disease and Non Candidates for Coronary Artery Intervention; F. Lee1, Y. Chen1, S. Chua2, M. Fu2, S. Pei1, H. Yip1. 1Cardiothoracic and Vascular Surgery, Chang Gung Mem Hosp, Kaohsiung, Taiwan, 2Cardiology, Chang Gung Mem Hosp, Kaohsiung, Taiwan, 3Hematology and Oncology, Chang Gung Mem Hosp, Kaohsiung, Taiwan

(484) Prognosis Estimation in Heart Transplant Candidates With the Transposition of Great Arteries (TGA) After Mustard or Senning Correction in the Childhood: The Retrospective Analysis; M. Hegarová1, Z. Dorazilová1, V. Melenovský1, J. Vrbská1, J. Malý2, I. Netuká1, J. Pirk2, I. Malek1. 1Clinic of Cardiology, IKEM, Prague, Czech Republic, 2Clinic of Cardiovascular Surgery, IKEM, Prague, Czech Republic

(485) Outcomes in Cardiac Transplant Recipients According to Pretransplant AT1R Antibody Levels and Donor AT1R Polymorphisms; M. Zacharias1, B. Hynes2, N. K. Sweitzer3, M. R. Johnson1, S. Akhter4, T. Ellis1, R. Dhingra1. 1Department of Medicine; Division of Cardiology, University of Wisconsin, Madison, WI, 2Department of Pathology, University of Wisconsin, Madison, WI, 3Department of Medicine; Division of Cardiology, University of Arizona Sarver Heart Center, Tucson, AZ, 4Department of Surgery; Division of Cardiothoracic Surgery, University of Wisconsin, Madison, WI


(487) MELD XI Predicts Early and Late Survival After Heart Transplantation Even in Patients Bridged With Left Ventricular Assist Device; S. Deg1, S. Al Kindi1, S. Kumar1, G. Oliveria1, S. Altarabshieh2, B. Sarayepoglu1, B. Medallion1, M. Gunwale1, C. El-Amri1, S. J. Park1. 1Cardiac Surgery, University Hospitals, Cleveland, OH, 2Cardiac Surgery, Queen Alia Heart Institute, Amman, Jordan

(488) Bariatric Surgery: A ‘Bridge to Transplant’ for Morbidly Obese Patients With Advanced Heart Failure; C. Lim1, O. M. Fisher2, D. Falkenback1, D. Boyd1, C. Hayward1, A. Keogh1, K. Samaras2, R. Lord1, P. Macdonald1. 1National Heart Centre Singapore, Singapore, Singapore, 2St Vincent’s Centre for Applied Medical Research, Sydney, Australia, 3Department of Anaesthesia, St Vincent’s Hospital, Sydney, Australia, 4Heart Transplant Unit, St Vincent’s Hospital, Sydney, Australia, 5Department of Endocrinology, St Vincent’s Hospital, Sydney, Australia, 6Department of Surgery, St Vincent’s Hospital, Sydney, Australia

(489) Does a Crumbling Bridging Strategy Put Patient at Risk for Cardiac Transplantation?: S. Mahr, P. Angleitner, T. Harberl, A. Aliabadi, D. Zimpfer, G. Laufner, A. Zuckermann. Cardiac Surgery, Medical University of Vienna, Vienna, Austria
(490) **Early and Mid-Term Predicted Survival in Transplant Eligible Elderly Patients Is Superior With Transplant Versus Left Ventricular Assist Device Bridge-to-Transplant Therapy;**
S. K. Singh1, D. K. Pujara1, E. Sandoval1, J. Anand1, L. Simpson1, A. B. Civitello1, H. R. Mallidi1. 1Transplant and Assist Devices, Baylor College of Medicine, Houston, TX, 2Transplant and Assist Devices, Texas Heart Institute, Houston, TX

(491) **Partial Pressure of End-Tidal Carbon Dioxide Predicts the Complication of Secondary Pulmonary Hypertension in Patients With Advanced Heart Failure;**
O. Seguchi1, A. Nakano2, K. Kuroda3, E. Hisamatsu4, T. Sato5, S. Nakajima2, T. Sato2, H. Sunami2, M. Yanase2, M. Kitakaze2, T. Nakatani1. 1Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, 2Development of Clinical Research, National Cerebral and Cardiovascular Center, Osaka, Japan, 3Development of Clinical Research, National Cerebral and Cardiovascular Center, Osaka, Japan

(492) **Should Surveillance Right Heart Catheterization Be Performed in Patients Listed for Heart Transplantation?**
M. Ahluwalia1, A. T. Owens, K. A. Forde-McLean, M. Jessup, R. C. Forde-McLean. Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

(493) **Risk of Heart Failure and Death Among Patients With Friedreich Ataxia Admitted for Non-Cardiac Etiologies;**

(494) **The Independent Predictive Value of Peak Oxygen Consumption, Left ventricular Strain and Atrial Remodelling in Patients With Dilated Cardiomyopathy;**

(495) **Management of Chagas Cardiomyopathy Patients Following Cardiac Transplantation: Implications From the Unos Database;**
A. Godier-Furnemont, V. K. Topkara, D. Mancini. Cardiology, Columbia University New York Presbyterian Hospital, New York, NY

(496) **Combined Kidney Transplant in Patients Referred for Advanced Therapies: Viable Option?**
M. Kittleson1, J. Patel1, F. Liu2, S. Siddiqui, L. Pipponiaj, D. H. Chang1, A. Hage1, M. Hamilton1, L. Czer1, A. Trento1, F. Esmailian1, J. A. Kobashigawa1. 1Cedars-Sinai Heart Institute, Los Angeles, CA, 2MD, Cedars-Sinai Heart Institute, Los Angeles, CA

(497) **Frailty as a Predictor of Outcomes in Heart Transplant- Eligible Patients With Advanced Heart Failure;**
S. R. Jha1, M. Hannu1, P. Newton1, K. Wilhelm1, C. Hayward1, A. Jabbour1, E. Kotyjar1, A. Keogh1, K. Dhital1, E. Granger1, P. Jansz1, P. Spratt1, E. Montgomery1, P. Tunnicliff1, S. Shaw1, P. MacDonald1. 1Heart & Lung Transplant Unit, St. Vincent’s Hospital, Sydney, Australia, 2Health Science, University of Technology, Sydney, Sydney, Australia, 3Psychiatry, St. Vincent’s Hospital, Sydney, Australia

(498) **Frailty Phenotype Is Associated With Survival as Predicted By the Seattle Heart Failure Model in Heart Failure Patients Referred for Advanced Therapies;**
L. A. Goldman, A. C. Alba, F. Foroutan, J. MacIver, H. J. Ross. Heart Failure and Cardiac Transplant Programs, Peter Munk Cardiac Center, University of Toronto, Toronto, ON, Canada

(499) **Characteristics and Predictors of Improvement in Patients Delisted for Recovery While Awaiting Heart Transplantation;**
S. Kumar, S. Al-Kindi, M. Ige, M. Ginwalla, C. ElAmm, S. Deo, S. Park, G. H. Oliveira. University Hospitals Case Medical Center, Cleveland, OH
(Agora 2)

(MCS, BSI, DMD, HF, HTX, ID, NHSAH, PATH, PEDS, PH, PHARM, PEEQ)

(500) Moved to Mini Oral Session 1

(501) Extremes of Obesity and LVAD Patient Morbidity and Mortality;
C. Henderson, K. Patel, G. Sayer, S. Fedson, G. Kim, T. Ota, C. Jurcsek, Y. Jeevanandam, N. Uriel. Medicine, University of Chicago, Chicago, IL, Surgery, University of Chicago, Chicago, IL

(502) Handgrip Strength Is a Predictor for Length of Stay in Patients Implanted With Left Ventricular Assist Devices;
G. Yost, M. Gregory, G. Bhat. Center for Heart Transplant and Assist Devices, Advocate Christ Medical Center, Oak Lawn, IL

(503) Outcomes Following an Individualized Management Strategy for Adult Patients on ECMO;
J. K. Wong, A. L. Melvin, D. J. Joshi, C. Y. Lee, P. A. Knight. Division of Cardiac Surgery, University of Rochester Medical Center, Rochester, NY

(504) Moved to Mini Oral Session 1

(505) Moved to Mini Oral Session 7

(506) Hemodynamic and Cerebrovascular Response to an Orthostatic Challenge in Patients With Continuous-Flow Left Ventricular Assist Devices;
W. K. Cornwell, T. Tarumi, A. Stickford, J. Kibe, C. Fitzsimmons, D. Markham, R. Zhang, Q. Fu, M. Drazner, B. Levine. Cardiology, Univ of Texas SW, Dallas, TX, Institute of Exercise and Environmental Medicine, Dallas, TX, Cardiology, Emory University, Atlanta, GA, Cardiology, Institute of Exercise and Environmental Medicine, Dallas, TX

(507) Comparison of Monitoring Unfractionated Heparin Using Anti-Xa vs. aPTT in Patients With Ventricular Assist Devices;
J. Waldron, J. Dow, R. Grayburn, N. Gaglianello, L. Baumann Kreuziger. Medical College of Wisconsin, Milwaukee, WI

(508) Substance Abuse and Left Ventricular Assist Device Outcomes: Does a History and Type of Use Matter?;

(509) Echocardiographic and Ambulatory B-Type Natriuretic Peptide Correlates in Patients Supported By a Left Ventricular Assist Device;
A. K. Mankad, V. P. Raje, G. Merinar, K. B. Shah. Hunter Holmes McGuire Veterans Hospital, Richmond, VA, Medical College of Virginia, Richmond, VA

(510) Extracorporeal Membrane Oxygenation Support in Refractory Cardiogenic Shock: Outcome, Treatment Strategies and Analysis of Risk Factors;
A. Loforte, E. Pilato, S. Martin Suarez, G. Jafrancesco, S. Castrovinc, M. Cefarelli, L. Potena, M. Masetti, G. Magnani, F. Grigioni, G. Frascaroli, G. Marinelli. Cardiovascular Surgery and Transplantation, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy
Recirculation During Venovenous Extracorporeal Membrane Oxygenation: A Comparative Mock Circulation Study; A. Xie1, I. D. Jayewardene1, A. Dinale2, P. Macdonald3, R. Pye4, K. Dhital5. 1Faculty of Medicine, University of New South Wales, Sydney, Australia, 2Department of Clinical Perfusion, St Vincent's Hospital, Sydney, Australia, 3Department of Cardiology, St Vincent's Hospital; Victor Chang Cardiac Research Institute, Sydney, Australia, 4Department of Anaesthetics, St Vincent's Hospital, Sydney, Australia, 5Department of Cardiothoracic Surgery, St Vincent's Hospital; Victor Chang Cardiac Research Institute, Sydney, Australia


Rest and Exercise Adaptation of the Right Ventricle in Long-Term Left Ventricular Assist Device Patients: A Prospective, Pilot Study; M. Aymami1, E. Donal2, J. Guihaire1, A. Le Helloco2, E. Galli2, F. Carré2, B. Lelong1, C. Chabanne1, H. Corbineau1, E. Flécher1. 1Department of Thoracic and Cardiovascular Surgery, Rennes University Hospital, Rennes, France, 2Cardiology and Cardiac Functional Explorations Department, Rennes University Hospital, Rennes, France

Outcomes After Heart Transplantation of Patients Bridged to Transplant With Short Term Assist Device Support; M. A. Castel1, R. Cartaña2, M. Cardona1, D. Pereda2, E. Sandovál2, M. Castella2, M. Farrero1, F. Pérez-Villa1. 1Department of Cardiology, Hospital Clinic Barcelona, Barcelona, Spain, 2Department of Cardiac Surgery, Hospital Clinic Barcelona, Barcelona, Spain

Moved to Mini Oral Session 7

Modulation of LV Loading and Arterial Pulsatility Affects PET/CT Coronary Flow Reserve in Continuous Flow LVAD Patients; M. Yuzefpolskaya1, M. R. Torres2, R. Weinberg1, A. Breskin1, R. A. Garan1, V. K. Topkara1, K. Takeda2, H. Takayama2, D. M. Mancini2, Y. Naka2, U. P. Jorde3, P. C. Colombo2, S. Bokhari1. 1Medicine, Columbia University, New York, NY, 2Surgery, Columbia University, New York, NY, 3Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA

Residual Mitral Regurgitation After Continuous Flow Left Ventricular Assist Device Implantation Impacts Right Ventricular Geometry and Function; H. Kassiss1, K. Cherukuri2, R. Agarwal1, M. Kanwar1, G. G. Sokos1, R. J. Moraca1, S. H. Bailey1, S. Murali2, R. L. Benza2, A. Raina1. 1Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, 2Department of Medicine, Allegheny General Hospital, Pittsburgh, PA

(519) Update on Post-Approval INTERMACs Registry of the HVAD System in Commercial Use;
1Vanderbilt University Medical Center, Nashville, TN, 2Barnes Jewish Hospital, St Louis, MO, 3MedStar Heart Institute, Washington DC, 4University of Chicago Medicine, Chicago, IL, 5Duke University School of Medicine, Durham, NC, 6Medical College of Wisconsin, Milwaukee, WI, 7University of Washington Medical Center, Milwaukee, WI, 8Tufts Medical Center, Boston, MA, 9University of Pittsburgh Medical Center, Pittsburgh, PA, 10Northwestern Memorial Hospital, Chicago, IL, 11Texas Heart Institute, Houston, TX

(520) The Harmonic Pattern of Ventricular Assist Device Audiosignals: Correlation to Pump Speed and Aortic Valve Opening;
1Faculty of Medicine, University of New South Wales, Sydney, Australia, 2Department of Cardiothoracic Surgery, St Vincent's Hospital, Sydney, Australia, 3Graduate School of Biomedical Engineering, University of New South Wales, Sydney, Australia

(521) WITHDRAWN

(522) Cerebral Hypoxia During Venoarterial Extracorporeal Membrane Oxygenation: An In-Vitro Study;
1Faculty of Medicine, University of New South Wales, Sydney, Australia, 2Department of Clinical Perfusion, St Vincent's Hospital, Sydney, Australia, 3Department of Cardiology, St Vincent's Hospital, Sydney, Australia

(523) VKORC1 Genotype Predicts Warfarin Dosing and INR Kinetics in Patients With Continuous-Flow Left Ventricular Assist Devices (CF-LVADs);
V. K. Topkara1, A. Levin1, K. Mody1, A. Garan1, B. Cagliostro2, M. A. Flannery1, R. Te-Frey1, F. Torres2, K. Takeda2, H. Takayama2, M. Yuzefpolskaya1, D. Mancini1, Y. Naka1, P. Colombo1, U. P. Jorde3, 1Cardiology, Columbia University New York Presbyterian Hospital, New York, NY, 2Cardiothoracic Surgery, Columbia University New York Presbyterian Hospital, New York, NY, 3Cardiology, Montefiore Medical Center, New York, NY

(524) Duration of Continuous-Flow Left Ventricular Assist Device Support Does Not Impact Heart Transplant Operative Variables and Long-Term Survival;
University of Wisconsin, Madison, WI

(525) Anatomical and Hemodynamic Response of the Right Ventricle During Increases in Left Ventricular Assist Device Speed;
G. T. Sayer1, K. Addetia1, S. Fedson1, E. Kruse1, K. Collins1, D. Rodgers1, C. Jurcevik1, T. Ota2, V. Jeewanandam2, R. Lang1, N. Uriel1, 1Medicine, University of Chicago Medical Center, Chicago, IL, 2Surgery, University of Chicago Medical Center, Chicago, IL

(526) Comparison of Hospitalization Rates With the HeartWare HVAD and HeartMate II Left Ventricular Assist Devices;
MedStar Heart Institute, Washington, DC
(527) Right Ventricular Failure After Left Ventricular Assist Device Implantation: The Importance of Preoperative Hemodynamic Profile; V. De Simone, M. Cipriani, A. Verde, A. Garascia, F. M. Turazza, F. Macera, V. Pacher, E. Ammirati, F. Milazzo, R. Paino, C. F. Russo, T. Colombo, C. Taglieri, L. Martinelli, F. Frigerio, C. Cardiology, University Hospital of Verona, Verona, Italy, C. Cardio-thoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy

(528) Full Percutaneous Temporary Right Ventricular Support By a Centrifugal Pump in Right Ventricular Failure After Left Ventricular Assist Device Implantation; G. Lebreton, C. Mastroianni, P. Demondion, A. Genton, P. Leprince. Cardiac Surgery, Pitie Salpetriere Hospital, 75013, France

(529) Left Atrial Pressure Monitoring for Early Post-Operative Management Following LVAD Implantation; I. Rajapreyar, M. Petrovic, S. Nathan, M. H. Akay, B. Kar, P. Loyalka, M. Patel, I. D. Gregoric. Center for Advanced Heart Failure, The University of Texas Health Science Center at Houston, Houston, TX


(532) At Left Ventricular Assist Device (LVAD) Implantation, Morphologic Differences Are Observed Between Patients With Improved Cardiac Function Allowing LVAD Removal and Patients With Prolonged LVAD Support as a Bridge to Transplantation; A. Segura, A. Hernandez, A. Baldwin, S. Carranza, P. Odegaard, L. Buja, O. Frazier. Cardiovascular Pathology Research, Texas Heart Institute, Houston, TX, C. Cardiology, St. Luke’s Hospital Medical Center, Houston, TX, C. Cardiothoracic Surgery, Texas Heart Institute, Houston, TX, C. Center for Cardiac Support, CHI St. Luke’s Health, Houston, TX, C. Center for Cardiac Support, Cardiovascular Surgery Research, Texas Heart Institute, Houston, TX


WITHDRAWN

Cellular Microparticles as Predictive Markers for Adverse Events in Patients With Implanted Ventricular Assist Devices; J. Walenga, W. Jeske, J. Schwartz, V. Escalante, B. Menapace, E. Coglianese, E. Kumar, A. Heroux, M. Bakhos. Thoracic-CV Surgery, Loyola University Chicago, Maywood, IL, 2Thoracic-CV Surgery, Loyola University Health System, Maywood, IL, 3Heart Failure/Cardiology, Loyola University Health System, Maywood, IL

Predictors of Aortic Valve Commissural Fusion in Patients Undergoing Left Ventricular Assist Device Therapy; D. N. Valencia, S. A. Kliethermas, J. I. Bailey, B. Duebner, E. Boyes, J. P. Schwartz, A. L. Heroux, E. Coglianese. Loyola University School of Medicine, Maywood, IL, 2Department of Public Health Sciences, Loyola University School of Medicine, Maywood, IL, 3Division of Cardiology, Loyola University Medical Center, Maywood, IL, 4Division of Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL


MELD XI Successfully Predicts Thirty Day Mortality in Patients Who Received Centrimag VAD for Acute Decompensated Heart Failure; L. Truby, A. Abadeer, K. Fujita, P. C. Schulze, M. Farr, M. Yuzefpolskaya, P. C. Colombo, K. Takeda, D. Mancini, Y. Nakal, H. Takayama. 1Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY, 2Department of Cardiology, Columbia University College of Physicians and Surgeons, New York, NY

Intra-Operative Indication Extracorporeal Membrane Oxygenation for Cardiopulmonary Support During Lung Transplantation: Risk Factors and Mid-Term Results; F. Ius, W. Sommer, I. Tudorache, M. Aysar, T. Siemeni, J. Salmon, M. Greer, J. Puntigam, M. Hoepfer, J. Gottlieb, T. Welte, A. Haverich, C. Kühni, G. Warnecke. 1Department of Cardiothoracic, Transplant and Vascular Surgery, Hanover Medical School, Hanover, Germany, 2Department of Respiratory Medicine, Hanover Medical School, Hanover, Germany

The Impact of Perioperative Bleeding on Long-Term Outcomes of Mechanical Circulatory Support; K. Lietz, M. L. Mooney, I. El Lakkis, C. J. Derber, U. M. Kelly, C. D. Wilson, A. C. Hoedt, P. W. Bourassa, B. H. Smith, M. F. McGrath, J. M. Herre. 1Division of Advanced Heart Failure, Sentara Norfolk General Hospital, Norfolk, VA, 2Division of Infectious Diseases, Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA

Radiologic Assessment of HeartMate II Position: Minimal Pump Migration After Long Term Support; R. M. Adamson, B. S. Bower, K. S. Sundareswaran, D. J. Farrar, W. P. Dombitsky. 1Cardiac Surgery, Sharp Memorial Hospital, San Diego, CA, 2Radiology, Sharp Memorial Hospital, San Diego, CA, 3Research and Scientific Affairs, Thoratec, Pleasanton, CA

Usefulness of Implantable Cardioverter Defibrillators in Patients Supported With Ventricular Assist Devices; A. Gkouziouta, S. Adamopoulos, A. Kostopoulou, G. Theodorakis, P. Strakis. Heart Failure, MCS and Transplant Unit, Onassis Cardiac Surgery Centre, Athens, Greece
(545) Utility of Cardiac Computed Tomography in Detecting Malposition of Left Ventricular Assist Devices Associated With Pump Thrombosis; M. Kassi, R. Adigun, S. Choi, A. M. Cordero-Reyes, A. Bhimaraj, B. H. Trachtenberg, G. Ashrith, M. Loebe, G. Torre-Amione, S. Chang, J. D. Estep. Cardiology, Houston Methodist Hospital, Houston, TX

(546) The Impact of Acute Kidney Injury in Patients With Postcardiotomy Cardiogenic Shock Requiring Mechanical Circulatory Support; S. Fukuhara1, L. Truby1, L. Vargas1, S. Hart1, D. Mancini2, P. Colombo2, V. Topkara2, M. Yuzefpolskaya2, K. Takeda1, Y. Naka1, H. Takayama1. 1Surgery, Columbia University Medical Center, New York, NY, 2Medicine, Columbia University Medical Center, New York, NY

(547) Japanese Multi-Center Outcomes With the HeartMate II in the Post-Approval Era: Focusing on Results in Patients With Small Body Size; M. Ono1, Y. Sawa1, T. Nakatani1, R. Tominaga1, Y. Matsu1, K. Yamazaki1, Y. Saiki1, H. Niinami1, G. Matsumiya1, H. Arai1. 1Dept. of Cardiovascular Surg., Univ. of Tokyo, Tokyo, Japan, 2Dept. of Cardiovascular Surg., Osaka Univ., Osaka, Japan, 3Dept. of Transplantation, National Cardiovascular Research Center, Osaka, Japan, 4Dept. of Cardiovascular Surg., Kyushu Univ., Fukuoka, Japan, 5Dept. of Cardiovascular Surg., Hokkaido Univ., Sapporo, Japan, 6Dept. of Cardiovascular Surg., Tokyo Women's Medical Univ., Tokyo, Japan, 7Dept. of Cardiovascular Surg., Tohoku Univ., Sendai, Japan, 8Dept. of Cardiovascular Surg., Saitama Medical Univ., Hidaka, Japan, 9Dept. of Cardiovascular Surg., Chiba Univ., Chiba, Japan, 10Dept. of Cardiovascular Surg., Tokyo Medical and Dental Univ., Tokyo, Japan

(548) Risk of Neurologic Complications in Patients With Total Artificial Heart; I. Tchoukina, L. R. Thacker, J. R. Coleman, M. D. Kozak, A. E. Gentry, M. P. Flattery, V. Kasirajan, D. G. Tang, K. B. Shah. Virginia Commonwealth University, Richmond, VA

(549) Implantable Cardioverter Defibrillator Therapy in Patients With Continuous Flow Ventricular Assist Device; S. Pecha, A. Bernhardt, S. Hakmi, Y. Yildirim, M. Barten, S. Willems, F. Wagner, H. Reischenspurner, T. Deuse, A. Aydin. Cardiovascular Surgery, Univ Hospital Hamburg, Hamburg, Germany

(550) Overview of a Newly Developed Hub and Spoke Extracorporeal Membrane Oxygenation Inter-Hospital Transport Program; B. Lima, J. A. Manos, M. Duncan, S. M. Noesges, W. Annotapipat, E. Stockard, O. O. Hernandez, A. E. Shafi, T. Chamogeorgakis, J. C. Machannaford, R. L. Smith, S. A. Hall, G. V. Gonzalez-Stawinski. Baylor University Medical Center, Dallas, TX

(551) Presence of Multifactorial, Acquired Hypercoagulability After Implantation of Left Ventricular Assist Devices or Total Artificial Hearts; H. J. Reich1, O. Tcherniantchouk2, F. A. Arabia3, F. Esmalian3, D. Ramzy4, L. D. Lam4, J. Morijuzuchi4, J. A. Dunnhill5, M. A. De Robertis1, L. Czer6. 1Surgery, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 2Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, 3Cardiothoracic Surgery, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, 4Pharmacology, Cedars-Sinai Medical Center, Los Angeles, CA, 5Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, 6Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA

(553) Reliability of the Freedom Driver After Total Artificial Heart Implantation;

(554) Risk of Thromboembolic Events After Short Term Discontinuation of Anticoagulation Following a Gastrointestinal Bleed;

(555) Age as Predictor of Clinical Outcomes after LVAD Placement;
L. Harvey1, C. Holley1, S. Roy1, P. Eckman1, R. Cogswell2, K. Liao1, R. John1. 1Surgery, University of Minnesota, Minneapolis, MN, 2Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN

(556) Choice of Initial Device Implant for INTERMACS Profiles 1 and 2 Patients in Cardiogenic Shock Determines Survival to Transplant or Recovery;
R. Cheng, B. Azarbal, F. Esmailian, A. Trento, J. A. Kobashigawa, F. A. Arabia, J. D. Moriguchi. Cedars-Sinai Heart Institute, Los Angeles, CA

(557) Bridge to Transplantation With Long-Term Mechanical Assist Device in Adults After Mustard Procedure;
J. Maly1, O. Szarszo1, J. Beski1, Z. Dorazilova1, J. Pirk1, I. Netuka1. 1Department of Cardiovascular Surgery, IKEM, Prague, Czech Republic

(558) Reduced Continuous-Flow LVAD Speed Does Not Decrease von Willebrand Factor Degradation;
J. Kang1, D. M. Zhang1, D. J. Restle1, F. Kalle1, M. A. Acker1, P. Atluri1, C. R. Bartoli1. 1Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA, 2Thoratec Corporation, Pleasanton, CA

(559) Decreased Pulmonary Artery Compliance Is Associated With Right Heart Failure and Reduced 6-Month Survival After Left Ventricular Assist Device;
E. W. Grandir1, J. A. Mazurek1, P. Zaman1, G. S. Troutman1, E. Voroch1, E. Y. Brait1, S. Sanerji1, D. Pedrotty1, J. N. Kirkpatrick1, K. B. Margules1, P. Atluri1, J. E. Rame1. 1Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, 2Penn Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, 3Division of Cardiovascular Diseases, Albert Einstein Medical Center, Philadelphia, PA, 4Division of Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA

(560) High Dose Antiplatelet Therapy Increases Early Bleeding Risk But Does Not Reduce Thrombotic Events in Patients With CF-LVADs;
O. Saeed1, A. Shah1, C. Guerrero1, J. Nguyen1, S. Patel1, D. Sims1, J. Shin1, D. D'Alessandro1, D. J. Goldstein1, U. Jorde1. 1Cardiology, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY, 2Medicine, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY, 3Cardiothoracic Surgery, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY

(561) Usefulness of Right Heart Assessment on Ramp Echocardiography After Continuous-Flow LVAD Implantation: A Missed Opportunity?
E. Joyce1, G. C. Stewart1, J. Rivero1, I. Gosev1, M. Hickey1, M. Leach1, M. M. Givertz2, G. S. Couper3, M. R. Mehra3. 1Cardiovascular Division, Department of Medicine, Brigham and Womans Hospital, Boston, MA, 2Division of Cardiovascular Surgery, Brigham and Womans Hospital, Boston, MA
(562) **Echocardiographic Right Heart Strain Analysis May Identify Left Ventricular Assist Device (VAD) Recipients Requiring Subsequent Right VAD Support;**

D. Charisopoulou, N. Banner, S. R. Andre, R. Shelley. Advanced Heart Failure and Transplantation, Royal Brompton and Harefield NHS Trust, London, United Kingdom

(563) **Do Warfarin Polymorphisms (VKORC1 and CYP2C9) Influence Maintenance Anticoagulation Variability in Patients With Continuous Flow Left Ventricular Assist Devices?**

N. A. Haglund1, P. B. Miller2, M. E. Davis3, C. Lai1, J. M. Stulak4, M. E. Keebler1, J. Boord1, S. Malaisi1, 1Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN, 2Pharmacology, Vanderbilt Univ Med Ctr, Nashville, TN, 3Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, 4Cardiac Surgery, Mayo Clinic, Rochester, TN

(564) **Are Continuous-Flow LVADs Associated With Vasoplegia at the Time of Heart Transplant?**

L. A. Goldraich, F. Foroutan, H. J. Ross, C. Serrick, M. McDonald, P. Billia, D. Delgado, T. Yau, R. J. Cusimano, V. Rao. Mechanical Circulatory Support and Cardiac Transplant Programs, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network., Toronto, ON, Canada

(565) **The Use of Octreotide to Treat Refractory Gastrointestinal Bleeding in Patients Supported With a Continuous-Flow Left Ventricular Assist Device;**

P. S. Dias, H. Hayes, J. Baumwol. Advanced Heart Failure & Cardiac Transplant Service, Royal Perth Hospital, Perth, Australia

(566) **Inflammation Mediated Fibrosis Is Regulated Through Distinct Gene-Gene Co-Expression Networks in the Failing Human Myocardium Before and After Left Ventricular Assist Device Support;**

V. K. Topkara1, A. Godier-Furnemont2, N. Bax2, B. Fine1, A. Garan1, M. Yuzefpolisikaya1, K. Takeda2, H. Takayama2, Y. Naka3, D. Mancini1, P. C. Colombo2, U. P. Jorde1, G. Venjak-Novakovic1. 1Cardiology, Columbia University New York Presbyterian Hospital, New York, NY, 2Biomedical Engineering, Columbia University New York Presbyterian Hospital, New York, NY, 3Cardiothoracic Surgery, Columbia University New York Presbyterian Hospital, New York, NY, 4Cardiology, Montefiore Medical Center, New York, NY

(567) **Does the Utilization of a Temporary External Anchoring Suture Increase the Risk of Driveline Infection After Implantation of a Left Ventricular Assist Device;**

M. Fudim1, C. L. Brown1, M. E. Davis2, M. Djunaidi2, M. R. Danter3, F. E. Harrel4, N. A. Haglund2, S. Malaisi1, 1Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN, 2Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, 3Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, 4Biostatistics, Vanderbilt Univ Med Ctr, Nashville, TN

(568) **Left Ventricular Assist Devices vs. the Total Artificial Heart: Which Causes More Cerebrovascular Accidents?**


(569) **Impella 5.0: Effective Short-Term Support in Acute Refractory Cardiogenic Shock of Various Etiologies;**

G. Lebreton, C. Mastroianni, A. Quessard, P. Leprince. Cardiac Surgery, Pitie Salpetriere Hospital, 75013, France

(570) **Gender Differences in the Risk of Neurological Events and Subsequent Outcome in Left Ventricular Assist Device Patients;**

S. Sherazi1, V. Kutyifa2, S. McNitt2, A. Paperno2, W. Hallinan1, L. Chen1, E. Storozynsky1, T. Massesy1, W. Zareba2, J. Alexisi1. 1Cardiology, University of Rochester, Rochester, NY, 2Cardiology Heart Research Follow-up Program, University of Rochester, Rochester, NY, 3Thoracic and Cardiovascular Surgery, University of Rochester, Rochester, NY
(571) Long-Term Outcomes After Limited Incision Left Ventricular Assist Device Implantation; J. Riebandt1, T. Haberl1, D. Wiedemann1, K. Dimitrov1, P. Simon1, R. Moayedifar1, H. Schima2, G. Laufer1, D. Zimpfer1. 1Cardiac Surgery, Medical Univ Vienna, Vienna, Austria, 2Medical Physics and Biomedical Engineering, Medical Univ Vienna, Vienna, Austria

(572) Large Incremental Changes in Pump Speed Are Required in Order to See Meaningful Changes in Invasively Measured Hemodynamics in Patients With HeartMate II Continuous Flow Left Ventricular Assist Devices (CF-LVADs); C. Eshelbrenner, A. M. Cordero-Reyes, A. Bhimaraj, B. H. Trachtenberg, G. Ashrith, M. Loebe, G. Torre-Amione, J. D. Estep. Cardiology, Houston Methodist Hospital, Houston, TX

(573) Driveline Infections in Left Ventricular Assist Devices: Review of Management Strategies and Outcomes; A. Abou el ela1, K. R. Balsara1, A. Lee1, S. M. Joseph2, J. Vader2, S. J. LaRue3, G. A. Ewald3, A. Keith1, S. C. Silvestry1, A. Itok1. 1Cardiovascular Surgery, Washington University Medical School, St. Louis, MO, Saint Louis, MO, 2Cardiovascular Diseases, Washington University Medical School, St. Louis, MO, Saint Louis, MO, 3Cardiovascular diseases, Washington University Medical School, St. Louis, MO, Saint Louis, MO

(574) LVAD Thrombosis Detection Using Third Harmonic Frequency Measured With 3D Accelerometer; I. Schalit1, A. Espinoza1, G. Sörensen2, A. E. Flände3, T. N. Hoel4, E. Gude5, H. Skulstad2, E. Fosse3, P. S. Halvorsen1. 1The Intervention Centre, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 2Department Of Cardiothoracic Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 3Department Of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway


(576) Detailed Endocardial Mapping Around the Left Ventricular Assist Device Inflow Cannula Facilitates Successful Ablation of Ventricular Tachycardia; J. D. Moss1, A. Vohra2, J. H. Shin3, H. M. Nayak1, M. C. Burkel1, N. Uriel1. 1Section of Cardiology, University of Chicago, Chicago, IL, 2Department of Medicine, University of Chicago, Chicago, IL, 3Mid-Atlantic Permanente Medical Group, Upper Marlboro, MD

(577) Incidence of Gastrointestinal Bleeds in Patients With Continuous-Flow Left Ventricular Assist Devices Prescribed Serotonergic Agents; J. Schultz1, H. Bream-Rouwenhorst1, R. Hobbs1, D. McDanel1, R. Tandon2, J. Goerbig-Campbell2. 1Department of Pharmaceutical Care, The University of Iowa Hospitals and Clinics, Iowa City, IA, 2Department of Internal Medicine, The University of Iowa Hospitals and Clinics, Iowa City, IA, 3Department of Internal Medicine – Cardiovascular Care, The University of Iowa Hospitals and Clinics, Iowa City, IA

(578) Poor Pre-Operative Pulmonary Function Tests (PFTs) Do Not Predict Worse Outcomes in Patients Undergoing LVAD Placement; F. Kamdar1, N. Sathnur1, D. Nieto2, A. Klaassen Kamdar1, K. Liao1, P. M. Eckman1, R. John1. 1University of Minnesota, Minneapolis, MN, 2Baylor College of Medicine, Houston, TX

(579) Mechanical Circulatory Support Is Feasible and Safe as Bridge to Transplant for Patients With Restrictive and Hypertrophic Cardiomyopathy; S. Al-Kindi, M. Ige, S. Kumar, C. ElAmm, M. Ginwalla, S. Deo, S. J. Park, G. H. Oliveira. University Hospitals Case Medical Center, Cleveland, OH
(580) **Histopathological Analysis of the Mitral Valve After Long-Term Mechanical Circulatory Support;**
Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Japan, 2Pathology, National Cerebral and Cardiovascular Center, Suita, Japan, 3Transplantation, National Cerebral and Cardiovascular Center, Suita, Japan

(581) **Medium-Term Circulatory Support for Cardiogenic Shock in a Developing Country: Do We Need a Long-Term Device?**
M. A. Villavicencio1, V. Rossel2, R. Larrea1, J. P. Peralta1, E. Larrain1.
J. S. Lim1, D. Donoso1, J. E. Martin1, J. Eduardo Rame1, P. Atur1.
1Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan, 2Department of Cardiology, University of Chile, Santiago, Chile, 3Division of Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan

(582) **Subclinical Hemorrhagic Cerebral Lesions Are Prevalent in Patients With Long Term Continuous-Flow LVAD Support;**
D. Yoshioka1, K. Toda1, T. Nakamura, S. Miyagawa1, Y. Yoshikawa1, S. Fukushima1, S. Saito1, T. Saito2, Y. Sawai1.
Cardiovascular surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan, 2Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

(583) **Device Geometry Does Not Predict Pump Thrombosis in HeartMate II Patients;**
J. J. Han1, A. C. Gaffey1, R. Scooppan1, G. Hung1, C. M. Venkataraman1, E. Phillips1, J. L. Howard1, M. A. Acker1, J. Eduardo Rame1, P. Atur1.
Surgery, University of Pennsylvania, Philadelphia, PA, 2Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, PA

(584) **Left Ventricular Dimension Decrement Index Early After LVAD Implantation: A Novel Risk Marker for Late Pump Thrombosis;**
E. Joyce1, G. C. Stewart1, M. Hickay1, J. Rivero1, J. Gosev2, M. Leach1, M. M. Givertz1, G. S. Couper1, M. R. Mehra1.
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA, 2Division of Cardiac Surgery, Brigham and Women's Hospital, Boston, MA

(585) **Change of Left Atrial Pressure, LAP Measured With a Wireless Implantable Pressure Sensor (Titan Sensor) During Echocardiographic RAMP-Test in HeartMate II Patients;**
L. Hubbert1, J. Baranowski2, B. Delshad1, H. Ahn1.
Department of Cardiology, and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden, 2Department of Clinical Physiology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden, 3Department of Thoracic and Vascular Surgery, and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden

(586) **The Total Artificial Heart (TAH) Experience at Cedar Sinai Medical Center;**
K. J. Koosamalasingh1, A. Kiankhooy1, D. Ramzy1, F. Esmailian1, A. Trento1, J. Morayghi2, J. Kobashigawa1, F. Arabi1.
Cardiothoracic Surgery, Cedar Sinai Medical Center, Los Angeles, CA, 2Cardiology, Cedar Sinai Medical Center, Los Angeles, CA

(587) **Single Center, 23 Year Experience With PFO Management During HeartMate LVAD Implants;**
R. M. Adamson1, W. P. Dembetsy1, K. K. Limmer1, H. Mehta2, B. Jasik1, P. Hoggland1.
Cardiac Surgery, Sharp Memorial Hospital, San Diego, CA, 2Cardiology, Sharp Memorial Hospital, San Diego, CA

(588) **Does Gender Make a Difference After Total Artificial Heart Implantation?**
Cedars-Sinai Heart Institute, Los Angeles, CA
(589) Dental Care in Left Ventricular Assist Devices (LVAD) Patients: A Survey of Dentists;
P. Kamdar1, F. Kamdar2, M. Roettger1, P. Eckman2. 1Primary Dental Care, University of Minnesota, Minneapolis, MN, 2Cardiology, University of Minnesota, Minneapolis, MN

(590) Renal Function Recover With Left Ventricular Assist Device Support;
A. Goodreau1, V. Kasirajan1, L. G. Wolfe1, G. Feldman2, M. A. Quader1. 1Cardio-Thoracic Surgery, Virginia Commonwealth University, Richmond, VA, 2Nephrology, Virginia Commonwealth University, Richmond, VA

(591) Preoperative and Postoperative Renal Dysfunction Is an Important Predictor of Survival After LVAD Implantation;
L. Harvey1, C. Hollley, S. Roy1, K. Majumder1, K. Liao2, P. Eckman2, R. John3. 1Surgery, University of Minnesota, Minneapolis, MN, 2Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, 3Surgery, Division of Cardiovascular Surgery, University of Minnesota, Minneapolis, MN

(592) Gastrointestinal Bleeding and Pump Thrombosis in Patients Receiving the INCOR Left Ventricular Assist Device: Results From a Retrospective Italian Multicenter Study;
A. Iacovoni1, P. Centofanti2, M. Attisani2, A. Verde3, M. Maiani4, A. Barometto1, A. Terzii, U. Livi1, M. Frigerio1, M. Rinaldi1. 1Cardiovascular Department Ospedale Papa Giovanni XXIII, Bergamo, Italy, 2Division of Cardiac Surgery – Città della Salute e della Scienza di Torino, Torino, Italy, 3Cardiothoracic and Vascular Department, Niguarda Ca’ Granda Hospital, Milan, Milano, Italy, 4Cardiothoracic Department, University Hospital, Udine, Udine, Italy

(593) Multidisciplinary Treatment for Acute Fulminant and Nonfulminant Myocarditis;
S. Saito1, K. Toda1, T. Nakamura1, S. Miyagawa1, Y. Yoshikawa1, S. Fukushima1, D. Yoshioaka1, T. Saito1, Y. Tsukamoto2, T. Ueno1, K. Kuratani1, Y. Sakata1, Y. Sawa1. 1Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan, 2Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan

(594) Aortic Valve Interventions: Durability and Morbidity in Patients on Continuous Flow LVAD Support;
J. A. Cowger1, C. Salerno2, F. D. Pagani3, K. D. Aaronson4, F. Billia5, V. Rao6. 1Cardiovascular Medicine, St. Vincent Heart Center of Indiana, Indianapolis, IN, 2Cardiac Surgery, St. Vincent Heart Center of Indiana, Indianapolis, IN, 3Cardiac Surgery, University of Michigan, Ann Arbor, MI, 4Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, 5Cardiovascular Medicine, University of Toronto, Toronto, ON, Canada, 6Cardiac Surgery, University of Toronto, Toronto, ON, Canada

(595) Bilateral Mini-Thoracotomy Versus Association of Upper-Mini-Sternotomy and Left Mini-Thoracotomy for LVAD Implantation: A Propensity Score Analysis;
J. Bejko, T. Bottio, M. Gallo, G. Bortolussi, R. Bianco, V. Tarzia, G. Gerosa. Cardio Surgery, Padova, Italy

(596) Palliative Care Effectively Guides Transition to Inpatient Hospice, Home Hospice or Home Services for End-of-Life Care of LVAD Patients;
S. Nakagawa1, C. Blinderman1, B. Cagliostro1, M. Flannery1, V. K. Topkara2, K. Takeda1, H. Takayama1, Y. Naka1, P. C. Columbus2, M. Yuzefpolskaya3. 1Columbia University, New York, NY, 2Medicine, Columbia University, New York, NY, 3Surgery, Columbia University, New York, NY
(597) Demography and Outcome Data of the Bern VAD-Program Retrieved From the Euromacs Registry; M. Susac1, K. Zuk1, T. M. de By2, B. Gahl3, D. Reineke1, L. Engberger3, B. Hugi-Mayr3, J. Zuber-Zibung1, J. Gummert4, R. Hetzer5, P. J. Mohacsi1, T. Carrel3. 1Cardiology, University Hospital, Bern, Switzerland, 2Euromacs Association, Berlin, Germany, 3Cardiovascular Surgery, University Hospital, Bern, Switzerland, 4Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Ruhr University Bochum, Bad Oeynhausen, Germany, 5German Heart Institute Berlin, Euromacs Association, Berlin, Germany

(598) Does Transvenous Lead Extraction Improve Outcomes for Ventricular Assist Device Patients?; I. Gosev1, M. Maytin2, J. I. Ejiofor1, M. Leacche1, S. McGurk1, R. M. John1, E. Joyce1, G. S. Couper1, L. M. Epstein2, Surgery, Brigham and Women's Hospital, Boston, MA, 3Medicine, Brigham and Women's Hospital, Boston, MA

(599) Extracorporeal Membrane Oxygenation for Concomitant Coronary Artery Bypass Grafting and Lung Transplantation; F. Ius1, W. Sommer1, I. Tudorache1, M. Avsar1, T. Siemen1, J. Saliman1, M. Greer2, J. Puntigam1, M. Hoeper1, J. Gottlieb1, T. Welte2, A. Haverich1, C. Kühn1, G. Warnecke1. 1Department of Cardiothoracic, Transplant and Vascular Surgery, Hanover Medical School, Hanover, Germany, 2Department of Respiratory Medicine, Hanover Medical School, Hanover, Germany

(600) WITHDRAWN


(602) C-Pulse® System Extra-Aortic Counterpulsation for Heart Failure: Driveline Infections and Management; M. S. Slaughter1, R. Cecere2, B. Sun3, S. Huprikar4, H. Hotz5. 1Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY, 2Division of Cardiothoracic Surgery, McGill University Health Center, Montreal, QC, Canada, 3Division of Cardiothoracic Surgery, Minneapolis Heart Institute Foundation, Minneapolis, MN, 4Infectious Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 5Cardiac Surgery, Cardio Centrum Berlin, Berlin, Germany

(603) Pre-Op Renal Failure Is Not Associated With Increased Mortality Following LVAD Implantation; K. R. Balsara1, A. Keith1, A. Abou El Ela1, S. M. Joseph1, G. A. Ewald2, C. S. Silvestry1, A. Itoh1. 1Surgery, Washington University in St Louis, St Louis, MO, 2Medicine, Washington University in St Louis, St Louis, MO

(604) The Use of Cardiac Resynchronization Therapy in Patients Supported By Continuous-Flow Left Ventricular Assist Device; A. R. Garan1, X. Mai1, A. Levine1, V. K. Topkara1, S. S. Thomas2, M. Yuzefpolskaya1, P. C. Colombo1, D. Mancini1, K. Takeda1, H. Takayama1, Y. Naka1, A. Jorde3, N. Uriel4. 1Columbia University, New York, NY, 2Harvard University, Boston, MA, 3Montefiore Medical Center, New York, NY, 4University of Chicago, Chicago, IL

(605) Sensitization and Changes in B Cell Subsets and Inflammatory Cytokines After VAD Implantation; M. H. Kwon1, J. M. Schaenman2, Y. Korin3, P. Rao3, N. Wisniewski2, C. Krystal1, F. Kandarian3, T. Sidwell1, G. Bondar2, M. Cardeiras1, M. C. Deng2, E. F. Reed1. 1Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, 2Immunogenetics Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, 3Immunogenetics Center, David Geffen School of Medicine at UCLA, Los Angeles, CA
Hepatic Function After Long-Term Continuous-Flow Left Ventricular Assist Device Support; J. Han1, K. Takeda1, H. Takayama1, P. A. Kurlansky1, P. C. Colombo2, M. Yuzefpolskaya2, S. Fukuhara1, L. K. Truby1, V. K. Topkara1, D. M. Mancini2, Y. Naka2. 1Department of Surgery, Columbia University Medical Center, New York, NY, 2Department of Medicine, Columbia University Medical Center, New York, NY

Ability to Obtain Blood Pressure Readings By Standard Automated Blood Pressure Monitor Helps Interpreting the Relationship Between Doppler Blood Pressure to Systolic Blood Pressure and Mean Arterial Pressure; P. C. Colombo1, K. Orlanes2, G. Lanier3, M. Yuzefpolskaya1, M. Flannery1, A. S. Shah1, S. D. Russell2, R. J. Tedford2. 1Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, 2Division of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, 3Department of Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD

Development of Pulmonary Hypertension in Patients With Left-Ventricular Assist Devices: Are Frequent Hemodynamic Assessments While on Transplant List Really Necessary?; R. J. Kalathiya1, B. A. Houston2, J. Chaisson1, G. R. Stevens2, C. Sciortino1, G. J. Whitman3, J. Schmitto2, A. Haverich2, D. Willemsen1. 1Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, 2Division of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, 3Department of Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD

The Effect of Exercise and Resistance Training on Physical Capacity of LVAD Patients – Analysis of Different Age Groups; N. Reiss1, P. Bartsch1, M. Altesellmeier1, A. Workowski1, S. Schulte-Eistrup1, H. Warnecke1, J. Schmitto2, A. Haverich2, D. Willemsen1. 1Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany, 2Medizinische Hochschule, Hannover, Germany

Similar Pressure and Volume Unloading With Different Geometrical Changes Between HVAD and HMII Detected During Hemodynamics 3D Echo Ramp Studies; N. Uriel1, G. T. Sayer1, K. Addetia1, S. Fedson1, K. Collins1, G. Kim1, E. Kruse1, G. Juricek1, D. Rodgers1, T. Otza1, V. Jeevanandum2, R. Lang1. 1Medicine, University of Chicago, Chicago, IL, 2Surgery, University of Chicago, Chicago, IL

Outcomes and Predictors of 30-Day and Long-Term Mortality in Case of Cardiopulmonary Resuscitation Requiring Extracorporeal Life Support in the Elderly; M. Pontailler1, P. Demondion, G. Lebreton, P. Leprince. Department of Thoracic & Cardio-Vascular Surgery, Pitié Salpêtrière Hospital, Paris, France

Multidisciplinary Approach to Managing GI Bleeding in the LVAD Population; L. H. Adcock1, A. Yehya2, T. Hrobowski2, K. McCants2, D. A. Dean1, R. Vanda3, P. Stewart1. 1Surgery, Piedmont Heart, Atlanta, GA, 2Advanced Heart Failure, Piedmont Heart, Atlanta, GA, 3Digestive Healthcare of Georgia, Atlanta, GA
(614) **CentriMag Short Term Ventricular Assist Device as a Bridge to Decision in Critical Cardiogenic Shock (INTERMACS 1) – The Manchester Experience;**
S. F. Hashmi, J. Hasan, K. Oommen, S. Shaw, S. G. Williams, N. Yonan, R. V. Venkateswaran. The Transplant Centre, University Hospital of South Manchester, Manchester, United Kingdom

(615) **The Effect of Severity of Renal Dysfunction on Clinical Outcomes in Patients With Continuous-Flow Left Ventricular Assist Device Implantation;**

(616) **Long-Term Ventricular Assist Device vs. Inotropic Therapy as a Bridge to Transplant in Heart Failure Patients With Pulmonary Hypertension and High Pulmonary Vascular Resistance: Pulmonary Hemodynamic and Post-Transplant Outcomes;**
C. Kunavarapu, B. Menchaca, A. Lonnong, M. Lopez, A. Mehr, M. Kwan. Advanced Heart Failure and Transplant, Texas Transplant Institute, San Antonio, TX, Methodist Heart Hospital, San Antonio, TX, Cardiology, University of Texas Health Science Center San Antonio, San Antonio, TX

(617) **Time-Dependent Gene Network Analysis Suggests Orchestrated Stage-Specific PMBC-Response to Injury in Mechanical Circulatory Support Related Organ Dysfunction Syndrome;**
N. Wisniewski, G. Bondar, M. Cadeiras, Y. Korin, J. Schaemen, E. Chang, M. Bakir, J. Chittoo, J. Maque, V. Groysberg, C. Starling, M. Kwon. Department of Medicine (Cardiology), University of California, Los Angeles, CA, Department of Pathology, University of California, Los Angeles, CA, Department of Medicine (Microbiology), University of California, Los Angeles, CA

(618) **Does the Specific Type of Caregiver Impact Readmission After Mechanical Circulatory Support Device Placement?;**

(619) **Simple RVOT Doppler Measurements in Addition to Hemodynamic Variables Can Help Identify Need for RVAD at Time of LVAD Placement;**
A. C. Gaffey, N. Desai, S. F. Lazar, F. H. Mccarthy, J. Han, R. Soopan, C. Venkataraman, K. McDermott, G. Hung, J. Wald, J. Gutscbe, M. A. Acker, P. Attrui, Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, PA, Division of Cardiology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA

(620) **Extracorporeal Membrane Oxygenation Is an Effective Bridge Strategy to Rescue Cardiovascular Collapse for Subsequent Transplant, Ventricular Assist Device, or Recovery;**
A. C. Gaffey, N. Desai, S. F. Lazar, F. H. Mccarthy, J. Han, R. Soopan, C. Venkataraman, K. McDermott, G. Hung, J. Wald, J. Gutscbe, M. A. Acker, P. Attrui, Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, PA, Division of Cardiology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA

(621) **Impella 5.0 as a Bridge to Cardiac Transplantation or Durable Left Ventricular Assist Device;**
S. A. Hall, B. Lima, P. Kale, J. J. Kuiper, S. Carey, E. A. Shafii, T. Chamoegorgakis, G. V. Gonzalez-Stawinski. Baylor University Medical Center, Dallas, TX
Comparison of GI Bleeding Rates Between Axial Flow and Centrifugal Flow LVADs;
F. H. Sheikh1, D. T. Majure1, J. Salcedo2, M. Hofmeyer1, G. Ruiz1, M. E. Rodrigo1, T. Elliott1, E. J. Molina1, S. W. Boyce1, S. S. Najjar1. 1MedStar Heart Institute, Washington, DC, 2MedStar Washington Hospital Center, Washington, DC

Long-Term Valvular Function and Outcomes Following Left Ventricular Assist Device Implantation: Is an Aggressive Approach Warranted?;
E. A. Gillaspie1, S. Dunlay2, S. Sharma1, S. Maltais1, L. D. Joyce1, D. L. Joyce1, R. C. Daly1, J. M. Stulak1. 1Cardiovascular Surgery, Mayo Clinic, Rochester, MN, 2Cardiovascular Diseases, Mayo Clinic, Rochester, MN

Recurrent Ventricular Tachycardia After Implantation of a Left Ventricular Assist Device: Is an Endocardial Ablation an Option?;
J. Fischer1, A. L. Meyer1, S. Lehmann1, S. Eifert1, A. Arya1, G. Hindricks2, F. W. Mohr1, J. Garbade1. 1Cardiac Surgery, University Leipzig Heartcenter, Leipzig, Germany, 2Electrophysiology, University Leipzig Heartcenter, Leipzig, Germany

A Patient-Specific Risk Model for Predicting Major Bleeding, Thromboembolic Events and Mortality After a Continuous Flow Left Ventricular Assist Device (CF-LVAD);
N. A. Loghmanpour1, J. F. Antaki1, P. M. Eckman2. 1Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA, 2Cardiovascular Division, University of Minnesota, Minneapolis, MN

Experience With Temporary RVAD Support in Patients Receiving the HVAD Left Ventricular Assist Device;
A. Schaefer, A. Bernhardt, M. Silaschi, M. J. Barten, F. M. Wagner, R. Reichenspurner, T. Deuse. Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany

Prior Sternotomy Does Not Affect Short and Long-Term Ventricular Assist Device Outcomes;
R. Sooppan1, J. Han1, A. Gaffey1, P. Patel1, G. Hung1, J. Howard1, E. Phillips1, M. Acker1, J. Rame1, P. Atluri1. 1Department of Surgery, University of Pennsylvania, Philadelphia, PA, 2Department of Cardiology, University of Pennsylvania, Philadelphia, PA

Concomitant Surgical Valve Procedures in Patients Undergoing LVAD Implantation;
T. Haberl1, J. Riebandt1, T. Schloeghofer1, S. Mahri1, D. Wiedemann1, K. Dimitrov1, P. Simon1, G. Laufer1, D. Zimpfer1. 1Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 2Center of Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria
Distractions During Lung Transplantation Surgery – Do Interruptions Matter?;
L. P. Ong, S. Kuravelli, S. Chan, N. Collins, T. Butt, S. C. Clark. Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom

Red Wine Consumption Is Linked to Clinical Improvement and Delisting From the Heart Transplant Waiting List;
H. Spaderna1, C. Ziegler2, S. Hellwig3, J. M. Smits4, G. Weidner5. 1Health Psychology, University of Trier, Trier, Germany, 2Health Psychology and Applied Psychological Assessment, University of Wuppertal, Wuppertal, Germany, 3Eurotransplant International Foundation, Leiden, Netherlands, 4Biology, San Francisco State University, San Francisco, CA

WITHDRAWN

Anticoagulation for VAD Patients: Can We Implement an Algorithm for Home Management Safely?;

Variability in Health Care Workers’ Practice Patterns and Heart Transplant Patients’ Medication Adherence Across 11 Countries – The BRIGHT Study;
S. Scalzo de Almeida1, L. Berben1, E. Baumgartner1, K. Denhaerynck2, F. Dobbels3, C. Russell4, S. M. De Geest5. 1Institute of Nursing Science, University of Basel, Basel, Switzerland, 2Health Services Research, KU Leuven, Leuven, Belgium, 3School of Nursing, University of Missouri-Kansas City, Kansas City, MO

Clinical and Gender Differences in Heart Transplant Recipients in the New Heart Study;
K. T. Hickey1, L. V. Doering2, B. Chen3, E. V. Carter4, D. Pickham4, C. Castillo5, D. M. Mancini6, M. Deng7, J. Kobashigawa7, B. J. Drew8. 1Cardiology, Columbia University, New York, NY, 2School of Nursing, University of California, Los Angeles, Los Angeles, CA, 3School of Nursing, University of California, San Francisco, San Francisco, CA, 4Department of Medicine, Stanford School of Medicine, Stanford, CA, 5Department of Medicine, Columbia University, New York, NY, 6Cardiology, Ronald Reagan UCLA Medical Center, Santa Monica, CA, 7Cedars-Sinai Heart Institute, Los Angeles, CA, 8Department of Physiological Nursing, University of California, San Francisco, San Francisco, CA

Parental Role in Care of Long Term Hospitalized Patients and Impact on Attachment and Development;
P. A. Koffin, L. M. Johnson, R. K. Ameduri. Department of Pediatrics, University of Minnesota, Minneapolis, MN

Care After Heart Transplant, No One Better Than Family: Wrong;
A Novel Sternal Instability Assessment Tool for Use Post Lung Transplant: Reliability and Early Results;
L. Fuller1, D. El-Ansary2, B. Button1, J. Bondarenko1, S. Marasco3, J. Gooi4, G. Snell5, A. Holland6. 1Physiotherapy Department, The Alfred Hospital, Melbourne, Australia, 2Physiotherapy Department, The University of Melbourne, Melbourne, Australia, 3Cardiothoracic Surgery Department, The Alfred Hospital, Melbourne, Australia, 4Cardiothoracic Surgery Department, The Alfred Hospital, Melbourne, Australia, 5Lung Transplant Department, The Alfred Hospital, Melbourne, Australia, 6Physiotherapy Department, La-Trobe University, The Alfred Hospital, Melbourne, Australia

Observational Study on Changes in BMI Post Non-CF Lung Transplantation Over a 3 Year Period;
R. Patel, M. Carby, A. Simon, A. Reed. Royal Brompton and Harefield Hospital NHS Trust, Middlesex, United Kingdom

Rate of Conversion From Destination LVAD to Bridge-to-Transplant – A Single Center Experience;
D. Eck, M. A. Wigger. Heart Transplant, Vanderbilt Medical Center, Nashville, TN

Predictors and Outcomes of Sleep Quality the First Year After Lung Transplantation;
A. Fatigati1, M. Alrawashdeh2, A. DeVito Dabbs3, J. Zaldonnis4, C. Bermudez3, 1Acute Care, The University of Pittsburgh, Pittsburgh, PA, 2Acute Care, The University of Pittsburgh School of Nursing, Pittsburgh, PA, 3Division of Cardiothoracic Transplantation, The University of Pittsburgh School of Medicine, Pittsburgh, PA

Factors Associated With Behavioral and Emotional Symptoms in School-Aged Youth After Pediatric Heart Transplantation: Preliminary Findings;
C. White-Williams1, P. Fazeli1, A. Crosswy1, M. Hubbard2, J. Kirklin1. 1University of Alabama, Birmingham, AL, 2Children’s of Alabama Hospital, Birmingham, AL

Quality of Life and Associated Factors in Patients 3 Months After Left Ventricular Assist Device Implantation;
N. Kato1, T. Jaarsma1, I. Okada2, T. Imamura2, Y. Kagami2, M. Endo1, M. Ono2, K. Kinugawa2, 1Social and Welfare Studies, Linköping University, Norrköping, Sweden, 2Therapeutic Strategy for Heart Failure, The University of Tokyo Graduate School of Medicine, Tokyo, Japan

Biological Underpinnings of the Reduction in Heart Failure Symptoms With Mechanical Circulatory Support;
C. S. Lee1, J. O. Mudd1, J. M. Gelow1, C. V. Chien1, S. O. Hiatt1, K. L. Grady2. 1Oregon Health & Science University, Portland, OR, 2Feinberg School of Medicine, Northwestern University, Chicago, IL

Cognitive Functioning Among De Novo Heart Transplant Recipients on Everolimus-Based Immunosuppression;
B. S. Bürker1, S. Andersson1, L. Gullestad2, E. Gude2, A. Relbo2, I. Grov2, U. F. Malt2, A. K. Andreassen2, A. E. Fiane3, I. H. Haraldsen3. 1Department of Psychosomatic Medicine, Oslo University Hospital – Rikshospitalet, Oslo, Norway, 2Department of Cardiology, Oslo University Hospital – Rikshospitalet, Oslo, Norway, 3Department of Research and Education, Oslo University Hospital – Rikshospitalet, Oslo, Norway

A Randomized Controlled Trial to Assess the Effect of Mindfulness Based Stress Reduction (MBSR) on Stress and Anxiety in Caregivers of Lung Transplant Patients;
A. J. Haines1, A. M. Blazecki1, L. Hoffman1, J. Choi, K. Spadaro2. 1Nursing, Acute and Tertiary Care, Univ Pittsburgh Sch Nursing, Pittsburgh, PA, 2Nursing, Chatham University, Pittsburgh, PA
(647) Emotional/Social and Illness-related Factors Influence Eating Behavior in NYHA Class III and IV Heart Failure Patients;
J. Salyer1, M. Flattery2, M. Maltby3, S. Weinland4, K. Shah5. 1Adult Health, VCU School of Nursing & Health System, Richmond, VA, 2Heart Failure/Transplant Program, VCU Health System, Richmond, VA, 3Social Work, VCU Health System, Richmond, VA, 4Psychiatry, MCV School of Medicine & VCU Health System, Richmond, VA, 5Heart Failure/Transplant Program, MCV School of Medicine & VCU Health System, Richmond, VA

(648) Patient/Doctor Talk Time During High-Quality in Advanced Heart Failure Indicative of Doctor’s Perception of How Well Patient Is Doing;
F. Raia1, L. Robinson2, S. Lee1, C. Alvarenga1, V. M. Rivera2, D. Nguyen2, J. S. Mistry1, G. Tellez1, A. Garfinkel1, M. Deng1. 1Education and Medicine, UCLA, Los Angeles, CA, 2Education, UCLA, Los Angeles, CA
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Affiliations</th>
</tr>
</thead>
<tbody>
<tr>
<td>(649)</td>
<td>The Effect of Dornase Alfa (rhDNase) on Recurrent Gram Negative Infections in Adult Cystic Fibrosis Lung Transplant Recipients</td>
<td>L. J. Stuckey, A. M. Clark, S. Chang, K. M. Chan, C. E. Bartos, T. C. Ojo</td>
<td>Pharmacy Services, University of Michigan Hospital and Health Systems, Ann Arbor, MI, College of Pharmacy, University of Michigan, Ann Arbor, MI, Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan Hospital and Health Systems, Ann Arbor, MI, Transplant Center, University of Michigan Hospital and Health Systems, Ann Arbor, MI</td>
</tr>
<tr>
<td>(650)</td>
<td>The Addition of a Specialist Pharmacist to Heart Transplant and Ventricular Assist Device Clinics – Early Trends in Patient Care</td>
<td>R. M. Gellatly, C. Livingstone, P. Bergin</td>
<td>Alfred Hospital, Melbourne, Australia</td>
</tr>
<tr>
<td>(651)</td>
<td>Posaconazole Delayed Release Tablets for Antifungal Prophylaxis in Lung Transplant Patients</td>
<td>J. M. Kozuch, A. A. Feist, G. Yung, L. Awdishu, R. F. Boettger, S. R. Hays</td>
<td>Department of Pharmacy, UC San Diego Health System, San Diego, CA, Division of Pulmonary Critical Care, UC San Diego Health System, San Diego, CA, Department of Pharmacy, University of California, San Francisco Medical Center, San Francisco, CA, Division of Pulmonary Medicine, University of California, San Francisco Medical Center, San Francisco, CA</td>
</tr>
<tr>
<td>(652)</td>
<td>Serial Monitoring of Plasma Voriconazole Levels in Lung Transplant Recipients: Results From a Single Centre Experience</td>
<td>H. Lyster, S. Soresi, N. Leaver, A. Hall, A. Simon, A. Reed, M. Carby</td>
<td>Royal Brompton &amp; Harefield NHS Foundation Trust, Middlesex, United Kingdom</td>
</tr>
<tr>
<td>(653)</td>
<td>Influence of Pantoprazole Dosages on Azole Plasma Concentrations in Lung Transplant Recipients</td>
<td>D. Stelzer, F. Ihle, A. Weber, N. Kneidinger, T. Meis, G. Zimmermann, R. Schramm, H. Winter, L. Frey, M. Vogeser, M. Andraschko, J. Behr, C. Neurohr</td>
<td>Department of Internal Medicine V / Hospital Pharmacy, University of Munich, Munich, Germany, Department of Internal Medicine V, University of Munich, Munich, Germany, Hospital Pharmacy, University of Munich, Munich, Germany, Department of Cardiac Surgery, University of Munich, Munich, Germany, Department of Thoracic Surgery, University of Munich, Munich, Germany, Department of Anesthesiology, University of Munich, Munich, Germany, Institute of Laboratory Medicine, University of Munich, Munich, Germany</td>
</tr>
</tbody>
</table>
Poster presenters and moderators will be present during the evening poster viewing session from 6:00 pm - 7:00 pm.

**ADULT LUNG FAILURE**

(Agora 2)

(LF, BSI, DMD, LTX, MCS)

(655) Clinical Factors Associated With Chronic Lung Allograft Dysfunction (CLAD) in the Swiss Transplant Cohort Study (STCS); A. Koutsokera, C. Benden, P. M. Soccal, J. P. Antonietti, L. P. Nicod, J. D. Aubert, 1Respiratory Medicine Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, 2Division of Pulmonary Medicine, University Hospital Zurich, Zurich, Switzerland, 3Respiratory Medicine Department, University Hospital of Geneva (HUG), Geneva, Switzerland, 4Respiratory Medicine Department, Centre Hospitalier Universitaire Vaudois (CHUV) and SysCLAD (Systems Prediction of Chronic Lung Allograft Dysfunction) Study, Lausanne, Switzerland, 5Respiratory Medicine Department, Centre Hospitalier Universitaire Vaudois (CHUV) and Swiss Transplant Cohort Study (STCS), Lausanne, Switzerland


(657) Aerosolized Liposomal Cyclosporine A in the Prevention of Bronchiolitis Obliterans Syndrome Following Lung Transplantation; C. Neurohr, V. Monforte, C. Knoop, P. Jaksh, J. Parmar, P. Ussetti, A. Sole, J. M. Müller-Quernheim, J. Borro, R. Kessler, H. Wirtz, J. Behr, 1Department of Internal Medicine V, University of Munich - Campus Grosshadern, Munich, Germany, 2Hospital Universitari Vall d’Hebron, Barcelona, Spain, 3Université Libre de Bruxelles, Brussels, Belgium, 4University of Vienna, Vienna, Austria, 5Papworth Hospital, Papworth, United Kingdom, 6University Puerta de Hierro, Madrid, Spain, 7Hospital Universitario La Fe, Valencia, Spain, 8Medical University Hospital, Freiburg, Germany, 9Complejo Hospitalario Universitario, La Coruna, Spain, 10Hospitaux Universitaires de Strasbourg, Strasbourg, France, 11Medical University Leipzig, Leipzig, Germany

(658) Incidence, Management, and Outcome of Non-Anastomotic Stenoses After Lung Transplantation; N. M. Mollberg, E. Howell, A. Cheng, M. S. Mulligan, University of Washington, Seattle, WA

(659) Survival After Lung Transplant in Alpha-1-Antitrypsin Deficiency Recipients Compared to Other Forms of Chronic Obstructive Pulmonary Disease; B. C. Gulack, A. M. Ganapathi, P. J. Speicher, G. Cherry, L. D. Snyder, R. D. Davis, M. G. Hartwig, 1Department of General Surgery, Duke University, Durham, NC, 2Duke University, Durham, NC, 3Department of Medicine, Duke University, Durham, NC
(669) Combined Lung-Kidney Transplantation: An Analysis of the UNOS/OPTN Database;
H. J. Reich¹, J. L. Chan², L. Czer³, J. Mirocha⁴, A. Annamalai⁵, W. Cheng⁶, S. C. Jordan⁷, G. Chaux⁸, D. Ramzy⁹, ¹Surgery, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ²Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, ³Cardiology, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Biostatistics and Bioinformatics, Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Cardiothoracic Surgery, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Nephrology, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Pulmonology and Critical Care, Lung Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

ADULT LUNG TRANSPLANT

(Agora 2)

(670) Assessment of Human Lungs Recovered From Uncontrolled Donation After Circulatory Determination of Death (uDCDD) Donors By Ex-Vivo Lung Perfusion (EVLP) and CT Scan;

(671) Enhanced Donor Organ Quality Assurance Using Novel Point-of-View Video Streaming Technology During Harvesting;
A. C. Baldwin¹, H. R. Mallidi², E. Sandoval², W. E. Cohn², G. Dranavalli⁴, A. D. Parulekar⁴, S. K. Singh². ¹Surgery, Yale School of Medicine, New Haven, CT, ²Transplant and Assist Devices, Baylor College of Medicine, Houston, TX, ³Cardiothoracic Transplant, Texas Heart Institute, Houston, TX, ⁴Pulmonary Medicine and Pulmonary Transplant, Baylor College of Medicine, Houston, TX

(672) Long-Term Outcome After Lung Transplantation Is Comparable Between Brain-Dead and Cardiac-Dead Donors;

(673) Surgical Strategy for Small Adult Chests in Lung Transplantation; Lobar vs. Standard Using a Pediatric Donor;

(674) Survival of Single Lung Transplant Recipients in 50 – 64 Year Age Group;
N. Sinha¹, M. Loebel¹, S. Scheinin¹, T. Kaleekal², B. Mankidy¹, S. Jyothula¹, B. Bruckner¹, D. Ren¹, H. Seetharamaju¹, L. Teeter¹, E. Suarez², A. Gaber³, ¹Pulmonary Transplant, Houston Methodist Hospital, Houston, TX, ²Thoracic Surgery, Houston Methodist Hospital, Houston, TX, ³Pulmonary, Newark Beth Israel Medical Center, Newark, NJ, ⁴Biostatistics, Houston Methodist Hospital, Houston, TX, ⁵JC Walter Jr Transplant Center, Houston Methodist Hospital, Houston, TX
Heart Failure With Preserved Ejection Fraction Is Not Associated With Increased Mortality After Lung Transplantation; R. J. Cogswell, M. Hertz. 1Cardiology, University of Minnesota Division of Cardiology, Minneapolis, MN, 2Pulmonary and Critical Care, University of Minnesota, Minneapolis, MN

The Changing Lung Transplant Candidate in the Post-LAS Era; C. J. Gries, V. Singh, M. George, J. M. Pilewski. 1Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, 2Medicine, University of Pittsburgh, Pittsburgh, PA

The South Australian Lung Transplant Unit – Outcomes From a Satellite Centre; M. X. Wong, A. Yeo, L. Sultan, M. Kelly, A. R. Glanville, M. Holmes, C. Holmes-Liew. 1South Australian Lung Transplant Unit, Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, Australia, 2Lung Transplant Service, Alfred Hospital, Melbourne, Australia, 3Lung Transplant Unit, St Vincent’s Hospital, Darlinghurst, Australia

Impact of Age and BMI on Survival in Lung Transplant Recipients; M. Latran, K. Lane, C. Shen, M. Baz, M. Duncan, C. Hage, D. Roe, Z. Hashmi, T. Wozniak, I. Wang. 1Pharmacy, Indiana University Health, Indianapolis, IN, 2Biostatistics, Indiana University School of Medicine, Indianapolis, IN, 3Pulmonary Critical Care, Indiana University Health, Indianapolis, IN, 4Transplant Surgery, Indiana University Health, Indianapolis, IN

Evaluation of Sarcopenia in Lung Transplant Candidates; D. Rozenberg, S. Mathur, L. Wickerson, N. A. Chowdhury, L. G. Singer. 1Medicine, Division of Respirology, Toronto Lung Transplant Program, University of Toronto and Toronto General Hospital, Toronto, ON, Canada, 2Physical Therapy, University of Toronto, Toronto, ON, Canada, 3Physical Therapy and Toronto Lung Transplant Program, University of Toronto and Toronto General Hospital, Toronto, ON, Canada

Factors Predicting Survival in Early Lung Retransplantation; A. A. Osho, S. A. Hirji, B. C. Gulack, A. M. Ganapathi, R. D. Davis, M. G. Hartwig. 1Department of Surgery, Massachusetts General Hospital, Boston, MA, 2Department of Surgery, Duke University Medical Center, Durham, NC, 3Department of Surgery, Duke University Medical Center, Durham, NC


Oropharyngeal Dysphagia and Aspiration After Lung Transplantation in the Current Era; R. Murthy, D. Williams, S. Kinnebrew, J. Waters, F. Torres, V. Kaza, W. S. Ring, M. Wait, M. Petz. 1Cardiothoracic Surgery, UT Southwestern Medical Center, Dallas, TX, 2Speech Therapy, UT Southwestern Medical Center, Dallas, TX, 3General Surgery, UT Southwestern Medical Center, Dallas, TX, 4Internal Medicine, UT Southwestern Medical Center, Dallas, TX
(684) AA Does Not Effect Neither 5YS Nor LOS;
T. Floreth1, M. P. Davila2, S. Mabbott3, M. Rolfe1. 1New Lung
Associates, Tampa, FL, 2Tampa General Hospital, Tampa, FL

(685) Methotrexate as a Treatment Strategy for Bronchiolitis
Obliterans Syndrome (BOS);
S. Sithamparanathan, L. Thirugnanasothy, K. Morley, A. J. Fisher, J.
L. Lordan, G. Meachery, G. Parry, P. Corris. Institute of Trans-
plantation, Freeman Hospital, The Newcastle upon Tyne NHS
Foundation Trust, Newcastle, United Kingdom

(686) Large Airway Oximetry and Hypoxia Related Gene
Expression in Bronchial Epithelium in Early Post-Lung
Transplantation;
S. Shofer1, B. Kraft1, M. Hartwig2, C. Piantadosi1. 1Pulmonary, Al-
lergy, and Critical Care, Duke University Medical Center, Durham,
NC, 2Thoracic Surgery, Duke University Medical Center, Durham,
NC

(687) Effect of Center Volume on Survival After Lung
Re-Transplantation;
A. J. Hayanga1, T. Vlahu2, J. D’Cunha3, H. K. Hayanga4, R. Girgis1, A.
Khalghani1. 1Cardiothoracic Surgery, Spectrum Health – Michigan
State University, Grand Rapids, MI, 2Cardiothoracic Surgery, Spectr-
um Health, Grand Rapids, MI, 3Cardiothoracic Surgery, University
of Pittsburgh Medical Center, Pittsburgh, PA, 4Cardiac Anesthesi-
ology, Johns Hopkins Medical Institutions, Baltimore, MD

(688) Perioperative ECMO Use in Lung Transplantation for
Severe Pulmonary Hypertension;
I. Tudorache1, W. Sommer1, F. Ius1, C. Kühn1, O. Wiesner2, J.
Hadem3, T. Führer3, M. Avsar4, N. Schwerk5, D. Böthig2, J. Gottlieb2,
T. Welte2, C. Bara1, A. Haverich1, M. Höper2, G. Warnecke1. 1Cardiac,
Thoracic, Transplantation and Vascular Surgery, Hannover Medical
School, Hannover, Germany, 2Pulmonology, Hannover Medical
School, Hannover, Germany, 3Department of Pediatric Pul-
monology, Hannover Medical School, Hannover, Germany

(689) Clinical Prediction Model for PGD Among Patients
With Pulmonary Hypertension;
M. Porteous1, D. J. Lederer3, S. M. Palmer2, E. Cantu4, R. J. Shah1, S.
Bellamy2, V. N. Lama1, S. M. Bhorade1, M. M. Crespo6, K. M. Wille3,
A. Localio1, J. B. Orens10, P. D. Shah10, A. B. Weinacker11, S. Arca-
soy4, D. S. Wilkes12, J. D. Christie1, S. M. Kawut1, J. M. Diamond1.
1Medicine, University of Pennsylvania, Philadelphia, PA, 2Medicine,
Columbia University Medical Center, New York, NY, 3Medicine,
Duke University, Durham, NC, 4Surgery, University of Pennsylva-
nia, Philadelphia, PA, 5Medicine, University of Pennsylvania, Philadelphia, PA,
6Medicine, University of Michigan Health System, Ann Arbor, MI, 7Medic-
ine, Northwestern University, Chicago, IL, 8Medicine, Uni-
versity of Pittsburgh Medical Center, Pittsburgh, PA, 9Medicine,
University of Alabama at Birmingham, Birmingham, AL, 10Med-
icine, Johns Hopkins University, Baltimore, MD, 11Medicine, Stanford
University Medical Center, Stanford, CA, 12Medicine, Indiana Uni-
versity, Indianapolis, IN

(690) Intraoperative Cardiopulmonary Support With
Extracorporeal Membrane Oxygenation in Lung
Transplantation: Favorable Outcomes in High Risk Patients;
F. Ius1, W. Sommer1, I. Tudorache1, M. Avsar2, T. Siemeni1, J. Salmon1,
M. Greer2, J. Optenhöfel1, M. Hooe2, J. Gottlieb2, T. Welte2, A.
Haverich1, C. Kühn1, G. Warnecke1. Department of Cardiothoracic,
Transplant and Vascular Surgery, Hanover Medical School,
Hanover, Germany, 2Department of Respiratory Medicine, Hanover
Medical School, Hanover, Germany

(691) Neutropenia Following Lung Transplantation;
D. Rosengarten, M. Fakterman, Y. Raviv, V. Rusano, B. D. Fox, M.
R. Kramer. Pulmonary Institute, Rabin Medical Center, Petach
 tikva, Israel

(693) Update on the Outcomes of Lung Transplantation After Hematopoietic Stem Cell Transplantation: A Single-Center Experience; S. Sugimoto, T. Oto, M. Okada, N. Iga, K. Miyoshi, M. Yamane, S. Miyoshi. General Thoracic Surgery, Okayama University Hospital, Okayama, Japan

(694) CLAD Is Different Down Under!; M. Malouf1, M. Harkess1, A. Middleton1, S. Yerkovich2, M. Benzmira1, A. Havryk1, M. Pitt1, P. Hopkins2, D. Chambers2, A. R. Glanville1, 1Lung Transplant Unit, St. Vincent’s Hospital, Sydney, Australia, 2Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia

(695) Is Systemic Lupus Erythematosus (SLE) Related Lung Disease a Contraindication to Lung Transplantation?; E. L. Bush1, H. Faust2, J. Lee3, J. Singer4, S. Hays5, L. Leard6, M. E. Kleinhenz7, G. Dincheva1, M. Brzezinski1, G. Wieseltahir1, C. W. Hoopes8, J. A. Golden9, J. Kukreja10. 1Division of Cardiothoracic Surgery, Univ California, San Fran, San Francisco, CA, 2Division of Pulmonary and Critical Care, Univ California, San Fran, San Francisco, CA, 3Department of Anesthesia, Univ California, San Fran, San Francisco, CA, 4Division of Cardiothoracic Surgery, University of Kentucky, Lexington, KY

(696) Lung Transplant (LT) for Non-Scleroderma Connective Tissue Lung Disease (NS-CTLD): Wasting a Precious Commodity?; J. Kukreja1, E. L. Bush1, C. W. Hoopes2, G. Dincheva1, M. Brzezinski9, J. Lee10, M. Kleinhenz11, L. Leard12, S. Hays13, J. Golden14, J. Singer15. 1Cardiothoracic Surgery, Univ of California, San Francisco, CA, 2Cardiothoracic Surgery, Univ of Kentucky, Lexington, KY, 3Anesthesi, San Francisco Veterans Administration Hospital, San Francisco, CA, 4Medicine, Univ of California, San Francisco, CA

(697) Lung Transplantation in Patients with Acute Exacerbations of Idiopathic Pulmonary Fibrosis: A Single Center Experience; L. Mudambi1, M. Pendurthi1, B. Mankidy2, N. Sinha2, S. Jyothula2, S. Scheinin2, B. Bruckner2, M. Fenton4, K. B. Jackson1, D. C. Lien1. 1Cardiothoracic Surgery, Univ of California, San Francisco, CA, 2Cardiothoracic Surgery, University of Kentucky, Lexington, KY, 3Anesthesi, San Francisco Veterans Administration Hospital, San Francisco, CA, 4Medicine, Univer- sity of Saskatchewan, Saskatoon, SK, Canada

(698) Effects of Coronary Artery Disease on Lung Transplantation; J. G. Weinkauf1, K. Halloran1, A. Kapasi1, R. A. Varughese2, J. Mullen3, S. Meyer4, J. Nagendran1, D. Freed5, B. Laing5, D. Helmersen6, M. Thakrar7, M. Fenton6, K. B. Jackson6, D. C. Lien1. 1Medicine, University of Alberta, Edmonton, AB, Canada, 2Medicine, University of Calgary, Calgary, AB, Canada, 3Surgery, University of Alberta, Edmonton, AB, Canada, 4Medicine, University of Saskatchewan, Saskatoon, SK, Canada

(700) Extracorporeal Membrane Oxygenation for Severe Primary Graft Dysfunction After Lung Transplantation: Short- and Long-Term Outcome and Quality of Life; H. Buscher1, A. Gianville2, C. Lee1, A. Jackson3, P. Nair4, M. Gopalakrishnan4. 1Intensive Care Medicine, St Vincent’s Hospital, Sydney, Australia, 2Lung Transplantation, St Vincent’s Hospital, Sydney, Australia, 3Anaesthesia, St Vincent’s Hospital, Sydney, Australia, 4Intensive care Medicine, St Vincent’s Hospital, Sydney, Australia

(701) Profiling of Peripheral Blood Mononuclear Cells Does Not Accurately Predict the Bronchiolitis Obliterans Syndrome After Lung Transplantation; K. Budding1, E. A. van de Graaf2, A. W. Paantjens1, T. Kardol-Hoenagel1, J. M. Kwakkel-van Erp1, D. A. van Kessel1, H. G. Otten1. 1Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Department of Respiratory Medicine, University Medical Center Utrecht, Utrecht, Netherlands, 3Center of Interstitial Lung Diseases, St Antonius Hospital Nieuwegein, Nieuwegein, Netherlands

(702) Donor, Recipient and Operative Variables Affect the Time Taken to Reach ‘Best’ Lung Function Following Transplantation; J. Fuller1, M. Paraskeva2, B. Borg1, J. Rolland1, G. Snell2, G. Westall2. 1Monash University, Melbourne, Australia, 2Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne, Australia, 3Allergy Laboratory, Monash University, Melbourne, Australia

(703) Analysis of a Modified Cytomegalovirus (CMV) Monitoring Algorithm for CMV Seropositive Lung Transplant Recipients; K. E. Schoeppler1, D. M. Lyu2, J. T. Crossno, Jr2, T. J. Grazia3, K. M. Vanderwest2, M. R. Zamora2. 1Pharmacy, University of Colorado Hospital, Aurora, CO, 2Pulmonary and Critical Care Medicine, University of Colorado School of Medicine, Aurora, CO

(704) Characteristics of De Novo Donor-Specific Anti-HLA Antibodies (DSAs) in Living-Donor Lobar Lung Transplantation Might Be Different From Those in Cadaveric Lung Transplantation; T. Kondo, F. Chen, M. Takahashi, K. Ohata, K. Hijiya, H. Motoyama, S. Tanaka, E. Miyamoto, T. Yamada, M. Sato, A. Aoyama, H. Date. Thoracic Surgery, Kyoto University, Kyoto, Japan

(705) Phrenic Nerve Injury During Lung Transplantation Increases Operative Morbidity and Reduces Survival; V. Aguirre Gutierrez, F. Rosenfeldt, A. Zimmet, S. Marasco, G. Westall. Cardiothoracic Unit, Alfred Hospital, Prahran, Australia

(706) Kinetics of Peripheral Blood Lymphocyte Subsets in Lung Transplant Recipients; B. Coiffard1, M. Pelardy2, C. Gomez3, A. Loudoun1, C. Brunet1, B. Coltey1, N. Dufeu1, P. Thomas1, M. Reynaud-Gaubert1. 1Department of Respiratory Medicine, Thoracic Surgery and Lung Transplantation, Assistance Publique – Hôpitaux de Marseille (AP-HM), Hôpital Nord, Marseille, France, 2Laboratory of Haematology, Assistance Publique – Hôpitaux de Marseille (AP-HM), Hôpital La Conception, Marseille, France, 3Laboratory of Haematology, Assistance Publique – Hôpitaux de Marseille (AP-HM), Hôpital La Conception, Marseille, France

(707) An Innovative Everolimus-Based Quadruple Low Immunosuppressive Regimen Compared to Standard Triple Regimen in Lung Transplant Recipients and Its Impact on Renal Function, Safety and Efficacy: The 4EVERLUNG Study Design; J. Gottlieb1, C. Neurohr1, J. Müller-Quernheim1, H. Wirtz1, T. Deuse1, U. Sommerwerck1, C. Knoßalla1, C. Wütt1, P. Wimmer1, M. Porstner2, M. Strüber1. 1EverLung Study Team, Germany, Germany, 2Novartis Pharma GmbH, Nuremberg, Germany
Prevalence of Acute and Chronic Renal Failure After Lung Transplantation;
A. Monnier1, T. Krummel1, O. Collange2, G. Haffner2, S. Hirschli, T. Dégo2, T. Hannedouche1, R. Kessler2. 1Nephrology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, 2Intensive Care Unit, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, 3Pneumology, Lung Transplantation Group, Hôpitaux Universitaires de Strasbourg, Strasbourg, France

Mast Cell Phenotypes in the Allograft After Lung Transplantation;
A. Banga1, N. G. Narula2, M. M. Budev3, X. Wang2, F. Hsieh3. 1Lung Transplant Program, Division of Pulmonary & Critical Care Medicine, UT Southwestern Medical Center, Dallas, TX, 2Medicine, Mayo Clinic, Jacksonville, FL, 3Cleveland Clinic, Cleveland, OH

Do We Really Need to Rush? Early and Mid Term Results of Lung Transplantation (Ltx) of Organs With Total Ischemic Time (ITT) Over 8 Hours – A Propensity Score Matched, Single-Center Analysis;

Does Lung Implantation By a Resident Affect Short-Term Outcomes?
D. Williams1, R. Murthy1, J. Waters2, J. M. DiMaio3, W. S. Ring1, M. Peltz1, M. Wait1. 1Cardiovascular and Thoracic Surgery, UT-Southwestern, Dallas, TX, 2General Surgery, UT-Southwestern, Dallas, TX, 3SpectralMD, Dallas, TX

Bile Acid in Bronchial Wash as a Useful Biomarker of Aspiration to Determine the Suitability of Donor Lungs for Transplantation;
D. Nakajima, S. Azad, T. Saito, T. K. Waddell, L. G. Singer, M. Liu, M. Cypel, S. Keshavjee. Toronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada

Optical Headmounted Wearable Technology in Heart and Lung Organ Procurement;
A. A. Rahim1, H. M. Mentis2, E. L. Bush1, J. Kukreja1, G. M. Wieselthaler1, P. R. Theodore1. 1Department of Surgery, University of California San Francisco, San Francisco, CA, 2Department of Information Systems, University of Maryland, Baltimore County, Baltimore, MD

Donation After Circulatory Death Mitigates the Deleterious Effects of Severe Primary Graft Dysfunction After Lung Transplantation;
L. A. Teeuwen1, E. A. Verschuren2, C. van de Wauwer3, M. Mariani1, V. Cernak1, A. O. Oude-Lansink1, M. E. Erasmus1, W. van der Bij1. 1Department of Cardiothoracic Surgery, University Medical Centre Groningen, Groningen, Netherlands, 2Department of Internal Medicine, University Medical Centre Groningen, Groningen, Netherlands, 3Department of Anesthesiology, University Medical Centre Groningen, Groningen, Netherlands, 4Department of Critical Care, University Medical Centre Groningen, Groningen, Netherlands

Safety and Efficacy of a Protocol for Monitoring Self-Expanding Metal Stents in Post Lung Transplant Central Airway Stenosis;
B. J. Mankidy1, J. K. Thachuthara-George2, M. Pendurthi2, T. Kaleeakal1, S. Jyothula1, N. Sinha1, H. Seetharamaju1, S. Scheinbin1, B. Bruckner1, M. Loebe2. 1Internal Medicine, Houston Methodist Hospital, Houston, TX, 2Internal Medicine, 740 S Limestone, Lexington, KY, 3Cardiovascular and Thoracic Surgery, Houston Methodist Hospital, Houston, TX
(717) Transplantation After Ex-Vivo Lung Perfusion: An Early Follow-Up;
1Dep. of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden, 2Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden, 3Dep. of Anesthesiology and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden, 4Dep. of Cardiothoracic surgery, Sahlgrenska University Hospital, Gothenburg, Sweden

(718) A Pilot Study of a Novel Dry Powder Tobramycin Inhaler in Cystic Fibrosis (CF) Patients Post Lung Transplantation (LTx);
S. Ivulich1, S. Fisher1, S. Maleki1, B. Levey2, M. Paraskeva2, G. Snell2.
1Department of Pharmacy, Alfred Hospital, Melbourne, Australia, 2Lung Transplant Service, Alfred Hospital, Melbourne, Australia

(719) Autoantibodies (Non-MHC Antibodies) in a Mouse Model of Chronic Rejection: Profiling By Antigen Microarrays;
Multiorgan Transplant, University of Toronto, Toronto, ON, Canada

(720) Combination Therapy Using Imatinib and Vatalanib Improves the Long-Term Outcome After Rat Lung Transplantation;
M. von Suesskind, L. Keil, C. Schmid, S. W. Hirt, K. Lehle. Cardiothoracic Surgery, University medical Center, Regensburg, Regensburg, Germany

(721) VEGF-B Overexpression Enhances Ischemia-Reperfusion Injury and the Innate Immune Response in Rat Heart Transplants;
A. Raissadati1, R. Tuuminen1, A. Dashkevich1, S. Syrjälä1, R. Arnaudova1, E. Rouvinen1, M. Keränien1, R. Krebs1, K. Alitalo2, A. Nykänen1, K. Lemström1. 1University of Helsinki, Transplantation Laboratory, Haartman Institute and Helsinki University Central Hospital, Cardiac Surgery, Heart and Lung Center, Helsinki, Finland, 2Molecular/Cancer Biology Program, Institute for Molecular Medicine Finland and Helsinki University Central Hospital, Research Programs Unit, Biomedicalum Helsinki, University of Helsinki, Helsinki, Finland

(722) Treatment With Donor Specific Alloantigen and Anti-CD4 mAb 3 Days After Lung Transplantation Differentially Affects Putative Effector and Regulatory T Cell Populations;
J. Hahn1, K. Jansson1, W. Sommer1, M. Aysari1, T. Siemen1, J. Salman1, A. Knoefel1, B. Schröder2, A. Haverich1, G. Warnecke1.
1Heart-, Thoracic-, Transplantation- and Vascular Surgery, Hannover Medical School, Hannover, Germany, 2Veterinary School of Medicine, Hannover, Germany

(723) IL-25 Attenuates Obliterative Bronchiolitis By Regulating the Polarization of Macrophages in Marine Orthotopic Tracheal Transplantation Models;
X. Zhou1, J. Liu2, Q. Meng1, J. Li1, Z. Guo2, Z. Liu2, H. Fan2. 1Institute of Heart Failure, Shanghai East Hospital, Tongji University, Shanghai, China, 2Department of Heart Failure, Shanghai East Hospital, Tongji University, Shanghai, China


Histone Deacetylase 2 is Decreased in Peripheral Blood Cytotoxic/Pro-Inflammatory CD8+ T and NK1.1-Like Lymphocytes Following Lung Transplant; G. Hodge. Royal Adelaide Hospital, Adelaide, Australia

The Impact of Perfusate Oxygenation During Ex-Vivo Lung Perfusion on Post-transplant Outcomes: Deoxygenated vs. Fully-Oxygenated; K. Noda, S. Haam, J. D’Cunha, J. D. Luketich, C. A. Bermudez, N. Shigemira. Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

Histone Deacetylase 2 is Decreased in Peripheral Blood Cytotoxic/Pro-Inflammatory CD8+ T and NK1.1-Like Lymphocytes Following Lung Transplant; G. Hodge. Royal Adelaide Hospital, Adelaide, Australia

A Modified Biventricular Working Heterotopic Rat Heart Transplant Model With Pressure Volume Loops Cardiac Function Analysis; W. Oriyanhan, D. D’Alessandro, R. Bello, Y. Xia, M. Follis, G. Moreno, R. Michler. Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY

PDGF-B Is Protective During Ischemia-Reperfusion Injury in Rat Cardiac Allografts; A. Dashkevich, R. Tuuminen, M. Keränen, A. Raisaadi, R. Krögel, T. Jokkinen, S. Ylä-Herttuala, A. Nykanen, K. Lennström. 1LMU Medical Centre LMU Medical Centre, Munich, Germany, 2Haartman Institute, University of Helsinki, Helsinki, Finland, 3University of Eastern Finland, Kuopio, Finland

Mitochondrial Calcium: The Missing Link Between Hypoxia and Quality in Lung Grafts During Ex-Vivo Lung Perfusion; K. Noda, S. Haam, J. D’Cunha, J. D. Luketich, C. A. Bermudez, N. Shigemira. Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA

Cardiac Troponin I Levels in Preservation Solution Predict Primary Graft Dysfunction After Heart Transplant; M. A. Schechter, K. W. Southeter, M. J. Watson, B. J. Feger, R. Mishra, J. N. Schroder, L. R. Dibernardo, M. Kuchibhatla, M. A. Daneshmand, C. B. Patel, J. G. Rogers, C. A. Milano, D. E. Bowles. 1Surgery, Duke, Durham, NC; 2Pathology, Duke, Durham, NC; 3Biostatistics and Bioinformatics, Duke, Durham, NC; 4Division of Cardiology, Department of Medicine, Duke, Durham, NC

Circulating Histone-Induced Lung Injury: A Novel Model of Damaged Lungs From Brain-Dead Donors; T. Murayama, M. Anraku, T. Murakawa, T. Yoshikawa, M. Inui, N. Hiyama, M. Kawashima, T. Tsuchiya, J. Ichinose, H. Hino, K. Nagayama, J. Nitadori, K. Kakimi, J. Nakajima. 1Thoracic Surgery, The University of Tokyo, Bunkyo ku, Japan; 2Immunotherapeutics, The University of Tokyo, Bunkyo ku, Japan
Acute Hyperglycemia Exacerbates Ischemia-Reperfusion Injury of the Lung By Activating TLR4 Signaling Pathway; M. Takahashi, F. Chen, T. Menju, K. Ohata, T. Kondo, H. Motoyama, K. Hijiya, T. Yamada, M. Sato, A. Aoyama, H. Date. Department of Thoracic Surgery, Kyoto University, Graduate School of Medicine, Kyoto, Japan

Impact of Initial Acidic Reperfusion on the Functional Recovery of DCD Hearts During Ex-Vivo Heart Perfusion; C. W. White1, E. Ambrose2, A. Müller2, J. Thliveris3, R. C. Arora1, G. Tian1, J. Nagendran1, L. V. Hryshko1, D. H. Freed3. 1Cardiac Surgery, University of Manitoba, Winnipeg, MB, Canada, 2Institute of Cardiovascular Sciences, St. Boniface Research Center, Winnipeg, MB, Canada, 3Human Anatomy and Cell Science, University of Manitoba, Winnipeg, MB, Canada, 1Institute for Biodiagnostics, National Research Council Canada, Winnipeg, MB, Canada, 2Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB, Canada.

Determination of Optimum Ventilation Strategy for Ex-Vivo Lung Perfusion: Comparing Negative and Positive Pressure Ventilation; K. Nelson1, S. M. Black2, E. Eren3, D. Hayes, Jr.4, C. Dumond5, S. Bennett5, S. Ghadiali6, B. A. Whiston6. 1Department of Biomedical Engineering, The Ohio State University, Columbus, OH, 2Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, 3University of Toledo, Toledo, OH, 4Department of Pediatrics, Nationwide Children’s Hospital, Columbus, OH


Hypoxic Pulmonary Vasoconstriction Is a More Accurate Parameter Than P/F Ratio to Measure Lung Function on Ex-Vivo Lung Perfusion; A. F. Alzamil1, S. Hatami1, C. W. White2, N. S. Aboelnazar1, S. Bozzo2, V. Vasanthan2, D. H. Freed2, J. Nagendran4. 1Department of Surgery, University of Alberta, Edmonton, AB, Canada, 2Cardiac Surgery, University of Manitoba, Winnipeg, MB, Canada, 3Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, 4Cardiac Surgery, University of Alberta, Edmonton, AB, Canada

Telomere Integrity as a Genetic Marker of Effective Treatment for Advanced Heart Failure; C. M. Statz1, J. Brown2, A. M. Ras3, K. D. Ballard4, D. Desai1, D. Fusco1, J. Hammond1, J. A. Gluck1, D. Wencker1. 1Cardiology, Hartford Hospital, Hartford, CT, 2Allied Health Sciences, University of Connecticut, Storrs, CT, 3Molecular and Cell Biology, University of Connecticut, Storrs, CT, 4Center for Advanced Heart Failure and Transplant, University of Kansas Medical Center, Kansas City, KS

Carbon Monoxide Attenuates Hyperacute Dysfunction and Microangiopathy in GalT-KO Pulmonary Xenotransplantation; H. Sahara1, H. Nagashima2, M. Sekijima1, K. Miura1, A. Kawai1, S. Waki1, K. Nakano1, H. Matsunari1, A. Shimizu1, K. Yamada1. 1Center for Advanced Biomedical Science and Swine Research, Kagoshima University, Kagoshima, Japan, 2Department of Life Sciences, School of Agriculture, Meiji University, Kawasaki, Japan

Xenogeneic glycans: Human Antibody Reactivity and Their Impact on Xenograft Rejection; G. W. Byrne1, Y. Lin2, Z. Du3, H. Kogelberg2, C. McGregor1. 1Cardiovascular Science, University College London, London, United Kingdom, 2Department of Surgery, Mayo Clinic, Rochester, MN

Moved to Mini Oral Session 12
(743) **Immunosuppression Using CD40 Costimulation Blockade in a Preclinical Cardiac Xenotransplantation Model;**

J. Abicht, T. Mayer, S. Guethoff, F. Werner, I. Lutzmann, M. C. Langenmayer, E. Wolf, D. Ayares, K. Reimann, B. Reichart, P. Brenner. 1Department of Anaesthesiology (LMU), Munich, Germany, 2Department of Cardiac Surgery (LMU), Munich, Germany, 3Department of Veterinary Pathology (LMU), Munich, Germany, 4Department of Molecular Animal Breeding and Biotechnology (LMU), Munich, Germany, 5Revivicor Inc., Blacksburg, VA, 6MassBiologics, University of Massachusetts, Boston, MA, 7Walter-Brendel-Centre (LMU), Munich, Germany

(744) WITHDRAWN

(745) **MicroRNA Expression Pattern in Patients with Ventricular Tachycardia and End-Stage Heart Failure;**

T. Calway, T. Bak, G. H. Kim, University of Chicago, Chicago, IL

(746) **Ex-Vivo Delivery of Inhaled Hydrogen Gas to the Donor Lung Ameliorates Post-Transplant Lung Injury in Pigs;**


(747) **The Heterotopic Thoracic Cardiac Xenotransplantation Model (Pig-to-Baboon): Results With and Without a Myelodepressive Protocol;**

P. Brenner, J. Abicht, S. Guethoff, S. Buchholz, T. Mayer, A. Bauer, S. Blanck, B. Kessler, E. Wolf, C. Becker, D. Ayares, C. Belka, C. Haql, B. Reichart. 1Dept. of Cardiac Surgery, University of Munich (LMU), Munich, Germany, 2Dept. of Anesthesiology, University of Munich, Munich, Germany, 3Dept. of Cardiac Surgery, University of Munich, Munich, Germany, 4Dept. of Anesthesiology, University of Munich, Munich, Germany, 5Walter-Brendel-Centre, University of Munich (LMU), Munich, Germany, 6Institut of Molecular Animal Breeding and Biotechnology, University of Munich (LMU), Munich, Germany, 7Institut of Molecular Animal Breeding and Biotechnology, University of Munich (LMU), Munich, Germany, 8Institut of Molecular Animal Breeding and Biotechnology, University of Munich (LMU), Munich, Germany, 9Revivicor Inc., Blacksburg, VA, 10Dept. of Radiation Oncology, University of Munich (LMU), Munich, Germany

(748) **Blockade of Glycoproteins Ib and IIb/IIIa Reduces Platelet Sequestration and PVR Rise in a Xenogeneic Lung Perfusion Model;**


(749) **Extended Life-Support Duration in a Xenogeneic Lung Transplantation Model Using Pigs With Multiple Genetic Modifications;**


(750) **Lineage Tracing of Host and Graft Cells After Lung Transplant and During Club Cell Ablation Induces Allograft Rejection;**

A. T. Perl, J. Woods, A. Gelman, M. Schecter, C. Towe. 1Pulmonary Biology, Cincinnati Children’s Hospital, Cincinnati, OH, 2Pulmonary Biology, Perinatal Institute, Cincinnati, OH, 3Radiology, Cincinnati Children’s Hospital, Cincinnati, OH, 4Cardiothoracic Surgery, Washington University, St Louis, MO, 5Pediatric Lung Transplant Program, Cincinnati Children’s Hospital, Cincinnati, OH

THURSDAY APRIL 16
**DONOR MANAGEMENT**

**ORGAN PRESERVATION HEART**

((Agora 2)

(DMD-HEART, HTX)

(751) **Ex-Vivo Heart Perfusion Using the Organ Care System Reduces the Donor Heart Cold Ischemia Time:**
A. Ardehali, C. Eisnenring, J. Kobashigawa. UCLA Sch of Med, Los Angeles, CA, Surgery, UCLA Sch of Med, Los Angeles, CA, Medicine, Cedars Sinai Medical Center, Los Angeles, CA

(752) **Ex-Vivo Heart Perfusion Using the Transmedics Organ Care System – A Single Center Experience:**

(753) **Twelve Hour Hypothermic Machine Perfusion for Donor Heart Preservation Leads to Improved Ultrastructural Characteristics Compared to Conventional Cold Storage:**
S. G. Michel, G. M. Lamuraglia II, M. L. Madariaga, M. K. Selig, E. A. Farkash, J. S. Allan, L. M. Anderson, J. C. Madsen. Cardiac Surgery, Ludwig-Maximilians-University, Muenchen, Germany, Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, Paragonix Technologies, Braintree, MA

(754) **The Potential of Transplanting Hearts From Donation After Circulatory Determined Death (DCD) Donors Within the United Kingdom:**
S. Messer, J. Lannon, E. Wong, C. Hopkinson, S. Fielding, R. Axell, S. Tsui, S. Large. Transplant Surgery, Papworth Hospital, Cambridgeshire, United Kingdom, Statistics and Clinical Studies, NHS Blood and Transplant, Bristol, United Kingdom, Research and Development, Papworth Hospital, Cambridgeshire, United Kingdom, Clinical Engineering, Addenbrookes Hospital, Cambridge, United Kingdom, Cardiothoracic Surgery, Papworth Hospital, Cambridgeshire, United Kingdom

(755) **Donor-Recipient Weight Matching in Adult Heart Transplantation:**
H. Bergenfeldt, B. Andersson, J. Nilsson. Cardiac Surgery, Skane University Hospital, Lund, Sweden, Surgery, Skane University Hospital, Lund, Sweden

(756) **The Value of Elective Status 1A Time and the Effects of Delayed Transplant Listing Among Registrants With Mechanical Circulatory Support:**

(757) **Is There a Risk of Cocaine and Methamphetamine Use in Heart Donors?**
(758) Effects of Coronary Angiography on Heart Procurement in Older Donors: Results From a French National Prospective Study; C. Cantrelle, C. Jasseron, I. Pipien, K. Pavaday, E. Epailly, C. Legeai, M. Redonnet, O. Huot, R. Dorent. Medical & Scientific, Agence de la Biomedecine, La Plaine Saint Denis, France, Chirurgie Thoracique, Hopitaux Universitaire de Strasbourg, Strasbourg, France, Chirurgie Thoracique, Hospital Charles Nicolle, Rouen, France

(759) Improving Donor Selection and Management: Insights From Eurotransplant Donor Score and Pathology Examination of Discarded Hearts; M. Sabatino, B. Barra, L. Potena, O. Leone, V. Manfredini, M. Masetti, T. Álvaro, L. Borgese, G. Marinelli, C. R apezzi, F. Gregioni. Heart and Lung Transplant Program, University of Bologna, Bologna, Italy, Pathology, Academic Hospital S. Orsola-Malpighi, Bologna, Italy, Emilia Romagna Organ Procurement Organization, Academic Hospital S. Orsola-Malpighi, Bologna, Italy, Cardiology, University of Bologna, Bologna, Italy

(760) Donor Time Management in Heart Transplantation – A Single-Center Experience; P. Lo, N. Sugianto, E. Granger, P. Jansz, P. Spratt, C. Hayward, A. Jabbour, E. Kotyvar, P. Macdonald, K. Dhital. Heart and Lung Transplant Unit, St Vincent’s Hospital, Darlinghurst, Australia

(761) Restoring Function to the DCD Human Heart Using ECMO Followed By Transportation and Functional Assessment on the TransMedics Organ Care System; S. Messer, R. Axell, P. White, M. Roman, S. Colah, T. Tritton, A. Whitehouse, O. Bermudez, M. Goddard, S. Tsui, A. Ali, S. Large. Transplant Surgery, Papworth Hospital, Cambridgeshire, United Kingdom, Clinical Engineering, Addenbrookes Hospital, Cambridge, United Kingdom, Cambridge Perfusion Services, Papworth Hospital, Cambridgeshire, United Kingdom, Department of Pathology, Papworth Hospital, Cambridgeshire, United Kingdom, Cardiothoracic Surgery, Papworth Hospital, Cambridge, United Kingdom

(762) ‘Pharmacological Conditioning’ Can Allow the Use of Aged Donor Hearts in Cardiac Transplantation; G. Kumarasinghe, L. Gao, M. Hicks, A. Doyle, H. Chew, A. Iyer, A. Jabbour, P. Macdonald. Heart and Lung Transplant Unit, St. Vincent’s Hospital, Darlinghurst, Australia, Cardiac Transplantation Laboratory, Victor Chang Cardiac Research Institute, Darlinghurst, Australia
(763) Radiographic Atelectasis Contributes to Donor Hypoxemia and Decreased Lung Utilization: Findings From 418 Donors in the Bold Study;
L. B. Ware1, D. R. Janz2, J. Nguyen2, J. Singer2, N. Neidlinger2, M. A. Matthay3, 1Vanderbilt University, Nashville, TN, 2California Transplant Donor Network, Oakland, CA, 3University of California San Francisco, San Francisco, CA

(764) Moved to Mini Oral Session 10

(765) Increasing Donor Lung Utilization: A Focus on Donor Age;
C. T. Holley1, R. F. Kelly1, R. Z. Brown1, M. I. Hertz1, K. D. Rudser1, C. W. Quinlan1, I. Cich1, S. J. Shumway1, G. Loor2, 1Surgery, University of Minnesota, Minneapolis, MN, 2Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN, 3Biostatistics, University of Minnesota, Minneapolis, MN, 4Pulmonology, University of Minnesota, Minneapolis, MN, 5University of Minnesota, Minneapolis, MN

(766) Moved to Mini Oral Session 10

(767) Donation After Circulatory Determination of Death Donor Characteristics and Lung Donor Utilization Within the United States;
J. J. Mooney1, H. Hedlin1, P. K. Mohabir1, R. V. Guillaumet2, R. Ha3, P. Chiu4, K. Patel1, D. Weill3, M. R. Nicolls1, G. S. Dhillon1, 1Department of Medicine, Stanford University, Stanford, CA, 2Department of Medicine, University of New Mexico, Albuquerque, NM, 3Department of Cardiothoracic Surgery, Stanford University, Stanford, CA

(768) Health of Potential Uncontrolled Donation After Circulatory Determination of Death (uDCDD) Lung Donors: Impact on the Size of the uDCDD Donor Pool;
T. M. Egant1, J. Requard2, S. Gazda3, N. Casey3, 1Surgery, U. North Carolina Sch Med, Chapel Hill, NC, 2Lung Banks of America, Chapel Hill, NC, 3Carolina Donor Services, Durham, NC

(769) The University of Minnesota Lung Donor Quality Index (UMN-DLQI): A Consensus-Based Scoring Tool for Lung Donor Evaluations;
G. Loor1, D. Radosevich1, I. Cich1, C. Lyon2, J. Morrow2, T. Grabowski2, C. Holley3, R. Kelly3, M. Hertz3, 1University of Minnesota, Minneapolis, MN, 2Fairview Medical Center, Minneapolis, MN

(770) Donor Age and Ischemic Time Are the Only Marginal Donor Criteria That Effect Survival for Lung Transplantation;
E. M. Schumer1, J. R. Trivedi, M. Bousamra, II, V. H. van Berkel, Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY

(771) Differential Outcomes for Long Term Ex-Vivo Lung Perfusion in a Porcine Model – With or Without Red Cells?;

(772) Impact of Age and Smoking History on the Selection of Donors for Lung Transplantation;
H. Schultz1, C. H. Møller2, M. Zemtsovski3, M. Perch1, J. Carlsen1, M. Iversen1, 1Cardiology, Section of Lung Transplantation, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 2Cardiothoracic Surgery, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, 3Thoracic Anaesthesia, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Marginal Donors: “It’s Not What You’ve Got – It’s What You Do With It”;
S. Kotecha, J. Hobson, J. Fuller, B. Levvey, G. Snell, G. Westall.
1Lung Transplant Service, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Australia,
2Monash University, Melbourne, Australia

Ultrastructural Changes in Epithelial and Endothelial Barriers During Ex-Vivo Lung Perfusion;
1Queen Elizabeth Hospital, Birmingham, United Kingdom, 2Free-
man Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom, 3Papworth Hospital, Papworth Everard, United Kingdom, 4Harefield Hospital and Imperial College London, Lon-
don, United Kingdom, 5Wythenshawe Hospital, Manchester, United Kingdom

Prolonged Lung Preservation at 24 Hours Using Donor Whole Blood Perfusion in the Organ Care System (OCS);

Lung Allocation Score Exception Requests Submitted to the OPTN/UNOS Lung Review Board: Characteristics and Trends;
K. M. Wille, L. B. Edwards, L. Robbins Callahan, A. R. McKoy, B. C. Cahill, E. P. Trulock, L. F. Angel, K. M. Chan. 1Univ of Alabama at Birmingham, Birmingham, AL, 2University of Utah, Salt Lake City, UT, 3Washington University School of Medicine, St. Louis, MO, 4University of Texas Health Sciences Center at San Antonio, San Antonio, TX, 5Pulmonary-Critical Care, Univ of Michigan, Ann Arbor, MI

WITHDRAWN
HEART TRANSPLANTATION

(778) An Evaluation of IgG, C1q and CDC in Detection of Anti-HLA Antibodies in Incidence of AMR in Heart Allograft Recipients:
R. Vasilescu1, E. Ho1, L. Li1, G. Vlad1, D. M. Mancini2. 1Pathology and Cell Biology, Columbia University, New York, NY, 2Department of Medicine, Columbia University, New York, NY

(779) Safety of the Use of Prothrombin Complex in Anticoagulated Patients Before Heart Transplantation:
J. González-Costello1, D. Couto1, P. Domènech3, G. Muntané1, S. Ortega3, J. Roca3, J. Salazar-Mendiguchía1, A. Miralles1, F. Sbraga1, A. Cequier1, N. Manito1. 1Area de Malalties del Cor, Hospital Universitari de Bellvitge, Barcelona, Spain, 2Area de Trombosi i Hemos- tasia, Hospital Universitari de Bellvitge, Barcelona, Spain, 3Banc de Sang i Teixits, Hospital Universitari de Bellvitge, Barcelona, Spain

(800) Moved to Mini Oral Session 8

(781) The Influence of Donor Brain Injury and Death Time on Heart Recipients Outcome:
A. Galeone1, M. Laali1, S. Ouldmar1, S. Varnous1, N. Alt-Hamou2, A. Pavie1, P. Léprince1. 1Department of Thoracic and Cardiovascular Surgery, La Pitié-Salpêtrière Hospital, Paris, France, 2Department of Anesthesiology, La Pitié-Salpêtrière Hospital, Paris, France

(782) Comparing Induction Immunosuppression With Basiliximab or Rabbit Anti-Thymocyte Globulin After Cardiac Transplantation: A Contemporary Experience:
O. Kiamanesh1, A. Khoosl2, E. Johansson2, S. Virani2, M. Davis2, A. Cheung2, J. Bashir2, A. Ignaszewski2, B. Munt2, A. Kaan2, M. Toma2. 1Cardiothoracic Surgery, University of British Columbia, Vancouver, BC, Canada, 2Division of Cardiology, University of British Columbia, Vancouver, BC, Canada, 3Division of Cardiac Surgery, University of British Co- lumbia, Vancouver, BC, Canada

(783) The Impact of Anti Angiotensin II Type 1 Receptor Antibodies in Human Leucocyte Antigen Antibodies Negative Recipients on Post – Heart Transplantation Outcome:
M. Urban1, T. Gazdic1, T. Slavcev3, I. Netuka1. 1Cardiac Surgery, IKEM, Prague, Czech Republic, 2Cardiology, IKEM, Prague, Czech Republic, 3Department of Immunology, IKEM, Prague, Czech Republic

(784) Low Level Donor Specific Antibodies at Transplant Does Not Appear to Be Associated With the development of Cardiac Allograft Vasculopathy After Heart Transplantation:

(785) Perioperative Prognostic Factors for Fontan Patients Undergoing Orthotopic Heart Transplant:
C. J. Berg1, B. Bauer1, A. Hageman1, L. C. Reardon1. 1David Geffen School of Medicine at UCLA, Los Angeles, CA, 2Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, CA

(786) Histopathological and Immunological Diagnostic Findings for Cardiac Allograft Antibody-Mediated Rejection Following Mechanical Circulatory Support:
K. Wassilew1, D. Kemper2, N. Lachmann2, M. Niemann2, C. Schöne- mann2. 1Cardiac Pathology Unit, Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany, 2Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany, 3Laboratory for Tissue Typing, Institute of Transfusion Medicine and Cell Therapy, Charité-Universitätsmedizin Berlin, Berlin, Germany
Left Ventricular Assist Device-Associated Allosensitization – Much More Than a Nuisance;

Significance of Subthreshold Values of Complement Activation in Myocardium After Cardiac Transplantation.;
I. Malek1, T. Gazdik2, M. Hegarová1, L. Voska2, J. Pirk2. 1Clinic of Cardiology, IKEM, Prague, Czech Republic, 2Clinic of Cardiac Surgery, IKEM, Prague, Czech Republic

Is It Important to Reduce the Heart Rate in Patients Early After Heart Transplantation?;
H. Bedanova1, J. Ondrasek1, P. Fila1, V. Horvath1, M. Orban2, P. Nemec1. 1Center of Cardiovascular and Transplant Surgery, Brno, Czech Republic, 2ICRC, Brno, Czech Republic

Use of Circulatory Arrest During Heart Transplantation Does Not Worsen Perioperative Survival;
R. A. Sorabella1, S. Krishnamoorthy1, M. Najjar1, E. Castillero1, A. Bader1, P. Flanagan1, D. Mancini2, Y. Naka1, H. Takayama1, I. George1. 1Cardiothoracic Surgery, Columbia University College of Physicians and Surgeons, New York, NY, 2Cardiology, Columbia University College of Physicians and Surgeons, New York, NY

Development of Hypertension in Heart Transplant Recipients Treated With Everolimus Vompared to a Cyclosporine Based Regimen;
A. K. Andreassen1, H. Eiskjær2, E. Gude1, D. Mølbak2, W. Stueflottten1, L. Gullestad1. 1Dept. of Cardiology, Oslo University Hospital, Oslo, Norway, 2Dept. of Cardiology, Aarhus University Hospital, Skejby, Denmark

Determinants of Restrictive Physiolog in HTx Patients;
T. S. Clemmensen, H. Eiskjær, B. B. Løgstrup, S. H. Poulsen. Department of Cardiology, Aarhus University Hospital, Skejby, Denmark

Routine Use of Donor Heart De Vega Tricuspid Annuloplasty in Orthotopic Heart Transplantation;
N. R. Teman1, A. H. Wu2, M. Masood1, M. A. Romano1, T. M. Koelling2, K. D. Aaronson1, F. D. Pagan1, J. W. Haft1. 1Cardiothoracic Surgery, University of Michigan Health System, Ann Arbor, MI, 2Internal Medicine, University of Michigan Health System, Ann Arbor, MI

Rapid Progression of Allograft Coronary Artery Stenosis Is Decreased in Patients Who Received Antithymocyte Globulin Induction at Time of Transplant;
R. Cheng, C. Vanichsarn, B. Azarbal, L. S. Czer, M. M. Kittleson, J. Patel, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

Outcomes of Alcohol Cardiomyopathy Post Heart Transplantation;

Clinical Relevance of ISHLT Definition of Primary Graft Dysfunction After Heart Transplantation: A Two Centers Experience;
G. Vitale1, M. Sabatino1, V. Manfredini1, L. Potena1, G. Di Cesare2, S. Martin-Suarez2, G. Kaffa2, G. Marinelli, C. Rapesti2, F. Clemenzi2, G. Grigioni1. 1Heart and Lung Transplant Program, University of Bologna, Bologna, Italy, 2ISMETT, Palermo, Italy

Gene Expression Profiling to Optimize Immunosuppression in Long-Term Heart Transplant Recipients;
M. E. Madosz, C. W. May, S. Desai, L. Cantwell, S. Phillips, P. Shah. Heart Failure/Transplant, Inova Transplant Center, Falls Church, VA
Identification of Clinically Relevant Unacceptable Antigens By Use of Titration Studies of Heart Transplant Patient Sera; R. H. Kerman, H. Mallidi, W. Etheridge, A. Civitello, P. Jindra. Surgery, Baylor College of Medicine, Houston, TX; Cardiology, Baylor College of Medicine, Houston, TX

Prevalence and Risk Factors for De Novo HLA Donor-Specific Antibodies in Adult Heart Transplant Recipients; L. A. Goldraich, A. C. Alba, J. R. Finn, R. J. Trinkham. Cardiac Transplant Program, Peter Munk Cardiac Center, University of Toronto, Toronto, ON, Canada; Histocompatibility Laboratory, University Health Network, University of Toronto, Toronto, ON, Canada

Drop in Estimated Glomerular Filtration Rate at 1 Year After Heart Transplantation – Concern for Poor Outcome; K. Ghaforian, J. Patel, M. Kittleson, E. Passano, F. Liu, S. Sidiqui, J. Yabuno, D. Geft, D. H. Chang, L. Czer, A. Trento, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

Prevalence and Risk Factors for De Novo HLA Donor-Specific Antibodies in Adult Heart Transplant Recipients; L. A. Goldraich, A. C. Alba, J. R. Finn, R. J. Trinkham. Cardiac Transplant Program, Peter Munk Cardiac Center, University of Toronto, Toronto, ON, Canada; Histocompatibility Laboratory, University Health Network, University of Toronto, Toronto, ON, Canada

Donor Hypernatremia Is an Independent Predictor of 1-Year Mortality Following Cardiac Transplantation; M. A. Schechter, C. B. Patel, J. G. Rogers, M. A. Daneshmand, J. N. Schroder, C. A. Milano. Department of Surgery, Duke University Medical Center, Durham, NC; Department of Medicine, Duke University Medical Center, Durham, NC

Recipients With Shorter Cardiopulmonary Bypass Time Achieve Improvement of Parasympathetic Reinnervation Within 6 Months After Heart Transplantation; T. Imamura, K. Kinugawa, T. Inaba, H. Maki, M. Hatano, O. Kinoshita, K. Nawata, M. Ono. Department of Therapeutic Strategy for Heart Failure, University of Tokyo, Tokyo, Japan; Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan; Department of Cardiac Surgery, University of Tokyo, Tokyo, Japan

Dietary-Derived Trimethylamine N-Oxide (TMAO) Levels Are Associated With Coronary Allograft Vasculopathy Following Heart Transplantation; S. M. Zeltzer, Z. Wang, L. Li, J. Coughlin, T. Hudec, M. Askar, D. G. Taylor, R. Starling, S. Hazen, W. H. Tang. Cellular and Molecular Medicine, Cleveland Clinic Cleveland Clinic, Cleveland, OH; Transplantation Center, Cleveland Clinic Cleveland Clinic, Cleveland, OH; Cardiovascular Medicine, Cleveland Clinic Cleveland Clinic, Cleveland, OH

Viral Presence in the Donor Heart, Its Evolution and Impact on Rejections in the Early Period After Heart Transplantation; J. Krejci, E. Ozabalova, P. Hudel, J. Godava, T. Freiberger, E. Nemcova, H. Bedanova, P. Nemec, L. Spinarová. Department of Cardiovascular Diseases, St. Anne’s University Hospital – ICR, Brno, Czech Republic; Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Republic
Cost Implications of Mechanical Circulatory Support for Primary Graft Dysfunction Following Heart Transplantation; A. A. Ali1, M. Schechter2, K. Southerton3, L. Harling4, J. Schroder2, C. Milano1. 1Papworth Hospital, Cambridge, United Kingdom, 2Cardiothoracic Surgery, Duke University Medical Center, Durham, NC, Imperial College, London, United Kingdom

Pre-Transplant Red Cell Distribution Width Predicts Short Term Outcome After Heart Transplantation; G. Pogliajen1, B. Podgorsek1, M. Sever2, I. Knezevic1, F. Haddad1, U. P. Jorde3, B. Vrtovec1. 1Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia, 2Department of Hematology, UMC Ljubljana, Ljubljana, Slovenia, 3Stanford Cardiovascular Institute, Stanford, CA, 4Albert Einstein College of Medicine, New York, NY

Moderate-to-Severe Left Ventricular Primary Graft Dysfunction Negatively Affects Long-Term Survival After Heart Transplantation in Asian Patients; B. Chong1, H. Kim1, S. Jung1, J. Kim2, M. Kim2, J. Kim2, J. Park1, S. Choo1, T. Yun1, C. Chung1, J. Lee1. 1Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Seoul, Korea, Republic of, 2Division of Cardiology, Asan Medical Center, Seoul, Korea, Republic of, 3Division of Pediatric Cardiac Surgery, Asan Medical Center, Seoul, Korea, Republic of


Inverse Monocytic Subset Profile in Blood and Tissue During Human Heart Transplant Rejection With a Simultaneous Predominance of M2 Macrophages at the Tissue Level; T. P. van den Bosch1, M. D. Kraaij1, K. Caliskan2, A. A. Constantinescu2, O. C. Manintveld1, P. J. Leenen3, C. C. Baan1, M. C. van Groningen4, A. T. Rowshani1. 1Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands, 2Cardiology, Erasmus Medical Center, Rotterdam, Netherlands, 3Immunology, Erasmus Medical Center, Rotterdam, Netherlands, 4Pathology, Erasmus Medical Center, Rotterdam, Netherlands

Pathogenicity of Pre-Transplant Donor-Specific Anti-HLA Antibodies in Heart Transplant Recipients; M. Kubanek1, T. Gazdic2, E. Svobodova3, A. Slavcev3, I. Netuka2, J. Pirk3, I. Malek1. 1Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 2Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 3Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

Gene-Expression Profiling to Monitor for Rejection – Which Patients Are Being Offered This Strategy?; J. Teuteberg1, T. Wolf2, P. Prasad2, G. Ewald3. 1University of Pittsburgh, Pittsburgh, PA, 2CareDx, Inc, Brisbane, CA, 3Washington University, St. Louis, MO

Extracorporeal Photopheresis in the Treatment of Complicated Acute Rejection After Heart Transplantation; S. Wallner1, J. Gökler2, U. Just3, R. Knobler3, T. Horner-Golden1, A. Zuckermann1. 1Department for Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 2Department for General Surgery, Medical University of Vienna, Vienna, Austria, 3Department for Dermatology, Medical University of Vienna, Vienna, Austria

Prognostic Value of Multislice Computed Tomography Coronary Angiography in Cardiac Transplant Recipients; C. Yu1, P. S. MacDonald1, A. M. Keogh1, C. S. Hayward1, E. Kotlyar1, J. M. Otton1, J. Huang1, M. Chang1, D. Bosheh2, B. Milner1, J. McCrohon1, N. Sammel1, M. Fenele1, A. Jabbour1. 1Cardiology, St Vincent's Hospital, Sydney, Australia, 2Radiology, St Vincent's Hospital, Sydney, Australia

Pathogenicity of Pre-Transplant Donor-Specific Anti-HLA Antibodies in Heart Transplant Recipients; M. Kubanek1, T. Gazdic2, E. Svobodova3, A. Slavcev3, I. Netuka2, J. Pirk3, I. Malek1. 1Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 2Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 3Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

Gene-Expression Profiling to Monitor for Rejection – Which Patients Are Being Offered This Strategy?; J. Teuteberg1, T. Wolf2, P. Prasad2, G. Ewald3. 1University of Pittsburgh, Pittsburgh, PA, 2CareDx, Inc, Brisbane, CA, 3Washington University, St. Louis, MO

Extracorporeal Photopheresis in the Treatment of Complicated Acute Rejection After Heart Transplantation; S. Wallner1, J. Gökler2, U. Just3, R. Knobler3, T. Horner-Golden1, A. Zuckermann1. 1Department for Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 2Department for General Surgery, Medical University of Vienna, Vienna, Austria, 3Department for Dermatology, Medical University of Vienna, Vienna, Austria

Prognostic Value of Multislice Computed Tomography Coronary Angiography in Cardiac Transplant Recipients; C. Yu1, P. S. MacDonald1, A. M. Keogh1, C. S. Hayward1, E. Kotlyar1, J. M. Otton1, J. Huang1, M. Chang1, D. Bosheh2, B. Milner1, J. McCrohon1, N. Sammel1, M. Fenele1, A. Jabbour1. 1Cardiology, St Vincent's Hospital, Sydney, Australia, 2Radiology, St Vincent's Hospital, Sydney, Australia
(815) Chronic Kidney Disease After Heart Transplantation: A Single Centre Retrospective Study at Skåne University Hospital in Lund 1988–2010; C. Söderlund, G. Rådegran. Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden

(816) High Prevalence of Myocardial Fibrosis in Patients After Heart Transplantation; M. R. Silva Filho1, D. T. Setuguti2, V. O. Carvalho1, L. A. Benvenuti1, L. F. Silva1, E. A. Bocchi1. Cardiology, INCOR – FMUSP, São Paulo, Brazil, 2HCFMUSP, São Paulo, Brazil, 1Pathology, FMUSP, São Paulo, Brazil

(817) Cardiac Allograft Vasculopathy Assessed By Quantitative Coronary Angiography: A Single Center Prospective Study; M. Pazdernik1, I. Malek1, V. Melnicky1, Maxini1, J. Malekova1, J. Franeckova2, A. Jabor2, V. Karmazin3, M. Hegarova1, J. Kautzner1. 1Department of Cardiology, IKEM, Prague, Czech Republic, 2Department of Laboratory Methods, IKEM, Prague, Czech Republic

(818) Vessel Shrinkage (Negative Remodeling) Is the Main Mechanism of Lumen Compromise in Allograft Vasculopathy – A Long-Term Serial Intravascular Ultrasound Study; K. Goto1, I. Iakovou2, A. Gkouziouta2, A. Maehara1, G. S. Mintz1, G. Karavolias1, V. Leontiadis2, V. Voudris1, G. Pavlides2, S. Adamopoulos2. 1Cardiovascular Research Foundation, Clinical Trial Center, Columbia University Medical Center, Center for Interventional Vascular Therapy, New York USA, NY, 2Cardiology Department, Onassis Cardiac Surgery Centre, Athens, Greece

(819) Potential Value of C4d Capillary Deposition in Myocardial Biopsies and NTproBNP, hs CRP in Serum as Markers of Prognosis in Patients After Heart Transplantation; T. Zielinski1, M. Sobieszczańska-Malek1, K. Komuda1, M. Karczmarz2, A. Browarek1, W. Grajkowska2, P. Kluge3, M. Pronicki1, S. Szymanska2, A. Parulski3, P. Bekta4, M. Karcz4, J. Rozanski3, J. Wisniewska1, J. Kautzner1. 1Heart Failure and Transplantology, Institute of Cardiology, Warsaw, Poland, 2Pathology Department, Children Health Memorial Hospital, Warsaw, Poland, 3Cardiac Surgery and Transplantology, Institute of Cardiology, Warsaw, Poland, 4Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland

(820) Common Carotid Artery Wall Rigidity Index Is a Marker of Cardiac Allograft Rejection; A. O. Shevchenko1, I. U. Tunyuaeva1, A. A. Nasby1, I. M. Ilynsky1, O. P. Shevchenko1, S. V. Gautier1, V. N. Poptzov1. 1Cardiology Dept., Academician VI.Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation, 2Functional Diagnostics Dept., Academician VI.Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation, 3Pathology Dept., Academician VI.Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation, 4Science Dept., Academician VI.Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation, 5Transplantology Dept., Academician VI.Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation, 6Intensive Care Unit, Academician VI.Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation


(822) Echocardiographic Assessment of Right Heart Function in Heart Transplant Recipients and the Relation to Central Hemodynamics; T. S. Clemmensen, H. Eiskjaer, B. B. Løgstrup, S. H. Poulsen. Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, Aarhus University Hospital, Aarhus, Denmark
Heart Transplantation With Generic Immunosuppression: A Developing Country Experience; M. A. Villavicencio, E. Larrain, R. Larrea, J. Peralta, V. Rossel, J. Sung, P. Rojo, M. Hurtado, E. Donoso, F. Gajardo. 1Unidad de Trasplante, Clinica Davila, Santiago, Chile, 2Unidad de Trasplante, Instituto Nacional del Tórax, Santiago, Chile


Acute Cellular Rejection Later Than One Year After Heart Transplantation: A Single Centre Retrospective Study at Skåne University Hospital in Lund 1988-2010; C. Söderlund, G. Rådegran. Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden

Cardiomyocyte Cell Targets of Humoral Rejection in Cardiac Transplantation: Experimental Modeling in Rats; A. Nguyen, R. Dorent, L. Louedec, A. Nicoletti, P. Nataf, J. Michel. Cardiovascular Surgery Department, Bichat-Claude Bernard Hospital, Paris, France

Title: A Tailored Immunosuppression Strategy After Heart Transplantation (HTx) Based on Preoperative Risk Prediction: Impact on One-year Rejection (REJ) and Infection (INF) Rates at a Single Center; M. Kanwar, A. Raina, O. Pappas, R. Agarwal, E. Horn, G. Sokos, S. Bailey, S. Murali, R. Benza. Cardiology, Allegheny General Hospital, Pittsburgh, PA

Parasympathetic Reinnervation Accompanied By Improved Post-Exercise Heart Rate Recovery and Quality of Life in Heart Transplant Recipients; T. Imamura, K. Kinugawa, T. Inaba, H. Maki, H. Hatano, O. Kinosita, K. Nawata, M. Ono. Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 2Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, 3Department of Cardiac Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

Serum-Derived Exosomal Proteome Analysis of Patients With Heart Failure and After Heart Transplantation; P. J. Kennel, R. Givens, D. Brunjes, E. Chen, E. Castillero, H. Takayama, Y. Naka, I. George, D. Mancini, P. C. Schulze. Columbia University Medical Center, New York City, NY

Echocardiographic Evaluation of Ventricular Function Early After Heart Transplantation; A. C. Ingvarsson, A. W. Evaldsson, G. Rådegran, J. Waktare, M. Stagmo, A. Roijer, C. J. Meurling. 1Department of Cardiology, Clinical Sciences Lund University, Skane University Hospital, Lund, Sweden, 2Liverpool Heart and Chest Hospital, Liverpool, United Kingdom

Gender-Mismatched Heart Transplants and Gene-Expression Profiling Score—Lessons From the Outcomes AlloMap® Registry (OAR); N. Sulemanjee, P. Prasad, T. Wolf, V. Thohan. Aurora Research Institute, St Luke's Medical Center, Milwaukee, WI, 2CareDx, Inc, Brisbane, CA

Exploring the Role of Non-HLA Antibodies in Primary Graft Dysfunction After Cardiac Transplantation; P. Shah, A. M. Jackson, M. C. Philogene, S. S. Desai, N. A. Burton, H. Nayer, A. Cochrane. 1Inova Translational Medicine Institute, Inova Fairfax Hospital, Falls Church, VA, 2Immunogenetics Laboratory, Johns Hopkins University, Baltimore, MD, 3Heart Failure and Transplantation, Inova Fairfax Hospital, Falls Church, VA, 4Cardiac Surgery, Inova Fairfax Hospital, Falls Church, VA, 5Pathology, Inova Fairfax Hospital, Falls Church, VA, 6Pharmacy, Inova Fairfax Hospital, Falls Church, VA
Optical Coherence Tomography Assessment of Coronary Artery Disease and Cardiac Allograft Vasculopathy: A Comparison With Intravascular Ultrasound; P. Mendes, K. Posina, K. Tanaka, S. Kumar, S. Al-Kindi, G. Attizzani, G. Oliveira, H. Bezerra. University Hospitals Case Medical Center, Cleveland, OH


Cancer Risk After Heart Transplantation Highly Elevated in Comparison to General Population; S. Jäämaa1, B. Salmela1, E. Pukkala2, K. Lemström1, J. Lommi1. 1Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland, 2Finnish Cancer Registry, Helsinki, Finland

Worldwide Survey of Paramyxoviridae Respiratory Infection Perceptions and Practices Among Adult Lung Transplant Centers; C. R. Ensor1, E. J. Kwak2, C. A. Merlo2, R. K. Avery2, L. Danziger-Ilsakov2, A. R. Glanville2, M. H. Nguyen2, J. B. Orens2, J. M. Pieleski1, B. A. Potoksi1, M. R. Zamora2, J. F. McDyer1. University of Pittsburgh, Pittsburgh, PA, 2Johns Hopkins University, Baltimore, MD, 3Children’s Hospital Medical Center of Cincinnati, Cincinnati, OH, 4St. Vincent’s Hospital, Sydney, Australia, 5University of Colorado, Denver, CO

Mycobacterium abscessus and Lung Transplantation: An International Survey; H. Bills1, G. Snell2, B. Levvey2, O. Morrissey2. Infectious Diseases, Central Clinical School, Monash University, Melbourne, Australia, 2Lung Transplant Service, Alfred Hospital, Melbourne, Australia, 3Infectious Diseases, Alfred Hospital, Melbourne, Australia


Viral Pneumonia Accelerates Graft Death and CLAD in Lung Transplant Recipients; P. R. Allyn1, E. L. Duffy2, R. M. Humphries1, R. Saggar1, S. S. Weight1, J. A. Belperio1, D. J. Ross1, A. Ardehali1, C. Tseng1, A. L. Gregson1. 1Department of Medicine, Division of Infectious Diseases, University of California Los Angeles, Los Angeles, CA, 2Department of Medicine, Statistics Core, University of California Los Angeles, Los Angeles, CA, 3Department of Pulmonary and Critical Care Medicine, University of California Los Angeles, Los Angeles, CA, 4Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California Los Angeles, Los Angeles, CA, 5Department of Surgery, Division of Cardiothoracic Surgery, University of California, Los Angeles, Los Angeles, CA
Everolimus and Valganciclovir Prophylaxis: How to Chase CMV But Not the Patient: Insights From PROTECT Randomized Study;  
B. Perciaccante1, G. Bianchi1, L. Potena1, P. Prestinenzi1, A. Chiereghin2, T. Lazzarotto2, M. Masetti1, C. Rapezzi1, G. Magnani1, F. Grigioni1. 1Heart and Lung Transplant Program, University of Bologna, Bologna, Italy, 2Microbiology Department, University of Bologna, Bologna, Italy

Hepatitis B Vaccination in Heart Transplant Recipients: Response Rate and Risk Factors for Loss of Immunity;  
E. S. Sukerman1, I. Echenique2, M. Angarone3, R. Gordon4, A. Anderson5, J. Rich6, A. Sauer7, T. Abicht4, V. Stosor1. 1Infectious Diseases, Northwestern University, Chicago, IL, 2Infectious Diseases, University of Toronto, Toronto, ON, Canada, 3School of Biosciences, Exeter University, Exeter, United Kingdom

The Utility of Novel Multi-Stage Testing for the Diagnosis of Pulmonary Aspergillosis in a Cohort of Lung Transplant Recipients;  
A. Shah1, A. Abdolrasouli1, S. Soresi2, S. Herbst1, A. Reed2, M. Carb4, C. R. Thornton1, L. Drumright1, S. Shaunak1, D. Armstrong-James1. 1Medicine, Imperial College London, London, United Kingdom, 2Lung Transplant Unit, Royal Brompton and Harefield NHS Trust, London, United Kingdom, 3School of Biosciences, Exeter University, Exeter, United Kingdom

Mortality From Aspergillosis After Heart Transplantation;  
S. Al-Kindi, S. Kumar, M. Ige, C. ElAmm, M. Ginwalla, S. Deo, S. J. Park, G. H. Oliveira. University Hospitals Case Medical Center, Cleveland, OH

Lung Transplant Recipients (LTRs) With Granulomas in the Explanted Lungs: Assessment of Outcomes Related to Non-Tuberculous Mycobacteria;  
D. Kabbani1, H. Kozlowski2, C. Chaparro2, L. Singer1, C. Rotstein2, S. Keshavjee2, S. Husain1. 1Infectious Diseases, University Health Network of University of Toronto, Toronto, ON, Canada, 2Lung Transplant Program, University Health Network of University of Toronto, Toronto, ON, Canada, 3Lung Transplant Program, University Health Network of University of Toronto, Toronto, ON, Canada

Most Effective In Vitro Antimicrobials for Treatment of Stenotrophomonas Maltophilia Infections in Cystic Fibrosis Lung Transplant Recipients;  
A. Perry1, D. Tierney1, J. D. Perry1, S. Peart1, G. Meachery1, F. K. Gould. 1Microbiology Department, Freeman Hospital, Newcastle upon Tyne, United Kingdom, 2Department of Cardiopulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom
Poster presenters and moderators will be present during the evening poster viewing session from 6:00 pm – 7:00 pm.

**EMERGING COUNTRIES**

(Agora 2) (ALL)

(846) **Identification of Emerging Micro RNA Markers for Heart Failure Development Using a Bioinformatic Approach;**
H. E. Verdejo, P. F. Castro, R. Artigas, I. Wichmann, A. Corvalan. Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile

(847) **Left Heart Disease Is Prevalent Among Patients With Echocardiographically Determined Pulmonary Hypertension;**
T. Weitsman, G. Weisz, R. Farkash, D. Meerkin, M. Klutstein, A. Butnaru, D. Rosenmann, T. Hasin. Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel

(848) **Modulation of Circulating Endothelial Progenitor Cells and Hsp27 Following Application of Ampaltzer Occluder in Patients With Flow-Induced Pulmonary Hypertension;**
C. Hsu1, J. Roan2, J. Wang1, C. Huang1, J. Chen1, C. Lam1. 1Institute of Clinical Medicine, Nat ’l Cheng Kung Univ, Tainan, Taiwan, 2Division of Cardiovascular Surgery, Nat ’l Cheng Kung Univ Hosp, Tainan, Taiwan, 3Department of Pediatrics, Nat ’l Cheng Kung Univ Hosp, Tainan, Taiwan, 4Department of Anesthesiology, Nat ’l Cheng Kung Univ Hosp, Tainan, Taiwan, 5Department of Internal Medicine, Nat ’l Cheng Kung Univ Hosp, Tainan, Taiwan

(849) **Pulmonary Hypertension: ECG-Gating CT Angiographic Evaluation of Functional Parameters Focusing on RVOT as Diagnostic Criteria;**
Y. Tsai1, C. Hsu2, C. Wang1. 1Department of Diagnostic Radiology, National Cheng-Kung University College of Medicine and Hospital, Tainan, Taiwan, 2Department of Internal Medicine, Cardiovascular Division, National Cheng-Kung University College of Medicine and Hospital, Tainan, Taiwan

(850) **Predicting Factors of a Fulminant Course of Critical Pulmonary Hypertension;**
W. T. Li1, C. H. Hsu2, C. J. Shih1. 1Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan, 2Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan, 3Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan

(851) **Evolution of a VAD Program at Ankara University After Reimbursement Issue Resolved in Turkey;**
R. A. Akar1, T. Sayin1, M. Sirlak1, B. Inan1, S. Durdu1, Z. Eyileten1, C. Ozdo1, M. Cakici1, E. Ozcinar1, M. Gerede1, I. Dincer1. 1Department of Cardiovascular Surgery, Ankara University School of Medicine, Ankara, Turkey, 2Department of Cardiology, Ankara University School of Medicine, Ankara, Turkey
Outcomes of Patients Implanted With Heartmate II LVAD Versus Heartware HVAD in an Asian Population; L. L. Chan1, C. Lim1, C. Sivathasan2, C. Lim2, T. Tan2, J. Soon2, K. Kerk2, B. Sim. 1Cardiology, National Heart Centre Singapore, Singapore, Singapore, 2Cardiothoracic and Vascular Surgery, National Heart Centre Singapore, Singapore, Singapore

Incidence of Tuberculosis Post Lung Transplantation: Single Centre Experience in Argentina; G. R. Wagner1, J. M. Osse1, J. O. Canive1, J. R. Ahumada1, T. P. Ibáñez1, R. R. Favaloro2, A. M. Bertolotti1. 1Lung Transplantation and Pneumonology, Fundación Favaloro, Buenos Aires, Argentina, 2Intrathoracic Transplantation and Heart Failure Division, Fundación Favaloro, Buenos Aires, Argentina

Therapeutical Implications of Clinical Characteristics of Patients With Chagas Cardiomyopathy and Decompensated Heart Failure; V. S. Issa, G. C. Lima, S. M. Ayub-Ferreira, S. G. Lage, M. T. Oliveira Jr, J. Nicolau, E. A. Bocchi. Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

Tacrolimus Monotherapy After Pediatric Heart Transplantation; A. Szabó, L. Ablonczy, C. Vilmányi, M. Szatmári. Pediatric Cardiac Center, Gottsegen György Hungarian Institute of Cardiology, Budapest, Hungary

Heart Transplantation a Therapeutic Intervention in Multi-Drug Resistant Ventricular Assist Related Infections?; A. Gkouziouta, S. Chatzianastasiou, N. Kogerakis, D. Degiannis, S. Adamopoulos, G. Sarogiou, P. Sifarakis. Heart Failure,MCS and Transplant Unit, Onassis Cardiac Surgery Centre, Athens, Greece

Impact of Native Lung Pneumonectomy in Single-Lung Transplant Recipients; V. Rusanov1, D. Rosengarten1, B. Fox1, B. Medallion1, M. Saute2, M. R. Kramer1. 1Pulmonary Institute, Rabin Medical Center, Petach-Tikva, Israel, 2Cardiothoracic Surgery, Rabin Medical Center, Petach-Tikva, Israel

The Outcomes of VAD Implantation in Ege University: The Largest Experience of Turkey; M. Ozbaran1, T. Yagdi1, C. Engin1, S. Nalbantgil2, S. Ertugay1, M. Zoghi2. 1Cardiovascular Surgery, Ege University Medical School Hospital, Izmir, Turkey, 2Cardiology, Ege University Medical School Hospital, Izmir, Turkey

Extracorporeal Membrane Oxygenation for Bridge to Heart Transplantation; S. S. Wang, N. H. Chi, C. H. Wang, S. C. Huang, N. K. Chou, H. Y. Yu, I. H. Wu, Y. S. Chen, W. J. Ko. Cardiovascular Surgery, National Taiwan University Hospital, Taipei, Taiwan

High Performance Liquid Chromatography Measured Metabolites of Endogenous Catecholamines and Their Relations to Chronic Kidney Disease and High Blood Pressure in Heart Transplant Recipients; P. Przybylski1, G. Wasilewski1, M. Wilusz2, K. Sztefko2, L. Janik1, E. Nowak1, J. Małyszko3. 1Jagiellonian University Medical College, Krakow, Poland, 2Dep. of Clinical Biochemistry, Jagiellonian University Medical College, Krakow, Poland, 3Department of Nephrology and Transplantology, Medical University, Białystok, Poland

Influence of Proliferation Signal Inhibitors on Vascular Endothelial Growth Factor Production in Heart Transplant Recipients; M. Zakliczynski, N. Kamienska, M. Zembala. Silesian Center for Heart Disease, Zabrze, Poland
(862) CHA2DS2-Vasc and HAS-BLED Scores as Predictors of Ischemic and Hemorrhagic Stroke Risk After Left Ventricular Assist Device Implantation; H. S. Kemal1, S. Ergügy2, N. Nalbantgil1, M. Zoghi1, C. Engin1, T. Yadıf2, M. Ozbaran3. 1Cardiology, Ege University Faculty of Medicine, Izmir, Turkey, 2Cardiovascular Surgery, Ege University Faculty of Medicine, Izmir, Turkey

(863) Early Atropine Administration During Dobutamine Stress Echocardiography After Heart Transplant: Worth It?; M. S. Lofrano-Alves, T. Weber, D. Rangel, J. Majeski, F. Bacal, W. Mathias Jr, E. Bocchi. Cardiology, University of Sao Paulo, Sao Paulo, Brazil


(865) Infarct Atypical Late Gadolinium Enhancement in Cardiac Transplant Patients Predicts 3-Year Survival; E. Simsek1, S. Nalbantgil1, N. Ceylan2, M. Zoghi2, H. S. Kemal3, S. Ergügy1, C. Engin1, T. Yadıf1, M. Ozbaran3. 1Cardiology, Batman State Hospital, Batman, Turkey, 2Radiology, Ege University School of Medicine, Izmir, Turkey, 3Cardiovascular Surgery, Ege University School of Medicine, Izmir, Turkey

(866) Lung Transplantation for Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience; H. Jung, W. Yu, C. Lee, S. Haam, J. Lee, H. Paik. Department of Thoracic and Cardiovascular Surgery, Yonse University College of Medicine, Seoul, Korea, Republic of

(867) Relationship Between Types of Social Support, Coping Strategies and Depression in Heart Transplant Recipients; M. Milaniak1, E. Wilczek – Rużyczka2, K. Wierzbicki3, P. Przybylewski2. 1心肺移植科, 2Andrzej Frycz Modrzewski Krakow University, Faculty of Health and Medical Science, 3Polish Transplant Coordinating Centre Poltransplant, Krakow, Poland

(868) Integrating Pedometer to the 6MWT in Patients With PH; V. E. Gregorietti1, G. R. Bortman2, R. E. Ferreyra3, S. V. Perrone1. 1Transplante Cardiaco-Pulmonary Hypertension, Hospital El Cruce, Buenos Aires, Argentina, 2Transplante Cardiaco, Sanatorio Trinidad Mitre, Buenos Aires, Argentina, 3Cardiology, Sanatorio Trinidad Mitre, Buenos Aires, Argentina


(870) If You Do Not Give – You Will Be the Last One to Get! A New Organ Allocation Policy in Israel Enhances Organ Donation; J. Lavee1, T. Ashkenazi2, J. B. Kessler3, A. Roth4, A. Stoler5. 1Heart Transplantation Unit, Leviev Heart Center, Sheba Medical Center, Ramat Gan, Israel, 2Israel National Transplant Center, Ministry of Health, Tel Aviv, Israel, 3Business Economics and Public Policy Department, Wharton University of Pennsylvania, Philadelphia, PA, 4Department of Economics, Stanford University, Stanford, CA, 5Driehaus College of Business, De Paul University, Chicago, IL

(871) ECMO as a Bridge-to-Transplant in Patients With Cardiogenic Shock; I. Knezevic1, G. Poglijaer2, J. Kaela1, V. Androcevic2, M. Racic1, M. Jelenic, B. Vrtovec2. 1Department of Cardiovascular Surgery, UMC Ljubljana, Ljubljana, Slovenia, 2Advanced Heart Failure and Transplantation Ctr, UMC Ljubljana, Ljubljana, Slovenia
Doubts and Misconceptions Concerning Organ Transplantation and Their Influence on One’s Attitude Towards Organ Donation – The Problematic Background of Social Education. A Report From Poland; E. Nowak, R. Pfizner, P. Przybyłowski, A. Kożynacka, L. Durajski, P. Przybyłowski. 1Department of Internal Medicine and Angiology, Brothers Hospitallers of St. John of God Hospital, Krakow, Poland, 2Department of Cardiovascular Surgery and Transplantology, Jagiellonian University Medical College, Krakow, Poland, 3Ludwik Rydygier’s Hospital, Krakow, Poland, 4Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland, 5Children’s Memorial Health Institute, Warsaw, Poland

Low Serum Testosterone May Be Associated With Graft Dysfunction Early After Heart Transplantation; G. Poglajen, M. Jensterle, N. Kravos, F. Haddad, B. Vrtovec. 1Advanced Heart Failure and Transplantation Ctr, UMC Ljubljana, Ljubljana, Slovenia, 2Department of Endocrinology, UMC Ljubljana, Ljubljana, Slovenia, 3Stanford Cardiovascular Institute, Stanford, CA

Survival Outcomes With Extracorporeal Membrane Oxygenation (ECMO) in Variable Indications: A 5-Year Single Center Experience; J. Kim, S. Lee, H. Lee, W. Cho, D. Kim. 1Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of, 2Pusan National University Hospital, Busan, Korea, Republic of

Analysis of Perception of Own Body and Attitudes Towards Organ Donation Within Polish and Turkish Societies; E. Makuch, K. Boniecka, B. Aygör, H. Liberska, A. Akar. 1Department of Cardiovascular and Thoracic, Ankara University, Ankara, Turkey, 2Psychology, Kazimierz Wielki University, Bydgoszcz, Poland
Comparative Analysis of the Impact of Stenotic Microvasculopathy on Survival After Heart Transplantation in Two Major European Transplant Centers; K. Aumayr¹, R. Ullrich¹, A. Zuckermann², K. Wassilew³. ¹Clinical Department of Pathology, Medical University Vienna, Vienna, Austria, ²Surgery and Cardiac Surgery, Medical University Vienna, Vienna, Austria, ³Cardiac Pathology Unit, Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

Both Recipient and Donor Cells Are Involved in Human Cardiac Allograft Vasculopathy; M. Huibers¹, N. de Jonge¹, E. Siera-de Koning¹, A. Gareau¹, R. de Weger¹. ¹Pathology, UMC Utrecht, Utrecht, Netherlands, ²Cardiology, UMC Utrecht, Utrecht, Netherlands, ³Internal Medicine, University of Manitoba, Winnipeg, MB, Canada

Is Pannus an Innocent Bystander in Mechanical Circulatory Support Thrombosis? Examining the Pathology of 50 Explanted Devices; A. Luk¹, A. C. Alba¹, H. J. Ross¹, D. Delgado¹, F. Bilia¹, M. McDonald¹, J. MacIver¹, J. Butany¹. ¹Division of Cardiology, University of Toronto, Toronto, ON, Canada, ²Department of Pathology, University of Toronto, Toronto, ON, Canada, ³Division of Cardiovascular Surgery, University of Toronto, Toronto, ON, Canada, ⁴Department of Pathology, University Health Network, Toronto, ON, Canada

Recurrence of Amyloid in Endomyocardial Biopsies Following Orthotopic Heart Transplantation; P. Kumar¹, F. Liou², J. Patel², L. S. Czer², J. A. Kobashigawa², D. J. Luthringer¹. ¹Pathology, Cedars Sinai Med Ctr, Los Angeles, CA, ²Cardiology, Cedars Sinai Heart Institute, Los Angeles, CA

Incidental Primary Malignant Neoplasms in Explanted Lungs at Transplantation; P. Sojitra¹, A. Muralidhar², S. Quddus³, D. F. Dilling³, S. Mehrotra¹, V. Ananthanarayanan¹. ¹Pathology, Loyola University Medical Center, Maywood, IL, ²Internal Medicine, Loyola University Medical Center, Maywood, IL, ³Pulmonary and Critical Care Medicine, Loyola University Medical Center, Maywood, IL

Comparative Analysis of Distribution of Acute Cellular Rejection and Antibody-Mediated Rejection With Emphasis on Time After Heart Transplantation in Two European Transplant Centers; K. Wassilew¹, T. Haberl², A. Zuckermann², K. Aumayr³. ¹Cardiac Pathology Unit, Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany, ²Cardiac Surgery Department, Medical University Vienna, Vienna, Austria, ³Clinical Department of Pathology, Medical University Vienna, Vienna, Austria

Cardiac Post-Transplant Biopsy Tissue Processing and Reporting Protocols for Rejection: A Comparative Survey of Routine Practice Across Three European Centres; A. Chaturvedi¹, K. Aumayr², K. Wassilew³. ¹Department of Histopathology, University Hospital of South Manchester (U.K.), Manchester, United Kingdom, ²Clinical Department of Pathology, Medical University Vienna, Vienna, Austria, ³Division Cardiac Pathology, Department of Cardiovascular and Thoracic Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

Cytokine and MicroRNA Profiles of Ectopic Lymphoid Structures in Cardiac Allograft Vasculopathy; M. Huibers¹, J. van Kuik², S. Beerthuijzen¹, E. Siera-de Koning¹, N. de Jonge², R. de Weger¹. ¹Pathology, UMC Utrecht, Utrecht, Netherlands, ²Cardiology, UMC Utrecht, Utrecht, Netherlands
Early Detection of Cardiac Allograft Vasculopathy (CAV) With Optical Coherence Tomography (OCT) in Pediatric Heart Transplant Recipients – Comparison to Angiographic Assessment;
S. Schubert1, E. Wellhofer2, B. Peters1, M. Kanaan1, F. Berger1.
1Dept. of Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany, 2Dept. of Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany

Do Pain and Withdrawal Issues Significantly Affect the Post-Transplant Recovery of Pediatric Ventricular Assist Device Recipients?;
D. Guadiz1, P. Shah2, J. Menteer1, M. Horn2, D. Dechant2, C. Buckley3, S. Turkel3, I. Brook2, C. Herrington2, J. Szmuszkoicz3. 1Cardiothoracic Transplant, Children's Hospital Los Angeles, Los Angeles, CA, 2Children's Hospital Los Angeles, Los Angeles, CA

Somatic Growth in Children With Ventricular Assist Device Support;
C. J. Vander Pluym1, K. R. Schmitt2, B. Hawkins1, J. Voelkner2, O. Miera1. 1Cardiology, Boston Children's Hospital, Boston, MA, 2Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany

Incidence and Long-Term Outcome in Patients With Protein Losing Enteropathy (PLE) After the Fontan Operation;
K. N. Pundi1, K. Pundi2, J. N. Johnson1, Z. Li1, P. W. O'Leary1, D. J. Driscoll1, F. Cetta1. 1Department of Pediatrics, Division of Pediatric Cardiology, Mayo Clinic, Rochester, MN, 2Mayo Medical School, Mayo Clinic, Rochester, MN, 3Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN

WITHDRAWN

Strain Analysis and Wall Motion Abnormalities Detection By Cardiac Magnetic Resonance: Utility in the Diagnosis of Coronary Allograft Vasculopathy;
N. N. Dedieu1, M. Fenton1, M. Silva Nodgueira Vieria1, J. Wong2, G. Greil3, M. Burch1, T. Hussain2. 1Paediatric Cardiology, Great Ormond St Hospital, London, United Kingdom, 2Imaging Science, Kings 's College London, London, United Kingdom

Eligibility for Cardiac Resynchronization Therapy for Systolic Heart Failure in Children With Cardiomyopathy;
A. R. Patel1, J. D. Rossano2, P. F. Kantor3, J. A. Towbin4, S. D. Colan5, M. D. Eventt1, J. L. Jefferies1, D. A. Dodd6, J. N. Silva8, J. D. Wilkinson10, S. E. Lipshultz11. 1University of California – San Francisco, San Francisco, CA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3Stollery Children's Hospital, Edmonton, AB, Canada, 4Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5Boston Children's Hospital, Boston, MA, 6Primary Children's Hospital, Salt Lake City, UT, 7Vanderbilt University, Nashville, TN, 8St Louis Children's Hospital, St. Louis, MO, 9Montefiore Medical Center, New York City, NY, 10Wayne State University School of Medicine, Detroit, MI, 11Wayne State University School of Medicine, Detroit, OH

Pediatric Heart Transplantation for Anthracycline Cardiomyopathy: A UNOS Database Review;
M. J. Bock, S. Sehgal, K. Gambetta, B. S. Marino, C. L. Backer, E. Pahl. Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

Pre-Transplant Ventricular Assist Device Utilization Varies By Hospital Environment;
T. Chan1, M. S. Kemna2, E. Albers1, B. J. Hong3, Y. M. Law1, J. M. Chen2, D. M. McMullan1. 1Critical Care, Seattle Children's Hospital, Seattle, WA, 2Cardiac Surgery, Seattle Children's Hospital, Seattle, WA, 3Cardiology, Seattle Children's Hospital, Seattle, WA

Pediatric Heart Transplantation (Peds, bsi, dmd, hf, HTX, id, mcs, nhsah, path, ph, pharm, peeq)
(893) Sudden Cardiac Death in Pediatric Patients Awaiting Heart Transplantation: Implantable Cardioverter Defibrillators Provide No Survival Benefit; I. El-Assaad1, S. G. Al-Kindi2, G. H. Oliveira2, G. J. Boyle3, P. F. Aziz3. 1Pediatrics, Cleveland Clinic Children’s, Cleveland, OH, 2Advanced Heart Failure Center, University Hospitals Case Medical Center, Cleveland, OH, 3Pediatric Cardiology, Cleveland Clinic Children’s, Cleveland, OH


(895) Influence of Chronic Kidney Disease (CKD) in Outcomes Post Heart Transplant (HT) in Pediatric Recipients; L. C. Reardon, A. Nsair, M. C. Deng, A. Ardehali, J. Alejos, E. C. DePasquale. UCLA, Los Angeles, CA

(896) Single Drug Immunosuppression for Infant Heart Transplant Recipients; S. M. Stack1, J. Eshelman1, B. A. Pietra2, S. D. Miyamoto1, S. R. Auerbach1. 1Pediatric Cardiology, Children’s Hospital Colorado, Aurora, CO, 2Pediatric Cardiology, Children’s Hospital Colorado, Aurora, CO

(897) Risk Factors for Declining Renal Function Over Time in a Cohort of Pediatric Heart Transplant Recipients; A. Kempenaar, C. Manlihot, B. W. McCrindle, A. I. Dipchand. Labatt Family Heart Centre, The Hospital for Sick Children, Toronto, ON, Canada

(898) Outcome, Prevalence and Risk Factors for Stroke Following Pediatric Heart Transplantation: An Analysis of the ISHLT Registry; C. Morgan, C. Manlihot, B. W. McCrindle, A. Dipchand. Cardiology, Hospital for Sick Children, Toronto, ON, Canada

(899) Acute Pancreatitis in Pediatric Patients With Ventricular Assist Devices; J. E. Ryan, W. S. Moore II, M. Priest, M. A. McCulloch, C. Pizarro, R. R. Davies. Cardiac Center, Nemours/Alfred I duPont Hospital for Children, Wilmington, DE

(900) Discharge Outcomes in Children Supported With Continuous Flow Left Ventricular Assist Devices; S. Chen1, A. Lin1, E. Liu1, L. J. May1, L. N. Doan2, K. Maeda3, O. Reinhardt2, S. A. Holland1, C. S. Almond1, D. N. Rosenthal1. 1Division of Pediatric Cardiology, Stanford University, Palo Alto, CA, 2Spectrum Child Health, Stanford University, Palo Alto, CA, 3Department of Cardiovascular Surgery, Stanford University, Palo Alto, CA

(901) Mid-term Outcomes After Transplantation Following Resuscitative Bilateral Pulmonary Artery Banding in High-Risk Single Ventricle Neonates and Infants: Single Center Experience; R. A. Murthy1, V. A. Sebastian1, A. W. Nugent1, J. M. Forbess1, K. J. Guleserian1. 1Cardiothoracic Surgery, UT Southwestern Medical Center/Children’s Medical Center, Dallas, TX

(902) Biomarkers to Risk Stratify Outcome in Acute Pediatric Heart Failure: Pilot Study of Asymmetric Dimethylarginine; A. Rocki1, S. Haymond1, A. Andrei1, E. Pahl1. 1Lurie Children’s Hospital, Northwestern University, Chicago, IL, 2Northwestern University, Chicago, IL

(903) Effect of Induction Therapy on Graft Survival in Pediatric Heart Transplantation: A Propensity Score Analysis of the UNOS Database; R. J. Butts, D. Davis, A. Savage, A. Burnette, M. Kavarana, A. Atz, P. Nietert. Medical Univ of South Carolina, Charleston, SC
New Onset Diabetes Mellitus After Heart Transplant in Children; S. Sehgal1, M. J. Bock1, H. L. Palac2, J. G. Gossett1, B. S. Marino1, C. L. Backer1, E. Pahl1. 1Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 2Department of Preventative Medicine, Northwestern University, Chicago, IL

Two Viable Surgical Options for Varying Degree of Pulmonary Vein Stenosis in Pediatric Heart Transplant Recipients; E. Jean-St-Michel, O. Honjo, C. Manlihot, A. Dipchand. Hospital for Sick Children, Toronto, ON, Canada

Cirrhosis in Patients Following the Fontan Operation: Incidence and Long-Term Outcomes; K. Pundi1, K. N. Pundi1, J. N. Johnson2, Z. Li1, D. J. Driscoll1, F. Ortega2. 1Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, 2Department of Pediatrics, Division of Pediatric Cardiology, Mayo Clinic, Rochester, MN

How Should the Effect of Persantine Be Measured Using Thromboelastography: Correlation and Agreement Between Percent ADP Inhibition and ADP Net G; M. Massicotte1, J. Conway2, L. May3, H. Buchholz4, C. Lo5, A. Bruce6, T. Tesoro7, D. Rosenthal6, C. Almond8. 1Thrombosis KIDCLOT, University of Alberta/Stollery Childrens Hospital, Edmonton, AB, Canada, 2Cardiology, University of Alberta/Stollery Childrens Hospital, Edmonton, AB, Canada, 3Cardiology, Stanford University, Stanford, CA, 4Cardiac Surgery, University of Alberta/Stollery Childrens Hospital, Edmonton, AB, Canada, 5Hematology, Stanford University, Stanford, CA, 6Hematology, University of Alberta/Stollery Childrens Hospital, Edmonton, AB, Canada, 7Pharmacy, Stanford University, Stanford, CA, 8Cardiology, Stanford University, Stanford, CA

Immune Profiling Pre/Post Berlin VAD Implant and Pre/Post Transplantation of Pediatric Heart Failure Patients; R. H. Kerman1, P. Jindra2, A. Jeewa3, S. Burki3, C. Fraser3. 1Baylor College of Medicine, Houston, TX, 2Surgery, Baylor College of Medicine, Houston, TX, 3Texas Children’s Hospital and Baylor College of Medicine, Houston, TX

HLA Donor Specific Antibody Production in ABO-Compatible Versus Incompatible Heart Transplant Recipients; C. Chen1, P. Warner2, E. L. Albers1, M. S. Kemna1, L. C. Permut2, B. J. Hong1, Y. M. Law1. 1Cardiology, Seattle Children’s Hospital, Seattle, WA, 2Immunogenetics/HLA Laboratory, Puget Sound Blood Center, Seattle, WA, 3Cardiac Surgery, Seattle Children’s Hospital, Seattle, WA

Automated Analysis of Histopathological Whole Slide Images to Diagnose Pediatric Heart Transplant Rejection; A. K. Bhatia1, J. H. Phan2, S. Kathari2, B. Shehata3, M. Wang4. 1Pediatric Cardiology, Emory University, Decatur, GA, 2Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, 3Pathology, Emory University, Atlanta, GA


Comparison of Right and Left Ventricular Systolic Function Indices in Duchenne Muscular Dystrophy: A Longitudinal Cardiac Magnetic Resonance Study; M. Mehmood1, K. N. Hor2, H. Al-Khalidi1, D. W. Benson1, J. L. Jeffries2, M. D. Taylor1, G. F. Egnaczky7, S. V. Raman3, S. Basu1, L. Cripe1, W. Mazur7. 1Wright State University, Dayton, OH, 2Nationwide Children’s Hospital, Columbus, OH, 3Duke University Medical Center, Durham, NC, 4Children’s Hospital of Wisconsin, Milwaukee, WI, 5Cincinnati Children’s Hospital, Cincinnati, OH, 6Cincinnati Children’s Hospital, Cincinnati, OH, 7The Christ Hospital, Cincinnati, OH, 8Ohio State University, Dayton, OH, 9Nationwide Children’s Hospital, Columbus, OH
Iron Deficiency in Pediatric Heart Failure Patients; D. Higgins, J. Otero, J. Freeburg, C. Jefferis Kirk, M. Kemna, E. Albers, Y. Law. Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA

What Is the Role for Neurodevelopmental Criteria in Patient Selection for Pediatric Heart and Lung Transplantation?; K. P. Daly, D. Freiberger, M. Oliva, C. Harrison, D. S. Kamin. Boston Children’s Hospital, Boston, MA

Multicenter Review of Heartware Ventricular Assist Device in Small Children; O. Miera1, R. Kirk2, H. Buchholz2, K. R. Schmitt1, I. Rebeyka3, N. Wrightson1, F. Berger1, M. Griselli2, J. Conway1. 1Deutsches Herzzentrum Berlin, Berlin, Germany, 2Freeman Hospital, Newcastle upon Tyne, United Kingdom, 3Stollery Children's Hospital, Edmonton, AB, Canada

Conversion to Proliferation Signal Inhibitors in Pediatric Heart Transplant Patients; C. Castleberry, B. Taylor, A. Hohlbein, T. D. Ryan, J. L. Jefferies, I. Wilmot, A. Lorts, C. Chin. Pediatric Cardiology, Cincinnati Children Hospital Medical Center, Cincinnati, OH

A Novel Non-Invasive Assay for the Detection of Rejection Using Cell-Free DNA; P. M. Gordon1, N. Chang1, V. Sajid1, V. Suresh1, L. Dimnik2, R. E. Lamont1, J. S. Parboosingh1, R. T. Pon1, D. Isaac1, S. C. Greenway1. 1Alberta Children's Hospital Research Institute, Calgary, AB, Canada, 2Molecular Diagnostic Laboratory, Calgary, AB, Canada. pancreatic, Alberta Children's Hospital Research Institute, Calgary, AB, Canada

Prolonged JTc Interval Increases Risk of Life-Threatening Arrhythmias in Children With Dilated Cardiomyopathy; S. Chen1, K. S. Motonaga1, S. A. Hollander1, C. S. Almond1, D. N. Rosenthal1, B. D. Kaufman1, L. J. May1, D. T. D. A. 2, A. M. Dubin1, S. R. Cerestik1. 1Division of Pediatric Cardiology, Stanford University, Palo Alto, CA, 2Department of Surgery, NYU Langone Medical Center, New York City, NY

Beyond 35% Ejection Fraction: Choosing Resynchronization PACing for Congenital Heart Patients as a Bridge to Transplant; P. Karpawich, Y. Sanil, H. Singh, K. Zelin. Cardiology, The Children's Hospital of Michigan, Wayne State University, Detroit, MI

Pacemaker Implantation in Pediatric Heart Transplant Recipients Is Predicted By Biatrial Anastomosis and Donor Age But Does Not Affect Survival; I. El-Assaad1, S. G. Al-Kindi2, G. H. Oliveira2, G. J. Boyle3, P. F. Aziz3. 1Pediatrics, Cleveland Clinic Children's, Cleveland, OH, 2Advanced Heart Failure Center, University Hospitals Case Medical Center, Cleveland, OH. 3Pediatric Cardiology, Cleveland Clinic Children’s, Cleveland, OH

Variability in Cardiomyopathy Admissions and Transplant Volume at US Children's Hospitals; M. J. O'Connor1, N. Wang2, J. Long2, Y. Huang2, K. Lin1, T. Singh3, J. L. Jefferies4, R. Shaddy5. 1Division of Cardiology, The Children's Hospital of Philadelphia, Philadelphia, PA, 2Department of Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, PA. 3Department of Cardiology, Boston Children's Hospital, Boston, MA. 4Division of Cardiology, Cincinnati Children's Hospital, Cincinnati, OH

Simple Score to Determine Risk of Early Rejection After Pediatric Heart Transplantation; R. J. Butts2, A. Savage1, A. M. Atz2, M. Heal2, A. Burnette2, M. Kavanagh1, S. Chowdhury1. 1Pediatrics, Medical University of South Carolina, Charleston, SC, 2Transplant Services, Medical University of South Carolina, Charleston, SC. 3Surgery, Medical University of South Carolina, Charleston, SC
(923) **Total Lymphoid Irradiation to Successfully Treat Refractory Rejection in Pediatric Heart Transplant Recipients**;
L. E. Hernandez, P. A. Kofflin, R. K. Ameduri. Department of Pediatrics, University of Minnesota, Minneapolis, MN

(924) **Cardiac Allograft Vasculopathy in Young Adults Who Underwent Heart Transplant in Childhood – A Serial Intravascular Ultrasound Study**;
M. A. Kuhn, L. N. Stoletniy, M. G. Stevenson, B. M. Gordon, A. J. Razzouk, R. E. Chinnock. Pediatrics, Loma Linda Univ, Loma Linda, CA, 2Cardiology, Loma Linda Univ, Loma Linda, CA

(925) **Incidence and Outcomes of Acute Kidney Injury Following Lung Transplantation in Pediatric Population: Retrospective Review**;
M. Gazzaneo, A. Akcan-Arikan, O. Papadias, R. Abelt, E. Melicoff, S. Kim, N. Crews, G. Mallory. 1Pediatric Pulmonary Transplantation, Texas Childrens Hospital, Houston, TX, 2Pediatric Pulmonary, Texas Childrens Hospital, Houston, TX

(926) **Adenovirus Infection After Pediatric Lung Transplantation: A Pediatric Center Experience and Development of a Clinical Practice Guideline**;
N. Crews, M. Ebenbichler, S. Kim, S. Nicholas, E. Melicoff, M. Gazzaneo, G. Mallory. Pediatric Pulmonary Transplantation, Texas Childrens Hospital, Houston, TX

(927) **Photopheresis for Chronic Rejection in Pediatric Lung Transplant Recipients**;
J. A. Blatter, D. Manley, A. Faro, P. Michelson, A. M. Beck, K. Geile, U. S. Boston, P. Eghtesady, S. Sweet. 1Department of Pediatrics, Washington University School of Medicine in St. Louis, Saint Louis, MO, 2Department of Cardiothoracic Surgery, Washington University School of Medicine in St. Louis, Saint Louis, MO
Degree of BNP Reduction Is Associated With Quality of Life After Left Ventricular Assist Device (LVAD) Implant; C. V. Chien1, J. M. Gelow1, J. O. Mudd1, C. Puckett1, S. Hiatt2, C. S. Lee3. Knight Cardiovascular Institute, Oregon Health & Sci Univ, Portland, OR, 2Oregon Health & Sci Univ, Portland, OR

Moved to Mini Oral Session 5

Caretaker’s Expectations and Roles in the Decision to Implant Continue Flow Left Ventricular Assist Devices; E. Stahl1, A. Smith2, R. Laskar2, D. Vega3, D. Nguyen4, A. Morris2, R. Cole2, D. Gupta2. Emory University, Atlanta, GA, 2Division of Cardiology, Emory University, Atlanta, GA, 3Division of Cardiothoracic Surgery, Emory University, Atlanta, GA

Reconceptualizing Shared Decision Making for Heart Failure; C. R. Bruce, R. Volk, J. S. Blumenthal-Barby. Center for Medical Ethics & Health Policy, Baylor College of Medicine, Houston, TX

Acceptability, Feasibility and Implementation of Preparedness Planning for Patients Receiving Left Ventricular Assist Device as Destination Therapy – A Single-Center, 5-Year Experience; K. M. Swetz1, B. P. Verduoom2, A. J. Luckhardt1, S. M. Dunlay1, J. M. Stulak1. Medicine, Section of Palliative Medicine, Mayo Clinic, Rochester, MN, 2Medicine, Section of Primary Care Medicine/Geriatrics, Mayo Clinic, Rochester, MN, 3Cardiovascular Surgery, Mechanical Circulatory Support Program, Mayo Clinic, Rochester, MN, 4Medicine, Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN

Patient Expectations of Continue Flow Left Ventricular Assist Devices; E. Stahl, A. Smith, R. Laskar, D. Vega, D. Nguyen, A. Morris, R. Cole, D. Gupta. Emory University, Atlanta, GA, 2Division of Cardiology, Emory University, Atlanta, GA, 3Division of Cardiothoracic Surgery, Emory University, Atlanta, GA

Outcome After Lung Transplantation of Patients on Extracorporeal Respiratory or Circulatory Support; A. Oude Lansink-Hartgring1, W. van der Bij1, M. E. Erasmus2, V. Gernak1, K. M. Vermeulen1, W. M. van den Bergh1. 1Department of Critical Care, University Medical Center Groningen, Groningen, Netherlands, 2Department of Pulmonary Diseases and Lung Transplantation, University Medical Center Groningen, Groningen, Netherlands, 3Department of Cardiothoracic Surgery, University Medical Center Groningen, Groningen, Netherlands, 4Department of Anesthesiology, University Medical Center Groningen, Groningen, Netherlands, 5Department of Epidemiology, University Medical Center Groningen, Groningen, Netherlands

Does Identifying Patients That Need Inpatient Rehabilitation After Continuous-Flow Left Ventricular Assist Device Placement Improve Outcomes?; S. Bensouda1, M. E. Davis1, M. Djunaidi1, M. R. Dans1, N. F. So1, S. Maltas1, N. A. Haglund1. 1Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, 2Vanderbilt Univ Med Ctr, Nashville, TN, 3PM&R, Vanderbilt Univ Med Ctr, Nashville, TN, 4Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN
Assessment of Patients’ and Caregivers’ Informational and Decisional Needs for Left Ventricular Assist Device Placement: Implications for Informed Consent and Shared Decision Making;
J. Blumenthal-Barby1, K. Kostick1, E. Delgado1, R. Volk2, H. Kaplan1, L. Wilhelms1, S. McCurdy1, J. Estep1, M. Loebe1, C. Bruce1. 1Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, 2Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, 3The University of Texas School of Public Health, Houston, TX, 4Houston Methodist DeBakey Heart & Vascular Center and J.C. Walter Jr. Transplant Center, Houston, TX

Cost Analysis of Leading Causes for LVAD Patient Readmissions;
A. A. Schmitt, T. Seiger, S. Anders, D. Sandler, N. Nair, T. B. Icenogle, Transplant and Mechanical Heart Program, Providence Sacred Heart Medical Center, Spokane, WA

Depression as a Predictor of Compliance and Morbidities After Orthotopic Heart Transplantation;
M. Delibasic1, B. Mohamedali1, N. Dobrilovic1, J. Raman2. 1Department of Internal Medicine, Mercy Hospital and Medical Center, Chicago, IL, 2Section of Cardiology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, 3Cardiovascular and Thoracic Surgery Department, Rush University Medical Center, Chicago, IL

Development and Validation of Patient-Centered Knowledge Scale for LVAD Placement;
K. M. Kostick1, C. Minard2, E. Delgado1, L. Wilhelms1, C. Bruce1, J. D. Estep3, M. Loebe1, R. Volk4, J. S. Blumenthal-Barby1. 1Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, 2Dan L. Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, 3DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, TX, 4Health Services Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX

Results of the HVAD Outpatient Management and Monitoring Survey for Optimal Outcomes;
T. Schlöglhofer1, D. Robson2, J. Bautz3, G. Soerensen4, F. Kaufmann5, L. Sweet6, N. Wrightson7. 1Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 2St. Vincent’s Hospital, Sydney, Australia, 3Prince Charles Hospital, Brisbane, Australia, 4Department of Cardiothoracic and Vascular Surgery, Oslo University Hospital, Oslo, Norway, 5Department of Cardiothoracic and Vascular Surgery, German Heart Institute Berlin, Berlin, Germany, 6HeartWare Inc., Framingham, MA, 7Freeman Hospital, Newcastle upon Tyne, United Kingdom

Functional Outcomes of Left Ventricular Assist Device Patients Receiving Inpatient Rehabilitation;
L. A. Coyle, K. Milkevitch, R. Adair, A. Tatooles, G. Bhat. Advocate Christ Medical Center, Oak Lawn, IL

System of Donor Hospital Transplant Coordinators Maintained and Financed By National Transplant Organization Improves Donation Rates;
T. Danek1, J. Czerwiński1, I. Milaniak1, M. Trunara2, A. Parulski3, P. Przybylowski4, R. Danielewicz2, T. Danek1, J. Czerwiński1, I. Milaniak1, M. Trunara2, A. Parulski3, P. Przybylowski4, R. Danielewicz2. 1Department of Cardiothoracic and Vascular Surgery, John Paul II Hospital 2. Andrzej Frycz Modrzewski Krakow University, Faculty of Health and Medical Science, Polish Transplant Coordinating Center Poltransplant, Warszawa, Poland, 3Polish Transplant Coordinating Center Poltransplant, Warszawa, Poland, 4Department of Anaesthesiology and Intensive Therapy, Międzyzdroje Specialist Hospita, Warszawa, Poland, 5Department of Cardiothoracic Surgery, The Cardinal Stefan Wyszyński Institute of Cardiology, Warszawa, Poland, 6Jagiellonian University Collegium Medicum, Krakow, Poland
PULMONARY HYPERTENSION

(Agora 2)

(PH, BSI, HF, HTX, LF, LTX, MCS, NHSAH, PHARM)

(943) WITHDRAWN

(944) De Novo Development of Pulmonary Arterial Hypertension in Association With Pregnancy: A Retrospective Case Series; L. Harper, J. Swiston, R. Levy, N. Brunner, J. Grewal, M. Idrees, M. Kies, University of British Columbia, Vancouver, BC, Canada, 2Division of Respiriology, University of British Columbia, Vancouver, BC, Canada, 3Division of Cardiology, University of British Columbia, Vancouver, BC, Canada

(945) Pulmonary Arterial Hypertension in the Setting of Pregnancy; M. Lyle, E. Fenstad, K. Arendt, R. Frantz, H. Connolly, C. Warnes, Internal Medicine, Mayo Clinic, Rochester, MN, 2Cardiovascular Diseases, Mayo Clinic, Rochester, MN, 3Anesthesiology, Mayo Clinic, Rochester, MN

(946) The Reliability of 6-Minute Walk Test to Predict Exercise Capacity in Patients With Pulmonary Hypertension; T. Fujino, M. Hatano, A. Yao, D. Nitta, H. Murooka, S. Minatsuki, T. Imamura, T. Inaba, H. Maki, K. Kinugawa, I. Komuro, Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan, 2Division for Health Service Promotion, The University of Tokyo, Tokyo, Japan, 3Department of Therapeutic Strategy for Heart Failure, The University of Tokyo, Tokyo, Japan

(947) Muscular Efficiency in Patients With Idiopathic Pulmonary Arterial Hypertension (iPAH): Impact on Clinical Severity and Survival; G. Valli, R. Badagliacca, S. Papa, M. Internullo, R. Poscia, B. Pezzuto, M. Nocioni, M. Mezzapesa, F. Pesce, G. Manzi, P. Palange, C. Vizza, Cardiovascular and Respiratory Disease, Sapienza University of Rome, Rome, Italy, 2Clinical Medicine, Sapienza University of Rome, Rome, Italy

(948) Normalized Right Isovolumic Relaxation Time and Post-Stress Myocardial Deformation Imaging Reveal Early Signs of Precapillary Pulmonary Hypertension: Insights From a Large Animal Model of Chronic Pressure Overload and Clinical Validation; D. Boulate, G. Giraldeau, J. Guihaire, B. Decante, M. Khiri, I. Schnittger, H. Humbert, J. C. Wu, R. T. Zamanian, E. Fadel, O. Mercier, F. Haddad, Laboratory of Surgical Research, Marie Lannelongue Surgical Center, Le Plessis Robinson, France, 2Cardiovascular Medicine, Stanford University, Stanford, CA, 3Adult Cardiac Surgery, Centre Hospitalo Universitaire de Rennes, Rennes, France, 4INSERM U999, Pulmonary Arterial Hypertension, Pathophysiology and Therapeutic Innovation, Marie Lannelongue Surgical Center, Le Plessis Robinson, France, 5Cardiovascular Institute, Stanford University, Stanford, CA, 6Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA, 7Biomarker and Phenotypic Core Laboratory, Cardiovascular Institute, Stanford University, Stanford, CA

(949) The Potential Utility of Serial NT-proBNP Measurements in Determining a Therapeutic Response in Group I Pulmonary Artery Hypertension; A. M. Wolfson, M. Maitland, V. Thomeas, C. Glassner-Kolman, M. Gomberg-Maitland, Internal Medicine, University of Chicago, Chicago, IL, 2Internal Medicine / Hematology-Oncology, University of Chicago, Chicago, IL, 3Internal Medicine / Cardiology, University of Chicago, Chicago, IL
Outcomes After Lung Transplantation for Pulmonary Hypertension Associated With End-Stage Pulmonary Disease; 
R. A. Varughese1, K. Halloran1, D. C. Lien1, A. Kapasi2, M. Thakrar1, D. Helmersen2, M. Fenton2, K. B. Jackson3, J. G. Weinkauf. 1Department of Medicine, University of Calgary, Calgary, AB, Canada, 2Department of Medicine, University of Alberta, Edmonton, AB, Canada, 3Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada

Impact of Left Ventricular Diastolic Dysfunction on Outcome Following Lung Transplant in Patients With Pulmonary Arterial Hypertension; 
A. Abriel1, M. de Perrot2, S. Azad3, J. Granton3. 1Soroka Medical Center, Ben-Gurion University, Sheva, Israel, 2Toronto General Hospital, Toronto, ON, Canada

The Diastolic Pulmonary Gradient Improves Rapidly After LVAD Implantation in Patients With End-Stage Heart Failure; 
R. J. Cogswell1, M. Colvin1, T. Thenappan1, C. Masri2. 1Cardiology, University of Minnesota Division of Cardiology, Minneapolis, MN, 2Cardiology, University of Washington, Division of Cardiology, Seattle, WA

Echocardiographic Predictors of Combined Pre- and Post-Capillary Pulmonary Hypertension in a Population of Systolic Heart Failure With WHO Group II Pulmonary Hypertension; 
G. Ashrith, N. Fida, M. Cordero-Reyes, J. Amione-Guerra, A. Bhimaraj, B. H. Trachtenberg, G. Torre-Amione, S. Nagueh, J. D. Estep. Cardiology, Houston Methodist Hospital, Houston, TX

Partial Pulmonary-Right Heart Oxygenator (PROxy) Support System: A Novel Strategy for Management of Severe Pulmonary Hypertension; 
M. Biscotti1, O. Wever-Pinzon2, M. Vuzeffopolyska2, H. Takayama1, Y. Naka1, E. B. Rosenzweig1, M. Bacchetta. Surgery, Columbia University Medical Center, New York, NY, 2Cardiology, Columbia University Medical Center, New York, NY, 3Pediatric Cardiology, Columbia University Medical Center, New York, NY

Right Ventricular Outflow Tract Doppler Envelope Mid-Systolic Notching Predicts Pulmonary Vascular Disease in Patients With Advanced Lung Disease; 

Measures of Gas Exchange During Six Minute Walk Test Predict Changes in Disease Severity in Pulmonary Artery Hypertension; 
H. E. Seale1, J. Harris1, K. Hall1, F. Kermeen1, N. R. Morris2. 1Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia, 2School of Allied Health Sciences, Griffith University, Gold Coast, Australia

Is Tricuspid Annular Calcification a Novel Marker of End-Stage Pulmonary Hypertension?; 
F. Kermeen1, T. Butler1, D. Seaton1, B. Shearer1, K. Aldridge1. 1Queensland Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Australia, 2Cardiology Department, The Prince Charles Hospital, Brisbane, Australia, 3Queensland Nuclear Imaging, The Prince Charles Hospital, Brisbane, Australia

A Comparative Study of Right Ventricular Strain to Established Echocardiographic Parameters in Pulmonary Hypertension; 
D. Seaton1, A. Yamada1, J. Chan2, B. Shearer1, K. Aldridge1, F. Kermeen1. 1Queensland Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Australia, 2Heart Foundation Research Centre, Griffith University, Gold Coast, Australia, 3Cardiology Department, The Prince Charles Hospital, Brisbane, Australia, 4Queensland Nuclear Imaging, The Prince Charles Hospital, Brisbane, Australia
Inhaled Treprostinil in Group-3 Pulmonary Hypertension;
M. Agarwal¹, A. B. Waxman²
¹Pulmonary Critical Care and Cardiovascular Medicine, Brigham & Women's Hospital, Boston, MA,
²Center for Pulmonary Heart Disease, Brigham & Women's Hosp, Boston, MA
(960) Successful Bridge to Heart Transplantation With 21 Months’ LVAD Support Under the Condition of VF-Fontan Circulation; Y. Itoda1, K. Nawata1, H. Yamauchi1, O. Kinoshita1, M. Kimura1, D. Arima1, T. Immamura2, M. Endo2, K. Kinugawa2, M. Ono1. 1Cardiac Surgery, The University of Tokyo Hospital, Tokyo, Japan, 2Department of Therapeutic Strategy for Heart Failure, The University of Tokyo Hospital, Tokyo, Japan, 3Department of Organ Transplantation, The University of Tokyo Hospital, Tokyo, Japan


(964) Severe, Reversible Right Ventricular Failure in a Patient With Hashimoto’s Thyroiditis; H. S. Magdo, K. R. Schumacher, M. S. Si, R. J. Gajarski, J. M. Friedland-Little. Congenital Heart Center, C.S. Mott Children’s Hospital, University of Michigan, Ann Arbor, MI

(965) Ehrlichiosis Induced Hemophagocytic Lymphohistiocytosis in a Lung Transplant Recipient; P. R. Aguilar, R. R. Hachem. Pulmonary & Critical Care Medicine, Washington Univ Sch Med, Saint Louis, MO

(966) Acute Left Coronary Compression Due to Type A Dissection – Cardiac Transplantation as Life Saving Treatment in a Young Marfan Patient; J. Dumfarth1, D. Hoefer2, G. Poelzl2, D. Baumgartner3, M. Kaufmann4, S. Eschertzhuber4, M. Grimm4, H. Antretter1. 1Dept. for Cardiac Surgery, University Clinic Innsbruck, Innsbruck, Austria, 2Dept. for Cardiology, University Clinic Innsbruck, Innsbruck, Austria, 3Dept. for Pediatric Cardiology, University Clinic Innsbruck, Innsbruck, Austria, 4Dept. for Anesthesiology and Intensive Care, University Clinic Innsbruck, Innsbruck, Austria

(967) Pulmonary Vein Stenosis Complicated By Early Thrombosis Post Single Lung Transplant; A. Daly, D. Eaton, J. J. Egan, K. C. Redmond. Profesor Eoin O’Malley National Centre for Cardiothoracics, Mater Misericordia University Hospital, Dublin 7, Ireland

(968) Secondary Hemochromatosis After Total Artificial Heart Implantation; I. Tchoukina, D. G. Tang, M. P. Flattery, K. B. Shah. Virginia Commonwealth University, Richmond, VA
(969) Prolonged Resuscitation and Cardiogenic Shock After Intoxication With European Yew (Taxus baccata): Complete Recovery After Intermittent Mechanical Circulatory Support; C. Baum1, S. Bohnen1, B. Sill2, S. Philipp3, S. Kluge1, H. Reichen-spurner7, S. Blankenberg1, G. Söffker1, M. J. Barten2, K. Sydow1. 1General and Interventional Cardiology, UHZ Hamburg, Hamburg, Germany, 2Cardiovascular Surgery, UHZ Hamburg, Hamburg, Ger-
many, 3General Cardiology and Intensive Care Medicine, Elbek-
liniken Stade, Stade, Germany, 4Intensive Care Medicine, UKE Hamburg, Hamburg, Germany

(970) Evaluating Quality in Ex-Vivo Lung Perfusion.; P. G. Sanchez1, G. J. Bittle1, K. Rajagopal1, I. Timoffe2, J. Kim3, A. T. Iacono1, J. S. Gammie1, S. M. Pham1, B. P. Griffith1. 1Cardiac Surgery, University of Maryland, Baltimore, MD, 2Medicine, University of Maryland, Baltimore, MD

(971) Excellent Outcomes in HIT With Therapeutic Apheresis Prior to CPB in Patients Undergoing Heart Transplantation; R. Tandon1, A. Tandon1, K. Light-McGroary1, V. Cotarian1. 1University of Iowa University of Iowa Hospitals and Clinics, Iowa City, IA, 2Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, 3Cardiology, University of Iowa University of Iowa Hospitals and Clinics, Iowa City, IA

(972) Transapical Transcatheter Aortic Valve Implantation (TA-TAVI) After Long-Term Heart Transplantation; M. Stelzmuller1, K. Uyanik-Unal1, B. Morai1, S. Sandner1, G. Lauffer1, A. Zuckermann1, W. Wissel1. 1Department of Cardiac Surgery, Medical University Vienna, Vienna, Austria, 2Department of Cardiac Tho-
racic Anaesthesia and Intensiv Care, Medical University Vienna, Vienna, Austria

(973) Transthyreitin Familial Cardiac Amyloidosis Donour Selection: Heart vs. Heart Liver Transplantation; K. J. Lyons1, G. A. Fishbein1, E. Depasquale1, R. Ardehali1, A. S. Baas1, M. Cadeiras1, D. Cruz1, M. C. Deng1. 1University of Los Angeles California, Los Angeles, CA

(974) Assessing Myocardial Recovery and Reserve Using Dobutamine Trans-Oesophageal Echocardiography (TOE) and Exercise Right Heart Catheterization (RHC) to Allow Safe Explantation of a Left Ventricular Assist Device (LVAD); M. B. Stokes1, P. Bergin1, D. M. Kaye1. 1Heart Centre, The Alfred Hospital, Prahan, Victoria, Australia

(975) Temporary and Durable Mechanical Circulatory Support for Single Ventricular Failure; J. L. Hermsen1, J. W. Smith1, C. Mahr1, K. K. Stout2, A. Rubio1, T. K. Jones1, E. D. Verrier1, F. R. Shaw1, V. Krieger2, J. D. PaI2, M. A. Beckman1, N. A. Mokadam1. 1Cardiothoracic Surgery, Univ Washington Med Ctr, Seattle, WA, 2Cardiology, Univ Washington Med Ctr, Seattle, WA, 3Cardiology, University of Tokyo, Tokyo, Japan

(976) A Case of Interferon-α Induced Pulmonary Arterial Hypertension After Living Liver Transplantation; T. Ko1, M. Hatano1, D. Nitta1, H. Muraoka1, S. Minazuki1, T. Imamura1, T. Inaba1, H. Maki1, A. Yao1, K. Kinugawa1, I. Komuro1. 1Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan

(977) Novel Aortic Valve Closure in Patient With Aortic Insufficiency After Placement of Left Ventricular Assist Device (LVAD); B. A. Smith1, N. Uriel1, V. Jeevanandam1, G. Kim1, G. Sayer1, S. Fed-
son1, T. Ota2, A. Shah1. 1Medicine, University of Chicago, Chicago, IL, 2Surgery, University of Chicago, Chicago, IL

(978) Informed Transplant Refusal of a Pediatric Patient; C. R. Bruce1, B. Trachtenberg1. 1Center for Medical Ethics & Health Policy, Baylor College of Medicine, Houston, TX, 2Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX

(980) Role of Electron Microscopic Evaluation in Transplant Decisions of Advanced Chemotherapy Induced Cardiomyopathy; J. Youn, S. Lee, S. Lee, Y. Youn, B. Chang, S. Kang. Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of. Division of Cardiovascular Surgery, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

(981) Nocardia Infections After Lung Transplantation: A Case Series; V. Rossetti, L. Morlacchi, M. Pappalatreta, P. Tarsia, P. Mendogni, F. Biasi. U.O. Broncopneumologia; Dipartimento di Fisiopatologia e dei Trapianti, IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy. U.O. Chirurgia Toracica e dei Trapianti di Polmone, IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy

(982) LVAD Implantation for Cardiac Allograft Failure in a Child: Achieving Long-Term Survival Without Wound or Infectious Complications; S. M. Haldeman, R. Davies, S. Gidding, M. McCulloch, C. Pizarro. Cardiology, A.T. duPont Hospital for Children, Wilmington, DE

(983) Early Progression of MGUS to Multiple Myeloma in a Heart Transplant Recipient: A Cautionary Tale; J. A. Hernandez-Montfort, D. A. Baran, I. Sabnani, P. Dhesi, S. Murthy, J. Pieretti, C. Gide², M. Camacho, M. J. Zucker. Heart Failure and Cardiac Transplant, Newark Beth Israel Medical Center, Jersey City, NJ. Transplant Center, Newark Beth Israel Medical Center, Jersey City, NJ

(984) Left Ventricular Assist Device Associated Culture-Negative Bartonella Henselae Endocarditis (Cat Scratch Fever); A. K. Mankad, H. Kapoor, K. B. Shah. Hunter Holmes McGuire Veterans Medical Center, Richmond, VA. Medical College of Virginia, Richmond, VA

(985) Mechanical Circulatory Support in a Child With Single Ventricle Heart Disease and MAPCAs; W. F. Carlo, F. B. Pearce, J. K. Kirklin. University of Alabama, Birmingham, AL

(986) Surgical Treatment for Tricuspid Valve Regurgitation Occurring Early After Heart Transplantation; E. Bollano, H. Liden, K. Karason, G. Dellgren. Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden. Cardiothoracic surgery, Sahlgrenska University Hospital, Gothenburg, Sweden

(987) EBV Associated Smooth Muscle Cell Tumor Secondary to Intestinal Post Transplant Lymphoproliferative Disease (PTLD) in a Child After Heart Transplant; N. Alami Laroussi, J. Conway, L. West, S. Desai, L. Mc Gonigle, B. Dicken, U. Urschel. Pediatric Cardiology, Stollery Children’s Hospital, Edmonton, AB, Canada. Pediatric Hematology Oncology, Stollery Children’s Hospital, Edmonton, AB, Canada. Pediatrics, Stollery Children’s Hospital, Edmonton, AB, Canada. Pediatric Surgery, Stollery Children’s Hospital, Edmonton, AB, Canada

(988) Pulmonary Hypertension in Antisynthetase Syndrome; M. Lyle, E. Fenstad, R. Frantz, G. Kane. Internal Medicine, Mayo Clinic, Rochester, MN. Cardiovascular Diseases, Mayo Clinic, Rochester, MN

(990) Heart Transplantation in Situs Inversus – A Case Report; J. Y. Song1, Y. C. Lin2, C. Y. Lin2, C. S. Tsai1. 1Division of Cardiovascular Surgery, Department of Surgery, Armed Forces Taichung General Hospital, Taichung, Taiwan, 2Division of Cardiovascular Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

(991) Serious Infection of the Left Ventricular Titanium Plug Used at the Time of HeartWare HVAD Explantation; B. Maxhera, A. Albert, A. Mehdiani, U. Boeken, A. Lichtenberg, D. Saeed. Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany

(992) Patient With JC-virus Infection and Progressive Multifocal Leukoencephalopathy After Heart Transplantation, Over 2 Years of Clinically Stable Infection on Low Dose Immunosuppression; P. Sundbom1, L. Hubbert1, C. Dahle1, L. Serrander3. 1Department of Cardiology and Department of Medical and Health Sciences, Linköping University, Linkoping, Sweden, 2Department of Neurology and Department of Clinical and Experimental Medicine, Linköping University, Linkoping, Sweden, 3Department of Infectious Diseases and Department of Clinical and Experimental Medicine, Linköping University, Linkoping, Sweden

(993) Development of Reye-Like Syndrome after Left Ventricular Assist Device Implantation for Mitochondrial Cardiomyopathy; T. Motokawa1, O. Seguchi1, E. Hisamatsu1, K. Kuroda1, T. Sato1, S. Nakajima1, H. Sunami1, T. Sato1, M. Yanase1, Y. Matsumoto1, H. Hata1, T. Fujita1, Y. Ikeda1, H. Ueda1, Y. Goto1, J. Kobayashi1, T. Nakatani1. 1National Cerebral and Cardiovascular Center, Osaka, Japan, 2National Center of Neurology and Psychiatry, Tokyo, Japan

(994) Obesity and Early Loss of Mobility in Two Adolescents With Becker Muscular Dystrophy Following HeartMate II Implantation; S. A. Hollander1, S. Rizzuto2, A. M. Hollander2, A. Lin1, E. Liu1, J. M. Murray1, C. S. Almond1, D. N. Rosenthal1. 1Pediatrics (Cardiology), Stanford University, Palo Alto, CA, 2Rehabilitation Services, Lucile Packard Children's Hospital, Stanford, Palo Alto, CA


(996) Eosinophilia, Rash and Overwhelming Sepsis in a Heart Transplant Recipient: DRESS vs Hyper IgE Syndrome; R. Tandon1, A. Tandon2, J. L. Goerbig-Campbell3. 1Medicine, University of Iowa University of Iowa Hospitals and Clinics, Iowa City, IA, 2Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, 3Cardiology, University of Iowa University of Iowa Hospitals and Clinics, Iowa City, IA

(998) Cutaneous Alternariosis Infection in a Heart Transplant Recipient;

(999) Successful Bilateral Lung Transplant in HIES;
E. A. Lendermon1, A. F. Freeman2, K. N. Olivier3, E. J. Kwak3, J. D’Cunha1, C. R. Ensor1, M. M. Crespo1, S. M. Holland2, C. A. Bermudez2, J. F. Dyer1. Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, 1Laboratory of Clinical Infectious Disease, NIAID, National Institutes of Health, Bethesda, MD, 2Division of Infectious Disease, University of Pittsburgh, Pittsburgh, PA, 3Division of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA

(1000) Circulatory Support Using Two Continuous Flow Assist Devices: A Case Series Employing a Novel Operative Approach;
D. P. Cork1, H. A. Tran1, J. Silva1, B. Greenberg1, D. Barnard1, E. D. Adler1, V. Pretorius2. 1Cardiology, University of California, San Diego, La Jolla, CA, 2Cardiothoracic Surgery, University of California, San Diego, La Jolla, CA

(1001) Laparoscopic Sleeve Gastrectomy as a Bridge to Transplant for Morbidly Obese LVAD Patients;

(1002) Prostate as Sanctuary Site: Relapsed Blastomycosis in a Lung Transplant Recipient;
M. E. Clement1, S. G. Norfolk2, J. M. Reynolds2, C. R. Wolfe1, E. K. Mazziar1. 1Division of Infectious Diseases, Duke University Medical Center, Durham, NC, 2Division of Pulmonary Medicine, Duke University Medical Center, Durham, NC

(1003) Severe Early Biventricular Manifestation of Arrhythmogenic Cardiomyopathy in Two Pediatric Patients With Compound Heterozygous Desmosomal Gene Mutations;
J. M. Friedland-Little, P. Arscott, H. S. Magdo, R. J. Gajarski, K. R. Schumacher. University of Michigan C.S. Mott Children’s Hospital, Ann Arbor, MI

(1004) Successful Utilization of a Lung From a Donor on Venoarterial Extracorporeal Membrane Oxygenator;
N. Sinha. Pulmonary Transplant, Houston Methodist Hospital, Houston, TX

(1005) Interventional Treatment of LVAD Outflow Graft Stenosis By Introduction of Bare Metal Stents in Two Cases;
T. Haberl1, D. Wiedemann1, J. Riebandt1, J. Horvat2, J. Kastner3, W. Matzek4, G. Lauffer1, D. Zimpfer1. 1Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, 2Center of Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria, 3Department of Cardiology, Medical University of Vienna, Vienna, Austria, 4Department of Interventional Radiology, Medical University of Vienna, Vienna, Austria

(1006) HeartWare Ventricular Assist Device (HVAD) for Management of Systemic Right Ventricular Failure and Pulmonary Hypertension in a Patient With Dextro-Transposition of the Great Arteries (d-TGA) and Previous Atrial Switch Procedure;
M. B. Stokes, A. S. Leet. Heart Centre, Alfred Hospital, Prahan, Australia

(1007) Successful Treatment of Disseminated Acanthamoebiasis in a Lung Transplant Recipient;
C. Lee1, D. Brezhnev1, V. H. Chan1, P. C. Zakowski2, S. Ghandehari1, G. E. Chaux1, J. A. Falk1. 1Pulmonary and Critical Care, Cedars Sinai Medical Center, Los Angeles, CA, 2Infectious Disease, Cedars Sinai Medical Center, Los Angeles, CA
Postpulmonary Hypertension Female Complicated with Left Ventricle Collapse and Cardiogenic Shock, Survived after Extracorporeal Membrane Oxygenation Support and Specific Pulmonary Hypertension Medications Use: Up to 4 Years Follow Up Report;
M. Huang1, C. Hsu2, P. Chen2. 1Cardiology, National Cheng Kung University, Taiwan, Tainan, Taiwan, 2Institute of Clinical Medicine, National Cheng Kung University, Taiwan, Tainan, Taiwan

Post-Transplant Lymphoproliferative Disorder After Heart Transplantation in Japanese Pediatric Recipients;
J. Narita1, S. Kogaki1, R. Higeno1, S. Mihara1, K. Takahashi1, K. Ozono2, N. Fukushima2, Y. Sawa3. 1Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan, 2Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

Calcineurin Inhibitor-Free Immunosuppression With Basiliximab in Critically Ill Pediatric Heart Transplant Recipients;
G. R. Vaughn1, B. J. Hong, M. S. Kemna, Y. M. Law, E. L. Albers. Pediatric Cardiology, Seattle Children’s Hospital, Seattle, WA

Severe Autoimmune Cytopenia After Pediatric Heart Transplantation;
H. T. Henderson1, M. D. Dee1, S. G. Kreissman2, J. A. Rothman1, M. P. Carboni1. 1Pediatric Cardiology, Duke University, Durham, NC, 2Pediatric Hematology & Oncology, Duke University, Durham, NC

Effective Treatment of Refractory Angina With Ranolazine in a Heart Transplant Recipient;
P. S. Bains1, M. Toma2, S. A. Virani3, A. Ignaszewski2, B. Munt1, A. Cheung1, J. Bashir2, S. J. Jyothula1, T. Kaleekal2, S. Scheinin3. 1Division of Cardiology, University of British Columbia, Vancouver, BC, Canada, 2Division of Cardiology, University of British Columbia, Vancouver, BC, Canada, 3Division of Cardiac Surgery, University of British Columbia, Vancouver, BC, Canada, 4Division of Cardiac Surgery, University of British Columbia, Vancouver, BC, Canada

Post-Operative Lung Allograft Dysfunction Secondary to Partial Left Anomalous Pulmonary Venous Disruption;
A. Goodarzi1, B. Mankidy2, N. Sinha3, S. Jyothula3, T. Kaleekal2, S. Scheinin3. 1Pulmonary and Critical Care, Baylor College of Medicine, Houston, TX, 2Medicine, Houston Methodist Hospital, Houston, TX, 3Surgery, Houston Methodist Hospital, Houston, TX

Adult Lung Transplantation for Hereditary Hemorrhagic Telangiectasia;

Treatment of End-Stage Cardiomyopathy in a Young Man With Duchenne Muscular Dystrophy Using a Centrifugal Flow Ventricular Assist Device;
D. Stoller1, F. Araj2, A. Amin2, J. Thibodeau3, C. Ramaciotti1, M. H. Drazner7, D. M. Meyer1, P. P. Mammen1. 1Department of Internal Medicine, University of Texas Southwestern, Dallas, TX, 2Department of Internal Medicine, Heart Failure Program, University of Texas Southwestern, Dallas, TX, 3Department of Pediatrics, University of Texas Southwestern, Dallas, TX, 4Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern, Dallas, TX, 5Department of Internal Medicine, Heart Failure Program, and Hamon Center for Regenerative Science, University of Texas Southwestern, Dallas, TX

Atrioventricular Block After Heart Transplantation in Pediatric Age: A Possible Sign of Rejection?
M. A. Castelluzzo1, F. Parisi1, D. Di Carlo1, S. Alferi1, G. Gutter1. 1Cardiology and Cardiac Surgery, Bambino Gesù Children Hospital, Rome, Italy, 2Cardiology and Cardiac Surgery, Bambino Gesù Children’s Hospital, Rome, Italy
(1017) Role of Total Artificial Heart in Patients With a Body Surface Area Less Than 1.7 m² Having a Good Outcome After Pectoralis Major Muscle Flap Chest Closure; J. A. Gomez-Abraham, T. Yoshizumi, A. Shiose, Y. Toyoda. Cardiovascular Surgery, Temple University School of Medicine, Philadelphia, PA

(1018) HeartMate II Left Ventricular Assist Device Implantation as an Alternative to Total Artificial Heart Placement in a Patient With Giant Mural Ventricular Thrombus; D. Schibliyski1, C. Haller1, M. Lenglinger1, B. Woerlne1, H. Magunia2, T. Walker1, P. Rosenberger1, C. Schlensak1. 1Department of Thoracic and Cardiovascular Surgery, University Medical Center, Tübingen, Germany; 2Department of Anesthesiology and Intensive Care Medicine, University Medical Center, Tübingen, Germany.

(1019) Implantation of a Subcutaneous Implantable Cardioverter-Defibrillator in a Patient With a HeartMate II Left Ventricular Assist Device; F. Raissi Shabari, A. Sundara Raman, B. Kar, P. Loyalka, R. Harihar. University of Texas Houston, Houston, TX

(1020) Double Donor Lobectomy Following Bilateral Sequential Single Lung Transplantation: A Case for Split Bilateral Lung Transplants; H. Tettel1, N. A. Burton1, E. A. Lefrak2, S. Ahmad1, O. A. Slobin1, C. M. Rosner1, S. D. Nathan1. 1Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, 2Inova Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, VA, 3Lung Transplant and Advanced Lung Disease Program, Inova Fairfax Hospital, Falls Church, VA

(1021) Right Ventricular Failure After Pediatric Heart Transplant: A Case of Mechanical Support in a High-Risk Patient; L. J. May1, J. Conway2, I. M. Rebeyka3, H. Buchholz3, D. B. Ross3, S. Urschel3. 1Department of Pediatrics (Cardiology), Stanford University, Palo Alto, CA, 2Department of Pediatrics (Cardiology), University of Alberta, Edmonton, AB, Canada, 3Department of Cardiothoracic Surgery, University of Alberta, Edmonton, AB, Canada

(1022) A Case of Fatal Hyperammonemia in a Lung Transplant Recipient in Australia; K. P. Lim1, T. Law2, P. Thyagarajan2, R. Larbalestier2, K. Ho3, G. Dobbs3, M. Lavender1, J. P. Wrobel1, M. Musk1. 1Advanced Lung Disease Unit, Royal Perth Hospital, Perth, Australia, 2Cardiothoracic Surgery Department, Royal Perth Hospital, Perth, Australia, 3Department of Critical Care, Royal Perth Hospital, Perth, Australia

(1023) WITHDRAWN

(1024) Patient With Pulmonary Hypertension Secondary to ANCA Vasculitis Treated Successfully With Steroid and Cyclophosphamide; P. Su1, L. Tsai1, C. Hsu2. 1Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan, 2Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan

(1025) Successful Percutaneous Trans-Catheter Treatment of Left Ventricular Assist Device Outflow Graft Stenosis With a Covered Stent; S. Kalantari-Tannenbaum, E. Retzer, G. Sayer, G. Kim, S. Fedson, C. Juricek, V. Jeevanandam, A. Shah, N. Uriel. Medicine, University of Chicago, Chicago, IL

(1026) Dobutamine Induced Eosinophilic Myocarditis and Right Heart Failure Requiring Emergent Biventricular Assist Device Implantation; V. P. Raje1, N. P. Lewis2, G. J. Katlaps2, K. B. Shah1, A. Mankad2. 1Medical College of Virginia, Richmond, VA, 2Hunter Holmes McGuire Veterans Medical Center, Richmond, VA
(1027) **Thrombus or Not a Thrombus? Left Ventricular Assist Device Dysfunction Due to Fibrosis;**
L. Glade1, J. D. Vega2, D. Nguyen2, R. T. Cole1, A. Morris1, S. R. Laskar1, D. Gupta. 1Cardiology, Emory University School of Medicine, Atlanta, GA, 2Cardiothoracic Surgery, Emory University Hospital, Atlanta, GA, 3Cardiology, Emory University Hospital, Atlanta, GA

(1028) **Cobalt-Chromium Toxicity: How to Recognize and Treat a Heavy Metal Heart;**
R. A. Davey, M. Kanwar, A. Raina, G. Sokos, R. Agarwal, R. Benza, S. Bailey, S. Murali. Advanced Heart Failure and Transplantation, Allegheny General Hospital, Pittsburgh, PA

(1029) **Vertebroplasty in a Lung Transplant Patient: Pulmonary Cement Embolism and Active Bleeding, an Exceptional Complication;**
D. Bennett1, A. Fossi1, M. Bellini2, P. Paladin1, L. Luzzi1, A. Cerase2, L. Voltolini1, P. Rottoli. 1Respiratory Diseases and Lung Transplantation, University of Siena, Siena, Italy, 2Neuroimaging and Neuroradiological Intervention, University of Siena, Siena, Italy, 3Thoracic Surgery, University of Siena, Siena, Italy

(1030) **Concomitant Pulmonary Thromboembolectomy and Orthotopic Cardiac Transplantation Following Biventricular Assist Device Implantation;**
A. Ghodsizad1, A. Lubitz1, J. Gomez-Abraham1, A. Shiose1, E. Leotta1, T. Yoshizumi1, J. Cooper1, D. Schwartz1, E. A. Hamad2, R. J. Alvarez1, D. Dries1, Y. Toyoda. 1Department of Cardiac Surgery, Temple University Hospital, Philadelphia, PA, 2Department of Cardiac Surgery, Temple University Hospital, PA, 3Department of Cardiology, Temple University Hospital, Philadelphia, PA

(1031) **HVAD Insertion Via Right Ventricular Interposition: A Novel Strategy for Biventricular Support;**
D. Joyce1, J. Stulak1, S. Kushwaha2, R. Daly1, L. D. Joyce1. 1Cardiovascular Surgery, Mayo Clinic, Rochester, MN, 2Cardiology, Mayo Clinic, Rochester, MN

(1032) **Cardio-Pulmonary Transplantation After 82 Days of Novalung as a Bridge;**

(1033) **17 Year Old Fontan Patient – Acute Embolic Myocardial Infarction, Heart Failure With Successful Bridge to Transplantation With Impella Device;**
S. R. Deshpande1, A. Dalal1, D. Kim1, M. Jokhadar2. 1Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA, 2Department of Cardiology, Emory University, Atlanta, GA

(1034) **Scedosporium apiospermum Involving the “Native Valve”: Fungal Endocarditis in an Orthotopic Heart Transplant Recipient;**
M. E. Clement, E. K. Maziarz. Division of Infectious Diseases, Duke University Medical Center, Durham, NC

(1035) **Severe Pulmonary Arterial Hypertension in a Pediatric Patient With Hemitruncus Arteriosus;**
J. A. Su1, S. R. Kumar2, A. L. Cheng2, C. D. Lew1, R. K. Chang4, F. F. Ing5, R. R. Szmuszkovicz2. 1Pediatric Cardiology, Children's Hospital of Los Angeles, Los Angeles, CA, 2Cardiothoracic Surgery, Children's Hospital of Los Angeles, Los Angeles, CA, 3Pediatric Pulmonology, Children's Hospital of Los Angeles, Los Angeles, CA, 4Pediatric Cardiology, Harbor-UCLA, Torrance, CA
INDEPENDENT EVENTS

APPROVED EDUCATIONAL ACTIVITIES

CONDUCTED BY INDUSTRY

during the

ISHLT 35\textsuperscript{th} Annual Meeting and Scientific Sessions

NOTE: These are independent events and are not an official part of the ISHLT Annual Meeting and Scientific Sessions.
WEDNESDAY, APRIL 15, 2015

TITLE: CTEPH Futures Think Tank: How can we do more for CTEPH Patients Today and Tomorrow?

CONDUCTED BY BAYER

This is a closed meeting. Attendance by invitation only.

TIME: 1:00 pm - 2:30 pm

LOCATION: Rizzo 6 in the Rhodes Exhibit Hall, Acropolis Congress Center

MEDIA CHAIR:
Jacqui Thornton (UK), Health correspondent and Chair, UK

Marc Humbert (FR), Director, Université Paris-Sud 11 & Vice Chairman, National Reference Centre for Pulmonary Hypertension, Department of Respiratory and Intensive Care Medicine, Hospital Antoine Béclère, Clamart, France

Deepa Gopalan (UK), Consultant Radiologist, Papworth, UK

Eckhard Mayer (DE), Director, Thoracic surgery, Kerckhoff Clinic, Germany

Paul Corris (UK), Professor of Thoracic Medicine Institute of Cellular Medicine,
THURSDAY, APRIL 16, 2015

TITLE: *Deeper Dive into HeartWare Clinical and Real-World Results*  
CONDUCTED BY HEARTWARE

TIME: 12:45 pm - 2:15 pm

LOCATION: Clio/Thalie Rooms,  
Acropolis Congress Center

---

THURSDAY, APRIL 16, 2015

TITLE: *AlloMap: New Advancements in Post-Heart Transplant Rejection Surveillance*  
CONDUCTED BY CAREDX

TIME: 12:45 pm - 2:15 pm

LOCATION: Euterp Room,  
Acropolis Congress Center

---

*Opening Introductions,*  
James Yee, MD (CareDx)

*Use of AlloMap in the AMR Era: Application of EIMAGE Results and Cedars-Sinai Experience,*  
Jon Kobashigawa, MD (Cedars-Sinai)

*New CARGO II Results from Bad Oeynhausen,*  
Uwe Schulz, MD (Bad Oeynhausen)

*Presentation of the PRME study a Multi-center AlloMap Trial Funded by France,*  
Laurent Sebbag, MD (Lyon)

*Evolution of AlloMap Use at Baylor University Medical Center, Dallas,*  
Shelley Hall, MD (Baylor)

*Use of Cell-free DNA in the Detection of Heart Transplant Rejection (and new findings with AlloMap),*  
Jon Kobashigawa, MD (Cedars-Sinai)

*Panel Discussion/Q&A: Drs. Kobashigawa and Schulz,*  
Drs. Kobashigawa and Schulz

*Closing Comments,*  
Jon Kobashigawa, MD
THURSDAY, APRIL 16, 2015

TITLE: CTEPH Patient Care: The Path to Avoid Missed Opportunities

CONDUCTED BY BAYER

TIME: 4:00 pm - 5:00 pm

LOCATION: Rizzo 7 in the Rhodes Exhibit Hall, Acropolis Congress Center

CHAIR: Ardeschir Ghofrani (Giessen, Germany)

4:00 PM: Opening and Introduction, Ardeschir Ghofrani, University of Giessen, Giessen, Germany

4:05 PM: CTEPH Patient Journey: From Diagnosis to Surgery, Stephan Rosenkranz, University of Cologne, Cologne, Germany

4:25 PM: CTEPH Patient Journey: Best Practice in Diagnosis and Management, Raymond L. Benza, Allegheny General Hospital, Pittsburgh, PA, USA

4:50 PM: Q & A, Facilitated by Ardeschir Ghofrani, University of Giessen, Giessen, Germany

5:00 PM: Adjourn
ALPHABETICAL LISTING:

ALERE HOME MONITORING 10
BAYER HEALTHCARE 32
BERLIN HEART 33
CARDIAC ASSIST 14
CARMAT 16
DIAxONHIT/CAREDX INC. 34
ELSEVIER 20
EVAHEART 11
HEARTWARE 42
INSTITUT GEORGES LOPEZ 7-8
ISHLT MECHANICALLY ASSISTED CIRCULATORY SUPPORT REGISTRY (IMACS) 57
ISHLT REGISTRY 58
JARVIK HEART 13
LOPHIUS BIOSCIENCES GMBH 12
LUNG BIOTECHNOLOGY 17
MAQUET GETINGE GROUP 54-55
MILLAR, INC. 2
MINNETRONIX, INC. 5
ONE LAMBDA 53
PHTS – PEDIATRIC HEART TRANSPLANT STUDY 56
RELIANTHEART 18-19
SCANLAN INTERNATIONAL, INC. 1
SUNSHINE HEART 9
SYNCARDIA SYSTEMS, INC. 15
TEVA 6
THORATEC CORPORATION 22
TRANSMEDICS INC 23
UNITED THERAPEUTICS EUROPE LIMITED 52
VIVOLINE MEDICAL AB 3-4
WISEPRESS 21
XVIVO PERFUSION AB 43
<table>
<thead>
<tr>
<th>Booth Number</th>
<th>Company Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>SCANLAN INTERNATIONAL, INC.</td>
</tr>
<tr>
<td>2</td>
<td>MILLAR, INC.</td>
</tr>
<tr>
<td>3-4</td>
<td>VIVOLINE MEDICAL AB</td>
</tr>
<tr>
<td>5</td>
<td>MINNETRONIX, INC.</td>
</tr>
<tr>
<td>6</td>
<td>TEVA</td>
</tr>
<tr>
<td>7-8</td>
<td>INSTITUT GEORGES LOPEZ</td>
</tr>
<tr>
<td>9</td>
<td>SUNSHINE HEART</td>
</tr>
<tr>
<td>10</td>
<td>ALERE HOME MONITORING</td>
</tr>
<tr>
<td>11</td>
<td>EVAHEART</td>
</tr>
<tr>
<td>12</td>
<td>LOPHIUS BIOSCIENCES GMBH</td>
</tr>
<tr>
<td>13</td>
<td>JARVIK HEART</td>
</tr>
<tr>
<td>14</td>
<td>CARDIAC ASSIST</td>
</tr>
<tr>
<td>15</td>
<td>SYNCARDIA SYSTEMS, INC.</td>
</tr>
<tr>
<td>16</td>
<td>CARMAT IMMEUBLE</td>
</tr>
<tr>
<td>17</td>
<td>LUNG BIOTECHNOLOGY</td>
</tr>
<tr>
<td>18-19</td>
<td>RELIANTHEART</td>
</tr>
<tr>
<td>20</td>
<td>ELSEVIER</td>
</tr>
</tbody>
</table>
Alere Home Monitoring, through its Alere VADCare® Program, provides equipment and services for VAD patients and hospital VAD departments. Our newest offering, the Alere VADWatch® Telemonitoring Program allows VAD Coordinators and Physicians to monitor patients after discharge by providing them with alerts when critical patient values are outside of a pre-established acceptable range. The Alere VADWatch® Tele-monitoring Program is perfectly designed to help reduce hospital readmissions. In addition, we enable VAD patients to monitor their INR at home using our industry leading home anticoagulation monitoring services.

Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. More information at www.healthcare.bayer.com.
Berlin Heart is the only company worldwide that develops, produces, and distributes implantable and paracorporeal ventricular assist devices for patients of every age and body size.

EXCOR® is a paracorporeal pulsatile VAD for uni- or biventricular support in newborns, children, adolescents, and adults. EXCOR® Pediatric is leading the worldwide market of pediatric VADs.

INCOR® is an implantable axial-flow LVAD for adults. INCOR® is the only 3rd generation axial flow pump with CE-mark approval.

The Berlin Heart EXCOR® Pediatric Ventricular Assist Device (EXCOR® Pediatric) is approved for use by the FDA under a Humanitarian Device Exemption. All other products are not FDA approved.

CardiacAssist, inventor of the TandemHeart® Extracorporeal Circulatory Support System, offers versatile MCS treatment options. Our classic Left Ventricular Bypass System leverages a unique transseptal cannula to completely bypass the LV to unload the ventricle up to 90%. The newly launched, PROTEK Duo™ Veno-Venous procedure kit provides a new percutaneous option for Extracorporeal Life Support. CardiacAssist also manufactures a top-of-the-line Arterial Cannulae, PROTEK17/15. Stop by our booth to learn more about our products.
CARMAT develops a bioprosthetic artificial heart that features bovine pericardial tissue for blood contacting surfaces and fully enclosed controls based on embedded sensors and electronics.

Diagnos it (Exclusive Distributor in Europe)  
63-65 Boulevard Massena, 75013  
Paris FRANCE  
www.diaxonhit.com

CareDx Inc. (Legal Manufacturer)  
3260 Bayshore Boulevard  
Brisbane, California, USA  
www.caredxinc.com

AlloMap is a blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment.

AlloMap can be used as a non-invasive method for the surveillance monitoring of stable transplant recipients showing no signs of rejection.

AlloMap is indicated for use in patients over 15 years and at least 2 months (>55 days) post-transplantation.

AlloMap is performed in a single laboratory in Europe under exclusive license to Diagnos it, assessing the gene expression profile of RNA.
ELSEVIER is a leading publisher of health science publications, advancing medicine by delivering superior reference information and decision support tools to doctors, nurses, health practitioners and students. With an extensive media spectrum-print, online and handheld, we are able to supply the information you need in the most convenient format.

EVAHEART

6655 Travis St. STE 590
Houston, TX 77030 USA

The EVAHEART Left Ventricular Assist System (LVAS)™ is a continuous-flow, hydraulically levitated centrifugal pump designed to support patients with end-stage heart failure as bridge-to-transplant therapy. The EVAHEART LVAS has been commercially available in Japan since 2010, and has successfully obtained CE marking approval.

Evaheart, Inc. (EVI) is a medical device company based in the Texas Medical center of Houston. EVI was established to gain regulatory approval and commercialize the EVAHEART LVAS in North America and to start distribution in Europe. Under an FDA-approved IDE, a bridge-to-transplant (BTT) clinical trial of the EVAHEART LVAS is currently ongoing in the US.
HeartWare is a global medical device company dedicated to delivering safe, high-performing and transformative therapies that enable patients with heart failure to get back to life. The company’s innovative technologies are creating advances in the miniaturization of Ventricular Assist Devices (VADs) leading to less invasive surgical procedures and increasing the patient population who may be suitable for VAD therapy. HeartWare’s breakthrough innovations begin with the HVAD® Pump, designed to be implanted next to the heart in the pericardial space avoiding the more invasive surgical procedures required with older LVAD technologies. The HVAD Pump is commercially available around the world.

IGL

As an international leader, GROUPE IGL develops manufactures and markets its proprietary products.

Celsior
Solution for organ preservation.
Celsior is an historical reference for heart preservation.
IMACS is an international registry intended to enroll and follow patients who receive durable mechanically assisted circulatory support devices (MCSD) in all countries and hospitals that wish to participate. Durable devices are defined as those devices that are capable of allowing patient discharge with the device in place.

The primary goal of the IMACS Registry is to create, implement and analyze a registry that contains high standards for complete enrollment of patients and complete and accurate submission of MCSD data that allows participating centers to engage in important outcomes research about mechanical support devices.

The ISHLT Transplant Registry was created to collect on-going, current information on the worldwide thoracic organ transplantation experience. Our registry is the only one of its kind. The data we maintain is utilized for scientific study and contributes to the body of knowledge regarding thoracic transplantation. Our goal is to identify overall and best practices for improving cardiothoracic patient care.

This year the exhibit will make center-specific information available for review by ISHLT Transplant Registry and DCD Registry participants. Data screens can be reviewed and we will provide guidance on enrollment, submission of data and data request services.
Jarvik Heart, Inc. is a privately held, New York based company that develops and manufactures miniaturized heart assist devices for the treatment of severe heart failure. The Jarvik 2000 is a battery-powered axial-flow left ventricular assist device (LVAD). It is the smallest implantable blood pump available for the long-term treatment of Heart Failure.

Lophius Biosciences GmbH is an innovative biotech company located in Regensburg, Germany. We are focusing on development, clinical validation and marketing of T cell based research tools and diagnostic systems for early diagnosis and immunmonitoring in the fields of transplantation, infectious and autoimmune diseases. We use our expertise in immunology and infectious diseases to improve personalized therapies with our diagnostic kits. The T Cell Tools are suitable for the development of adjuvant free vaccines as well as for the ex vivo expansion of T cells, the identification of new T cell epitopes and to test novel drugs and immune therapies.
LUNG BIOTECHNOLOGY, INC.
1040 Spring Street
Silver Spring, MD

Lung Biotechnology is focused on the commercialization, research and development of unique products to address the unmet medical needs of patients. We believe serving others is more than just a responsibility – it’s a privilege. We try to breathe life into everything we do, and pride ourselves on contributing time and resources to help patients with fatal lung diseases.

MAQUET GETINGE GROUP
Kehler Str. 31
76437 Rastatt, Germany
www.maquet.com

The CARDIOHELP System is the world’s smallest portable heart-lung support system designed to treat and to transport patients needing extracorporeal life support (ECLS). The system offers short term and prolonged ECLS as a bridge to transplant, bridge to explant, bridge to bridge and bridge to destination.

CARDIOSAVE represents a giant leap forward in functionality and versatility. With its large touchscreen display, dramatically smaller and lighter design, and seamless transition from in-hospital use to transport mode, this revolutionary IABP redefines counterpulsation therapy.
Millar is committed to making the improbable possible in cardiovascular diagnostics and research by delivering products that enable a deeper understanding of hemodynamic function. From clean, pressure waveforms with the Mikro-Cath™ pressure catheter to plotting the complete cardiac cycle with the Inca® PV Loop System, expert insight is within reach. Millar is a unique provider of cardiovascular products that cover device and drug development from the first animal model through the final clinical trial.

Minnetronix offers leading expertise in Customizable VAD Power and Control Technology for ventricular assist devices – from today’s percutaneous systems to future fully implantable solutions. Minnetronix brings heart assist developers unparalleled proven experience, robust enabling intellectual property, quality systems, and end-to-end service from design through verification and manufacturing.

Technologies include the Magic™ PE Percutaneous Controller, the Magic™ TE Transcutaneous Power Controller, and proprietary TETS technologies. Minnetronix has completed 24 VAD-related programs for 14 customers, including current commercial scale production of power and control for a PMA-approved VAD System. The company is FDA Registered, and ISO 13485 Certified.
One Lambda, Inc. is a leader in transplant diagnostics and offers a broad range of products to support clinicians and laboratories in the management of transplant patients. Donor specific antibody (DSA) testing and monitoring are specific tools which support this process. Visit the One Lambda booth to discover how we can help you improve the standard of care in DSA monitoring, featuring our LABScreen® Single Antigen assays and our recent introduction of our biomarker products.

The Pediatric Heart Transplant Study (PHTS) is an international registry established in 1993 for pediatric patients listed for heart transplantation. PHTS is dedicated to the advancement of the science and treatment of children during listing for and following heart transplantation. The purposes of the group are to establish and maintain a prospective, event driven database for heart transplantation, to encourage and stimulate basic and clinical research in the field of pediatric heart transplantation, and to promote new therapeutic strategies. The ultimate goal is to improve patient outcomes. The registry resides at the University of Alabama at Birmingham.
LVAD, Full Flow 92 Grams, remotely monitored True Flow Measurement.

https://www.youtube.com/watch?v=jqrcU7mp6bY

VAD Maintenance System to service multiple LVADs; HVAD, HMII and HA5.

http://reliantheart.com/for-medical-professionals/future-innovation/

Forward Compatibility
Forward compatibility is the ability of a design to gracefully accept input intended for later versions of itself. Our philosophy is to leave no patient behind.

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3,000 titanium and stainless steel instrument designs including needle holders, forceps, scissors, clamps and specialty instruments. Featured instruments include the SCANLAN® LEGACY titanium needle holders and forceps, full line of VATS / MIS Thoracoscopic instruments including the Chitwood Clamp, Knot Pusher, and SUPER CUT™ Suture Cutter; Axial Handle needle holders and forceps, SUPER CUT™ Scissors and Rendina needle holder. Single-use products include: VASCU-STATT® bulldog clamps, Aorta/Vein Punch and A/C Locator® graft markers. Also offering custom instrument designs and modifications for your individual needs.

The C-Pulse® Heart Assist System is a balloon counter-pulsation technology used to treat patients with moderate to severe heart failure (Class III/ Ambulatory Class IV). The implantable device is placed outside the bloodstream and gives patients the ability to disconnect from the system. Preliminary results of the C-Pulse System have indicated relief of heart failure symptoms, improved quality of life and cardiac function, and reduced the need for heart failure hospitalization. The C-Pulse implant procedure can be performed minimally invasively. The European Post-Market Study (OPTIONS HF) and the US Investigational Pivotal Trial (COUNTER HF™) are currently underway.
The SynCardia temporary Total Artificial Heart (TAH-t) is the world’s only FDA, Health Canada and CE approved Total Artificial Heart. The TAH-t is currently approved as a bridge to transplant for patients dying from end-stage biventricular failure. The 13.5 lb Freedom® portable driver has received CE approval in Europe and FDA approval in the U.S. The Freedom driver is designed to provide mobility for stable TAH-t patients both inside and outside the hospital. Visit the booth for updates on our growing clinical experience, and the Destination Therapy and 50cc Adult/Pediatric TAH-t clinical studies.
Thoratec® Corporation is a world leader in device-based mechanical circulatory support therapies. For over 35 years, the company has innovated and delivered technologies to save, support and restore failing hearts, allowing advanced heart failure patients to reclaim their lives. Thoratec is committed to discovering new, groundbreaking ways to serve a broader patient population through improved clinical outcomes, less-invasive procedures, and significant enhancements to quality of life. Thoratec’s portfolio includes the HeartMate and CetriMag® product lines.
TransMedics is dedicated to enabling increased utilization of donor organs for transplantation while enhancing patient outcomes and improving cost-effectiveness of transplant programs. The TransMedics® Organ Care System is a portable, advanced ex-vivo perfusion, monitoring and organ recruitment platform for heart and lung transplantation that is intended to maintain donor organs in a functioning state from donor to recipient.

The OCS™ HEART and LUNG systems are CE-marked and in clinical use in leading European transplant centers, and pivotal FDA clinical trials have concluded in leading global Heart & Lung transplant centers comparing the OCS™ to cold storage.
United Therapeutics Corporation is a biotechnology company focused on the development and commercialisation of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions including pulmonary arterial hypertension (PAH). From the United States to Europe to Asia Pacific, we are proud of our multicultural business environment where employees can collaborate with people all over the world. As a group, we are relentless in our pursuit of “medicines for life”® and continue our research into treatments for cancer and some of the world’s most complicated viral illnesses.

EU/CORP/FEB15/004 date of preparation February 2015
Vivoline Medical is a Swedish research-based company which develops and manufactures equipment in the field of thoracic transplantation. The first product on the market was Vivoline® LS1, now spread over a large part of the world. Vivoline® LS1 is the world’s leading system, designed for making EVLP in an automatic way and thus helping medical centers to increase efficiency and meet the needs for transplantable organs.

The future-oriented company Vivoline Medical will show a new version of lung evaluation system in the booth at ISHLT 2015.
XVIVO manufactures and markets solutions for transplantation designed to preserve and evaluate organs and tissues prior to transplantation. The XPS™ is a flexible and comprehensive platform for normothermic EVLP empowering the user to remain in control of the entire process. Our principle solutions are Perfadex® for hypothermic flushing and preservation of donor lungs during transport and STEEN Solution™ for normothermic ex vivo lung evaluation and assessment. Our products are CE-marked and approved by the FDA.

**XVIVO aims to:**

- minimize ischemia-reperfusion injury by improving the solutions used for ex-vivo preservation of organs.
- extend the safe ex-vivo preservation time for organs prior to transplantation.
- increase organ availability and transplantation success rates by introduction of new transplantation concepts and techniques
Le coffre-fort voyage...

Voyez-vous l’année prochaine!

Safe travels...
See you next year!
FUTURE MEETINGS

2016
36th Annual Meeting and Scientific Sessions
WASHINGTON DC
April 27-30, 2016

2017
37th Annual Meeting and Scientific Sessions
SAN DIEGO, CA
April 5-8, 2017